GDG,question_id,included_article_id,included_postfulltext,included_reference,same_study_diff_article,notes,author_1_extract,year_pub_extract,author_year_format,included_article_doi,included_article_pmid,oa_id,ss_id,title_if_unavailable,title,pmid_sent,doi_sent
1.0,1.2,1,16.0,"Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Adaway J, Keevil B, Atkin SL. Salivary testosterone measurement in women with and without polycystic ovary syndrome. Sci Rep. 2017 Jun 15;7(1):3589. doi: 10.1038/s41598-017-03945-w. PMID: 28620242; PMCID: PMC5472559.",primary_citation,,Sathyapalan T,2017,"Sathyapalan T et al., 2017",10.1038/s41598-017-03945-w,28620242.0,,,,Salivary testosterone measurement in women with and without polycystic ovary syndrome,pmid:28620242,
1.0,1.2,2,16.0,"Bansal, P, Sardana, K, Arora, P, Khurana, A, Garga, UC, Sharma, L. A prospective study of anti-mullerian hormone and other ovarian and adrenal hormones in adult female acne. Dermatologic Therapy. 2020; 33:e13974. https://doi.org/10.1111/dth.13974 ",primary_citation,,Bansal,2020,"Bansal et al., 2020",10.1111/dth.13974,,,,,A prospective study of anti‐mullerian hormone and other ovarian and adrenal hormones in adult female acne,pmid:33185003,10.1111/dth.13974
1.0,1.2,3,16.0,"Imran H. J, Dhaher S. A, Mansour M. A. A. Testosterone or Dehydroepiandrosterone Sulfate as A Biomarker for Hirsutism in Women with Polycystic Ovary Syndrome. Biomed Pharmacol J 2020;13(4). DOI: https://dx.doi.org/10.13005/bpj/2056 ",primary_citation,,Imran H. J,2020,"Imran H. J et al., 2020",10.13005/bpj/2056,,,,,Testosterone or Dehydroepiandrosterone Sulfate as a Biomarker for Hirsutism in Women with Polycystic Ovary Syndrome,,10.13005/bpj/2056
1.0,1.2,4,16.0,"Khashchenko E, Uvarova E, Vysokikh M, Ivanets T, Krechetova L, Tarasova N, Sukhanova I, Mamedova F, Borovikov P, Balashov I, Sukhikh G. The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents. J Clin Med. 2020 Jun 11;9(6):1831. doi: 10.3390/jcm9061831. PMID: 32545404; PMCID: PMC7355484.",primary_citation,,Khashchenko E,2020,"Khashchenko E et al., 2020",10.3390/jcm9061831,32545404.0,,,,The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents,pmid:32545404,
1.0,1.2,5,16.0,"Chen, F., Chen, M., Zhang, W. et al. Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS. J Ovarian Res 14, 32 (2021). https://doi.org/10.1186/s13048-021-00781-5 ",primary_citation,,Chen,2021,"Chen et al., 2021",10.1186/s13048-021-00781-5,,,,,Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS,pmid:33583431,10.1186/s13048-021-00781-5
1.0,1.2,6,16.0,"Grassi, G.; Polledri, E.; Fustinoni, S.; Chiodini, I.; Ceriotti, F.; D’Agostino, S.; Filippi, F.; Somigliana, E.; Mantovani, G.; Arosio, M.; et al. Hyperandrogenism by Liquid Chromatography Tandem Mass Spectrometry in PCOS: Focus on Testosterone and Androstenedione. J. Clin.Med.2021,10,119. https://doi.org/10.3390/jcm10010119   ",primary_citation,,Grassi,2021,"Grassi et al., 2021",10.3390/jcm10010119,,,,,Hyperandrogenism by Liquid Chromatography Tandem Mass Spectrometry in PCOS: Focus on Testosterone and Androstenedione,pmid:33396396,10.3390/jcm10010119
1.0,1.2,7,16.0,"Beitl K, Dewailly D, Seemann R, Hager M, Bünker J, Mayrhofer D, Holzer I and Ott J (2022) Polycystic Ovary Syndrome Phenotype D Versus Functional Hypothalamic Amenorrhea With Polycystic Ovarian Morphology: A Retrospective Study About a Frequent Differential Diagnosis. Front. Endocrinol. 13:904706. doi:10.3389/fendo.2022.904706",primary_citation,,Beitl K,2022,"Beitl K et al., 2022",10.3389/fendo.2022.904706,,,,,Polycystic Ovary Syndrome Phenotype D Versus Functional Hypothalamic Amenorrhea With Polycystic Ovarian Morphology: A Retrospective Study About a Frequent Differential Diagnosis,pmid:35721741,10.3389/fendo.2022.904706
1.0,1.2,8,16.0,"Kumar H, Halder A, Sharma M, Jain M, Kalsi AK.Dihydrotestosterone- A Potential Biomarker of Hyperandrogenaemia in Polycystic Ovary Syndrome: A Case-control Study from North IndiaJ Clin of Diagn Res.2022; 16(2):QC09-QC14. https://www.doi.org/10.7860/JCDR/2022/51169.15962 ",primary_citation,,Kumar H,2022,"Kumar H et al., 2022",10.7860/jcdr/2022/51169.15962,,,246715314.0,,Dihydrotestosterone- A Potential Biomarker of Hyperandrogenaemia in Polycystic Ovary Syndrome: A Case-control Study from North India,,10.7860/jcdr/2022/51169.15962
1.0,1.2,9,16.0,"Koskinen, P., T. A. Penttila, et al. (1996). ""Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome."" Fertil Steril. 1996 Mar;65(3):517-22. doi: 10.1016/s0015-0282(16)58146-1",primary_citation,,Koskinen,1996,"Koskinen et al., 1996",10.1016/s0015-0282(16)58146-1,,,21873315.0,,Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome,pmid:8774279,10.1016/s0015-0282(16)58146-1
1.0,1.2,10,16.0,"Escobar‐Morreale, H. F., M. Asuncion, et al. (2001). ""Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies."" Eur J Endocrinol. 2001 Nov;145(5):619-24. doi:10.1530/eje.0.1450619",primary_citation,,Escobar‐Morreale,2001,"Escobar‐Morreale et al., 2001",10.1530/eje.0.1450619,,,,,Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies,pmid:11720881,10.1530/eje.0.1450619
1.0,1.2,11,16.0,"Hahn, S., W. Kuehnel, et al. (2007). ""Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome."" Clinical Chemistry & Laboratory Medicine 45(2): 202‐7. Clin Chem Lab Med. 2007;45(2):202-7. doi: 10.1515/CCLM.2007.031.",primary_citation,,Hahn,2007,"Hahn et al., 2007",10.1515/cclm.2007.031,,,,,Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome,pmid:17311509,10.1515/cclm.2007.031
1.0,1.2,12,16.0,"Stener‐Victorin, E., G. Holm, et al. (2010). ""Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome?"" J Clin Endocrinol Metab. 2010 Feb;95(2):810-9. doi: 10.1210/jc.2009-1908.",primary_citation,,Stener‐Victorin,2010,"Stener‐Victorin et al., 2010",10.1210/jc.2009-1908,,,,,Are There Any Sensitive and Specific Sex Steroid Markers for Polycystic Ovary Syndrome?,pmid:20016048,10.1210/jc.2009-1908
1.0,1.2,13,16.0,"Bili, E., et al. (2014). ""The combination of ovarian volume and outline has better diagnostic accuracy than prostate‐specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs)."" Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:32-5. doi: 10.1016/j.ejogrb.2014.05.006 ",primary_citation,,Bili,2014,"Bili et al., 2014",10.1016/j.ejogrb.2014.05.006,,,,,The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs),pmid:24965976,10.1016/j.ejogrb.2014.05.006
1.0,1.2,14,16.0,"Wael A. Salameh, Mildred M. Redor-Goldman, Nigel J. Clarke, Ruchi Mathur, Ricardo Azziz, Richard E. Reitz. Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria. Fertility and Sterility® Vol. 101, No. 4, April 2014 0015-0282. http://dx.doi.org/10.1016/j.fertnstert.2013.12.056 ",primary_citation,,Wael A. Salameh,1990,"Wael A. Salameh et al., 1990",10.1016/j.fertnstert.2013.12.056,,,,,Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria,pmid:24534279,10.1016/j.fertnstert.2013.12.056
1.0,1.2,15,16.0,"Villarroel, C., et al. (2015). ""Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents."" Gynecological Endocrinology 31(8): 625‐629. Gynecol Endocrinol. 2015;31(8):625-9. doi: 10.3109/09513590.2015.1025380. ",primary_citation,,Villarroel,2015,"Villarroel et al., 2015",10.3109/09513590.2015.1025380,,,,,Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents,pmid:26190534,10.3109/09513590.2015.1025380
1.0,1.2,16,16.0,"Rudnicka, E., et al. (2016). ""Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome ‐ a new insight."" Gynecol Endocrinol. 2016 Nov;32(11):931-935. doi: 10.1080/09513590.2016.1200552.",primary_citation,,Rudnicka,2016,"Rudnicka et al., 2016",10.1080/09513590.2016.1200552,,,,,Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome – a new insight,pmid:27426018,10.1080/09513590.2016.1200552
1.0,1.3,17,7.0,"Amiri M, Ramezani Tehrani F, Nahidi F, Bidhendi Yarandi R, Behboudi-Gandevani S, Azizi F. Association between biochemical hyperandrogenism parameters and Ferriman-Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta-regression analysis. Clin Endocrinol (Oxf). 2017 Sep;87(3):217-230. doi: 10.1111/cen.13389. Epub 2017 Jun 30. PMID: 28575537.",primary_citation,SR,Amiri M,2017,"Amiri M et al., 2017",10.1111/cen.13389,28575537.0,,,,Association between biochemical hyperandrogenism parameters and Ferriman‐Gallwey score in patients with polycystic ovary syndrome: A systematic review and meta‐regression analysis,pmid:28575537,
1.0,1.3,18,7.0,"Amato MC, Galluzzo A, Merlino S, Mattina A, Richiusa P, Criscimanna A, Giordano C. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome. Eur J Endocrinol. 2006 Dec;155(6):859-65. doi: 10.1530/eje.1.02290. PMID: 17132756.",primary_citation,prior search,Amato MC,2006,"Amato MC et al., 2006",10.1530/eje.1.02290,17132756.0,,,,Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome,pmid:17132756,
1.0,1.3,19,7.0,"Panidis D, Tziomalos K, Papadakis E, Chatzis P, Kandaraki EA, Tsourdi EA, Vosnakis C, Katsikis I. The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome. Eur J Endocrinol. 2013 May 3;168(6):871-7. doi: 10.1530/EJE-13-0039. PMID: 23557988.",primary_citation,prior search,Panidis D,2013,"Panidis D et al., 2013",10.1530/eje-13-0039,23557988.0,,,,The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome,pmid:23557988,
1.0,1.3,20,7.0,"Quinn M, Shinkai K, Pasch L, Kuzmich L, Cedars M, Huddleston H. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. Fertil Steril. 2014 Apr;101(4):1129-34. doi: 10.1016/j.fertnstert.2014.01.003. Epub 2014 Feb 15. PMID: 24534277.",primary_citation,prior search,Quinn M,2014,"Quinn M et al., 2014",10.1016/j.fertnstert.2014.01.003,24534277.0,,,,Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features,pmid:24534277,
1.0,1.3,21,7.0,"Imran H. J, Dhaher S. A, Mansour M. A. A. Testosterone or Dehydroepiandrosterone Sulfate as A Biomarker for Hirsutism in Women with Polycystic Ovary Syndrome. Biomed Pharmacol J 2020;13(4).",primary_citation,,Imran H. J,2020,"Imran H. J et al., 2020",10.13005/bpj/2056,,,,,Testosterone or Dehydroepiandrosterone Sulfate as a Biomarker for Hirsutism in Women with Polycystic Ovary Syndrome,,10.13005/bpj/2056
1.0,1.3,22,7.0,"Kumar, H., Halder, A., Sharma, M., Jain, M., & Kalsi, A. (2022). Dihydrotestosterone- A Potential Biomarker of Hyperandrogenaemia in Polycystic Ovary Syndrome: A Case-control Study from North India. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. doi: 10.7860/jcdr/2022/51169.15962",primary_citation,,Kumar,2022,"Kumar et al., 2022",10.7860/jcdr/2022/51169.15962,,,,,Dihydrotestosterone- A Potential Biomarker of Hyperandrogenaemia in Polycystic Ovary Syndrome: A Case-control Study from North India,,10.7860/jcdr/2022/51169.15962
1.0,1.3,23,7.0,"Leerasiri, P., Wongwananuruk, T., Indhavivadhana, S., Techatraisak, K., Rattanachaiyanont, M., & Angsuwathana, S. (2016). Correlation of clinical and biochemical hyperandrogenism in Thai women with polycystic ovary syndrome. Journal Of Obstetrics And Gynaecology Research, 42(6), 678-683. doi: 10.1111/jog.12945",primary_citation,,Leerasiri,2016,"Leerasiri et al., 2016",10.1111/jog.12945,,,,,Correlation of clinical and biochemical hyperandrogenism in <scp>Thai</scp> women with polycystic ovary syndrome,pmid:26890011,10.1111/jog.12945
1.0,1.3,24,7.0,"Yang Y, Ouyang N, Ye Y, Hu Q, Du T, Di N, Xu W, Azziz R, Yang D, Zhao X. The predictive value of total testosterone alone for clinical hyperandrogenism in polycystic ovary syndrome. Reprod Biomed Online. 2020 Oct;41(4):734-742. doi: 10.1016/j.rbmo.2020.07.013. Epub 2020 Jul 21. PMID: 32912651.",primary_citation,,Yang Y,2020,"Yang Y et al., 2020",10.1016/j.rbmo.2020.07.013,32912651.0,,,,The predictive value of total testosterone alone for clinical hyperandrogenism in polycystic ovary syndrome,pmid:32912651,
1.0,"1.4.1, 1.4.2",25,27.0,"Ahmad AK, Quinn M, Kao CN, Greenwood E, Cedars MI, Huddleston HG. Improved diagnostic performance for the diagnosis of polycystic ovary syndrome using age-stratified criteria. Fertil Steril 2019;111:787–793. DOI: 10.1016/j.fertnstert.2018.11.044",primary_citation,,Ahmad AK,2019,"Ahmad AK et al., 2019",10.1016/j.fertnstert.2018.11.044,,,,,Improved diagnostic performance for the diagnosis of polycystic ovary syndrome using age-stratified criteria,pmid:30871762,10.1016/j.fertnstert.2018.11.044
1.0,"1.4.1, 1.4.2",26,27.0,"Allemand MC, Tummon IS, Phy JL, Foong SC, Dumesic DA, Session DR. Diagnosis of polycystic ovaries by three-dimensional transvaginal ultrasound. Fertil Steril 2006;85:214–219. DOI: 10.1016/j.fertnstert.2005.07.1279",primary_citation,,Allemand MC,2006,"Allemand MC et al., 2006",10.1016/j.fertnstert.2005.07.1279,,,,,Diagnosis of polycystic ovaries by three-dimensional transvaginal ultrasound,pmid:16412756,10.1016/j.fertnstert.2005.07.1279
1.0,"1.4.1, 1.4.2",27,27.0,"Alsamarai S, Adams JM, Murphy MK, Post MD, Hayden DL, Hall JE, Welt CK. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab 2009;94:4961–4970. DOI: 10.1210/jc.2009-0839",primary_citation,,Alsamarai S,2009,"Alsamarai S et al., 2009",10.1210/jc.2009-0839,,,,,Criteria for Polycystic Ovarian Morphology in Polycystic Ovary Syndrome as a Function of Age,pmid:19846740,10.1210/jc.2009-0839
1.0,"1.4.1, 1.4.2",28,27.0,"Bili AE, Dampala K, Iakovou I, Tsolakidis D, Giannakou A, Tarlatzis BC. The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs). Eur J Obstet Gynecol Reprod Biol 2014;179:32–35. DOI: 10.1016/j.ejogrb.2014.05.006",primary_citation,,Bili AE,2014,"Bili AE et al., 2014",10.1016/j.ejogrb.2014.05.006,,,,,The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs),pmid:24965976,10.1016/j.ejogrb.2014.05.006
1.0,"1.4.1, 1.4.2",29,27.0,"Carmina E, Campagna AM, Fruzzetti F, Lobo RA. AMH measurement versus ovarian ultrasound in the diagnosis of polycystic ovary syndrome in different phenotypes. Endocr Pract 2016;22:287–293. DOI: 10.4158/EP15903.OR",primary_citation,,Carmina E,2016,"Carmina E et al., 2016",10.4158/ep15903.or,,,,,Amh Measurement Versus Ovarian Ultrasound In The Diagnosis Of Polycystic Ovary Syndrome In Different Phenotypes,pmid:26523627,10.4158/ep15903.or
1.0,"1.4.1, 1.4.2",30,27.0,"Chen Y, Li L, Chen X, Zhang Q, Wang W, Li Y, Yang D. Ovarian volume and follicle number in the diagnosis of polycystic ovary syndrome in Chinese women. Ultrasound Obstet Gynecol 2008;32:700–703. DOI: 10.1002/uog.5393",primary_citation,,Chen Y,2008,"Chen Y et al., 2008",10.1002/uog.5393,,,,,Ovarian volume and follicle number in the diagnosis of polycystic ovary syndrome in Chinese women,pmid:18773451,10.1002/uog.5393
1.0,"1.4.1, 1.4.2",31,27.0,"Chen Y, Yang D, Li L, Chen X. The role of ovarian volume as a diagnostic criterion for Chinese adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2008; 21:347-350. DOI: https://doi.org/10.1016/j.jpag.2008.01.081 ",primary_citation,,Chen Y,2008,"Chen Y et al., 2008",10.1016/j.jpag.2008.01.081,,,,,The Role of Ovarian Volume As a Diagnostic Criterion for Chinese Adolescents with Polycystic Ovary Syndrome,pmid:19064229,10.1016/j.jpag.2008.01.081
1.0,"1.4.1, 1.4.2",32,27.0,"Christ JP, Willis AD, Brooks ED, Brink H Vanden, Jarrett BY, Pierson RA, Chizen DR, Lujan ME. Follicle number, not assessments of the ovarian stroma, represents the best ultrasonographic marker of polycystic ovary syndrome. Fertil Steril 2014;101:280–287. DOI: 10.1016/j.fertnstert.2013.10.001",primary_citation,,Christ JP,2014,"Christ JP et al., 2014",10.1016/j.fertnstert.2013.10.001,,,,,"Follicle number, not assessments of the ovarian stroma, represents the best ultrasonographic marker of polycystic ovary syndrome",pmid:24188871,10.1016/j.fertnstert.2013.10.001
1.0,"1.4.1, 1.4.2",33,27.0,"Çiraci S, Tan S, Özcan AŞ, Aslan A, Keskin HL, Ateş ÖF, Akçay Y, Arslan H. Contribution of real-time elastography in diagnosis of polycystic ovary syndrome. Diagnostic Interv Radiol 2015;21:118–122. DOI: 10.5152/dir.2014.14094",primary_citation,,Çiraci S,2015,"Çiraci S et al., 2015",10.5152/dir.2014.14094,,,,,Contribution of real-time elastography in diagnosis of polycystic ovary syndrome,pmid:25616270,10.5152/dir.2014.14094
1.0,"1.4.1, 1.4.2",34,27.0,"Dewailly D, Alebić M, Duhamel A, Stojanović N. Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles. Hum Reprod 2014;29:2536–2543. DOI: 10.1093/humrep/deu242",primary_citation,,Dewailly D,2014,"Dewailly D et al., 2014",10.1093/humrep/deu242,,,,,Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles,pmid:25267785,10.1093/humrep/deu242
1.0,"1.4.1, 1.4.2",35,27.0,"Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A, Catteau-Jonard S. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 2011;26:3123–3129. DOI: 10.1093/humrep/der297",primary_citation,,Dewailly D,2011,"Dewailly D et al., 2011",10.1093/humrep/der297,,,,,Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries,pmid:21926054,10.1093/humrep/der297
1.0,"1.4.1, 1.4.2",36,27.0,"Diamanti-Kandarakis E, Livadas S, Katsikis I, Piperi C, Mantziou A, Papavassiliou AG, Panidis D. Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome. J Bone Miner Metab 2011;29:201–206. DOI: https://dx.doi.org/10.1007/s00774-010-0211-2 ",primary_citation,,Diamanti-Kandarakis E,2011,"Diamanti-Kandarakis E et al., 2011",10.1007/s00774-010-0211-2,,,,,Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome,pmid:20694489,10.1007/s00774-010-0211-2
1.0,"1.4.1, 1.4.2",37,27.0,"Ersen E, Özgür DT, Özüm T. Is shear wave elastography relevant in the diagnosis of polycystic ovarian syndrome? Med Ultrason 2019;21:158-162. DOI: 10.11152/mu-1849 ",primary_citation,,Ersen E,2019,"Ersen E et al., 2019",10.11152/mu-1849,,,,,Is shear wave elastography relevant in the diagnosis of polycystic ovarian syndrome?,pmid:31063519,10.11152/mu-1849
1.0,"1.4.1, 1.4.2",38,27.0,"Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: ovarian stroma/total area ratio. Fertil Steril 2001;76:326–331. DOI: 10.1016/s0015-0282(01)01919-7",primary_citation,,Fulghesu AM,2001,"Fulghesu AM et al., 2001",10.1016/s0015-0282(01)01919-7,,,2551667.0,,A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio,pmid:11476780,10.1016/s0015-0282(01)01919-7
1.0,"1.4.1, 1.4.2",39,27.0,"Jarrett BY, Brink H Vanden, Brooks ED, Hoeger KM, Spandorfer SD, Pierson RA, Chizen DR, Lujan ME. Impact of right–left differences in ovarian morphology on the ultrasound diagnosis of polycystic ovary syndrome. Fertil Steril 2019;112:939–946. DOI: 10.1016/j.fertnstert.2019.06.016",primary_citation,,Jarrett BY,2019,"Jarrett BY et al., 2019",10.1016/j.fertnstert.2019.06.016,,,,,Impact of right–left differences in ovarian morphology on the ultrasound diagnosis of polycystic ovary syndrome,pmid:31395310,10.1016/j.fertnstert.2019.06.016
1.0,"1.4.1, 1.4.2",40,27.0,"Jonard S, Robert Y, Dewailly D. Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries. Hum Reprod 2005;20:2893–2898. DOI: 10.1093/humrep/dei159",primary_citation,,Jonard S,2005,"Jonard S et al., 2005",10.1093/humrep/dei159,,,,,Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries,pmid:16006474,10.1093/humrep/dei159
1.0,"1.4.1, 1.4.2",41,27.0,"Kar S, Swoyam S. 2D and 3D trans-vaginal sonography to determine cut-offs for ovarian volume and follicle number per ovary for diagnosis of polycystic ovary syndrome in Indian women. J Reprod Infertil 2018;19:146–151. ",primary_citation,,Kar S,2018,"Kar S et al., 2018",,30167395.0,,,,2D and 3D Trans-vaginal Sonography to Determine Cut-offs for Ovarian Volume and Follicle Number per Ovary for Diagnosis of Polycystic Ovary Syndrome in Indian Women,pmid:30167395,
1.0,"1.4.1, 1.4.2",42,27.0,"Khashchenko E, Uvarova E, Vysokikh M, Ivanets T, Krechetova L, Tarasova N, Sukhanova I, Mamedova F, Borovikov P, Balashov I, Sukhikh, G. The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents. J of Clin Med 2020;9. DOI: 10.3390/jcm9061831",primary_citation,,Khashchenko E,2020,"Khashchenko E et al., 2020",10.3390/jcm9061831,,,,,The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents,pmid:32545404,10.3390/jcm9061831
1.0,"1.4.1, 1.4.2",43,27.0,"Kim HJ, Adams JM, Gudmundsson JA, Arason G, Pau CT, Welt CK. Polycystic ovary morphology: age-based ultrasound criteria. Fertil Steril 2017;108:548–553. DOI: 10.1016/j.fertnstert.2017.07.005",primary_citation,,Kim HJ,2017,"Kim HJ et al., 2017",10.1016/j.fertnstert.2017.07.005,,,,,Polycystic ovary morphology: age-based ultrasound criteria,pmid:28807396,10.1016/j.fertnstert.2017.07.005
1.0,"1.4.1, 1.4.2",44,27.0,"Köninger A, Koch L, Edimiris P, Enekwe A, Nagarajah J, Kasimir-Bauer S, Kimmig R, Strowitzki T, Schmidt B. Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome. Arch Gynecol Obstet 2014;290:1023–1030. DOI: 10.1007/s00404-014-3317-2",primary_citation,,Köninger A,2014,"Köninger A et al., 2014",10.1007/s00404-014-3317-2,,,,,Anti-Mullerian Hormone: an indicator for the severity of polycystic ovarian syndrome,pmid:24961320,10.1007/s00404-014-3317-2
1.0,"1.4.1, 1.4.2",45,27.0,"Kösüs N, Kösüs A, Turhan NÖ. Relationship of ovarian volume with mean platelet volume and lipid profile in patients with polycystic ovary syndrome. Exp Ther Med 2011;2:1141–1144. DOI: 10.3892/etm.2011.327",primary_citation,,Kösüs N,2011,"Kösüs N et al., 2011",10.3892/etm.2011.327,,,,,Relationship of ovarian volume with mean platelet volume and lipid profile in patients with polycystic ovary syndrome,pmid:22977634,10.3892/etm.2011.327
1.0,"1.4.1, 1.4.2",46,27.0,"Kösüs N, Kösüs A, Turhan NÖ, Kamalak Z. Do threshold values of ovarian volume and follicle number for diagnosing polycystic ovarian syndrome in Turkish women differ from western countries? Eur J Obstet Gynecol Reprod Biol 2011;154:177–181. DOI: 10.1016/j.ejogrb.2010.10.007",primary_citation,,Kösüs N,2011,"Kösüs N et al., 2011",10.1016/j.ejogrb.2010.10.007,,,,,Do threshold values of ovarian volume and follicle number for diagnosing polycystic ovarian syndrome in Turkish women differ from western countries?,pmid:21051133,10.1016/j.ejogrb.2010.10.007
1.0,"1.4.1, 1.4.2",47,27.0,"Le NSV, Le MT, Nguyen ND, Tran NQT, Nguyen QHV, Cao TN. A cross-sectional study on potential ovarian volume and related factors in women with polycystic ovary syndrome from infertile couples. Int J Womens Health 2021;13:793–801. DOI: 10.2147/IJWH.S329082",primary_citation,,Le NSV,2021,"Le NSV et al., 2021",10.2147/ijwh.s329082,,,,,A Cross-Sectional Study on Potential Ovarian Volume and Related Factors in Women with Polycystic Ovary Syndrome from Infertile Couples,pmid:34512036,10.2147/ijwh.s329082
1.0,"1.4.1, 1.4.2",48,27.0,"Lie Fong S, Laven JSE, Duhamel A, Dewailly D. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis. Hum Reprod 2017;32:1723–1731. DOI: 10.1093/humrep/dex226",primary_citation,,Lie Fong S,2017,"Lie Fong S et al., 2017",10.1093/humrep/dex226,,,,,Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis,pmid:28854584,10.1093/humrep/dex226
1.0,"1.4.1, 1.4.2",49,27.0,"Lujan ME, Jarrett BY, Brooks ED, Reines JK, Peppin AK, Muhn N, Haider E, Pierson RA, Chizen DR. Updated ultrasound criteria for polycystic ovary syndrome: Reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod 2013;28:1361–1368. DOI: 10.1093/humrep/det062",primary_citation,,Lujan ME,2013,"Lujan ME et al., 2013",10.1093/humrep/det062,,,,,Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume,pmid:23503943,10.1093/humrep/det062
1.0,"1.4.1, 1.4.2",50,27.0,"Özay, OE, Özay AC, Gün, I. Comparison of stromal thickness and doppler findings in polycystic ovary syndrome and healthy women with ultrasonographic evidence of polycystic ovaries? A cross-sectional study. J Obstet Gynaecol 2022;42: 2367-2372. DOI: 10.1080/01443615.2022.2054684",primary_citation,,Özay,2022,"Özay et al., 2022",10.1080/01443615.2022.2054684,,,,,Comparison of stromal thickness and doppler findings in polycystic ovary syndrome and healthy women with ultrasonographic evidence of polycystic ovaries? A cross-sectional study,pmid:35611830,10.1080/01443615.2022.2054684
1.0,"1.4.1, 1.4.2",51,27.0,"Villa P, Rossodivita A, Sagnella F, Moruzzi MC, Mariano N, Lassandro AP, Pontecorvi A, Scambia G, Lanzone A. Ovarian volume and gluco-insulinaemic markers in the diagnosis of PCOS during adolescence. Clin Endocrinol 2013;78:285-290. DOI: 10.1111/j.1365-2265.2012.04475.x",primary_citation,,Villa P,2013,"Villa P et al., 2013",10.1111/j.1365-2265.2012.04475.x,,,,,Ovarian volume and gluco‐insulinaemic markers in the diagnosis of <scp>PCOS</scp> during adolescence,pmid:22724514,10.1111/j.1365-2265.2012.04475.x
1.0,"1.4.1, 1.4.2",52,27.0,"Villaroel C, López P, Merino PM, Iñiguez G, Sir-Petermann T, Codner E. Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents. Gynecol Endocinol 2015;31:625-629. DOI: 10.3109/09513590.2015.1025380",primary_citation,,Villaroel C,2015,"Villaroel C et al., 2015",10.3109/09513590.2015.1025380,,,,,Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents,pmid:26190534,10.3109/09513590.2015.1025380
1.0,"1.4.1, 1.4.2",53,27.0,"Wongwananuruk T, Panichyawat N, Indhavivadhana S, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Pratumvinit B, Sa-nga-areekul N. Accuracy of anti-Müllerian hormone and total follicles count to diagnose polycystic ovary syndrome in reproductive women. Taiwan J Obstet Gynecol 2018;57:499–506. DOI: 10.1016/j.tjog.2018.06.004",primary_citation,,Wongwananuruk T,2018,"Wongwananuruk T et al., 2018",10.1016/j.tjog.2018.06.004,,,,,Accuracy of anti-Müllerian hormone and total follicles count to diagnose polycystic ovary syndrome in reproductive women,pmid:30122568,10.1016/j.tjog.2018.06.004
1.0,"1.5.1, 1.5.2",54,53.0,"Agrawal, N.; Sharma, R. Correlation of anti-müllerian hormone with clinical, hormonal and ultrasonographic parameters in pcos and normo-ovulatory women: An experience of single tertiary care center. Ital J Gynaecol Obstet 2018;30(4):37-43.",primary_citation,,Agrawal,2018,"Agrawal et al., 2018",10.9790/0853-1602085156,,,52258305.0,,"Correlation of Anti-Mullerian Hormone with clinical, hormonal and ultrasonographic parameters in PCOS and normo-ovulatory women",,10.9790/0853-1602085156
1.0,"1.5.1, 1.5.2",55,53.0,"Ahmed N, Batarfi AA, Bajouh OS, Bakhashab S. Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms. Diagnostics (Basel). 2019 Oct 1;9(4):136. doi: 10.3390/diagnostics9040136. PMID: 31581541; PMCID: PMC6963945.",primary_citation,,Ahmed N,2019,"Ahmed N et al., 2019",10.3390/diagnostics9040136,31581541.0,,,,Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms,pmid:31581541,
1.0,"1.5.1, 1.5.2",56,53.0,"Al-Jefout M, Alnawaiseh C, Saleh M, Warwar K. Anti-Müllerianhormone (AMH) new cutoff as a possible tool for thediagnosis of polycystic ovary syndrome (PCOS). J Biomed Sci Res. 2021;3(2):139. Doi: 10.36266/JBSR/139.",primary_citation,,Al-Jefout M,2021,"Al-Jefout M et al., 2021",,,,,,,,
1.0,"1.5.1, 1.5.2",57,53.0,"Al-Naffakh AS, Risan FA. Assessment of anti-Mullerian hormone and anti ovarian antibody in the sera of patients with polycystic ovarian syndrome in AL-Najaf Al-Ashraf Province. Medico-Legal Update 2020;20(1):600–8. Doi: 10.37506/v20/i1/2020/mlu/194384.",primary_citation,,Al-Naffakh AS,2020,"Al-Naffakh AS et al., 2020",10.37506/v20/i1/2020/mlu/194384,,,,,Assessment of Anti-Mullerian Hormone and Anti Ovarian Antibody in the Sera of Patients with Polycystic Ovarian Syndrome in AL-Najaf Al-Ashraf Province,,10.37506/v20/i1/2020/mlu/194384
1.0,"1.5.1, 1.5.2",58,53.0,"Aydoğmuş H, Kelekçi S, Elmalı F, Aydoğmuş S. Can we use serum Anti-Mullerian hormone to differentiate the diagnosis between polycystic ovary syndrome patients and healthy women with polycystic ovarian morphology and regular menstrual cycles. Saudi Med J. 2018 Oct;39(10):1011-1016. doi: 10.15537/smj.2018.10.23413. PMID: 30284584; PMCID: PMC6201027.",primary_citation,,Aydoğmuş H,2018,"Aydoğmuş H et al., 2018",10.15537/smj.2018.10.23413,30284584.0,,,,Can we use serum Anti-Mullerian hormone to differentiate the diagnosis between polycystic ovary syndrome patients and healthy women with polycystic ovarian morphology and regular menstrual cycles,pmid:30284584,
1.0,"1.5.1, 1.5.2",59,53.0,"Bakeer E, Radwan R, El Mandoury A, El Rahman AA, Gad M, El Maksoud SA. Anti-Müllerian Hormone as a Diagnostic Marker in Egyptian Infertile Polycystic Ovary Syndrome Females: Correlations with Vitamin D, Total Testosterone, Dyslipidemia and Anthropometric Parameters. J Med Biochem. 2018 Dec 1;37(4):448-455. doi: 10.1515/jomb-2017-0068. PMID: 30584404; PMCID: PMC6298483.",primary_citation,,Bakeer E,2018,"Bakeer E et al., 2018",10.1515/jomb-2017-0068,30584404.0,,,,"Anti-Müllerian Hormone as a Diagnostic Marker in Egyptian Infertile Polycystic Ovary Syndrome Females: Correlations with Vitamin D, Total Testosterone, Dyslipidemia and Anthropometric Parameters",pmid:30584404,
1.0,"1.5.1, 1.5.2",60,53.0,"Bansal P, Sardana K, Arora P, Khurana A, Garga UC, Sharma L. A prospective study of anti-mullerian hormone and other ovarian and adrenal hormones in adult female acne. Dermatol Ther. 2020 Nov;33(6):e13974. doi: 10.1111/dth.13974. Epub 2020 Jul 27. PMID: 33185003.",primary_citation,,Bansal P,2020,"Bansal P et al., 2020",10.1111/dth.13974,33185003.0,,,,A prospective study of anti‐mullerian hormone and other ovarian and adrenal hormones in adult female acne,pmid:33185003,
1.0,"1.5.1, 1.5.2",61,53.0,"Bell RJ, Islam RM, Skiba MA, Herbert D, Martinez Garcia A, Davis SR. Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study. Hum Reprod. 2021 Dec 27;37(1):109-118. doi: 10.1093/humrep/deab232. PMID: 34741176.",primary_citation,,Bell RJ,2021,"Bell RJ et al., 2021",10.1093/humrep/deab232,34741176.0,,,,Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study,pmid:34741176,
1.0,"1.5.1, 1.5.2",62,53.0,"Bozdag G, Mumusoglu S, Coskun ZY, Yarali H, Yildiz BO. Anti-Müllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population. Reprod Biomed Online. 2019 Sep;39(3):522-529. doi: 10.1016/j.rbmo.2019.04.002. Epub 2019 Apr 10. PMID: 31182353.",primary_citation,,Bozdag G,2019,"Bozdag G et al., 2019",10.1016/j.rbmo.2019.04.002,31182353.0,,,,Anti-Müllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population,pmid:31182353,
1.0,"1.5.1, 1.5.2",63,53.0,"Calzada M, López N, Noguera JA, Mendiola J, Hernández AI, Corbalán S, Sanchez M, Torres AM. AMH in combination with SHBG for the diagnosis of polycystic ovary syndrome. J Obstet Gynaecol. 2019 Nov;39(8):1130-1136. doi: 10.1080/01443615.2019.1587604. Epub 2019 Jun 17. PMID: 31208261.",primary_citation,,Calzada M,2019,"Calzada M et al., 2019",10.1080/01443615.2019.1587604,31208261.0,,,,AMH in combination with SHBG for the diagnosis of polycystic ovary syndrome,pmid:31208261,
1.0,"1.5.1, 1.5.2",64,53.0,"Casadei L, Fanisio F, Sorge RP, Collamarini M, Piccolo E, Piccione E. The diagnosis of PCOS in young infertile women according to different diagnostic criteria: the role of serum anti-Müllerian hormone. Arch Gynecol Obstet. 2018 Jul;298(1):207-215. doi: 10.1007/s00404-018-4803-8. Epub 2018 May 25. PMID: 29802450.",primary_citation,,Casadei L,2018,"Casadei L et al., 2018",10.1007/s00404-018-4803-8,29802450.0,,,,The diagnosis of PCOS in young infertile women according to different diagnostic criteria: the role of serum anti-Müllerian hormone,pmid:29802450,
1.0,"1.5.1, 1.5.2",65,53.0,"Cengiz H, Ekin M, Dagdeviren H, Yildiz Ş, Kaya C, Kanawati A. Comparison of serum anti-Müllerian hormone levels in normal weight and overweight-obese adolescent patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014 Sep;180:46-50. doi: 10.1016/j.ejogrb.2014.06.018. Epub 2014 Jun 28. PMID: 25036408.",primary_citation,,Cengiz H,2014,"Cengiz H et al., 2014",10.1016/j.ejogrb.2014.06.018,25036408.0,,,,Comparison of serum anti-Müllerian hormone levels in normal weight and overweight–obese adolescent patients with polycystic ovary syndrome,pmid:25036408,
1.0,"1.5.1, 1.5.2",66,53.0,"Deveer M, Deveer R, Basaran O, Turkcu UO, Akbaba E, Cullu N, Turhan N, Kucuk M, Kasap B. Serum Copeptin, Pentraxin 3, Anti-Mullerian Hormone Levels With Echocardiography and Carotid Artery Intima-Media Thickness in Adolescents With Polycystic Ovary Syndrome. J Clin Med Res. 2015 Dec;7(12):989-94. doi: 10.14740/jocmr2375w. Epub 2015 Oct 23. PMID: 26566413; PMCID: PMC4625820.",primary_citation,,Deveer M,2015,"Deveer M et al., 2015",10.14740/jocmr2375w,26566413.0,,,,"Serum Copeptin, Pentraxin 3, Anti-Mullerian Hormone Levels With Echocardiography and Carotid Artery Intima-Media Thickness in Adolescents With Polycystic Ovary Syndrome",pmid:26566413,
1.0,"1.5.1, 1.5.2",67,53.0,"Dietz de Loos A, Hund M, Buck K, Meun C, Sillman J, Laven JSE. Antimüllerian hormone to determine polycystic ovarian morphology. Fertil Steril. 2021 Oct;116(4):1149-1157. doi: 10.1016/j.fertnstert.2021.05.094. PMID: 34579824.",primary_citation,,Dietz de Loos A,2021,"Dietz de Loos A et al., 2021",10.1016/j.fertnstert.2021.05.094,34579824.0,,,,Antimüllerian hormone to determine polycystic ovarian morphology,pmid:34579824,
1.0,"1.5.1, 1.5.2",68,53.0,"Evliyaoglu O, Imöhl M, Weiskirchen R, van Helden J. Age-specific reference values improve the diagnostic performance of AMH in polycystic ovary syndrome. Clin Chem Lab Med. 2020 Jul 28;58(8):1291-1301. doi: 10.1515/cclm-2019-1059. PMID: 32069226.",primary_citation,,Evliyaoglu O,2020,"Evliyaoglu O et al., 2020",10.1515/cclm-2019-1059,32069226.0,,,,Age-specific reference values improve the diagnostic performance of AMH in polycystic ovary syndrome,pmid:32069226,
1.0,"1.5.1, 1.5.2",69,53.0,"Farooq S, Baloch S, Awan S, Fakharunissa. Relationship of Anti-Mullerian Hormone in Polycystic Ovary Syndrome Patients with Different Subgroups. Pak J Med Health Sci 2022;16(5):612-615. No doi",primary_citation,,Farooq S,2022,"Farooq S et al., 2022",10.53350/pjmhs22165612,,,,,Relationship of Anti-Mullerian Hormone in Polycystic Ovary Syndrome Patients with Different Subgroups,,10.53350/pjmhs22165612
1.0,"1.5.1, 1.5.2",70,53.0,"Fu H, Lin Y, Deng X, Wu L. Correlation between anti-Mullerian hormone levels and antral follicle counts in polycystic ovary and metabolic syndromes. Syst Biol Reprod Med. 2021 Apr;67(2):112-120. doi: 10.1080/19396368.2020.1860155. Epub 2021 Jan 7. PMID: 33406916.",primary_citation,,Fu H,2021,"Fu H et al., 2021",10.1080/19396368.2020.1860155,33406916.0,,,,Correlation between anti-Mullerian hormone levels and antral follicle counts in polycystic ovary and metabolic syndromes,pmid:33406916,
1.0,"1.5.1, 1.5.2",71,53.0,"Gabr H, Marei ES, The Relation between Anti-Mullerian Hormone with Antral Follicle Count and Ovarian Volume in Polycystic Ovary Syndrome. Arab Journal of Nuclear Sciences and Applications 2019;52(2):84-93. ",primary_citation,,Gabr H,2019,"Gabr H et al., 2019",10.21608/ajnsa.2019.3711.1087,,,,,Relation between Anti-Müllerian Hormone with Antral Follicle Count and Ovarian Volume in Polycystic Ovary Syndrome,,10.21608/ajnsa.2019.3711.1087
1.0,"1.5.1, 1.5.2",72,53.0,"Indran IR, Huang Z, Khin LW, Chan JKY, Viardot-Foucault V, Yong EL. Simplified 4-item criteria for polycystic ovary syndrome: A bridge too far? Clin Endocrinol (Oxf). 2018 Aug;89(2):202-211. doi: 10.1111/cen.13755. Epub 2018 Jun 19. PMID: 29851127.",primary_citation,,Indran IR,2018,"Indran IR et al., 2018",10.1111/cen.13755,29851127.0,,,,Simplified 4‐item criteria for polycystic ovary syndrome: A bridge too far?,pmid:29851127,
1.0,"1.5.1, 1.5.2",73,53.0,"Jacob SL, Field HP, Calder N, Picton HM, Balen AH, Barth JH. Anti-Müllerian hormone reflects the severity of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017 Mar;86(3):395-400. doi: 10.1111/cen.13269. Epub 2016 Dec 1. PMID: 27805276.",primary_citation,,Jacob SL,2017,"Jacob SL et al., 2017",10.1111/cen.13269,27805276.0,,,,Anti-Müllerian hormone reflects the severity of polycystic ovary syndrome,pmid:27805276,
1.0,"1.5.1, 1.5.2",74,53.0,"Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet. 2016 Feb;293(2):447-56. doi: 10.1007/s00404-015-3889-5. Epub 2015 Sep 25. PMID: 26408006.",primary_citation,,Jamil AS,2016,"Jamil AS et al., 2016",10.1007/s00404-015-3889-5,26408006.0,,,,Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria,pmid:26408006,
1.0,"1.5.1, 1.5.2",75,53.0,"Kakkad V, Reddy NS, Nihlani H, Gundewar T. Age-related diagnostic threshold of anti-Müllerian hormone for polycystic ovarian syndrome. Int J Gynecol Obstet. 2021;153:443–448. https://doi.org/10.1002/ijgo.13515",primary_citation,,Kakkad V,2021,"Kakkad V et al., 2021",10.1002/ijgo.13515,,,,,Age‐related diagnostic threshold of anti‐Müllerian hormone for polycystic ovarian syndrome,pmid:33275771,10.1002/ijgo.13515
1.0,"1.5.1, 1.5.2",76,53.0,"Khashchenko E, Uvarova E, Vysokikh M, Ivanets T, Krechetova L, Tarasova N, Sukhanova I, Mamedova F, Borovikov P, Balashov I, Sukhikh G. The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents. J Clin Med. 2020 Jun 11;9(6):1831. doi: 10.3390/jcm9061831. PMID: 32545404; PMCID: PMC7355484.",primary_citation,,Khashchenko E,2020,"Khashchenko E et al., 2020",10.3390/jcm9061831,32545404.0,,,,The Relevant Hormonal Levels and Diagnostic Features of Polycystic Ovary Syndrome in Adolescents,pmid:32545404,
1.0,"1.5.1, 1.5.2",77,53.0,"Kim JY, Tfayli H, Michaliszyn SF, Lee S, Nasr A, Arslanian S. Anti-Müllerian Hormone in Obese Adolescent Girls With Polycystic Ovary Syndrome. J Adolesc Health. 2017 Mar;60(3):333-339. doi: 10.1016/j.jadohealth.2016.10.015. Epub 2016 Dec 18. PMID: 27998701; PMCID: PMC5326592.",primary_citation,,Kim JY,2017,"Kim JY et al., 2017",10.1016/j.jadohealth.2016.10.015,27998701.0,,,,Anti-Müllerian Hormone in Obese Adolescent Girls With Polycystic Ovary Syndrome,pmid:27998701,
1.0,"1.5.1, 1.5.2",78,53.0,"Kumari A, Tiwari HC, Srivastav R. Comparative Evaluation of Diagnostic Efficacy of Serum Anti-Müllerian Hormone and Ultrasound in Polycystic Ovarian Syndrome. J South Asian Feder Obs Gynae 2018; 10 (2):98-103",primary_citation,,Kumari A,2018,"Kumari A et al., 2018",10.5005/jp-journals-10006-1569,,,,,Comparative Evaluation of Diagnostic Efficacy of Serum Anti-Müllerian Hormone and Ultrasound in Polycystic Ovarian Syndrome,,10.5005/jp-journals-10006-1569
1.0,"1.5.1, 1.5.2",79,53.0,"Le MT, Le VNS, Le DD, Nguyen VQH, Chen C, Cao NT. Exploration of the role of anti-Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2019 Apr;90(4):579-585. doi: 10.1111/cen.13934. Epub 2019 Feb 10. PMID: 30636332.",primary_citation,,Le MT,2019,"Le MT et al., 2019",10.1111/cen.13934,30636332.0,,,,Exploration of the role of anti‐Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome,pmid:30636332,
1.0,"1.5.1, 1.5.2",80,53.0,"Li H, He YL, Li R, Wong C, Sy B, Lam CW, Lam K, Peng HM, Mu S, Schooling M, Yeung W, Ho PC, Ng E. Age-specific reference ranges of serum anti-müllerian hormone in healthy women and its application in diagnosis of polycystic ovary syndrome: a population study. BJOG. 2020 May;127(6):720-728. doi: 10.1111/1471-0528.16147. Epub 2020 Feb 25. PMID: 32009280.",primary_citation,,Li H,2020,"Li H et al., 2020",10.1111/1471-0528.16147,32009280.0,,,,Age‐specific reference ranges of serum anti‐müllerian hormone in healthy women and its application in diagnosis of polycystic ovary syndrome: a population study,pmid:32009280,
1.0,"1.5.1, 1.5.2",81,53.0,"Lie Fong S, Laven JSE, Duhamel A, Dewailly D. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis. Hum Reprod. 2017 Aug 1;32(8):1723-1731. doi: 10.1093/humrep/dex226. PMID: 28854584.",primary_citation,,Lie Fong S,2017,"Lie Fong S et al., 2017",10.1093/humrep/dex226,28854584.0,,,,Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis,pmid:28854584,
1.0,"1.5.1, 1.5.2",82,53.0,"Lin YH, Chiu WC, Wu CH, Tzeng CR, Hsu CS, Hsu MI. Antimüllerian hormone and polycystic ovary syndrome. Fertil Steril. 2011 Jul;96(1):230-5. doi: 10.1016/j.fertnstert.2011.04.003. Epub 2011 May 5. PMID: 21549367.",primary_citation,,Lin YH,2011,"Lin YH et al., 2011",10.1016/j.fertnstert.2011.04.003,21549367.0,,,,Antimüllerian hormone and polycystic ovary syndrome,pmid:21549367,
1.0,"1.5.1, 1.5.2",83,53.0,"Mahajan N, Kaur J. Establishing an Anti-Müllerian Hormone Cutoff for Diagnosis of Polycystic Ovarian Syndrome in Women of Reproductive Age-Bearing Indian Ethnicity Using the Automated Anti-Müllerian Hormone Assay. J Hum Reprod Sci. 2019 Apr-Jun;12(2):104-113. doi: 10.4103/jhrs.JHRS_149_18. PMID: 31293324; PMCID: PMC6594116.",primary_citation,,Mahajan N,2019,"Mahajan N et al., 2019",10.4103/jhrs.jhrs_149_18,31293324.0,,,,Establishing an Anti-Müllerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using the automated Anti-Müllerian hormone assay,pmid:31293324,
1.0,"1.5.1, 1.5.2",84,53.0,"Matsuzaki T, Munkhzaya M, Iwasa T, Tungalagsuvd A, Yano K, Mayila Y, Yanagihara R, Tokui T, Kato T, Kuwahara A, Matsui S, Irahara M. Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome. Endocr J. 2017 May 30;64(5):531-541. doi: 10.1507/endocrj.EJ16-0501. Epub 2017 Apr 1. PMID: 28381699.",primary_citation,,Matsuzaki T,2017,"Matsuzaki T et al., 2017",10.1507/endocrj.ej16-0501,28381699.0,,,,Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome,pmid:28381699,
1.0,"1.5.1, 1.5.2",85,53.0,"Okcu NT, Nazik H, Akduman AT, Uncu G. The relation between the serum anti-Mullerian hormone levels and follicle count in polycystic ovary syndrome. The European Research Journal. P -2149-3189;4;N1 doi: 10.18621/eurj.332118",primary_citation,,Okcu NT,,"Okcu NT et al., ",10.18621/eurj.332118,,,,,The relation between serum anti-Mullerian hormone levels and follicle count in polycystic ovary syndrome,,10.18621/eurj.332118
1.0,"1.5.1, 1.5.2",86,53.0,"Oueslati I, Hammami MB, Boukriba S, Ben Hadj Hassen H, Yazidi M, Chaker F, Mizouni H, Feki M, Chihaoui M. Anti Mullerian hormone as a diagnostic tool for polycystic ovary syndrome in women of reproductive age with morbid obesity. Horm Mol Biol Clin Investig. 2022 May 5. doi: 10.1515/hmbci-2021-0078. Epub ahead of print. PMID: 35506902.",primary_citation,,Oueslati I,2022,"Oueslati I et al., 2022",10.1515/hmbci-2021-0078,35506902.0,,,,Anti Mullerian hormone as a diagnostic tool for polycystic ovary syndrome in women of reproductive age with morbid obesity,pmid:35506902,
1.0,"1.5.1, 1.5.2",87,53.0,"Pankhurst MW, Shorakae S, Rodgers RJ, Teede HJ, Moran LJ. Efficacy of predictive models for polycystic ovary syndrome using serum levels of two antimüllerian hormone isoforms (proAMH and AMHN,C). Fertil Steril. 2017 Nov;108(5):851-857.e2. doi: 10.1016/j.fertnstert.2017.08.012. PMID: 29079276.",primary_citation,,Pankhurst MW,2017,"Pankhurst MW et al., 2017",10.1016/j.fertnstert.2017.08.012,29079276.0,,,,"Efficacy of predictive models for polycystic ovary syndrome using serum levels of two antimüllerian hormone isoforms (proAMH and AMHN,C)",pmid:29079276,
1.0,"1.5.1, 1.5.2",88,53.0,"Prieto-Sánchez MT, Hernández-Peñalver AI, Sánchez-Ferrer ML, Mendiola J, Torres-Cantero AM. Anogenital distance and anti-Müllerian hormone combined improves the diagnosis of polycystic ovary syndrome. Hum Fertil (Camb). 2022 Apr;25(2):274-282. doi: 10.1080/14647273.2020.1795574. Epub 2020 Jul 27. PMID: 32713212.",primary_citation,,Prieto-Sánchez MT,2022,"Prieto-Sánchez MT et al., 2022",10.1080/14647273.2020.1795574,32713212.0,,,,Anogenital distance and anti-Müllerian hormone combined improves the diagnosis of polycystic ovary syndrome,pmid:32713212,
1.0,"1.5.1, 1.5.2",89,53.0,"Quinn MM, Kao CN, Ahmad AK, Haisenleder DJ, Santoro N, Eisenberg E, Legro RS, Cedars MI, Huddleston HG; NIH/NICHD Reproductive Medicine Network. Age-stratified thresholds of anti-Müllerian hormone improve prediction of polycystic ovary syndrome over a population-based threshold. Clin Endocrinol (Oxf). 2017 Dec;87(6):733-740. doi: 10.1111/cen.13415. Epub 2017 Aug 4. PMID: 28681949.",primary_citation,,Quinn MM,2017,"Quinn MM et al., 2017",10.1111/cen.13415,28681949.0,,,,Age‐stratified thresholds of anti‐Müllerian hormone improve prediction of polycystic ovary syndrome over a population‐based threshold,pmid:28681949,
1.0,"1.5.1, 1.5.2",90,53.0,"Ramezani Tehrani F, Rahmati M, Mahboobifard F, Firouzi F, Hashemi N, Azizi F. Age-specific cut-off levels of anti-Müllerian hormone can be used as diagnostic markers for polycystic ovary syndrome. Reprod Biol Endocrinol. 2021 May 22;19(1):76. doi: 10.1186/s12958-021-00755-8. PMID: 34022904; PMCID: PMC8140506.",primary_citation,,Ramezani Tehrani F,2021,"Ramezani Tehrani F et al., 2021",10.1186/s12958-021-00755-8,34022904.0,,,,Age-specific cut-off levels of anti-Müllerian hormone can be used as diagnostic markers for polycystic ovary syndrome,pmid:34022904,
1.0,"1.5.1, 1.5.2",91,53.0,"Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Atkin SL. Anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018 Feb;88(2):258-262. doi: 10.1111/cen.13517. Epub 2017 Dec 7. PMID: 29144548.",primary_citation,,Sathyapalan T,2018,"Sathyapalan T et al., 2018",10.1111/cen.13517,29144548.0,,,,Anti‐Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome,pmid:29144548,
1.0,"1.5.1, 1.5.2",92,53.0,"Savas-Erdeve S, Keskin M, Sagsak E, Cenesiz F, Cetinkaya S, Aycan Z. Do the Anti-Müllerian Hormone Levels of Adolescents with Polycystic Ovary Syndrome, Those Who Are at Risk for Developing Polycystic Ovary Syndrome, and Those Who Exhibit Isolated Oligomenorrhea Differ from Those of Adolescents with Normal Menstrual Cycles? Horm Res Paediatr. 2016;85(6):406-11. doi: 10.1159/000446111. Epub 2016 May 13. PMID: 27173790.",primary_citation,,Savas-Erdeve S,2016,"Savas-Erdeve S et al., 2016",10.1159/000446111,27173790.0,,,,"Do the Anti-Müllerian Hormone Levels of Adolescents with Polycystic Ovary Syndrome, Those Who Are at Risk for Developing Polycystic Ovary Syndrome, and Those Who Exhibit Isolated Oligomenorrhea Differ from Those of Adolescents with Normal Menstrual Cycles?",pmid:27173790,
1.0,"1.5.1, 1.5.2",93,53.0,"Saxena, U., Ramani, M. & Singh, P. Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome. J Obstet Gynecol India 68, 117–122 (2018). https://doi.org/10.1007/s13224-017-1066-4",primary_citation,,Saxena,2018,"Saxena et al., 2018",10.1007/s13224-017-1066-4,,,,,Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome,pmid:29662281,10.1007/s13224-017-1066-4
1.0,"1.5.1, 1.5.2",94,53.0,"Sharma P, Chawla R, Ahuja R, et al. Anti-Müllerian Hormone as a Surrogate Marker for Hormonal Dysfunction and Sonographic Pattern in Polycystic Ovarian Syndrome. J South Asian Feder Obst Gynae 2019;11(3):175–180. doi: 10.5005/jp-journals-10006-1674",primary_citation,,Sharma P,2019,"Sharma P et al., 2019",10.5005/jp-journals-10006-1674,,,,,Anti-Müllerian Hormone as a Surrogate Marker for Hormonal Dysfunction and Sonographic Pattern in Polycystic ovarian syndrome,,10.5005/jp-journals-10006-1674
1.0,"1.5.1, 1.5.2",95,53.0,"Shi X, Peng D, Liu Y, Miao X, Ye H, Zhang J. Advantages of Serum Anti-Müllerian Hormone as a Marker for Polycystic Ovarian Syndrome. Lab Med. 2019 Jul 16;50(3):236-242. doi: 10.1093/labmed/lmy068. PMID: 30535164.",primary_citation,,Shi X,2019,"Shi X et al., 2019",10.1093/labmed/lmy068,30535164.0,,,,Advantages of Serum Anti-Müllerian Hormone as a Marker for Polycystic Ovarian Syndrome,pmid:30535164,
1.0,"1.5.1, 1.5.2",96,53.0,"Singh S, Firdaus A, Choudhary R, Dhama V. Role of antimullerian hormone as a diagnostic tool for polycystic ovary syndrome. Int J Reprod Contracept Obstet Gynecol. 2020;9(9):3730. DOI: 10.18203/2320-1770.ijrcog20203847.",primary_citation,,Singh S,2020,"Singh S et al., 2020",10.18203/2320-1770.ijrcog20203847,,,,,Role of anti-mullerian hormone as a diagnostic tool for polycystic ovary syndrome,,10.18203/2320-1770.ijrcog20203847
1.0,"1.5.1, 1.5.2",97,53.0,"Song DK, Oh JY, Lee H, Sung YA. Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Müllerian hormone cutoff value. Korean J Intern Med. 2017 Jul;32(4):690-698. doi: 10.3904/kjim.2016.038. Epub 2016 Nov 30.",primary_citation,,Song DK,2017,"Song DK et al., 2017",10.3904/kjim.2016.038,,,,,Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Müllerian hormone cutoff value,pmid:27899014,10.3904/kjim.2016.038
1.0,"1.5.1, 1.5.2",98,53.0,"Song J, Park Y, Cho HW, Lee SG, Kim S, Lim JB. Age-group-specific reference intervals for anti-Müllerian hormone and its diagnostic performance for polycystic ovary syndrome in a Korean population. J Clin Lab Anal. 2021 Jul;35(7):e23861. doi: 10.1002/jcla.23861. Epub 2021 Jun 7. PMID: 34097316; PMCID: PMC8274997.",primary_citation,,Song J,2021,"Song J et al., 2021",10.1002/jcla.23861,34097316.0,,,,Age‐group‐specific reference intervals for anti‐Müllerian hormone and its diagnostic performance for polycystic ovary syndrome in a Korean population,pmid:34097316,
1.0,"1.5.1, 1.5.2",99,53.0,"Sova H, Unkila-Kallio L, Tiitinen A, Hippeläinen M, Perheentupa A, Tinkanen H, Puukka K, Bloigu R, Piltonen T, Tapanainen JS, Morin-Papunen L. Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes. Gynecol Endocrinol. 2019 Jul;35(7):595-600. doi: 10.1080/09513590.2018.1559807. Epub 2019 Jan 22. PMID: 30668196.",primary_citation,,Sova H,2019,"Sova H et al., 2019",10.1080/09513590.2018.1559807,30668196.0,,,,"Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes",pmid:30668196,
1.0,"1.5.1, 1.5.2",100,53.0,"Tola H, Abbas M, Alhassan EA, Shrif NE, Rida M. Assessment of the Role of the Anti-Mullerian Hormone, Luteinizing Hormone/Follicle Stimulating Hormone Ratio in the Diagnosis of Polycystic Ovary Syndrome in Sudanese Women. Open Access Maced J Med Sci. 2018;6(7):1244-1247. Published 2018 Jul 17.",primary_citation,,Tola H,2018,"Tola H et al., 2018",10.3889/oamjms.2018.260,30087729.0,,,,"Assessment of the Role of the Anti-Mullerian Hormone, Luteinizing Hormone/Follicle Stimulating Hormone Ratio in the Diagnosis of Polycystic Ovary Syndrome in Sudanese Women",pmid:30087729,
1.0,"1.5.1, 1.5.2",101,53.0,"Tunҫ S, and Ozkan B. Analysis of New Biomarkers for the Diagnosis of Polycystic Ovary Syndrome in Adolescents Ergenlerde Polikistik Over Sendromu Tanisi icin Yeni Biyobelirteclerin Analizi. The Journal of Current Pediatrics, vol. 19, no. 3, Dec. 2021, pp. 311+. Gale OneFile: Health and Medicine.",primary_citation,,Tunҫ S,2021,"Tunҫ S et al., 2021",10.4274/jcp.2021.22599,,,,,Analysis of New Biomarkers for the Diagnosis of Polycystic Ovary Syndrome in Adolescents,,10.4274/jcp.2021.22599
1.0,"1.5.1, 1.5.2",102,53.0,"Vagios S, James KE, Sacha CR, Hsu JY, Dimitriadis I, Bormann CL, Souter I. A patient-specific model combining antimüllerian hormone and body mass index as a predictor of polycystic ovary syndrome and other oligo-anovulation disorders. Fertil Steril. 2021 Jan;115(1):229-237. doi: 10.1016/j.fertnstert.2020.07.023.",primary_citation,,Vagios S,2021,"Vagios S et al., 2021",10.1016/j.fertnstert.2020.07.023,,,,,A patient-specific model combining antimüllerian hormone and body mass index as a predictor of polycystic ovary syndrome and other oligo-anovulation disorders,pmid:33077236,10.1016/j.fertnstert.2020.07.023
1.0,"1.5.1, 1.5.2",103,53.0,"Villarroel C, López P, Merino PM, Iñiguez G, Sir-Petermann T, Codner E. Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents. Gynecol Endocrinol. 2015;31(8):625-9. doi: 10.3109/09513590.2015.1025380. Epub 2015 Jul 20. PMID: 26190534.",primary_citation,,Villarroel C,2015,"Villarroel C et al., 2015",10.3109/09513590.2015.1025380,26190534.0,,,,Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents,pmid:26190534,
1.0,"1.5.1, 1.5.2",104,53.0,"Wissing ML, Mikkelsen AL, Kumar A, Kalra B, Pors SE, Flachs EM, Andersen CY. Associations of different molecular forms of antimüllerian hormone and biomarkers of polycystic ovary syndrome and normal women. Fertil Steril. 2019 Jul;112(1):149-155.e1.",primary_citation,,Wissing ML,2019,"Wissing ML et al., 2019",10.1016/j.fertnstert.2019.03.002,,,,,Associations of different molecular forms of antimüllerian hormone and biomarkers of polycystic ovary syndrome and normal women,pmid:31056306,10.1016/j.fertnstert.2019.03.002
1.0,"1.5.1, 1.5.2",105,53.0,"Wongwananuruk T, Panichyawat N, Indhavivadhana S, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Pratumvinit B, Sa-Nga-Areekul N. Accuracy of anti-Müllerian hormone and total follicles count to diagnose polycystic ovary syndrome in reproductive women. Taiwan J Obstet Gynecol. 2018 Aug;57(4):499-506.",primary_citation,,Wongwananuruk T,2018,"Wongwananuruk T et al., 2018",10.1016/j.tjog.2018.06.004,,,,,Accuracy of anti-Müllerian hormone and total follicles count to diagnose polycystic ovary syndrome in reproductive women,pmid:30122568,10.1016/j.tjog.2018.06.004
1.0,"1.5.1, 1.5.2",106,53.0,"Yue CY, Lu LK, Li M, Zhang QL, Ying CM. Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women. PLoS One. 2018 Aug 28;13(8):e0203129.",primary_citation,,Yue CY,2018,"Yue CY et al., 2018",10.1371/journal.pone.0203129,,,,,Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women,pmid:30153296,10.1371/journal.pone.0203129
1.0,1.6,107,47.0,"Asfari MM, Sarmini MT, Baidoun F, et al. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. BMJ Open Gastroenterology. 2020;7(1):08. doi: 10.1136/bmjgast-2019-000352",primary_citation,,Asfari MM,2020,"Asfari MM et al., 2020",10.1136/bmjgast-2019-000352,,,,,Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome,pmid:32784205,10.1136/bmjgast-2019-000352
1.0,1.6,108,47.0,"Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2745-2749. doi: 10.1210/jc.2003-032046",primary_citation,,Azziz R,2004,"Azziz R et al., 2004",10.1210/jc.2003-032046,15181052.0,,,,The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population,pmid:15181052,
1.0,1.6,109,47.0,"Christensen SB, Black MH, Smith N, et al. Prevalence of polycystic ovary syndrome in adolescents. Fertility & Sterility. 2013;100(2):470-477. doi: 10.1016/j.fertnstert.2013.04.001",primary_citation,,Christensen SB,2013,"Christensen SB et al., 2013",10.1016/j.fertnstert.2013.04.001,,,,,Prevalence of polycystic ovary syndrome in adolescents,pmid:23756098,10.1016/j.fertnstert.2013.04.001
1.0,1.6,110,47.0,"Gabrielli L, Aquino EM. Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare. Reproductive Biology & Endocrinology. 2012;10:96. doi:10.1186/1477-7827-10-96",primary_citation,,Gabrielli L,2012,"Gabrielli L et al., 2012",10.1186/1477-7827-10-96,,,,,"Polycystic ovary syndrome in Salvador, Brazil: a prevalence study in primary healthcare",pmid:23173761,10.1186/1477-7827-10-96
1.0,1.6,111,47.0,"Greenwood EA, Yaffe K, Wellons MF, Cedars MI, Huddleston HG. Depression Over the Lifespan in a Population-Based Cohort of Women With Polycystic Ovary Syndrome: Longitudinal Analysis. Journal of Clinical Endocrinology & Metabolism. 2019;104(7):2809-2819. doi: 10.1210/jc.2019-00234",primary_citation,,Greenwood EA,2019,"Greenwood EA et al., 2019",10.1210/jc.2019-00234,,,,,Depression Over the Lifespan in a Population-Based Cohort of Women With Polycystic Ovary Syndrome: Longitudinal Analysis,pmid:30985868,10.1210/jc.2019-00234
1.0,1.6,112,47.0,"Guo L, Gordon NP, Chandra M, Dayo O, Lo JC. The Risks of Polycystic Ovary Syndrome and Diabetes Vary by Ethnic Subgroup Among Young Asian Women. Diabetes Care. 2021;44(6):e129-e130. doi: 10.2337/dc21-0373",primary_citation,,Guo L,2021,"Guo L et al., 2021",10.2337/dc21-0373,,,,,The Risks of Polycystic Ovary Syndrome and Diabetes Vary by Ethnic Subgroup Among Young Asian Women,pmid:33905346,10.2337/dc21-0373
1.0,1.6,113,47.0,"He Y, Tian J, Blizzard L, et al. Associations of childhood adiposity with menstrual irregularity and polycystic ovary syndrome in adulthood: the Childhood Determinants of Adult Health Study and the Bogalusa Heart Study. Human Reproduction. 2020;35(5):1185-1198.  doi:10.1093/humrep/deaa069",primary_citation,,He Y,2020,"He Y et al., 2020",10.1093/humrep/deaa069,,,,,Associations of childhood adiposity with menstrual irregularity and polycystic ovary syndrome in adulthood: the Childhood Determinants of Adult Health Study and the Bogalusa Heart Study,pmid:32344436,10.1093/humrep/deaa069
1.0,1.6,114,47.0,"Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Journal of Clinical Endocrinology & Metabolism. 1998;83(9):3078-3082. doi: 10.1210/jcem.83.9.5090",primary_citation,,Knochenhauer ES,1998,"Knochenhauer ES et al., 1998",10.1210/jcem.83.9.5090,,,,,Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study<sup>1</sup>,pmid:9745406,10.1210/jcem.83.9.5090
1.0,1.6,115,47.0,"Meyer ML, Sotres-Alvarez D, Steiner A, et al. Associations of self-reported polycystic ovary syndrome (PCOS), irregular menstrual cycles, and the metabolic syndrome in premenopausal hispanic/latina women in the hispanic community health study/study of latinos (HCHS/SOL). Journal of Women's Health. 2018;27(11):1425. doi: 10.1210/clinem/dgaa012 ",primary_citation,,Meyer ML,2018,"Meyer ML et al., 2018",10.1210/clinem/dgaa012,,,,,Polycystic Ovary Syndrome Signs and Metabolic Syndrome in Premenopausal Hispanic/Latina Women: the HCHS/SOL Study,pmid:31917455,10.1210/clinem/dgaa012
1.0,1.6,116,47.0,"Moran C, Tena G, Moran S, Ruiz P, Reyna R, Duque X. Prevalence of polycystic ovary syndrome and related disorders in mexican women. Gynecologic & Obstetric Investigation. 2010;69(4):274-280. doi: 10.1159/000277640 ",primary_citation,,Moran C,2010,"Moran C et al., 2010",10.1159/000277640,,,,,Prevalence of Polycystic Ovary Syndrome and Related Disorders in Mexican Women,pmid:20110726,10.1159/000277640
1.0,1.6,117,47.0,"Morrison JA, Glueck CJ, Daniels S, Wang P, Stroop D. Adolescent oligomenorrhea in a biracial schoolgirl cohort: a simple clinical parameter predicting impaired fasting glucose plus type 2 diabetes mellitus, insulin, glucose, insulin resistance, and centripetal obesity from age 19 to 25 years. Metabolism: Clinical & Experimental. 2011;60(9):1285-1293. doi: 10.1016/j.metabol.2011.01.012",primary_citation,,Morrison JA,2011,"Morrison JA et al., 2011",10.1016/j.metabol.2011.01.012,,,,,"Adolescent oligomenorrhea in a biracial schoolgirl cohort: a simple clinical parameter predicting impaired fasting glucose plus type 2 diabetes mellitus, insulin, glucose, insulin resistance, and centripetal obesity from age 19 to 25 years",pmid:21419463,10.1016/j.metabol.2011.01.012
1.0,1.6,118,47.0,"Wang ET, Calderon-Margalit R, Cedars MI, et al. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstetrics & Gynecology. 2011;117(1):6-13. doi:10.1097/AOG.0b013e31820209bb",primary_citation,,Wang ET,2011,"Wang ET et al., 2011",10.1097/aog.0b013e31820209bb,,,,,Polycystic Ovary Syndrome and Risk for Long-Term Diabetes and Dyslipidemia,pmid:21173640,10.1097/aog.0b013e31820209bb
1.0,1.6,119,47.0,"Deswal R, Dang AS, Nanda S. Prevalence of Poly Cystic Ovary Syndrome (PCOS) in North Indian women. Indian Journal of Health and Wellbeing. 2014;5(6):742-744.",primary_citation,,Deswal R,2014,"Deswal R et al., 2014",,,W2221924240,,Prevalence of Poly Cystic Ovary Syndrome (PCOS) in North Indian women,Prevalence of Poly Cystic Ovary Syndrome (PCOS) in North Indian Women,,
1.0,1.6,120,47.0,"Kaewnin J, Vallibhakara O, Arj-Ong Vallibhakara S, et al. Prevalence of polycystic ovary syndrome in Thai University adolescents. Gynecological Endocrinology. 2018;34(6):476-480. doi: 10.1080/09513590.2017.1409716",primary_citation,,Kaewnin J,2018,"Kaewnin J et al., 2018",10.1080/09513590.2017.1409716,,,,,Prevalence of polycystic ovary syndrome in Thai University adolescents,pmid:29202617,10.1080/09513590.2017.1409716
1.0,1.6,121,47.0,"Kumarapeli V, Seneviratne RDA, Wijeyaratne CN, Yapa RMSC, Dodampahala SH. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semiurban population in Sri Lanka. American Journal of Epidemiology. 2008;168(3):321-328. doi: 10.1093/aje/kwn137",primary_citation,,Kumarapeli V,2008,"Kumarapeli V et al., 2008",10.1093/aje/kwn137,,,,,A Simple Screening Approach for Assessing Community Prevalence and Phenotype of Polycystic Ovary Syndrome in a Semiurban Population in Sri Lanka,pmid:18550559,10.1093/aje/kwn137
1.0,1.6,122,47.0,"Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. Journal of Pediatric & Adolescent Gynecology. 2011;24(4):223-227. doi:10.1016/j.jpag.2011.03.002",primary_citation,,Nidhi R,2011,"Nidhi R et al., 2011",10.1016/j.jpag.2011.03.002,,,,,Prevalence of Polycystic Ovarian Syndrome in Indian Adolescents,pmid:21600812,10.1016/j.jpag.2011.03.002
1.0,1.6,123,47.0,"Vidya Bharathi R, Swetha S, Neerajaa J, et al. An epidemiological survey: Effect of predisposing factors for PCOS in Indian urban and rural population. Middle East Fertility Society Journal. 2017;22(4):313-316. doi: 10.1016/j.mefs.2017.05.007",primary_citation,,Vidya Bharathi R,2017,"Vidya Bharathi R et al., 2017",10.1016/j.mefs.2017.05.007,,,,,An epidemiological survey: Effect of predisposing factors for PCOS in Indian urban and rural population,,10.1016/j.mefs.2017.05.007
1.0,1.6,124,47.0,"Assens M, Dyre L, Henriksen LS, et al. Menstrual Pattern, Reproductive Hormones, and Transabdominal 3D Ultrasound in 317 Adolescent Girls. Journal of Clinical Endocrinology and Metabolism. 2020;105(9):E3257-E3266. doi:10.1210/clinem/dgaa355",primary_citation,,Assens M,2020,"Assens M et al., 2020",10.1210/clinem/dgaa355,,,,,"Menstrual Pattern, Reproductive Hormones, and Transabdominal 3D Ultrasound in 317 Adolescent Girls",pmid:32506132,10.1210/clinem/dgaa355
1.0,1.6,125,47.0,"Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. Journal of Clinical Endocrinology & Metabolism. 2000;85(7):2434-2438. doi: 10.1210/jcem.85.7.6682",primary_citation,,Asuncion M,2000,"Asuncion M et al., 2000",10.1210/jcem.85.7.6682,,,,,A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain1,pmid:10902790,10.1210/jcem.85.7.6682
1.0,1.6,126,47.0,"Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. Journal of Clinical Endocrinology & Metabolism. 1999;84(11):4006-4011. doi: 10.1210/jcem.84.11.6148",primary_citation,,Diamanti-Kandarakis E,1999,"Diamanti-Kandarakis E et al., 1999",10.1210/jcem.84.11.6148,,,,,A Survey of the Polycystic Ovary Syndrome in the Greek Island of Lesbos: Hormonal and Metabolic Profile,pmid:10566641,10.1210/jcem.84.11.6148
1.0,1.6,127,47.0,"Gambineri A, Fanelli F, Prontera O, et al. Prevalence of hyperandrogenic states in late adolescent and young women: epidemiological survey on italian high-school students. J Clin Endocrinol Metab. 2013;98(4):1641-1650. doi: 10.1210/jc.2012-3537",primary_citation,,Gambineri A,2013,"Gambineri A et al., 2013",10.1210/jc.2012-3537,,,,,Prevalence of Hyperandrogenic States in Late Adolescent and Young Women: Epidemiological Survey on Italian High-School Students,pmid:23436925,10.1210/jc.2012-3537
1.0,1.6,128,47.0,"Mumm H, Kamper-Jorgensen M, Nybo Andersen AM, Glintborg D, Andersen M. Birth weight and polycystic ovary syndrome in adult life: a register-based study on 523,757 Danish women born 1973-1991. Fertility & Sterility. 2013;99(3):777-782. doi: 10.1016/j.fertnstert.2012.11.004",primary_citation,,Mumm H,1973,"Mumm H et al., 1973",10.1016/j.fertnstert.2012.11.004,,,,,"Birth weight and polycystic ovary syndrome in adult life: a register-based study on 523,757 Danish women born 1973–1991",pmid:23200688,10.1016/j.fertnstert.2012.11.004
1.0,1.6,129,47.0,"Valgeirsdottir H, Vanky E, Sundstrom-Poromaa I, et al. Prenatal exposures and birth indices, and subsequent risk of polycystic ovary syndrome: a national registry-based cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. 2019;126(2):244-251. doi: 10.1111/1471-0528.15236",primary_citation,,Valgeirsdottir H,2019,"Valgeirsdottir H et al., 2019",10.1111/1471-0528.15236,,,,,"Prenatal exposures and birth indices, and subsequent risk of polycystic ovary syndrome: a national registry‐based cohort study",pmid:29896923,10.1111/1471-0528.15236
1.0,1.6,130,47.0,"Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Human Reproduction. 2012;27(10):3067-3073. doi:10.1093/humrep/des232",primary_citation,,Yildiz BO,2012,"Yildiz BO et al., 2012",10.1093/humrep/des232,,,,,"Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria",pmid:22777527,10.1093/humrep/des232
1.0,1.6,131,47.0,"Dargham SR, Ahmed L, Kilpatrick ES, Atkin SL. The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population. PLoS ONE [Electronic Resource]. 2017;12(7):e0181467. doi: 10.1371/journal.pone.0181467",primary_citation,,Dargham SR,2017,"Dargham SR et al., 2017",10.1371/journal.pone.0181467,,,,,The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population,pmid:28723965,10.1371/journal.pone.0181467
1.0,1.6,132,47.0,"Dargham SR, Shewehy AE, Dakroury Y, Kilpatrick ES, Atkin SL. Prediabetes and diabetes in a cohort of Qatari women screened for polycystic ovary syndrome. Scientific Reports. 2018;8(1):3619. doi: 10.1038/s41598-018-21987-6",primary_citation,,Dargham SR,2018,"Dargham SR et al., 2018",10.1038/s41598-018-21987-6,,,,,Prediabetes and diabetes in a cohort of Qatari women screened for polycystic ovary syndrome,pmid:29483674,10.1038/s41598-018-21987-6
1.0,1.6,133,47.0,"Esmaeilzadeh S, Delavar MA, Amiri M, Khafri S, Pasha NG. Polycystic ovary syndrome in Iranian adolescents. International Journal of Adolescent Medicine & Health. 2014;26(4):559-565. doi:  10.1515/ijamh-2013-03",primary_citation,,Esmaeilzadeh S,2014,"Esmaeilzadeh S et al., 2014",10.1515/ijamh-2013-0335,,,,,Polycystic ovary syndrome in Iranian adolescents,pmid:24447981,10.1515/ijamh-2013-0335
1.0,1.6,134,47.0,"Farhadi-Azar M, Behboudi-Gandevani S, Rahmati M, et al. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study. Frontiers in Endocrinology. 2022;13:825528. doi: 10.3389/fendo.2022.825528",primary_citation,,Farhadi-Azar M,2022,"Farhadi-Azar M et al., 2022",10.3389/fendo.2022.825528,,,,,"The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study",pmid:35299965,10.3389/fendo.2022.825528
1.0,1.6,135,47.0,"Mehrabian F, Khani B, Kelishadi R, Ghanbari E. The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynologia Polska. 2011;62(3):238-242. ",primary_citation,,Mehrabian F,2011,"Mehrabian F et al., 2011",,21717406.0,,,,The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria.,pmid:21717406,
1.0,1.6,136,47.0,"Musmar S, Afaneh A, Mo'alla H. Epidemiology of polycystic ovary syndrome: a cross sectional study of university students at An-Najah national university-Palestine. Reproductive Biology & Endocrinology. 2013;11:47. doi: 10.1186/1477-7827-11-47",primary_citation,,Musmar S,2013,"Musmar S et al., 2013",10.1186/1477-7827-11-47,,,,,Epidemiology of polycystic ovary syndrome: a cross sectional study of university students at An-Najah national university-Palestine,pmid:23688000,10.1186/1477-7827-11-47
1.0,1.6,137,47.0,"Pramodh S. Exploration of lifestyle choices, reproductive health knowledge, and polycystic ovary syndrome (Pcos) awareness among female emirati university students. International Journal of Women's Health. 2020;12:927-938. doi: 10.2147/IJWH.S272867",primary_citation,,Pramodh S. Exploration of lifestyle choices,2020,"Pramodh S. Exploration of lifestyle choices et al., 2020",10.2147/ijwh.s272867,,,,,"&lt;p&gt;Exploration of Lifestyle Choices, Reproductive Health Knowledge, and Polycystic Ovary Syndrome (PCOS) Awareness Among Female Emirati University Students&lt;/p&gt;",pmid:33149703,10.2147/ijwh.s272867
1.0,1.6,138,47.0,"Salehpour S, Shirvani HE, Entezari A. Evaluation of the prevalence of polycystic ovarian syndrome among adolescent (15-18 years old) girls in Tehran during 2005-2006. International Journal of Fertility and Sterility. 2010;4(3):122-127.",primary_citation,,Salehpour S,2005,"Salehpour S et al., 2005",10.22074/ijfs.2010.45808,,,,,Evaluation of the Prevalence of Polycystic Ovarian Syndrome among Adolescent (15-18 Years Old) Girls in Tehran during 2005-2006,,10.22074/ijfs.2010.45808
1.0,1.6,139,47.0,"Sharif E, Rahman S, Zia Y, Rizk NM. The frequency of polycystic ovary syndrome in young reproductive females in Qatar. Int J Womens Health. 2017;9:1-10. doi: 10.2147/IJWH.S120027",primary_citation,,Sharif E,2017,"Sharif E et al., 2017",10.2147/ijwh.s120027,,,,,The frequency of polycystic ovary syndrome in young reproductive females in Qatar,pmid:28031728,10.2147/ijwh.s120027
1.0,1.6,140,47.0,"Tehrani FR, Simbar M, Tohidi M, Hosseinpanah F, Azizi F. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reproductive Biology & Endocrinology. 2011;9:39. doi: 10.1186/1477-7827-9-144",primary_citation,,Tehrani FR,2011,"Tehrani FR et al., 2011",10.1186/1477-7827-9-144,,,,,The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study,pmid:22044512,10.1186/1477-7827-9-144
1.0,1.6,141,47.0,"Boyle JA, Cunningham J, O'Dea K, Dunbar T, Norman RJ. Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Medical Journal of Australia. 2012;196(1):62-66. doi: 10.5694/mja11.10553",primary_citation,,Boyle JA,2012,"Boyle JA et al., 2012",10.5694/mja11.10553,,,,,"Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia",pmid:22256938,10.5694/mja11.10553
1.0,1.6,142,47.0,"Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. European Journal of Obstetrics, Gynecology, & Reproductive Biology. 2008;139(1):59-64. doi: 10.1016/j.ejogrb.2007.12.018",primary_citation,,Chen X,2008,"Chen X et al., 2008",10.1016/j.ejogrb.2007.12.018,,,,,Prevalence of polycystic ovary syndrome in unselected women from southern China,pmid:18378061,10.1016/j.ejogrb.2007.12.018
1.0,1.6,143,47.0,"Dashti S, Latiffah Abdul L, Habibah Abdul H, et al. Prevalence of Polycystic Ovary Syndrome among Malaysian Female University Staff. Journal of Midwifery & Reproductive Health. 2019;7(1):1560-1568. doi: 10.22038/jmrh.2018.30370.1329",primary_citation,,Dashti S,2019,"Dashti S et al., 2019",10.22038/jmrh.2018.30370.1329,,,,,Prevalence of Polycystic Ovary Syndrome among Malaysian Female University Staff,,10.22038/jmrh.2018.30370.1329
1.0,1.6,144,47.0,"Davis SR, Knight S, White V, Claridge C, Davis BJ, Bell R. Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women. Gynecological Endocrinology. 2002;16(6):443-446. doi: 10.1080/gye.16.6.443.446",primary_citation,,Davis SR,2002,"Davis SR et al., 2002",10.1080/gye.16.6.443.446,,,,,Preliminary indication of a high prevalence of polycystic ovary syndrome in indigenous Australian women,pmid:12626030,10.1080/gye.16.6.443.446
1.0,1.6,145,47.0,"Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Human Reproduction. 2013;28(9):2562-2569. doi:10.1093/humrep/det262",primary_citation,,Li R,2013,"Li R et al., 2013",10.1093/humrep/det262,,,,,Prevalence of polycystic ovary syndrome in women in China: a large community-based study,pmid:23814096,10.1093/humrep/det262
1.0,1.6,146,47.0,"Jiao J, Fang Y, Wang T, Wang Z, Zhou M, Wang X. Epidemiologic investigation of polycystic ovarian syndrome (PCOS) in Han ethnic women of reproductive age in Liaoning Province, China. Clinical & Experimental Obstetrics & Gynecology. 2014;41(3):304-309. doi: 10.12891/ceog16282014",primary_citation,,Jiao J,2014,"Jiao J et al., 2014",10.12891/ceog16282014,,,,,"Epidemiologic investigation of polycystic ovarian syndrome (PCOS) in Han ethnic women of reproductive age in Liaoning Province, China",pmid:24992782,10.12891/ceog16282014
1.0,1.6,147,47.0,"Kim JH, Jung MH, Hong SH, Moon N, Kang DR. Age-Adjusted Prevalence and Characteristics of Women with Polycystic Ovarian Syndrome in Korea: A Nationwide Population-Based Study (2010-2019). Yonsei Medical Journal. 2022;63(8):794-798. doi: 10.3349/ymj.2022.63.8.794",primary_citation,,Kim JH,2010,"Kim JH et al., 2010",10.3349/ymj.2022.63.8.794,,,,,Age-Adjusted Prevalence and Characteristics of Women with Polycystic Ovarian Syndrome in Korea: A Nationwide Population-Based Study (2010–2019),pmid:35914763,10.3349/ymj.2022.63.8.794
1.0,1.6,148,47.0,"Maredia H, Hawley NL, Lambert-Messerlian G, et al. Reproductive health, obesity, and cardiometabolic risk factors among Samoan women. American Journal of Human Biology. 2018;30(3):e23106. doi:10.1002/ajhb.23106",primary_citation,,Maredia H,2018,"Maredia H et al., 2018",10.1002/ajhb.23106,,,,,"Reproductive health, obesity, and cardiometabolic risk factors among Samoan women",pmid:29663637,10.1002/ajhb.23106
1.0,1.6,149,47.0,"Min D, Jang IS, Park S. Preventive Behavior Intentions for Polycystic Ovary Syndrome in Young Students. Metabolic Syndrome & Related Disorders. 2022;20(5):273-279. doi: 10.1089/met.2021.0123",primary_citation,,Min D,2022,"Min D et al., 2022",10.1089/met.2021.0123,,,,,Preventive Behavior Intentions for Polycystic Ovary Syndrome in Young Students,pmid:35262419,10.1089/met.2021.0123
1.0,1.6,150,47.0,"Park YJ, Shin H, Jeon S, Cho I, Kim YJ. Menstrual Cycle Patterns and the Prevalence of Premenstrual Syndrome and Polycystic Ovary Syndrome in Korean Young Adult Women. Healthcare (Basel). 2021 Jan 7;9(1):56. doi: 10.3390/healthcare9010056. PMID: 33430265; PMCID: PMC7825721.",primary_citation,,Park YJ,2021,"Park YJ et al., 2021",10.3390/healthcare9010056,33430265.0,,,,Menstrual Cycle Patterns and the Prevalence of Premenstrual Syndrome and Polycystic Ovary Syndrome in Korean Young Adult Women,pmid:33430265,
1.0,1.6,151,47.0,"Yang R, Li Q, Zhou Z, et al. Changes in the prevalence of polycystic ovary syndrome in China over the past decade. Lancet Reg Health West Pac. 2022;25:100494. doi: 10.1016/j.lanwpc.2022.100494",primary_citation,,Yang R,2022,"Yang R et al., 2022",10.1016/j.lanwpc.2022.100494,,,,,Changes in the prevalence of polycystic ovary syndrome in China over the past decade,pmid:35669932,10.1016/j.lanwpc.2022.100494
1.0,1.6,152,47.0,"Zhuang J, Liu Y, Xu L, et al. Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China. Gynecologic & Obstetric Investigation. 2014;77(4):217-223. doi: 10.1159/000358485",primary_citation,,Zhuang J,2014,"Zhuang J et al., 2014",10.1159/000358485,,,,,"Prevalence of the Polycystic Ovary Syndrome in Female Residents of Chengdu, China",pmid:24751759,10.1159/000358485
1.0,1.8,153,20.0,"Berni TR, Morgan CL, Rees DA. Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study. J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3369-e3380. doi: 10.1210/clinem/dgab392. PMID: 34061968; PMCID: PMC8372630",primary_citation,,Berni TR,2021,"Berni TR et al., 2021",10.1210/clinem/dgab392,34061968.0,,,,Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study,pmid:34061968,
1.0,1.8,154,20.0,"Calderon-Margalit R, Siscovick D, Merkin SS, Wang E, Daviglus ML, Schreiner PJ, Sternfeld B, Williams OD, Lewis CE, Azziz R, Schwartz SM, Wellons MF. Prospective association of polycystic ovary syndrome with coronary artery calcification and carotid-intima-media thickness: the Coronary Artery Risk Development in Young Adults Women's study. Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2688-94. doi: 10.1161/ATVBAHA.114.304136. Epub 2014 Oct 30. PMID: 25359859.",primary_citation,,Calderon-Margalit R,2014,"Calderon-Margalit R et al., 2014",10.1161/atvbaha.114.304136,25359859.0,,,,Prospective Association of Polycystic Ovary Syndrome With Coronary Artery Calcification and Carotid-Intima-Media Thickness,pmid:25359859,
1.0,1.8,155,20.0,"Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod. 2000 Apr;15(4):785-9. doi: 10.1093/humrep/15.4.785. PMID: 10739820.",primary_citation,,Cibula D,2000,"Cibula D et al., 2000",10.1093/humrep/15.4.785,10739820.0,,,,"Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome",pmid:10739820,
1.0,1.8,156,20.0,"Ding DC, Tsai IJ, Wang JH, Lin SZ, Sung FC. Coronary artery disease risk in young women with polycystic ovary syndrome. Oncotarget. 2018 Jan 4;9(9):8756-8764. doi: 10.18632/oncotarget.23985. PMID: 29492235; PMCID: PMC5823557.",primary_citation,,Ding DC,2018,"Ding DC et al., 2018",10.18632/oncotarget.23985,29492235.0,,,,Coronary artery disease risk in young women with polycystic ovary syndrome,pmid:29492235,
1.0,1.8,157,20.0,"Forslund M, Schmidt J, Brännström M, Landin-Wilhelmsen K, Dahlgren E. Morbidity and mortality in PCOS: A prospective follow-up up to a mean age above 80 years. Eur J Obstet Gynecol Reprod Biol. 2022 Apr;271:195-203. doi: 10.1016/j.ejogrb.2022.02.020. Epub 2022 Feb 23. PMID: 35220175.",primary_citation,,Forslund M,2022,"Forslund M et al., 2022",10.1016/j.ejogrb.2022.02.020,35220175.0,,,,Morbidity and mortality in PCOS: A prospective follow-up up to a mean age above 80 years,pmid:35220175,
1.0,1.8,158,20.0,"Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol. 2018 Mar 8;17(1):37. doi: 10.1186/s12933-018-0680-5. PMID: 29519249; PMCID: PMC5844097.",primary_citation,,Glintborg D,2018,"Glintborg D et al., 2018",10.1186/s12933-018-0680-5,29519249.0,,,,Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome,pmid:29519249,
1.0,1.8,159,20.0,"Iftikhar S, Collazo-Clavell ML, Roger VL, St Sauver J, Brown RD Jr, Cha S, Rhodes DJ. Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med. 2012 Mar;70(2):74-80. PMID: 22418753; PMCID: PMC3582228.",primary_citation,,Iftikhar S,2012,"Iftikhar S et al., 2012",,22418753.0,,,,Risk of cardiovascular events in patients with polycystic ovary syndrome.,pmid:22418753,
1.0,1.8,160,20.0,"Lunde O, Tanbo T. Polycystic ovary syndrome: a follow-up study on diabetes mellitus, cardiovascular disease and malignancy 15-25 years after ovarian wedge resection. Gynecol Endocrinol. 2007 Dec;23(12):704-9. doi: 10.1080/09513590701705189. PMID: 18075845.",primary_citation,,Lunde O,2007,"Lunde O et al., 2007",10.1080/09513590701705189,18075845.0,,,,"Polycystic ovary syndrome: A follow-up study on diabetes mellitus, cardiovascular disease and malignancy 15–25 years after ovarian wedge resection",pmid:18075845,
1.0,1.8,161,20.0,"Mahboobifard F, Rahmati M, Niknam A, Rojhani E, Momenan AA, Azizi F, Ramezani Tehrani F. Impact of Polycystic Ovary Syndrome on Silent Coronary Artery Disease and Cardiovascular Events; A Long-term Population-based Cohort Study. Arch Med Res. 2022 Apr;53(3):312-322. doi: 10.1016/j.arcmed.2021.11.001. Epub 2021 Nov 22. PMID: 34823887.",primary_citation,,Mahboobifard F,2022,"Mahboobifard F et al., 2022",10.1016/j.arcmed.2021.11.001,34823887.0,,,,Impact of Polycystic Ovary Syndrome on Silent Coronary Artery Disease and Cardiovascular Events; A Long-term Population-based Cohort Study,pmid:34823887,
1.0,1.8,162,20.0,"Mani H, Levy MJ, Davies MJ, Morris DH, Gray LJ, Bankart J, Blackledge H, Khunti K, Howlett TA. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin Endocrinol (Oxf). 2013 Jun;78(6):926-34. doi: 10.1111/cen.12068. Epub 2013 Apr 6. PMID: 23046078.",primary_citation,,Mani H,2013,"Mani H et al., 2013",10.1111/cen.12068,23046078.0,,,,Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20‐year retrospective cohort study,pmid:23046078,
1.0,1.8,163,20.0,"Meun C, Franco OH, Dhana K, Jaspers L, Muka T, Louwers Y, Ikram MA, Fauser BCJM, Kavousi M, Laven JSE. High Androgens in Postmenopausal Women and the Risk for Atherosclerosis and Cardiovascular Disease: The Rotterdam Study. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1622-1630. doi: 10.1210/jc.2017-02421. PMID: 29408955.",primary_citation,,Meun C,2018,"Meun C et al., 2018",10.1210/jc.2017-02421,29408955.0,,,,High Androgens in Postmenopausal Women and the Risk for Atherosclerosis and Cardiovascular Disease: The Rotterdam Study,pmid:29408955,
1.0,1.8,164,20.0,"Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. J Clin Endocrinol Metab. 2012 Sep;97(9):3251-60. doi: 10.1210/jc.2012-1690. Epub 2012 Jul 5. PMID: 22767635.",primary_citation,,Morgan CL,2012,"Morgan CL et al., 2012",10.1210/jc.2012-1690,22767635.0,,,,"Evaluation of Adverse Outcome in Young Women with Polycystic Ovary Syndrome<i>Versus</i>Matched, Reference Controls: A Retrospective, Observational Study",pmid:22767635,
1.0,1.8,165,20.0,"Ollila ME, Kaikkonen K, Järvelin MR, Huikuri HV, Tapanainen JS, Franks S, Piltonen TT, Morin-Papunen L. Self-Reported Polycystic Ovary Syndrome Is Associated With Hypertension: A Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol Metab. 2019 Apr 1;104(4):1221-1231. doi: 10.1210/jc.2018-00570. PMID: 30445634; PMCID: PMC7296204.",primary_citation,,Ollila ME,1966,"Ollila ME et al., 1966",10.1210/jc.2018-00570,30445634.0,,,,Self-Reported Polycystic Ovary Syndrome Is Associated With Hypertension: A Northern Finland Birth Cohort 1966 Study,pmid:30445634,
1.0,1.8,166,20.0,"Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab. 2011 Dec;96(12):3794-803. doi: 10.1210/jc.2011-1677. Epub 2011 Sep 28. PMID: 21956415.",primary_citation,,Schmidt J,2011,"Schmidt J et al., 2011",10.1210/jc.2011-1677,21956415.0,,,,Cardiovascular Disease and Risk Factors in PCOS Women of Postmenopausal Age: A 21-Year Controlled Follow-Up Study,pmid:21956415,
1.0,1.8,167,20.0,"Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000 May;52(5):595-600. doi: 10.1046/j.1365-2265.2000.01000.x. PMID: 10792339.",primary_citation,,Wild S,2000,"Wild S et al., 2000",10.1046/j.1365-2265.2000.01000.x,10792339.0,,,,Cardiovascular disease in women with polycystic ovary syndrome at long‐term follow‐up: a retrospective cohort study,pmid:10792339,
1.0,1.8,168,20.0,"Bolijn R, Onland-Moret NC, Asselbergs FW, van der Schouw YT. Reproductive factors in relation to heart failure in women: A systematic review. Maturitas. 2017 Dec;106:57-72. doi: 10.1016/j.maturitas.2017.09.004. Epub 2017 Sep 9. PMID: 29150167.",primary_citation,SR,Bolijn R,2017,"Bolijn R et al., 2017",10.1016/j.maturitas.2017.09.004,29150167.0,,,,Reproductive factors in relation to heart failure in women: A systematic review,pmid:29150167,
1.0,1.8,169,20.0,"Helvaci N, Yildiz BO. Cardiovascular health and menopause in aging women with polycystic ovary syndrome. Expert Rev Endocrinol Metab. 2020 Jan;15(1):29-39. doi: 10.1080/17446651.2020.1719067. Epub 2020 Jan 28. PMID: 31990594.",primary_citation,SR,Helvaci N,2020,"Helvaci N et al., 2020",10.1080/17446651.2020.1719067,31990594.0,,,,Cardiovascular health and menopause in aging women with polycystic ovary syndrome,pmid:31990594,
1.0,1.8,170,20.0,"Ramezani Tehrani F, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2020 Jan;36(1):12-23. doi: 10.1080/09513590.2019.1650337. Epub 2019 Aug 6. PMID: 31385729.",primary_citation,SR,Ramezani Tehrani F,2020,"Ramezani Tehrani F et al., 2020",10.1080/09513590.2019.1650337,31385729.0,,,,Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis,pmid:31385729,
1.0,1.8,171,20.0,"Wekker V, van Dammen L, Koning A, Heida KY, Painter RC, Limpens J, Laven JSE, Roeters van Lennep JE, Roseboom TJ, Hoek A. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020 Nov 1;26(6):942-960. doi: 10.1093/humupd/dmaa029. PMID: 32995872; PMCID: PMC7600286.",primary_citation,SR,Wekker V,2020,"Wekker V et al., 2020",10.1093/humupd/dmaa029,32995872.0,,,,Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis,pmid:32995872,
1.0,1.8,172,20.0,"Glintborg D, Hass Rubin K, Nybo M, Abrahamsen B, Andersen M. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. Eur J Endocrinol. 2015 May;172(5):627-38. doi: 10.1530/EJE-14-1108. Epub 2015 Feb 5. PMID: 25656495.",primary_citation,prior search,Glintborg D,2015,"Glintborg D et al., 2015",10.1530/eje-14-1108,25656495.0,,,,Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome,pmid:25656495,
1.0,1.8,173,20.0,"Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod. 2003 Jul;18(7):1438-41. doi: 10.1093/humrep/deg289. PMID: 12832369.",primary_citation,prior search,Haakova L,2003,"Haakova L et al., 2003",10.1093/humrep/deg289,12832369.0,,,,Pregnancy outcome in women with PCOS and in controls matched by age and weight,pmid:12832369,
1.0,1.8,174,20.0,"Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage. J Clin Endocrinol Metab. 2015 Mar;100(3):911-9. doi: 10.1210/jc.2014-3886. Epub 2014 Dec 22. Erratum in: J Clin Endocrinol Metab. 2015 Jun;100(6):2502. PMID: 25532045.",primary_citation,prior search,Hart R,2015,"Hart R et al., 2015",10.1210/jc.2014-3886,25532045.0,,,,The Potential Implications of a PCOS Diagnosis on a Woman's Long-Term Health Using Data Linkage,pmid:25532045,
1.0,1.8,175,20.0,"Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Apr;91(4):1357-63. doi: 10.1210/jc.2005-2430. Epub 2006 Jan 24. PMID: 16434451.",primary_citation,prior search,Lo JC,2006,"Lo JC et al., 2006",10.1210/jc.2005-2430,16434451.0,,,,Epidemiology and Adverse Cardiovascular Risk Profile of Diagnosed Polycystic Ovary Syndrome,pmid:16434451,
1.0,1.8,176,20.0,"Merz CN, Shaw LJ, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-DeHoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. J Womens Health (Larchmt). 2016 Sep;25(9):875-81. doi: 10.1089/jwh.2015.5441. Epub 2016 Jun 6. PMID: 27267867; PMCID: PMC5311460.",primary_citation,prior search,Merz CN,2016,"Merz CN et al., 2016",10.1089/jwh.2015.5441,27267867.0,,,,Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome,pmid:27267867,
1.0,1.8,177,20.0,"Okoroh EM, Boulet SL, George MG, Craig Hooper W. Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome. Thromb Res. 2015 Dec;136(6):1165-8. doi: 10.1016/j.thromres.2015.10.022. Epub 2015 Oct 17. PMID: 26489726; PMCID: PMC4861991.",primary_citation,prior search,Okoroh EM,2015,"Okoroh EM et al., 2015",10.1016/j.thromres.2015.10.022,26489726.0,,,,"Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome",pmid:26489726,
1.0,1.8,178,20.0,"Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol. 1998 Jul;51(7):581-6. doi: 10.1016/s0895-4356(98)00035-3. PMID: 9674665.",primary_citation,prior search,Pierpoint T,1998,"Pierpoint T et al., 1998",10.1016/s0895-4356(98)00035-3,9674665.0,,,,Mortality of Women with Polycystic Ovary Syndrome at Long-term Follow-up,pmid:9674665,
1.0,1.8,179,20.0,"Polotsky AJ, Allshouse AA, Crawford SL, Harlow SD, Khalil N, Kazlauskaite R, Santoro N, Legro RS. Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. The Journal of Clinical Endocrinology & Metabolism. 2014 Jun 1;99(6):2120-7.",primary_citation,prior search,Polotsky AJ,2014,"Polotsky AJ et al., 2014",10.1210/jc.2013-4170,,,,,Hyperandrogenic Oligomenorrhea and Metabolic Risks Across Menopausal Transition,pmid:24517154,10.1210/jc.2013-4170
1.0,1.8,180,20.0,"Sirmans SM, Parish RC, Blake S, Wang X. Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population. J Investig Med. 2014 Aug;62(6):868-74. doi: 10.1097/01.JIM.0000446834.90599.5d. PMID: 24844662.",primary_citation,prior search,Sirmans SM,2014,"Sirmans SM et al., 2014",10.1097/01.jim.0000446834.90599.5d,24844662.0,,,,Epidemiology and Comorbidities of Polycystic Ovary Syndrome in an Indigent Population,pmid:24844662,
1.0,1.9.1,181,18.0,"Anagnostis, P. et al. Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies. Endocrine 74, 245-253, doi:https://dx.doi.org/10.1007/s12020-021-02801-2 (2021).",primary_citation,,Anagnostis,2021,"Anagnostis et al., 2021",10.1007/s12020-021-02801-2,,,,,Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies,pmid:34176074,10.1007/s12020-021-02801-2
1.0,1.9.1,182,18.0,"Begum, N., Arayousuf, N., Farooq, M. S., Chowdhury, M. A. K. & Ferdous, M. Association of Impaired Glucose Tolerance and Insulin Resistance in Women with Polycystic Ovary Syndrome. Bangladesh Journal of Obstetrics and Gynecology 34(2), 93-98, doi:https://dx.doi.org/10.3329/BJOG.V34I2.58273 (2019).",primary_citation,,Begum,2019,"Begum et al., 2019",10.3329/bjog.v34i2.58273,,,,,Association of Impaired Glucose Tolerance and Insulin Resistance in Women with Polycystic Ovary Syndrome,,10.3329/bjog.v34i2.58273
1.0,1.9.1,183,18.0,"Carmina, E., Nasrallah, M. P., Guastella, E. & Lobo, R. A. Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily. Clin Endocrinol (Oxf) 91, 553-560, doi:https://dx.doi.org/10.1111/cen.14063 (2019).",primary_citation,,Carmina,2019,"Carmina et al., 2019",10.1111/cen.14063,,,,,Characterization of metabolic changes in the phenotypes of women with polycystic ovary syndrome in a large Mediterranean population from Sicily,pmid:31306504,10.1111/cen.14063
1.0,1.9.1,184,18.0,"Dargham, S. R., Shewehy, A. E., Dakroury, Y., Kilpatrick, E. S. & Atkin, S. L. Prediabetes and diabetes in a cohort of Qatari women screened for polycystic ovary syndrome. Sci 8, 3619, doi:https://dx.doi.org/10.1038/s41598-018-21987-6 (2018).",primary_citation,,Dargham,2018,"Dargham et al., 2018",10.1038/s41598-018-21987-6,,,,,Prediabetes and diabetes in a cohort of Qatari women screened for polycystic ovary syndrome,pmid:29483674,10.1038/s41598-018-21987-6
1.0,1.9.1,185,18.0,"Forslund, M. et al. Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: Importance of obesity and abdominal fat distribution. Human Reproduction Open 2020(1) (no pagination), doi:https://dx.doi.org/10.1093/hropen/hoz042 (2020).",primary_citation,,Forslund,2020,"Forslund et al., 2020",10.1093/hropen/hoz042,,,,,Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution,pmid:31976382,10.1093/hropen/hoz042
1.0,1.9.1,186,18.0,"Fuad, Z. F. & Alobaidy, E. J. Association of hba1c levels with body mass index in a patient diagnosed with polycystic ovary syndrome. Indian Journal of Public Health Research and Development 9(7), 298-303, doi:https://dx.doi.org/10.5958/0976-5506.2018.00659.9 (2018).",primary_citation,,Fuad,2018,"Fuad et al., 2018",10.5958/0976-5506.2018.00659.9,,,,,Association of HbA1c Levels with Body Mass Index in a Patient Diagnosed with Polycystic Ovary Syndrome,,10.5958/0976-5506.2018.00659.9
1.0,1.9.1,187,18.0,"Kakoly, N. S. et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Human Reproduction Update 24, 455-467, doi:10.1093/humupd/dmy007 (2018).",primary_citation,,Kakoly,2018,"Kakoly et al., 2018",10.1093/humupd/dmy007,,,,,"Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression",pmid:29590375,10.1093/humupd/dmy007
1.0,1.9.1,188,18.0,"Kazemi Jaliseh, H. et al. Polycystic ovary syndrome is a risk factor for diabetes and prediabetes in middle-aged but not elderly women: a long-term population-based follow-up study. Fertility & Sterility 108, 1078-1084, doi:10.1016/j.fertnstert.2017.09.004 (2017).",primary_citation,,Kazemi Jaliseh,2017,"Kazemi Jaliseh et al., 2017",10.1016/j.fertnstert.2017.09.004,,,,,Polycystic ovary syndrome is a risk factor for diabetes and prediabetes in middle-aged but not elderly women: a long-term population-based follow-up study,pmid:29202960,10.1016/j.fertnstert.2017.09.004
1.0,1.9.1,189,18.0,"Kazemi, M. et al. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort. J Obstet Gynaecol Can 41, 1453-1460, doi:10.1016/j.jogc.2018.11.026 (2019).",primary_citation,,Kazemi,2018,"Kazemi et al., 2018",10.1016/j.jogc.2018.11.026,,,,,Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort,pmid:30712903,10.1016/j.jogc.2018.11.026
1.0,1.9.1,190,18.0,"Kiconco, S. et al. Natural history of polycystic ovary syndrome: A systematic review of cardiometabolic outcomes from longitudinal cohort studies. Clin Endocrinol (Oxf) 96, 475-498, doi:10.1111/cen.14647 (2022).",primary_citation,,Kiconco,2022,"Kiconco et al., 2022",10.1111/cen.14647,,,,,Natural history of polycystic ovary syndrome: A systematic review of cardiometabolic outcomes from longitudinal cohort studies,pmid:34894357,10.1111/cen.14647
1.0,1.9.1,191,18.0,"Liao, W. T., Huang, J. Y., Lee, M. T., Yang, Y. C. & Wu, C. C. Higher risk of type 2 diabetes in young women with polycystic ovary syndrome: A 10-year retrospective cohort study. World J Diabetes 13, 240-250, doi:10.4239/wjd.v13.i3.240 (2022).",primary_citation,,Liao,2022,"Liao et al., 2022",10.4239/wjd.v13.i3.240,,,,,Higher risk of type 2 diabetes in young women with polycystic ovary syndrome: A 10-year retrospective cohort study,pmid:35432752,10.4239/wjd.v13.i3.240
1.0,1.9.1,192,18.0,"Meun, C. et al. The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 92, 150-158, doi:10.1111/cen.14117 (2020).",primary_citation,,Meun,2020,"Meun et al., 2020",10.1111/cen.14117,,,,,The cardiovascular risk profile of middle‐aged women with polycystic ovary syndrome,pmid:31638273,10.1111/cen.14117
1.0,1.9.1,193,18.0,"Ng, N. Y. H. et al. Progression of glucose intolerance and cardiometabolic risk factors over a decade in Chinese women with polycystic ovary syndrome: A case-control study. PLoS Med 16, e1002953, doi:10.1371/journal.pmed.1002953 (2019).",primary_citation,,Ng,2019,"Ng et al., 2019",10.1371/journal.pmed.1002953,,,,,Progression of glucose intolerance and cardiometabolic risk factors over a decade in Chinese women with polycystic ovary syndrome: A case-control study,pmid:31652273,10.1371/journal.pmed.1002953
1.0,1.9.1,194,18.0,"Rubin, K. H., Glintborg, D., Nybo, M., Abrahamsen, B. & Andersen, M. Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 102, 3848-3857, doi:10.1210/jc.2017-01354 (2017).",primary_citation,,Rubin,2017,"Rubin et al., 2017",10.1210/jc.2017-01354,,,,,Development and Risk Factors of Type 2 Diabetes in a Nationwide Population of Women With Polycystic Ovary Syndrome,pmid:28938447,10.1210/jc.2017-01354
1.0,1.9.1,195,18.0,"Ryu, K. J. et al. Risk of type 2 diabetes is increased in nonobese women with polycystic ovary syndrome: the National Health Insurance Service-National Sample Cohort Study. Fertil Steril 115, 1569-1575, doi:10.1016/j.fertnstert.2020.12.018 (2021).",primary_citation,,Ryu,2020,"Ryu et al., 2020",10.1016/j.fertnstert.2020.12.018,,,,,Risk of type 2 diabetes is increased in nonobese women with polycystic ovary syndrome: the National Health Insurance Service-National Sample Cohort Study,pmid:33509630,10.1016/j.fertnstert.2020.12.018
1.0,1.9.1,196,18.0,"Vuguin, P. et al. Alterations in Glucose Effectiveness and Insulin Dynamics: Polycystic Ovary Syndrome or Body Mass Index. Horm Res Paediatr 87, 359-367, doi:10.1159/000471804 (2017).",primary_citation,,Vuguin,2017,"Vuguin et al., 2017",10.1159/000471804,,,,,Alterations in Glucose Effectiveness and Insulin Dynamics: Polycystic Ovary Syndrome or Body Mass Index,pmid:28478437,10.1159/000471804
1.0,1.9.1,197,18.0,"Wekker, V. et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update 26, 942-960, doi:10.1093/humupd/dmaa029 (2020).",primary_citation,,Wekker,2020,"Wekker et al., 2020",10.1093/humupd/dmaa029,,,,,Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis,pmid:32995872,10.1093/humupd/dmaa029
1.0,1.9.1,198,18.0,"Zhu, S. et al. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril 111, 168-177, doi:10.1016/j.fertnstert.2018.09.013 (2019).",primary_citation,,Zhu,2018,"Zhu et al., 2018",10.1016/j.fertnstert.2018.09.013,,,,,Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis,pmid:30611404,10.1016/j.fertnstert.2018.09.013
1.0,1.9.1,199,18.0,"Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006;166:2081–2086.",primary_citation,prior search,Alvarez-Blasco F,2006,"Alvarez-Blasco F et al., 2006",10.4183/aeb.2022.417,,,,,Prevalence and Characteristics of the Polycystic Ovarian Syndrome in Overweight and Obese Premenopausal Women,pmid:37152875,10.4183/aeb.2022.417
1.0,1.9.1,200,18.0,"Attaoua R, Ait El Mkadem S, Radian S, Fica S, Hanzu F, Albu A, Gheorghiu M, Coculescu M, Grigorescu F. FTO gene associates to metabolic syndrome in women with polycystic ovary syndrome. Biochem Biophys Res Commun 2008; 373:230–234.",primary_citation,prior search,Attaoua R,2008,"Attaoua R et al., 2008",10.1016/j.bbrc.2008.06.039,,,,,FTO gene associates to metabolic syndrome in women with polycystic ovary syndrome,pmid:18572014,10.1016/j.bbrc.2008.06.039
1.0,1.9.1,201,18.0,"Bhattacharya SM,. Polycystic ovary syndrome and abnormalities in glucose tolerance. Int J Gynaecol Obstet 2009;105:29–31.",primary_citation,prior search,Bhattacharya SM,2009,"Bhattacharya SM et al., 2009",10.1016/j.ijgo.2008.11.031,,,,,Polycystic ovary syndrome and abnormalities in glucose tolerance,pmid:19155002,10.1016/j.ijgo.2008.11.031
1.0,1.9.1,202,18.0,"Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr Diabetes Rev 2006;6:77–83.",primary_citation,prior search,Boudreaux MY,2006,"Boudreaux MY et al., 2006",10.1007/s11892-006-0056-1,,,,,Risk of T2DM and impaired fasting glucose among pcos subjects: Results of an 8-year follow-up,pmid:16522285,10.1007/s11892-006-0056-1
1.0,1.9.1,203,18.0,"Boyle JA, Cunningham J, Norman RJ, Dunbar T, O’Dea K. Polycystic ovary syndrome and metabolic syndrome in Indigenous Australian women. Intern Med J 2015;45:1247–1254.",primary_citation,prior search,Boyle JA,2015,"Boyle JA et al., 2015",10.1111/imj.12910,,,,,Polycystic ovary syndrome and metabolic syndrome in Indigenous Australian women,pmid:26387977,10.1111/imj.12910
1.0,1.9.1,204,18.0,"Celik C, Tasdemir N, Abali R, Bastu E, Yilmaz M. Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study. Fertility & Sterility 2014;101:1123–1128.e1121.",primary_citation,prior search,Celik C,2014,"Celik C et al., 2014",10.1016/j.fertnstert.2013.12.050,,,,,Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study,pmid:24502891,10.1016/j.fertnstert.2013.12.050
1.0,1.9.1,205,18.0,"Ciampelli M, Fulghesu AM, Murgia F, Guido M, Cucinelli F, Apa R, Caruso A, Lanzone A. Acute insulin response to intravenous glucagon in polycystic ovary syndrome. Hum Reprod 1998;13:847–851.",primary_citation,prior search,Ciampelli M,1998,"Ciampelli M et al., 1998",10.1093/humrep/13.4.847,,,,,Acute insulin response to intravenous glucagon in polycystic ovary syndrome,pmid:9619535,10.1093/humrep/13.4.847
1.0,1.9.1,206,18.0,"Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of noninsulin dependent diabetes mellitus, arterial hypertension, and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785–789.",primary_citation,prior search,Cibula D,2000,"Cibula D et al., 2000",10.1093/humrep/15.4.785,,,,,"Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome",pmid:10739820,10.1093/humrep/15.4.785
1.0,1.9.1,207,18.0,"Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol 2005;62:37–43.",primary_citation,prior search,Diamanti-Kandarakis E,2005,"Diamanti-Kandarakis E et al., 2005",10.1111/j.1365-2265.2004.02170.x,,,,,Increased levels of serum advanced glycation end‐products in women with polycystic ovary syndrome,pmid:15638868,10.1111/j.1365-2265.2004.02170.x
1.0,1.9.1,208,18.0,"Dos Reis RM, Foss MC, de Moura MD, Ferriani RA, Silva de Sá MF. Insulin secretion in obese and non-obese women with polycystic ovary syndrome and its relationship with hyperandrogenism. Gynecol Endocrinol 1995;9:45–50.",primary_citation,prior search,Dos Reis RM,1995,"Dos Reis RM et al., 1995",10.3109/09513599509160190,,,,,Insulin secretion in obese and non-obese women with polycystic ovary syndrome and its relationship with hyperandrogenism,pmid:7793299,10.3109/09513599509160190
1.0,1.9.1,209,18.0,"Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001;281:E392–E399.",primary_citation,prior search,Dunaif A,2001,"Dunaif A et al., 2001",10.1152/ajpendo.2001.281.2.e392,,,,,Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS),pmid:11440917,10.1152/ajpendo.2001.281.2.e392
1.0,1.9.1,210,18.0,"Echiburu B, Perez-Bravo F, Maliqueo M, Sanchez F, Crisosto N, Sir-Petermann T. Polymorphism T–C (−34 base pairs) of gene CYP17 promoter in women with polycystic ovary syndrome is associated with increased body weight and insulin resistance: a preliminary study. Metab Clin Exp 2008;57:1765–1771.",primary_citation,prior search,Echiburu B,2008,"Echiburu B et al., 2008",10.1016/j.metabol.2008.08.002,,,,,Polymorphism T → C (−34 base pairs) of gene CYP17 promoter in women with polycystic ovary syndrome is associated with increased body weight and insulin resistance: a preliminary study,pmid:19013303,10.1016/j.metabol.2008.08.002
1.0,1.9.1,211,18.0,"Faloia E, Canibus P, Gatti C, Frezza F, Santangelo M, Garrapa GG, Boscaro M. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest 2004;27:424–429.",primary_citation,prior search,Faloia E,2004,"Faloia E et al., 2004",10.1007/bf03345285,,,,,"Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome",pmid:15279073,10.1007/bf03345285
1.0,1.9.1,212,18.0,"Fulghesu A, Magnini R, Portoghese E, Angioni S, Minerba L, Melis GB. Obesityrelated lipid profile and altered insulin incretion in adolescents with polycystic ovary syndrome. J Adolesc Health 2010;46:474–481.",primary_citation,prior search,Fulghesu A,2010,"Fulghesu A et al., 2010",10.1016/j.jadohealth.2009.10.008,,,,,Obesity-Related Lipid Profile and Altered Insulin Incretion in Adolescents With Polycystic Ovary Syndrome,pmid:20413084,10.1016/j.jadohealth.2009.10.008
1.0,1.9.1,213,18.0,"Glintborg D, Hass Rubin K, Nybo M, Abrahamsen B, Andersen M. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. Eur J Endocrinol 2015;172:627–638.",primary_citation,prior search,Glintborg D,2015,"Glintborg D et al., 2015",10.1530/eje-14-1108,,,,,Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome,pmid:25656495,10.1530/eje-14-1108
1.0,1.9.1,214,18.0,"Hossain N, Stepanova M, Afendy A, Nader F, Younossi Y, Rafiq N, Goodman Z, Younossi ZM. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol 2011;46:479–484.",primary_citation,prior search,Hossain N,2011,"Hossain N et al., 2011",10.3109/00365521.2010.539251,,,,,Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS),pmid:21114431,10.3109/00365521.2010.539251
1.0,1.9.1,215,18.0,"Huang J, Ni R, Chen X, Huang L, Mo Y, Yang D. Metabolic abnormalities in adolescents with polycystic ovary syndrome in south China. Reprod Biol Endocrinol 2010;8:142.",primary_citation,prior search,Huang J,2010,"Huang J et al., 2010",10.1186/1477-7827-8-142,,,,,Metabolic abnormalities in adolescents with polycystic ovary syndrome in south china,pmid:21083920,10.1186/1477-7827-8-142
1.0,1.9.1,216,18.0,"Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Poromaa IS. Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome—a long term follow-up. Hum Reprod 2011; 26:1462–1468.",primary_citation,prior search,Hudecova M,2011,"Hudecova M et al., 2011",10.1093/humrep/der065,,,,,Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome--a long term follow-up,pmid:21427116,10.1093/humrep/der065
1.0,1.9.1,217,18.0,"Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005;90:3236–3242.",primary_citation,prior search,Legro RS,2005,"Legro RS et al., 2005",10.1210/jc.2004-1843,,,,,Changes in Glucose Tolerance over Time in Women with Polycystic Ovary Syndrome: A Controlled Study,pmid:15797965,10.1210/jc.2004-1843
1.0,1.9.1,218,18.0,"Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. Journal of Clinical Endocrinology & Metabolism 2006;91:1275–1283.",primary_citation,prior search,Leibel NI,2006,"Leibel NI et al., 2006",10.1210/jc.2005-1707,,,,,Relationship of Adolescent Polycystic Ovary Syndrome to Parental Metabolic Syndrome,pmid:16449341,10.1210/jc.2005-1707
1.0,1.9.1,219,18.0,"Lerchbaum E, Gruber HJ, Schwetz V, Giuliani A, Moller R, Pieber TR, ObermayerPietsch B. Fatty liver index in polycystic ovary syndrome. Eur J Endocrinol 2011; 165:935–943.",primary_citation,prior search,Lerchbaum E,2011,"Lerchbaum E et al., 2011",10.1530/eje-11-0614,,,,,Fatty liver index in polycystic ovary syndrome,pmid:21937505,10.1530/eje-11-0614
1.0,1.9.1,220,18.0,"Li L, Chen X, He Z, Zhao X, Huang L, Yang D. Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents. J Pediatr Adolesc Gynecol 2012;25:390–395.",primary_citation,prior search,Li L,2012,"Li L et al., 2012",10.1016/j.jpag.2012.07.006,,,,,Clinical and Metabolic Features of Polycystic Ovary Syndrome among Chinese Adolescents,pmid:23089573,10.1016/j.jpag.2012.07.006
1.0,1.9.1,221,18.0,"Liang SJ, Liou TH, Lin HW, Hsu CS, Tzeng CR, Hsu MI. Obesity is the predominant predictor of impaired glucose tolerance and metabolic disturbance in polycystic ovary syndrome. Acta Obstetricia et Gynecologica Scandinavica 2012;91:1167–1172.",primary_citation,prior search,Liang SJ,2012,"Liang SJ et al., 2012",10.1111/j.1600-0412.2012.01417.x,,,,,Obesity is the predominant predictor of impaired glucose tolerance and metabolic disturbance in polycystic ovary syndrome,pmid:22497305,10.1111/j.1600-0412.2012.01417.x
1.0,1.9.1,222,18.0,"Marquez JL, Pacheco A, Valdes P, Salazar LA. Association between CAPN10 UCSNP-43 gene polymorphism and polycystic ovary syndrome in Chilean women. Clin Chim Acta 2008;398:5–9.",primary_citation,prior search,Marquez JL,2008,"Marquez JL et al., 2008",10.1016/j.cca.2008.07.028,,,,,Association between CAPN10 UCSNP-43 gene polymorphism and polycystic ovary syndrome in Chilean women,pmid:18722363,10.1016/j.cca.2008.07.028
1.0,1.9.1,223,18.0,"Moini A, Eslami B. Familial associations between polycystic ovarian syndrome and common diseases. J Assist Reprod Genet 2009;26:123–127.",primary_citation,prior search,Moini A,2009,"Moini A et al., 2009",10.1007/s10815-009-9297-7,,,,,Familial associations between polycystic ovarian syndrome and common diseases,pmid:19205868,10.1007/s10815-009-9297-7
1.0,1.9.1,224,18.0,"Nur MM, Newman IM, Siqueira LM. Glucose metabolism in overweight Hispanic adolescents with and without polycystic ovary syndrome. Pediatrics 2009;124: e496–e502.",primary_citation,prior search,Nur MM,2009,"Nur MM et al., 2009",10.1542/peds.2008-2050,,,,,Glucose Metabolism in Overweight Hispanic Adolescents With and Without Polycystic Ovary Syndrome,pmid:19706563,10.1542/peds.2008-2050
1.0,1.9.1,225,18.0,"Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Prevalence of polycystic ovary syndrome among the privately insured, United States, 2003-2008. American Journal of Obstetrics & Gynecology 2012;207:299.e291–299.e297.",primary_citation,prior search,Okoroh EM,2003,"Okoroh EM et al., 2003",10.1016/j.ajog.2012.07.023,,,,,"Prevalence of polycystic ovary syndrome among the privately insured, United States, 2003-2008",pmid:22921097,10.1016/j.ajog.2012.07.023
1.0,1.9.1,226,18.0,"Ozegowska K, Pawelczyk L. Cardiometabolic risk in patients with polycystic ovary syndrome. Gineko Pol 2015;86:840–848.",primary_citation,prior search,Ozegowska K,2015,"Ozegowska K et al., 2015",10.17772/gp/59131,,,,,Cardiometabolic risk in patients with polycystic ovary syndrome.,pmid:26817316,10.17772/gp/59131
1.0,1.9.1,227,18.0,"Phy JL, Conover CA, Abbott DH, Zschunke MA, Walker DL, Session DR, Tummon IS, Thornhill AR, Lesnick TG, Dumesic DA. Insulin and messenger ribonucleic acid expression of insulin receptor isoforms in ovarian follicles from nonhirsute ovulatory women and polycystic ovary syndrome patients. J Clin Endocrinol Metab 2004; 89:3561–3566.",primary_citation,prior search,Phy JL,2004,"Phy JL et al., 2004",10.1210/jc.2003-031888,,,,,Insulin and Messenger Ribonucleic Acid Expression of Insulin Receptor Isoforms in Ovarian Follicles from Nonhirsute Ovulatory Women and Polycystic Ovary Syndrome Patients,pmid:15240646,10.1210/jc.2003-031888
1.0,1.9.1,228,18.0,"Rajkhowa M, Talbot JA, Jones PW, Clayton RN. Polymorphism of glycogen synthetase gene in polycystic ovary syndrome. Clin Endocrinol 1996;44:85–90.",primary_citation,prior search,Rajkhowa M,1996,"Rajkhowa M et al., 1996",10.1046/j.1365-2265.1996.658474.x,,,,,Polymorphism of glycogen synthetase gene in polycystic ovary syndrome,pmid:8706299,10.1046/j.1365-2265.1996.658474.x
1.0,1.9.1,229,18.0,"Sawathiparnich P, Weerakulwattana L, Santiprabhob J, Likitmaskul S. Obese adolescent girls with polycystic ovary syndrome (PCOS) have more severe insulin resistance measured by HOMA-IR score than obese girls without PCOS. Journal of the Medical Association of Thailand 2005;88 Suppl 8:S33–S37.",primary_citation,prior search,Sawathiparnich P,2005,"Sawathiparnich P et al., 2005",,,W96216759,23693651.0,Obese adolescent girls with polycystic ovary syndrome (PCOS) have more severe insulin resistance measured by HOMA-IR score than obese girls without PCOS,Obese adolescent girls with polycystic ovary syndrome (PCOS) have more severe insulin resistance measured by HOMA-IR score than obese girls without PCOS.,pmid:16856423,
1.0,1.9.1,230,18.0,"Sir-Petermann T, Angel B, Maliqueo M, Santos JL, Riesco MV, Toloza H, PerezBravo F. Insulin secretion in women who have polycystic ovary syndrome and carry the Gly972Arg variant of insulin receptor substrate-1 in response to a high-glycemic or low-glycemic carbohydrate load. Nutrition 2004;20:905–910.",primary_citation,prior search,Sir-Petermann T,2004,"Sir-Petermann T et al., 2004",10.1016/j.nut.2004.08.017,,,,,Insulin secretion in women who have polycystic ovary syndrome and carry the Gly972Arg variant of insulin receptor substrate-1 in response to a high-glycemic or low-glycemic carbohydrate load,pmid:15474880,10.1016/j.nut.2004.08.017
1.0,1.9.1,231,18.0,"Valderhaug TG, Hertel JK, Nordstrand N, Dale PO, Hofso D, Hjelmesaeth J. The association between hyperandrogenemia and the metabolic syndrome in morbidly obese women. Diabetol Metab Syndr 2015;7:46.",primary_citation,prior search,Valderhaug TG,2015,"Valderhaug TG et al., 2015",10.1186/s13098-015-0040-5,,,,,The association between hyperandrogenemia and the metabolic syndrome in morbidly obese women,pmid:26015809,10.1186/s13098-015-0040-5
1.0,1.9.1,232,18.0,"Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A. Diastolic dysfunction, and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001;76:511–516.",primary_citation,prior search,Yarali H,2001,"Yarali H et al., 2001",10.1016/s0015-0282(01)01937-9,,,,,Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome,pmid:11532474,10.1016/s0015-0282(01)01937-9
1.0,1.9.1,233,18.0,"Zhao X, Zhong J, Mo Y, Chen X, Chen Y, Yang D. Association of biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese women with polycystic ovary syndrome. Int J Gynaecol Obstet 2010; 108:148–151.",primary_citation,prior search,Zhao X,2010,"Zhao X et al., 2010",10.1016/j.ijgo.2009.09.021,,,,,Association of biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese women with polycystic ovary syndrome,pmid:19932893,10.1016/j.ijgo.2009.09.021
1.0,1.9.1,234,18.0,"Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929–1935.",primary_citation,prior search,Apridonidze T,2005,"Apridonidze T et al., 2005",10.1210/jc.2004-1045,15623819.0,,,,Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome,pmid:15623819,
1.0,1.9.2,235,6.0,"Altemimi MT, Musa AK, Mansour AA. The Performance of Glycated Hemoglobin vs. Oral Glucose Tolerance Test in the Diagnosis of Glycemic Disorders among Women with Polycystic Ovary Syndrome in Southern Iraq. The Indonesian Biomedical Journal. 2021 Jun 14;13(2):178-85.",primary_citation,,Altemimi MT,2021,"Altemimi MT et al., 2021",10.1210/jendso/bvab048.891,,,,,The Performance of Glycated Hemoglobin Versus Oral Glucose Tolerance Test in the Diagnosis of Glycemic Disorders Among Women With Polycystic Ovary Syndrome in Southern Iraq,,10.1210/jendso/bvab048.891
1.0,1.9.2,236,6.0,"Ortiz-Flores AE, Luque-Ramírez M, Fernández-Durán E, Alvarez-Blasco F, Escobar-Morreale HF. Diagnosis of disorders of glucose tolerance in women with polycystic ovary syndrome (PCOS) at a tertiary care center: fasting plasma glucose or oral glucose tolerance test? Metabolism. 2019 Apr;93:86-92. doi: 10.1016/j.metabol.2019.01.015. Epub 2019 Jan 30. PMID: 30710572.",primary_citation,,Ortiz-Flores AE,2019,"Ortiz-Flores AE et al., 2019",10.1016/j.metabol.2019.01.015,30710572.0,,,,Diagnosis of disorders of glucose tolerance in women with polycystic ovary syndrome (PCOS) at a tertiary care center: fasting plasma glucose or oral glucose tolerance test?,pmid:30710572,
1.0,1.9.2,237,6.0,"Lerchbaum E, Schwetz V, Giuliani A, Obermayer-Pietsch B. Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method. Human Reproduction. 2013 Sep 1;28(9):2537-44.",primary_citation,,Lerchbaum E,2013,"Lerchbaum E et al., 2013",10.1093/humrep/det255,,,,,Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method,pmid:23756702,10.1093/humrep/det255
1.0,1.9.2,238,6.0,"Li HW, Lam KS, Tam S, Lee VC, Yeung TW, Cheung PT, Yeung WS, Ho PC, Ng EH Screening for dysglycaemia by oral glucose tolerance test should be recommended in all women with polycystic ovary syndrome. Human Reproduction. 2015 Sep 1;30(9):2178-83.",primary_citation,,Li HW,2015,"Li HW et al., 2015",10.1093/humrep/dev166,,,,,Screening for dysglycaemia by oral glucose tolerance test should be recommended in all women with polycystic ovary syndrome,pmid:26202923,10.1093/humrep/dev166
1.0,1.9.2,239,6.0,"Magnussen LV, Mumm H, Andersen M, Glintborg D. Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome. Fertility and sterility. 2011 Nov 1;96(5):1275-80.",primary_citation,,Magnussen LV,2011,"Magnussen LV et al., 2011",10.1016/j.fertnstert.2011.08.035,,,,,Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome,pmid:21982282,10.1016/j.fertnstert.2011.08.035
1.0,1.9.2,240,6.0,"Zhen Y, Yang P, Dong R, Wu Y, Sang Y, Du X, Wang Y, Song Q, Yu L, Rao X. Effect of HbA1C detection on the diagnostic screening for glucose metabolic disorders in polycystic ovary syndrome. Clinical and Experimental Obstetrics & Gynecology. 2014 Feb 10;41(1):58-61.",primary_citation,,Zhen Y,2014,"Zhen Y et al., 2014",10.12891/ceog16312014,,,,,Effect of HbA1C detection on the diagnostic screening for glucose metabolic disorders in polycystic ovary syndrome,pmid:24707685,10.12891/ceog16312014
1.0,1.10.,241,10.0,"de Sousa G, Schlüter B, Menke T, Trowitzsch E, Andler W, Reinehr T. Relationships between polysomnographic variables, parameters of glucose metabolism, and serum androgens in obese adolescents with polycystic ovarian syndrome. J Sleep Res. 2011 Sep;20(3):472-8. doi: 10.1111/j.1365-2869.2010.00902.x. Epub 2010 Dec 29. PMID: 21199038.",primary_citation,,de Sousa G,2011,"de Sousa G et al., 2011",10.1111/j.1365-2869.2010.00902.x,21199038.0,,,,"Relationships between polysomnographic variables, parameters of glucose metabolism, and serum androgens in obese adolescents with polycystic ovarian syndrome",pmid:21199038,
1.0,1.10.,242,10.0,"Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001 Mar;86(3):1175-80. doi: 10.1210/jcem.86.3.7316. PMID: 11238505.",primary_citation,,Fogel RB,2001,"Fogel RB et al., 2001",10.1210/jcem.86.3.7316,11238505.0,,,,Increased Prevalence of Obstructive Sleep Apnea Syndrome in Obese Women with Polycystic Ovary Syndrome<sup>1</sup>,pmid:11238505,
1.0,1.10.,243,10.0,"Hachul H, Polesel DN, Tock L, Carneiro G, Pereira AZ, Zanella MT, Tufik S, Togeiro SM. Sleep disorders in polycystic ovary syndrome: influence of obesity and hyperandrogenism. Rev Assoc Med Bras (1992). 2019 Mar;65(3):375-383. doi: 10.1590/1806-9282.65.3.375. Epub 2019 Apr 11. PMID: 30994836.",primary_citation,,Hachul H,1992,"Hachul H et al., 1992",10.1590/1806-9282.65.3.375,30994836.0,,,,Sleep disorders in polycystic ovary syndrome: influence of obesity and hyperandrogenism,pmid:30994836,
1.0,1.10.,244,10.0,"Helvaci N, Karabulut E, Demir AU, Yildiz BO. Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature. Endocr Connect. 2017 Oct;6(7):437-445. doi: 10.1530/EC-17-0129. Epub 2017 Jul 24. PMID: 28739562; PMCID: PMC5574283.",primary_citation,,Helvaci N,2017,"Helvaci N et al., 2017",10.1530/ec-17-0129,28739562.0,,,,Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature,pmid:28739562,
1.0,1.10.,245,10.0,"Nandalike K, Agarwal C, Strauss T, Coupey SM, Isasi CR, Sin S, Arens R. Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome. Sleep Med. 2012 Dec;13(10):1307-12. doi: 10.1016/j.sleep.2012.07.002. Epub 2012 Aug 23. PMID: 22921588; PMCID: PMC3509263..",primary_citation,,Nandalike K,2012,"Nandalike K et al., 2012",10.1016/j.sleep.2012.07.002,22921588.0,,,,Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome,pmid:22921588,
1.0,1.10.,246,10.0,"Suri J, Suri JC, Chatterjee B, Mittal P, Adhikari T. Obesity may be the common pathway for sleep-disordered breathing in women with polycystic ovary syndrome. Sleep Med. 2016 Aug;24:32-39. doi: 10.1016/j.sleep.2016.02.014. Epub 2016 Aug 16. PMID: 27810183.",primary_citation,,Suri J,2016,"Suri J et al., 2016",10.1016/j.sleep.2016.02.014,27810183.0,,,,Obesity may be the common pathway for sleep-disordered breathing in women with polycystic ovary syndrome,pmid:27810183,
1.0,1.10.,247,10.0,"Tasali E, Van Cauter E, Hoffman L, Ehrmann DA. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 Oct;93(10):3878-84. doi: 10.1210/jc.2008-0925. Epub 2008 Jul 22. PMID: 18647805; PMCID: PMC2579653.",primary_citation,,Tasali E,2008,"Tasali E et al., 2008",10.1210/jc.2008-0925,18647805.0,,,,Impact of Obstructive Sleep Apnea on Insulin Resistance and Glucose Tolerance in Women with Polycystic Ovary Syndrome,pmid:18647805,
1.0,1.10.,248,10.0,"Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001 Feb;86(2):517-20. doi: 10.1210/jcem.86.2.7185. PMID: 11158002.",primary_citation,,Vgontzas AN,2001,"Vgontzas AN et al., 2001",10.1210/jcem.86.2.7185,11158002.0,,,,Polycystic Ovary Syndrome Is Associated with Obstructive Sleep Apnea and Daytime Sleepiness: Role of Insulin Resistance<sup>1</sup>,pmid:11158002,
1.0,1.10.,249,10.0,"Yang HP, Kang JH, Su HY, Tzeng CR, Liu WM, Huang SY. Apnea-hypopnea index in nonobese women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2009 Jun;105(3):226-9. doi: 10.1016/j.ijgo.2009.02.004. Epub 2009 Apr 5. PMID: 19345941.",primary_citation,,Yang HP,2009,"Yang HP et al., 2009",10.1016/j.ijgo.2009.02.004,19345941.0,,,,Apnea–hypopnea index in nonobese women with polycystic ovary syndrome,pmid:19345941,
1.0,1.10.,250,10.0,"Kahal H, Kyrou I, Uthman OA, Brown A, Johnson S, Wall PDH, Metcalfe A, Parr DG, Tahrani AA, Randeva HS. The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome: a systematic review and meta-analysis. Sleep Breath. 2020 Mar;24(1):339-350. doi: 10.1007/s11325-019-01835-1. Epub 2019 May 20. PMID: 31111411; PMCID: PMC7127997.",primary_citation,,Kahal H,2020,"Kahal H et al., 2020",10.1007/s11325-019-01835-1,31111411.0,,,,The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome: a systematic review and meta-analysis,pmid:31111411,
1.0,1.11,251,23.0,"Aldarazi K, Omran H, Jassim NM. Endometrial hyperplasia in asymptomatic subfertile population. J Gynecol Obstet Hum Reprod. 2022 Apr;51(4):102337. doi: 10.1016/j.jogoh.2022.102337. Epub 2022 Feb 10. PMID: 35151930.",primary_citation,,Aldarazi K,2022,"Aldarazi K et al., 2022",10.1016/j.jogoh.2022.102337,35151930.0,,,,Endometrial hyperplasia in asymptomatic subfertile population,pmid:35151930,
1.0,1.11,252,23.0,"Beavis AL, Najjar O, Cheskin LJ, Mangal R, Rositch AF, Langham G, Fader AN. Prevalence of endometrial cancer symptoms among overweight and obese women presenting to a multidisciplinary weight management center. Gynecol Oncol Rep. 2020 Sep 11;34:100643. doi: 10.1016/j.gore.2020.100643. PMID: 32995455; PMCID: PMC7502818.",primary_citation,,Beavis AL,2020,"Beavis AL et al., 2020",10.1016/j.gore.2020.100643,32995455.0,,,,Prevalence of endometrial cancer symptoms among overweight and obese women presenting to a multidisciplinary weight management center,pmid:32995455,
1.0,1.11,253,23.0,"Ding DC, Chen W, Wang JH, Lin SZ. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: A population-based cohort study in Taiwan. Medicine (Baltimore). 2018 Sep;97(39):e12608. doi: 10.1097/MD.0000000000012608. ",primary_citation,,Ding DC,2018,"Ding DC et al., 2018",10.1097/md.0000000000012608,,,,,"Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer",pmid:30278576,10.1097/md.0000000000012608
1.0,1.11,254,23.0,"Elfayomy AK, Soliman BS. Risk Factors Associated with the Malignant Changes of Symptomatic and Asymptomatic Endometrial Polyps in Premenopausal Women. J Obstet Gynaecol India. 2015 May;65(3):186-92. doi: 10.1007/s13224-014-0576-6. Epub 2014 Jun 1. PMID: 26085741; PMCID: PMC4464569.",primary_citation,,Elfayomy AK,2015,"Elfayomy AK et al., 2015",10.1007/s13224-014-0576-6,26085741.0,,,,Risk Factors Associated with the Malignant Changes of Symptomatic and Asymptomatic Endometrial Polyps in Premenopausal Women,pmid:26085741,
1.0,1.11,255,23.0,"Escobedo LG, Lee NC, Peterson HB, Wingo PA. Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. Obstet Gynecol. 1991 Jan;77(1):124-8. PMID: 1984211.",primary_citation,,Escobedo LG,1991,"Escobedo LG et al., 1991",10.1016/0020-7292(91)90508-3,1984211.0,,,,Infertility‐associated endometrial cancer risk may be limited to specific subgroups of infertile women,pmid:1984211,
1.0,1.11,256,23.0,"Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM; Australian Ovarian Cancer Study Group and Australian National Endometrial Cancer Study Group. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control. 2010 Dec;21(12):2303-8. doi: 10.1007/s10552-010-9658-7. Epub 2010 Oct 17. PMID: 20953904.",primary_citation,,Fearnley EJ,2010,"Fearnley EJ et al., 2010",10.1007/s10552-010-9658-7,20953904.0,,,,Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case–control study,pmid:20953904,
1.0,1.11,257,23.0,"Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol. 2015 Jan;136(1):99-103. doi: 10.1016/j.ygyno.2014.11.012. Epub 2014 Nov 20. PMID: 25451694.",primary_citation,,Gottschau M,2015,"Gottschau M et al., 2015",10.1016/j.ygyno.2014.11.012,25451694.0,,,,Risk of cancer among women with polycystic ovary syndrome: A Danish cohort study,pmid:25451694,
1.0,1.11,258,23.0,"Hachisuga T, Fukuda K, Iwasaka T, Hirakawa T, Kawarabayashi T, Tsuneyoshi M. Endometrioid adenocarcinomas of the uterine corpus in women younger than 50 years of age can be divided into two distinct clinical and pathologic entities based on anatomic location. Cancer. 2001 Nov 15;92(10):2578-84. doi: 10.1002/1097-0142(20011115)92:10<2578::aid-cncr1610>3.0.co;2-v. PMID: 11745192.",primary_citation,,Hachisuga T,2001,"Hachisuga T et al., 2001",10.1002/1097-0142(20011115)92:10<2578::aid-cncr1610>3.0.co;2-v,11745192.0,,,,Endometrioid adenocarcinomas of the uterine corpus in women younger than 50 years of age can be divided into two distinct clinical and pathologic entities based on anatomic location,pmid:11745192,
1.0,1.11,259,23.0,"Ho SP, Tan KT, Pang MW, Ho TH. Endometrial hyperplasia and the risk of endometrial carcinoma. Singapore Med J. 1997 Jan;38(1):11-5. PMID: 9269346.",primary_citation,,Ho SP,1997,"Ho SP et al., 1997",,9269346.0,,,,Endometrial hyperplasia and the risk of endometrial carcinoma.,pmid:9269346,
1.0,1.11,260,23.0,"Iatrakis G, Zervoudis S, Saviolakis A, et al. Women younger than 50 years with endometrial cancer. Eur J Gynaecol Oncol 2006; 27: 399–400.  ",primary_citation,,Iatrakis G,2006,"Iatrakis G et al., 2006",,17009635.0,,23955757.0,,Women younger than 50 years with endometrial cancer.,pmid:17009635,
1.0,1.11,261,23.0,"Kilicdag EB, Haydardedeoglu B, Cok T, Parlakgumus AH, Simsek E, Bolat FA. Polycystic ovary syndrome and increased polyp numbers as risk factors for malignant transformation of endometrial polyps in premenopausal women. Int J Gynaecol Obstet. 2011 Mar;112(3):200-3. doi: 10.1016/j.ijgo.2010.10.014. Epub 2011 Jan 17. PMID: 21247566.",primary_citation,,Kilicdag EB,2011,"Kilicdag EB et al., 2011",10.1016/j.ijgo.2010.10.014,21247566.0,,,,Polycystic ovary syndrome and increased polyp numbers as risk factors for malignant transformation of endometrial polyps in premenopausal women,pmid:21247566,
1.0,1.11,262,23.0,"Okamura Y, Saito F, Takaishi K, Motohara T, Honda R, Ohba T, Katabuchi H. Polycystic ovary syndrome: early diagnosis and intervention are necessary for fertility preservation in young women with endometrial cancer under 35 years of age. Reprod Med Biol. 2016 Dec 5;16(1):67-71. doi: 10.1002/rmb2.12012. PMID: 29259453; PMCID: PMC5715875.",primary_citation,,Okamura Y,2016,"Okamura Y et al., 2016",10.1002/rmb2.12012,29259453.0,,,,Polycystic ovary syndrome: early diagnosis and intervention are necessary for fertility preservation in young women with endometrial cancer under 35 years of age,pmid:29259453,
1.0,1.11,263,23.0,"Pillay OC, Te Fong LF, Crow JC, Benjamin E, Mould T, Atiomo W, Menon PA, Leonard AJ, Hardiman P. The association between polycystic ovaries and endometrial cancer. Hum Reprod. 2006 Apr;21(4):924-9. doi: 10.1093/humrep/dei420. Epub 2005 Dec 16. ",primary_citation,,Pillay OC,2006,"Pillay OC et al., 2006",10.1093/humrep/dei420,,,,,The association between polycystic ovaries and endometrial cancer,pmid:16361289,10.1093/humrep/dei420
1.0,1.11,264,23.0,"Rosen, Monica W., Tasset, Julia, Kobernik, Emily K., Smith, Yolanda R., Johnston, Carolyn, & Quint, Elisabeth H. (2019). Risk Factors for Endometrial Cancer or Hyperplasia in Adolescents and Women 25 Years Old or Younger. Journal of Pediatric & Adolescent Gynecology, 32(5), 546- 549. ",primary_citation,,Rosen,2019,"Rosen et al., 2019",10.1016/j.jpag.2019.06.004,,,,,Risk Factors for Endometrial Cancer or Hyperplasia in Adolescents and Women 25 Years Old or Younger,pmid:31226466,10.1016/j.jpag.2019.06.004
1.0,1.11,265,23.0,"Shu XO, Brinton LA, Zheng W, Gao YT, Fan J, Fraumeni JF Jr. A population-based case-control study of endometrial cancer in Shanghai, China. Int J Cancer. 1991 Aug 19;49(1):38-43. doi: 10.1002/ijc.2910490108. PMID: 1874568.",primary_citation,,Shu XO,1991,"Shu XO et al., 1991",10.1002/ijc.2910490108,1874568.0,,,,"A population‐based case‐control study of endometrial cancer in shanghai, china",pmid:1874568,
1.0,1.11,266,23.0,"Uehara, T., Mitsuhashi, A., & Shozu, M. (2020). The impact of pre-existing polycystic ovary syndrome on endometrial cancer recurrence. European Journal Of Gynaecological Oncology, 41(5), 668. doi: 10.31083/j.ejgo.2020.05.5038",primary_citation,,Uehara,2020,"Uehara et al., 2020",10.31083/j.ejgo.2020.05.5038,,,,,The impact of preexisting polycystic ovary syndrome on endometrial cancer recurrence,,10.31083/j.ejgo.2020.05.5038
1.0,1.11,267,23.0,"Zucchetto A, Serraino D, Polesel J, Negri E, De Paoli A, Dal Maso L, Montella M, La Vecchia C, Franceschi S, Talamini R. Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur J Cancer Prev. 2009 Aug;18(4):316-21. doi: 10.1097/cej.0b013e328329d830. PMID: 19554665.",primary_citation,,Zucchetto A,2009,"Zucchetto A et al., 2009",10.1097/cej.0b013e328329d830,19554665.0,,,,Hormone-related factors and gynecological conditions in relation to endometrial cancer risk,pmid:19554665,
1.0,1.11,268,23.0,"Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014 Sep-Oct;20(5):748-58. doi: 10.1093/humupd/dmu012. Epub 2014 Mar 30. ",primary_citation,SR,Barry JA,2014,"Barry JA et al., 2014",10.1093/humupd/dmu012,,,,,"Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis",pmid:24688118,10.1093/humupd/dmu012
1.0,1.11,269,23.0,"Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online. 2009 Sep;19(3):398-405. doi: 10.1016/s1472-6483(10)60175-7. PMID: 19778486.",primary_citation,SR,Chittenden BG,2009,"Chittenden BG et al., 2009",10.1016/s1472-6483(10)60175-7,19778486.0,,,,Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review,pmid:19778486,
1.0,1.11,270,23.0,"Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012 May;27(5):1327-31. doi: 10.1093/humrep/des042. Epub 2012 Feb 24. PMID: 22367984.",primary_citation,SR,Haoula Z,2012,"Haoula Z et al., 2012",10.1093/humrep/des042,22367984.0,,,,Evaluating the association between endometrial cancer and polycystic ovary syndrome,pmid:22367984,
1.0,1.11,271,23.0,"Li Z, Wang YH, Wang LL, Hu DT, Teng Y, Zhang TY, Yan ZY, Wang F, Zou YF. Polycystic ovary syndrome and the risk of endometrial, ovarian and breast cancer: An updated meta-analysis. Scott Med J. 2022 Aug;67(3):109-120. doi: 10.1177/00369330221107099.  ",primary_citation,SR,Li Z,2022,"Li Z et al., 2022",10.1177/00369330221107099,,,,,"Polycystic ovary syndrome and the risk of endometrial, ovarian and breast cancer: An updated meta-analysis",pmid:35686317,10.1177/00369330221107099
1.0,1.11,272,23.0,"Niwa K, Imai A, Hashimoto M, Yokoyama Y, Mori H, Matsuda Y, Tamaya T. A case-control study of uterine endometrial cancer of pre- and post-menopausal women. Oncol Rep. 2000 Jan-Feb;7(1):89-93. PMID: 10601598.",primary_citation,prior search,Niwa K,2000,"Niwa K et al., 2000",10.3892/or.7.1.89,10601598.0,,,,A case-control study of uterine endometrial cancer of pre- and post-menopausal women.,pmid:10601598,
1.0,1.11,273,23.0,"Wild S, Pierpoint T, Jacobs H, et al. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000; 3: 101–105. ",primary_citation,prior search,Wild S,2000,"Wild S et al., 2000",10.1080/1464727002000198781,,,,,Long-term consequences of polycystic ovary syndrome: Results of a 31 year follow-up study,pmid:11844363,10.1080/1464727002000198781
1.0,1.12,274,60.0,"Baillargeon JP, Carpentier AC. Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetologia. 2007 Dec;50(12):2424-32. doi: 10.1007/s00125-007-0831-9. Epub 2007 Sep 27. PMID: 17898989; PMCID: PMC3846531.",primary_citation,,Baillargeon JP,2007,"Baillargeon JP et al., 2007",10.1007/s00125-007-0831-9,17898989.0,,,,"Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects",pmid:17898989,
1.0,1.12,275,60.0,"Coviello AD, Sam S, Legro RS, Dunaif A. High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity. J Clin Endocrinol Metab. 2009 Nov;94(11):4361-6. doi: 10.1210/jc.2009-1333. Epub 2009 Oct 16. PMID: 19837913; PMCID: PMC2775643.",primary_citation,,Coviello AD,2009,"Coviello AD et al., 2009",10.1210/jc.2009-1333,19837913.0,,,,High Prevalence of Metabolic Syndrome in First-Degree Male Relatives of Women with Polycystic Ovary Syndrome Is Related to High Rates of Obesity,pmid:19837913,
1.0,1.12,276,60.0,"Crisosto N, Echiburú B, Maliqueo M, Luchsinger M, Rojas P, Recabarren S, Sir-Petermann T. Reproductive and metabolic features during puberty in sons of women with polycystic ovary syndrome. Endocr Connect. 2017 Nov;6(8):607-613. doi: 10.1530/EC-17-0218. Epub 2017 Sep 14. PMID: 28912339; PMCID: PMC5640572. (primary citation)",primary_citation,,Crisosto N,2017,"Crisosto N et al., 2017",10.1530/ec-17-0218,28912339.0,,,,Reproductive and metabolic features during puberty in sons of women with polycystic ovary syndrome,pmid:28912339,
1.0,1.12,277,60.0,"SIR-PETERMANN, T., VANTMAN, N., CONCHA, F., ECHIBURU, B., PEREIRA, C., DE GUEVARA, A. L., CRISOSTO, N. R., PEREZ-BRAVO, F. A. & SANTOS, J. L. 2014. Metabolic Profile and Eating Behavior Score in Prepubertal and Early Pubertal Sons of Women with Polycystic Ovary Syndrome. Endocr. Rev., 35, 2.",samestudy_276,,SIR-PETERMANN,2014,"SIR-PETERMANN et al., 2014",,,,,Metabolic Profile and Eating Behavior Score in Prepubertal and Early Pubertal Sons of Women with Polycystic Ovary Syndrome,,,
1.0,1.12,278,60.0,"Crisosto N, Ladrón de Guevara A, Echiburú B, Maliqueo M, Cavada G, Codner E, Paez F, Sir-Petermann T. Higher luteinizing hormone levels associated with antimüllerian hormone in postmenarchal daughters of women with polycystic ovary syndrome. Fertil Steril. 2019 Feb;111(2):381-388. doi: 10.1016/j.fertnstert.2018.10.011. Epub 2018 Dec 7. PMID: 30527840.",primary_citation,,Crisosto N,2019,"Crisosto N et al., 2019",10.1016/j.fertnstert.2018.10.011,30527840.0,,,,Higher luteinizing hormone levels associated with antimüllerian hormone in postmenarchal daughters of women with polycystic ovary syndrome,pmid:30527840,
1.0,1.12,279,60.0,"deWilde MA, Eising JB, Gunning MN, Koster MPH, Evelein AMV, Dalmeijer GW, Uiterwaal CSPM, Eijkemans MJC, Ent CKV, Meijboom FJ, Fauser BCJM. Cardiovascular and Metabolic Health of 74 Children From Women Previously Diagnosed With Polycystic Ovary Syndrome in Comparison With a Population-Based Reference Cohort. Reprod Sci. 2018 Oct;25(10):1492-1500. doi: 10.1177/1933719117749761. Epub 2018 Jan 10. PMID: 29320957.",primary_citation,,deWilde MA,2018,"deWilde MA et al., 2018",10.1177/1933719117749761,29320957.0,,,,Cardiovascular and Metabolic Health of 74 Children From Women Previously Diagnosed With Polycystic Ovary Syndrome in Comparison With a Population-Based Reference Cohort,pmid:29320957,
1.0,1.12,280,60.0,"Diamanti-Kandarakis E, Alexandraki K, Bergiele A, Kandarakis H, Mastorakos G, Aessopos A. Presence of metabolic risk factors in non-obese PCOS sisters: evidence of heritability of insulin resistance. J Endocrinol Invest. 2004 Nov;27(10):931-6. doi: 10.1007/BF03347535. PMID: 15762040.",primary_citation,,Diamanti-Kandarakis E,2004,"Diamanti-Kandarakis E et al., 2004",10.1007/bf03347535,15762040.0,,,,Presence of metabolic risk factors in non-obese PCOS sisters: Evidence of heritability of insulin resistance,pmid:15762040,
1.0,1.12,281,60.0,"Harnois-Leblanc S, Trottier A, Leblanc S, Battista MC, Geller DH, Baillargeon JP. Evolution of metabolic alterations 5 Years after early puberty in a cohort of girls predisposed to polycystic ovary syndrome. Reprod Biol Endocrinol. 2017 Jul 24;15(1):56. doi: 10.1186/s12958-017-0275-0. PMID: 28738839; PMCID: PMC5525344. (primary citation)",primary_citation,,Harnois-Leblanc S,2017,"Harnois-Leblanc S et al., 2017",10.1186/s12958-017-0275-0,28738839.0,,,,Evolution of metabolic alterations 5 Years after early puberty in a cohort of girls predisposed to polycystic ovary syndrome,pmid:28738839,
1.0,1.12,282,60.0,"Leblanc, S. H., Leblanc, S., Battista, M. C., Geller, D. H., & Baillargeon, J. P. (2016). Evolution of metabolic alterations 5 years after peri-pubertal years in young girls genetically predisposed to polycystic ovary syndrome compared to age-matched control girls. Endocrine Reviews, 37(2 Supplement 1). doi:https://dx.doi.org/10.1210/endo-meetings.2016.RE.5.SUN-156",samestudy_281,,Leblanc,2016,"Leblanc et al., 2016",,,,,,,,
1.0,1.12,283,60.0,"Joharatnam J, Barber TM, Webber L, Conway GS, McCarthy MI, Franks S. Determinants of dyslipidaemia in probands with polycystic ovary syndrome and their sisters. Clin Endocrinol (Oxf). 2011 Jun;74(6):714-9. doi: 10.1111/j.1365-2265.2011.03983.x. PMID: 21521255; PMCID: PMC4625580. (primary citation)",primary_citation,,Joharatnam J,2011,"Joharatnam J et al., 2011",10.1111/j.1365-2265.2011.03983.x,21521255.0,,,,Determinants of dyslipidaemia in probands with polycystic ovary syndrome and their sisters,pmid:21521255,
1.0,1.12,284,60.0,"Franks S, Webber LJ, Goh M, Valentine A, White DM, Conway GS, Wiltshire S, McCarthy MI. Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries. J Clin Endocrinol Metab. 2008 Sep;93(9):3396-402. doi: 10.1210/jc.2008-0369. Epub 2008 Jun 17. PMID: 18559912.",samestudy_283,,Franks S,2008,"Franks S et al., 2008",10.1210/jc.2008-0369,18559912.0,,,,Ovarian Morphology Is a Marker of Heritable Biochemical Traits in Sisters with Polycystic Ovaries,pmid:18559912,
1.0,1.12,285,60.0,"Karthik S, Vipin VP, Kapoor A, Tripathi A, Shukla M, Dabadghao P. Cardiovascular disease risk in the siblings of women with polycystic ovary syndrome. Hum Reprod. 2019 Aug 1;34(8):1559-1566. doi: 10.1093/humrep/dez104. PMID: 31299073. (primary citation)",primary_citation,,Karthik S,2019,"Karthik S et al., 2019",10.1093/humrep/dez104,31299073.0,,,,Cardiovascular disease risk in the siblings of women with polycystic ovary syndrome,pmid:31299073,
1.0,1.12,286,60.0,"Subramaniam K, Tripathi A, Dabadghao P. Familial clustering of metabolic phenotype in brothers of women with polycystic ovary syndrome. Gynecol Endocrinol. 2019 Jul;35(7):601-603. doi: 10.1080/09513590.2019.1566451. Epub 2019 Feb 6. PMID: 30727783.",samestudy_285,,Subramaniam K,2019,"Subramaniam K et al., 2019",10.1080/09513590.2019.1566451,30727783.0,,,,Familial clustering of metabolic phenotype in brothers of women with polycystic ovary syndrome,pmid:30727783,
1.0,1.12,287,60.0,"Karthik, S, Vipin, VP, Kapoor, A, Tripathi, A, Shukla, M & Dabadghao, P 2019, ‘Cardiovascular disease risk in the siblings of women with polycystic ovary syndrome’, Human Reproduction, vol. 34, no. 8, pp. 1559–1566.",samestudy_285,,Karthik,2019,"Karthik et al., 2019",10.1093/humrep/dez104,31299073.0,,,,Cardiovascular disease risk in the siblings of women with polycystic ovary syndrome,pmid:31299073,
1.0,1.12,288,60.0,"Kent SC, Gnatuk CL, Kunselman AR, Demers LM, Lee PA, Legro RS. Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2008 May;93(5):1662-9. doi: 10.1210/jc.2007-1958. Epub 2008 Feb 12. PMID: 18270257; PMCID: PMC2386683.",primary_citation,,Kent SC,2008,"Kent SC et al., 2008",10.1210/jc.2007-1958,18270257.0,,,,Hyperandrogenism and Hyperinsulinism in Children of Women with Polycystic Ovary Syndrome: A Controlled Study,pmid:18270257,
1.0,1.12,289,60.0,"Krysiak R, Basiak M, Szkróbka W, Okopień B. The Impact of Telmisartan on Cardiometabolic Risk Factors in Hypertensive Male Siblings of Women With Polycystic Ovary Syndrome. J Clin Pharmacol. 2021 Sep;61(9):1165-1173. doi: 10.1002/jcph.1872. Epub 2021 Jun 17. PMID: 33837974.",primary_citation,,Krysiak R,2021,"Krysiak R et al., 2021",10.1002/jcph.1872,33837974.0,,,,The Impact of Telmisartan on Cardiometabolic Risk Factors in Hypertensive Male Siblings of Women With Polycystic Ovary Syndrome,pmid:33837974,
1.0,1.12,290,60.0,"Krysiak R, Szkróbka W, Okopień B. The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome. Pharmacol Rep. 2021 Feb;73(1):261-268. doi: 10.1007/s43440-020-00135-w. Epub 2020 Jul 21. Erratum in: Pharmacol Rep. 2021 Oct;73(5):1481. PMID: 32696349; PMCID: PMC8149333.",primary_citation,,Krysiak R,2021,"Krysiak R et al., 2021",10.1007/s43440-020-00135-w,32696349.0,,,,The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome,pmid:32696349,
1.0,1.12,291,60.0,"Kulshreshtha B, Sharma N, Pant S, Prasad A, Chitkara A, Pahuja B, Pahuja I. Predictors of Metabolic Syndrome among Polycystic Ovary Syndrome Sisters. J Hum Reprod Sci. 2019 Oct-Dec;12(4):334-340. doi: 10.4103/jhrs.JHRS_172_18. Epub 2019 Dec 17. PMID: 32038085; PMCID: PMC6937762.",primary_citation,,Kulshreshtha B,2019,"Kulshreshtha B et al., 2019",10.4103/jhrs.jhrs_172_18,32038085.0,,,,Predictors of metabolic syndrome among polycystic ovary syndrome sisters,pmid:32038085,
1.0,1.12,292,60.0,"Legro RS, Kunselman AR, Stetter CM, Gnatuk CL, Estes SJ, Brindle E, Vesper HW, Botelho JC, Lee PA, Dodson WC. Normal Pubertal Development in Daughters of Women With PCOS: A Controlled Study. J Clin Endocrinol Metab. 2017 Jan 1;102(1):122-131. doi: 10.1210/jc.2016-2707. PMID: 27778640; PMCID: PMC5413094.",primary_citation,,Legro RS,2017,"Legro RS et al., 2017",10.1210/jc.2016-2707,27778640.0,,,,Normal Pubertal Development in Daughters of Women With PCOS: A Controlled Study,pmid:27778640,
1.0,1.12,293,60.0,"Lenarcik, A., Bidzinska-Speichert, B. and Tworowska-Bardzinska, U. (2011) ‘Metabolic Abnormalities in Siblings of Women with Polycystic Ovary Syndrome’, ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 20(2), pp. 165–175. ",primary_citation,,Lenarcik,2011,"Lenarcik et al., 2011",,,,74019465.0,Metabolic Abnormalities in Siblings of Women with Polycystic Ovary Syndrome,,,
1.0,1.12,294,60.0,"Li J, Cui L, Jiang X, Zhao H, Zhao S, Shi Y, Wei D, You L, Ma J, Chen ZJ. Transmission of polycystic ovary syndrome susceptibility single-nucleotide polymorphisms and their association with phenotype changes in offspring. Hum Reprod. 2020 Jul 1;35(7):1711-1718. doi: 10.1093/humrep/deaa125. PMID: 32619219. (primary citation)",primary_citation,,Li J,2020,"Li J et al., 2020",10.1093/humrep/deaa125,32619219.0,,,,Transmission of polycystic ovary syndrome susceptibility single-nucleotide polymorphisms and their association with phenotype changes in offspring,pmid:32619219,
1.0,1.12,295,60.0,"Zhang Z, Liu Y, Lv J, Zhang D, Hu K, Li J, Ma J, Cui L, Zhao H. Differential Lipidomic Characteristics of Children Born to Women with Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2021 Aug 9;12:698734. doi: 10.3389/fendo.2021.698734. PMID: 34434168; PMCID: PMC8380809.",samestudy_294,,Zhang Z,2021,"Zhang Z et al., 2021",10.3389/fendo.2021.698734,34434168.0,,,,Differential Lipidomic Characteristics of Children Born to Women with Polycystic Ovary Syndrome,pmid:34434168,
1.0,1.12,296,60.0,"Raissouni N, Kolesnikov A, Purushothaman R, Sinha S, Bhandari S, Bhangoo A, Malik S, Mathew R, Baillargeon JP, Hernandez MI, Rosenbaum M, Ten S, Geller D. Altered glucose disposition and insulin sensitivity in peri-pubertal first-degree relatives of women with polycystic ovary syndrome. Int J Pediatr Endocrinol. 2012 May 29;2012(1):14. doi: 10.1186/1687-9856-2012-14. PMID: 22643321; PMCID: PMC3477027. (primary citation)",primary_citation,,Raissouni N,2012,"Raissouni N et al., 2012",10.1186/1687-9856-2012-14,22643321.0,,,,Altered glucose disposition and insulin sensitivity in peri-pubertal first-degree relatives of women with polycystic ovary syndrome,pmid:22643321,
1.0,1.12,297,60.0,"Trottier, A., Battista, M. C., Carpentier, A., Simoneau-Roy, J., Geller, D., & Baillargeon, J. P. (2011). Early metabolic and endocrine perturbations in pre- or peripubertal girls with a first degree relative with polycystic ovary syndrome. Fertility and sterility, 96(3), S129-S129. doi:10.1016/j.fertnstert.2011.07.502",samestudy_296,,Trottier,2011,"Trottier et al., 2011",10.1016/j.fertnstert.2011.07.502,,,,,Early metabolic and endocrine perturbations in pre- or peripubertal girls with a first degree relative with polycystic ovary syndrome,,10.1016/j.fertnstert.2011.07.502
1.0,1.12,298,60.0,"Trottier, A., Battista, M. C., Simoneau-Roy, J., Carpentier, A., Geller, D. H., & Baillargeon, J. P. (2011). Early metabolic and endocrine perturbations in first-degree relative adolescent girls of polycystic ovary syndrome women. Endocrine Reviews, 32(3 Meeting Abstracts). ",samestudy_296,,Trottier,2011,"Trottier et al., 2011",10.1210/endo-meetings.2011.part2.p32.p2-239,,W4253108685,,,Early Metabolic and Endocrine Perturbations in First-Degree Relative Adolescent Girls of Polycystic Ovary Syndrome Women,,
1.0,1.12,299,60.0,"Trottier A, Battista MC, Geller DH, Moreau B, Carpentier AC, Simoneau-Roy J, Baillargeon JP. Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome. Fertil Steril. 2012 Dec;98(6):1627-34. doi: 10.1016/j.fertnstert.2012.08.025. Epub 2012 Sep 15. PMID: 22985947; PMCID: PMC3902032.",samestudy_296,,Trottier A,2012,"Trottier A et al., 2012",10.1016/j.fertnstert.2012.08.025,22985947.0,,,,Adipose tissue insulin resistance in peripubertal girls with first-degree family history of polycystic ovary syndrome,pmid:22985947,
1.0,1.12,300,60.0,"Recabarren SE, Smith R, Rios R, Maliqueo M, Echiburú B, Codner E, Cassorla F, Rojas P, Sir-Petermann T. Metabolic profile in sons of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 May;93(5):1820-6. doi: 10.1210/jc.2007-2256. Epub 2008 Jan 29. PMID: 18230657. (primary citation)

",primary_citation,,Recabarren SE,2008,"Recabarren SE et al., 2008",10.1210/jc.2007-2256,18230657.0,,,,Metabolic Profile in Sons of Women with Polycystic Ovary Syndrome,pmid:18230657,
1.0,1.12,301,60.0,"Recabarren SE, Sir-Petermann T, Rios R, Maliqueo M, Echiburú B, Smith R, Rojas-García P, Recabarren M, Rey RA. Pituitary and testicular function in sons of women with polycystic ovary syndrome from infancy to adulthood. J Clin Endocrinol Metab. 2008 Sep;93(9):3318-24. doi: 10.1210/jc.2008-0255. Epub 2008 Jun 10. PMID: 18544620.",samestudy_300,,Recabarren SE,2008,"Recabarren SE et al., 2008",10.1210/jc.2008-0255,18544620.0,,,,Pituitary and Testicular Function in Sons of Women with Polycystic Ovary Syndrome from Infancy to Adulthood,pmid:18544620,
1.0,1.12,302,60.0,"Recabarren SE, et al. (2008) Metabolic profile in sons of women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab doi:10.1210/jc.2007-2256.",samestudy_300,,Recabarren SE,2008,"Recabarren SE et al., 2008",10.1210/jc.2007-2256,,,,,Metabolic Profile in Sons of Women with Polycystic Ovary Syndrome,pmid:18230657,10.1210/jc.2007-2256
1.0,1.12,303,60.0,"Sam S, Legro RS, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Aug;90(8):4797-802. doi: 10.1210/jc.2004-2217. Epub 2005 May 17. PMID: 15899949; PMCID: PMC4428585. (primary citation)",primary_citation,,Sam S,2005,"Sam S et al., 2005",10.1210/jc.2004-2217,15899949.0,,,,Dyslipidemia and Metabolic Syndrome in the Sisters of Women with Polycystic Ovary Syndrome,pmid:15899949,
1.0,1.12,304,60.0,"Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14956-60. doi: 10.1073/pnas.95.25.14956. PMID: 9843997; PMCID: PMC24557.",samestudy_303,,Legro RS,1998,"Legro RS et al., 1998",10.1073/pnas.95.25.14956,9843997.0,,,,Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome,pmid:9843997,
1.0,1.12,305,60.0,"Legro RS, Bentley-Lewis R, Driscoll D, Wang SC, Dunaif A. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab. 2002 May;87(5):2128-33. doi: 10.1210/jcem.87.5.8513. PMID: 11994352; PMCID: PMC4429513.",samestudy_303,,Legro RS,2002,"Legro RS et al., 2002",10.1210/jcem.87.5.8513,11994352.0,,,,Insulin Resistance in the Sisters of Women with Polycystic Ovary Syndrome: Association with Hyperandrogenemia Rather Than Menstrual Irregularity,pmid:11994352,
1.0,1.12,306,60.0,"Sam S, Legro RS, Essah PA, Apridonidze T, Dunaif A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A. 2006 May 2;103(18):7030-5. doi: 10.1073/pnas.0602025103. Epub 2006 Apr 21. PMID: 16632599; PMCID: PMC1459013. (primary citation)",primary_citation,,Sam S,2006,"Sam S et al., 2006",10.1073/pnas.0602025103,16632599.0,,,,Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome,pmid:16632599,
1.0,1.12,307,60.0,"Taylor MC, Reema Kar A, Kunselman AR, Stetter CM, Dunaif A, Legro RS. Evidence for increased cardiovascular events in the fathers but not mothers of women with polycystic ovary syndrome. Hum Reprod. 2011 Aug;26(8):2226-31. doi: 10.1093/humrep/der101. Epub 2011 Apr 19. PMID: 21505042; PMCID: PMC3137384.",samestudy_306,,Taylor MC,2011,"Taylor MC et al., 2011",10.1093/humrep/der101,21505042.0,,,,Evidence for increased cardiovascular events in the fathers but not mothers of women with polycystic ovary syndrome,pmid:21505042,
1.0,1.12,308,60.0,"Legro RS, Roller RL, Dodson WC, Stetter CM, Kunselman AR, Dunaif A. Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives. J Clin Endocrinol Metab. 2010 Feb;95(2):789-99. doi: 10.1210/jc.2009-1849. Epub 2009 Dec 4. PMID: 19965924; PMCID: PMC2840854.",samestudy_311,,Legro RS,2010,"Legro RS et al., 2010",10.1210/jc.2009-1849,19965924.0,,,,Associations of Birthweight and Gestational Age with Reproductive and Metabolic Phenotypes in Women with Polycystic Ovarian Syndrome and Their First-Degree Relatives,pmid:19965924,
1.0,1.12,309,60.0,"Legro RS, Kunselman AR, Demers L, Wang SC, Bentley-Lewis R, Dunaif A. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002 May;87(5):2134-8. doi: 10.1210/jcem.87.5.8387. PMID: 11994353; PMCID: PMC4428582.",samestudy_311,,Legro RS,2002,"Legro RS et al., 2002",10.1210/jcem.87.5.8387,11994353.0,,,,Elevated Dehydroepiandrosterone Sulfate Levels as the Reproductive Phenotype in the Brothers of Women with Polycystic Ovary Syndrome,pmid:11994353,
1.0,1.12,310,60.0,"Sam S, Sung YA, Legro RS, Dunaif A. Evidence for pancreatic beta-cell dysfunction in brothers of women with polycystic ovary syndrome. Metabolism. 2008 Jan;57(1):84-9. doi: 10.1016/j.metabol.2007.08.010. PMID: 18078863; PMCID: PMC2710887.",samestudy_311,,Sam S,2008,"Sam S et al., 2008",10.1016/j.metabol.2007.08.010,18078863.0,,,,Evidence for pancreatic β-cell dysfunction in brothers of women with polycystic ovary syndrome,pmid:18078863,
1.0,1.12,311,60.0,"Sam S, Coviello AD, Sung YA, Legro RS, Dunaif A. Metabolic phenotype in the brothers of women with polycystic ovary syndrome. Diabetes Care. 2008 Jun;31(6):1237-41. doi: 10.2337/dc07-2190. Epub 2008 Mar 10. PMID: 18332151; PMCID: PMC2897239. (primary citation)",primary_citation,,Sam S,2008,"Sam S et al., 2008",10.2337/dc07-2190,18332151.0,,,,Metabolic Phenotype in the Brothers of Women with Polycystic Ovary Syndrome,pmid:18332151,
1.0,1.12,312,60.0,"Sir-Petermann T, Cartes A, Maliqueo M, Vantman D, Gutiérrez C, Toloza H, Echiburú B, Recabarren SE. Patterns of hormonal response to the GnRH agonist leuprolide in brothers of women with polycystic ovary syndrome: a pilot study. Hum Reprod. 2004 Dec;19(12):2742-7. doi: 10.1093/humrep/deh512. Epub 2004 Sep 9. PMID: 15358722.",primary_citation,,Sir-Petermann T,2004,"Sir-Petermann T et al., 2004",10.1093/humrep/deh512,15358722.0,,,,Patterns of hormonal response to the GnRH agonist leuprolide in brothers of women with polycystic ovary syndrome: a pilot study,pmid:15358722,
1.0,1.12,313,60.0,"Sir-Petermann T, Ladrón de Guevara A, Codner E, Preisler J, Crisosto N, Echiburú B, Maliqueo M, Sánchez F, Perez-Bravo F, Cassorla F. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome. Reprod Sci. 2012 Apr;19(4):383-90. doi: 10.1177/1933719111424444. Epub 2012 Feb 16. PMID: 22344736. (primary citation)

",primary_citation,,Sir-Petermann T,2012,"Sir-Petermann T et al., 2012",10.1177/1933719111424444,22344736.0,,,,Relationship Between Anti-Müllerian Hormone (AMH) and Insulin Levels During Different Tanner Stages in Daughters of Women With Polycystic Ovary Syndrome,pmid:22344736,
1.0,1.12,314,60.0,"Maliqueo M, Sir-Petermann T, Pérez V, Echiburú B, de Guevara AL, Gálvez C, Crisosto N, Azziz R. Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009 Sep;94(9):3282-8. doi: 10.1210/jc.2009-0427. Epub 2009 Jun 30. PMID: 19567527.",samestudy_313,,Maliqueo M,2009,"Maliqueo M et al., 2009",10.1210/jc.2009-0427,19567527.0,,,,Adrenal Function during Childhood and Puberty in Daughters of Women with Polycystic Ovary Syndrome,pmid:19567527,
1.0,1.12,315,60.0,"Crisosto N, Codner E, Maliqueo M, Echiburú B, Sánchez F, Cassorla F, Sir-Petermann T. Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007 Jul;92(7):2739-43. doi: 10.1210/jc.2007-0267. Epub 2007 May 8. PMID: 17488788.",samestudy_313,,Crisosto N,2007,"Crisosto N et al., 2007",10.1210/jc.2007-0267,17488788.0,,,,Anti-Müllerian Hormone Levels in Peripubertal Daughters of Women with Polycystic Ovary Syndrome,pmid:17488788,
1.0,1.12,316,60.0,"Maliqueo M, Galgani JE, Pérez-Bravo F, Echiburú B, de Guevara AL, Crisosto N, Sir-Petermann T. Relationship of serum adipocyte-derived proteins with insulin sensitivity and reproductive features in pre-pubertal and pubertal daughters of polycystic ovary syndrome women. Eur J Obstet Gynecol Reprod Biol. 2012 Mar;161(1):56-61. doi: 10.1016/j.ejogrb.2011.12.012. Epub 2012 Jan 23. PMID: 22277163.",samestudy_313,,Maliqueo M,2012,"Maliqueo M et al., 2012",10.1016/j.ejogrb.2011.12.012,22277163.0,,,,Relationship of serum adipocyte-derived proteins with insulin sensitivity and reproductive features in pre-pubertal and pubertal daughters of polycystic ovary syndrome women,pmid:22277163,
1.0,1.12,317,60.0,"Sir-Petermann T, Angel B, Maliqueo M, Carvajal F, Santos JL, Pérez-Bravo F. Prevalence of Type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia. 2002 Jul;45(7):959-64. doi: 10.1007/s00125-002-0836-3. Epub 2002 Apr 26. PMID: 12136394.",samestudy_313,,Sir-Petermann T,2002,"Sir-Petermann T et al., 2002",10.1007/s00125-002-0836-3,12136394.0,,,,Prevalence of Type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome,pmid:12136394,
1.0,1.12,318,60.0,"Sir-Petermann, T.; Angel, B.; Maliqueo, M.; Perez-Bravo, F. Glucose tolerance, insulin secretion and insulin resistance in parents of women with polycystic ovary sindrome. Diabetologia 2001;44:A86-A86.",samestudy_313,,Sir-Petermann,2001,"Sir-Petermann et al., 2001",10.1007/bf03180172,,,,,"Abstracts of the 37th Annual Meeting of the EASD Glasgow, United Kingdom, 9–13 September 2001",,10.1007/bf03180172
1.0,1.12,319,60.0,"Sir-Petermann T, Codner E, Maliqueo M, Echiburú B, Hitschfeld C, Crisosto N, Pérez-Bravo F, Recabarren SE, Cassorla F. Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Aug;91(8):3105-9. doi: 10.1210/jc.2005-2693. Epub 2006 May 23. PMID: 16720659.",samestudy_313,,Sir-Petermann T,2006,"Sir-Petermann T et al., 2006",10.1210/jc.2005-2693,16720659.0,,,,Increased Anti-Müllerian Hormone Serum Concentrations in Prepubertal Daughters of Women with Polycystic Ovary Syndrome,pmid:16720659,
1.0,1.12,320,60.0,"Sir-Petermann T, Codner E, Pérez V, Echiburú B, Maliqueo M, Ladrón de Guevara A, Preisler J, Crisosto N, Sánchez F, Cassorla F, Bhasin S. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009 Jun;94(6):1923-30. doi: 10.1210/jc.2008-2836. Epub 2009 Feb 17. PMID: 19223518; PMCID: PMC2730345.",samestudy_313,,Sir-Petermann T,2009,"Sir-Petermann T et al., 2009",10.1210/jc.2008-2836,19223518.0,,,,Metabolic and Reproductive Features before and during Puberty in Daughters of Women with Polycystic Ovary Syndrome,pmid:19223518,
1.0,1.12,321,60.0,"Echiburú B, Pérez-Bravo F, Maliqueo M, Ladrón de Guevara A, Gálvez C, Crisosto N, Sir-Petermann T. CAG repeat polymorphism of androgen receptor gene and X-chromosome inactivation in daughters of women with polycystic ovary syndrome (PCOS): relationship with endocrine and metabolic parameters. Gynecol Endocrinol. 2012 Jul;28(7):516-20. doi: 10.3109/09513590.2011.650744. Epub 2012 Feb 17. PMID: 22724574.",samestudy_313,,Echiburú B,2012,"Echiburú B et al., 2012",10.3109/09513590.2011.650744,22724574.0,,,,CAG repeat polymorphism of androgen receptor gene and X-chromosome inactivation in daughters of women with polycystic ovary syndrome (PCOS): relationship with endocrine and metabolic parameters,pmid:22724574,
1.0,1.12,322,60.0,"Sir-Petermann T, Maliqueo M, Codner E, Echiburú B, Crisosto N, Pérez V, Pérez-Bravo F, Cassorla F. Early metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007 Dec;92(12):4637-42. doi: 10.1210/jc.2007-1036. Epub 2007 Sep 11. PMID: 17848407.",samestudy_313,,Sir-Petermann T,2007,"Sir-Petermann T et al., 2007",10.1210/jc.2007-1036,17848407.0,,,,Early Metabolic Derangements in Daughters of Women with Polycystic Ovary Syndrome,pmid:17848407,
1.0,1.12,323,60.0,"Torchen LC, Fogel NR, Brickman WJ, Paparodis R, Dunaif A. Persistent apparent pancreatic β-cell defects in premenarchal PCOS relatives. J Clin Endocrinol Metab. 2014 Oct;99(10):3855-62. doi: 10.1210/jc.2014-1474. Epub 2014 Jul 16. PMID: 25029420; PMCID: PMC4184072. (primary citation)",primary_citation,,Torchen LC,2014,"Torchen LC et al., 2014",10.1210/jc.2014-1474,25029420.0,,,,Persistent Apparent Pancreatic β-Cell Defects in Premenarchal PCOS Relatives,pmid:25029420,
1.0,1.12,324,60.0,"TORCHEN, L., FOGEL, N. R., BRICKMAN, W., PAPARODIS, R. & DUNAIF, A. 2013. Persistent defects in pancreatic beta-cell function in early pubertal female relatives of women with polycystic ovary syndrome in a three year longitudinal study. Endocrine Reviews, 34.",samestudy_323,,TORCHEN,2013,"TORCHEN et al., 2013",,,,,Persistent defects in pancreatic beta-cell function in early pubertal female relatives of women with polycystic ovary syndrome in a three year longitudinal study,,,
1.0,1.12,325,60.0,"TORCHEN, L. C., FOGEL, N. R., BRICKMAN, W. J., MAURAS, N. & DUNAIF, A. 2012. Beta-cell dysfunction and hyperandrogenemia in PCOS early pubertal female relatives. Endocrine Reviews, 33.",samestudy_323,,TORCHEN,2012,"TORCHEN et al., 2012",,,,,Beta-cell dysfunction and hyperandrogenemia in PCOS early pubertal female relatives,,,
1.0,1.12,326,60.0,"Torchen LC, Idkowiak J, Fogel NR, O'Neil DM, Shackleton CH, Arlt W, Dunaif A. Evidence for Increased 5α-Reductase Activity During Early Childhood in Daughters of Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2016 May;101(5):2069-75. doi: 10.1210/jc.2015-3926. Epub 2016 Mar 18. PMID: 26990942; PMCID: PMC4870855.",primary_citation,,Torchen LC,2016,"Torchen LC et al., 2016",10.1210/jc.2015-3926,26990942.0,,,,Evidence for Increased 5α-Reductase Activity During Early Childhood in Daughters of Women With Polycystic Ovary Syndrome,pmid:26990942,
1.0,1.12,327,60.0,"Unlühizarci K, Ozocak M, Tanriverdi F, Atmaca H, Keleştimur F. Investigation of hypothalamo-pituitary-gonadal axis and glucose intolerance among the first-degree female relatives of women with polycystic ovary syndrome. Fertil Steril. 2007 Jun;87(6):1377-82. doi: 10.1016/j.fertnstert.2006.11.075. Epub 2007 Mar 6. PMID: 17336975.",primary_citation,,Unlühizarci K,2007,"Unlühizarci K et al., 2007",10.1016/j.fertnstert.2006.11.075,17336975.0,,,,Investigation of hypothalamo-pituitary-gonadal axis and glucose intolerance among the first-degree female relatives of women with polycystic ovary syndrome,pmid:17336975,
1.0,1.12,328,60.0,"Vipin VP, Dabadghao P, Shukla M, Kapoor A, Raghuvanshi AS, Ramesh V. Cardiovascular disease risk in first-degree relatives of women with polycystic ovary syndrome. Fertil Steril. 2016 May;105(5):1338-1344.e3. doi: 10.1016/j.fertnstert.2016.01.024. Epub 2016 Feb 4. PMID: 26852421.",primary_citation,,Vipin VP,2016,"Vipin VP et al., 2016",10.1016/j.fertnstert.2016.01.024,26852421.0,,,,Cardiovascular disease risk in first-degree relatives of women with polycystic ovary syndrome,pmid:26852421,
1.0,1.12,329,60.0,"Wang Y, Guo L, Jiang J, Wang F, Hardiman PJ, Qu F. Development of 1-2 years Offspring Born to Mothers with Polycystic Ovary Syndrome. J Coll Physicians Surg Pak. 2021 Oct;31(10):1186-1190. doi: 10.29271/jcpsp.2021.10.1186. PMID: 34601839.",primary_citation,,Wang Y,2021,"Wang Y et al., 2021",10.29271/jcpsp.2021.10.1186,34601839.0,,,,Development of 1-2 years Offspring Born to Mothers with Polycystic Ovary Syndrome,pmid:34601839,
1.0,1.12,330,60.0,"Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 May;88(5):2031-6. doi: 10.1210/jc.2002-021499. PMID: 12727950.",primary_citation,,Yildiz BO,2003,"Yildiz BO et al., 2003",10.1210/jc.2002-021499,12727950.0,,,,"Glucose Intolerance, Insulin Resistance, and Hyperandrogenemia in First Degree Relatives of Women with Polycystic Ovary Syndrome",pmid:12727950,
1.0,1.12,331,60.0,"Yilmaz M, Bukan N, Ersoy R, Karakoç A, Yetkin I, Ayvaz G, Cakir N, Arslan M. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod. 2005 Sep;20(9):2414-20. doi: 10.1093/humrep/dei070. Epub 2005 May 12. PMID: 15890734. (primary citation)",primary_citation,,Yilmaz M,2005,"Yilmaz M et al., 2005",10.1093/humrep/dei070,15890734.0,,,,"Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome",pmid:15890734,
1.0,1.12,332,60.0,"Yilmaz M, Ergün MA, Karakoç A, Yurtçu E, Yetkin I, Ayvaz G, Cakir N, Arslan M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in first-degree relatives of subjects with polycystic ovary syndrome. Gynecol Endocrinol. 2005 Oct;21(4):206-10. doi: 10.1080/09513590500231593. PMID: 16316841.",samestudy_331,,Yilmaz M,2005,"Yilmaz M et al., 2005",10.1080/09513590500231593,16316841.0,,,,Pro12Ala polymorphism of the<i>peroxisome proliferator-activated receptor-γ</i>gene in first-degree relatives of subjects with polycystic ovary syndrome,pmid:16316841,
1.0,1.12,333,60.0,"Zhang F, Ying L, Zhang Q, Wang F, Qu F. Association between maternal polycystic ovary syndrome and early childhood growth: a continuous observation from 3 months to 6 years of age. J Assist Reprod Genet. 2022 Feb;39(2):461-471. doi: 10.1007/s10815-021-02378-9. Epub 2022 Jan 20. Erratum in: J Assist Reprod Genet. 2022 Jan 31;: PMID: 35048272; PMCID: PMC8956758.",primary_citation,,Zhang F,2022,"Zhang F et al., 2022",10.1007/s10815-021-02378-9,35048272.0,,,,Association between maternal polycystic ovary syndrome and early childhood growth: a continuous observation from 3 months to 6 years of age,pmid:35048272,
2.0,2.1.1 / 2.1.2,334,36.0,"Bazarganipour, F.; Taghavi, S. A.; Asemi, Z.; Allan, H.; Khashavi, Z.; Safarzadeh, T.; Pourchangiz, S.; Zare, F.; Ghasemi, S.; Karimi, Z.; Azizi Kutenaee, M. The impact of irritable bowel syndrome on health-related quality of life in women with polycystic ovary syndrome. Health & Quality of Life Outcomes Jul 13 2020;18(1):226 2020 Jul 13",primary_citation,,Bazarganipour,2020,"Bazarganipour et al., 2020",10.1186/s12955-020-01428-7,,,,,The impact of irritable bowel syndrome on health-related quality of life in women with polycystic ovary syndrome,pmid:32660493,10.1186/s12955-020-01428-7
2.0,2.1.1 / 2.1.2,335,36.0,"Boivin, M. J.; Fatehi, F.; Phillips-Chan, A. E.; Richardson, J. R.; Summers, A. N.; Foley, S. A. Exploratory study of a screening measure for polycystic ovarian syndrome, quality of life assessment, and neuropsychological evaluation BMC Women's Health 06 23 2020;20(1):132 2 020 06 23",primary_citation,,Boivin,2020,"Boivin et al., 2020",10.1186/s12905-020-00994-8,,,,,"Exploratory study of a screening measure for polycystic ovarian syndrome, quality of life assessment, and neuropsychological evaluation",pmid:32576264,10.1186/s12905-020-00994-8
2.0,2.1.1 / 2.1.2,336,36.0,"Borghi, L.; Leone, D.; Vegni, E.; Galiano, V.; Lepadatu, C.; Sulpizio, P.; Garzia, E. Psychological distress, anger and quality of life in polycystic ovary syndrome: associations with biochemical, phenotypical and socio- demographic factors. Journal of Psychosomatic Obstetrics & Gynecology 06 2018;39(2):128-137 2018 06",primary_citation,,Borghi,2018,"Borghi et al., 2018",10.1080/0167482x.2017.1311319,,,,,"Psychological distress, anger and quality of life in polycystic ovary syndrome: associations with biochemical, phenotypical andsocio-demographic factors",pmid:28385114,10.1080/0167482x.2017.1311319
2.0,2.1.1 / 2.1.2,337,36.0,"Coban OG, Tulaci OD, Adanir AS, Onder A. Psychiatric disorders, self-esteem, and quality of life in adolescents with polycystic ovary syndrome. J. Pediatr. Adolesc. Gynecol. 2019; 32: 600–4.",primary_citation,,Coban OG,2019,"Coban OG et al., 2019",10.1016/j.jpag.2019.07.008,,,,,"Psychiatric Disorders, Self-Esteem, and Quality of Life in Adolescents with Polycystic Ovary Syndrome",pmid:31362114,10.1016/j.jpag.2019.07.008
2.0,2.1.1 / 2.1.2,338,36.0,"Donbaloglu, Z.; Tuhan, H.; Coban, O. G.; Kizilay, D. O.; Ismailoglu, E.; Onder, A.; Acar, S.; Bedel, A.; Cetiner, E. B.; Singin, B.; Erdem, H.; Parlak, M. Hyperandrogenism correlates with psychological symptoms in adolescents with polycystic ovary syndrome. Clinical Pediatric Endocrinology 05 Apr 2022;31(2)():68-76 2022 05 Apr",primary_citation,,Donbaloglu,2022,"Donbaloglu et al., 2022",10.1297/cpe.2022-0010,,,,,Hyperandrogenism correlates with psychological symptoms in adolescents with polycystic ovary syndrome,pmid:35431449,10.1297/cpe.2022-0010
2.0,2.1.1 / 2.1.2,339,36.0,"Jose, S. A.; Ravi, R.; Murthy, M. K. Quality of life in women with polycystic ovarian syndrome: Requisite of clinical pharmacist intervention. Asian Journal of Pharmaceutical and Clinical Research. Conference: 3rd International Conference on Academic and Industrial Innovations: Transitions in Pharmaceutical, Medical and Biosciences, INNOPHARM 2018;11(11): 2018",primary_citation,,Jose,2018,"Jose et al., 2018",10.22159/ajpcr.2019.v12i11.34426,,,,,QUALITY OF LIFE IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME: REQUISITE OF CLINICAL PHARMACIST INTERVENTION,,10.22159/ajpcr.2019.v12i11.34426
2.0,2.1.1 / 2.1.2,340,36.0,"Kahal, H.; Kilpatrick, E.; Rigby, A.; Coady, A.; Atkin, S. The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls. Gynecological Endocrinology Feb 2019;35(2):142-145 2019 Feb",primary_citation,,Kahal,2019,"Kahal et al., 2019",10.1080/09513590.2018.1505848,,,,,The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls,pmid:30599799,10.1080/09513590.2018.1505848
2.0,2.1.1 / 2.1.2,341,36.0,"Kaluzna, M.; Nomejko, A.; Slowinska, A.; Wachowiak-Ochmanska, K.; Pikosz, K.; Ziemnicka, K.; Ruchala, M. Lower sexual satisfaction in women with polycystic ovary syndrome and metabolic syndrome. Endocrine connections September 2021;10(9)():1035-1044 2021 September",primary_citation,,Kaluzna,2021,"Kaluzna et al., 2021",10.1530/ec-21-0257,,,,,Lower sexual satisfaction in women with polycystic ovary syndrome and metabolic syndrome,pmid:34319905,10.1530/ec-21-0257
2.0,2.1.1 / 2.1.2,342,36.0,"Karjula, S.; Morin-Papunen, L.; Franks, S.; Auvinen, J.; Jarvelin, M. R.; Tapanainen, J. S.; Jokelainen, J.; Miettunen, J.; Piltonen, T. T. Population-based Data at Ages 31 and 46 Show Decreased HRQoL and Life Satisfaction in Women with PCOS Symptoms. Journal of Clinical Endocrinology & Metabolism 06 01 2020;105(6):01 2020 06 01",primary_citation,,Karjula,2020,"Karjula et al., 2020",10.1210/clinem/dgz256,,,,,Population-based Data at Ages 31 and 46 Show Decreased HRQoL and Life Satisfaction in Women with PCOS Symptoms,pmid:31970392,10.1210/clinem/dgz256
2.0,2.1.1 / 2.1.2,343,36.0,"Kutlu, O. Evaluation of quality of life of patients with hirsutism among Turkish women: A single-center cross- sectional study. Journal of Cosmetic Dermatology Nov 2020;19(11):3053-3057",primary_citation,,Kutlu,2020,"Kutlu et al., 2020",10.1111/jocd.13563,,,,,Evaluation of quality of life of patients with hirsutism among Turkish women: A single‐center cross‐sectional study,pmid:32564506,10.1111/jocd.13563
2.0,2.1.1 / 2.1.2,344,36.0,"Lidaka, L.; Lazdane, G.; Kivite-Urtane, A.; Gailite, L.; Dzivite-Krisane, I.; Stokenberga, I. Health-related quality of life and binge eating among adolescent girls with PCOS. Clinical and Experimental Obstetrics and Gynecology 2019;46(5)():831-832",primary_citation,,Lidaka,2019,"Lidaka et al., 2019",10.31083/j.ceog4903057,,,,,Health-related quality of life and binge eating among adolescent girls with PCOS,,10.31083/j.ceog4903057
2.0,2.1.1 / 2.1.2,345,36.0,"Ozcan Dag, Z.; Alpua, M.; Isik, Y.; Buturak, S. V.; Tulmac, O. B.; Turkel, Y. The evaluation of temperament and quality of life in patients with polycystic ovary syndrome Gynecological Endocrinology Mar 2017;33(3):250-253 2017 Mar",primary_citation,,Ozcan Dag,2017,"Ozcan Dag et al., 2017",10.1080/09513590.2016.1254610,,,,,The evaluation of temperament and quality of life in patients with polycystic ovary syndrome,pmid:27908217,10.1080/09513590.2016.1254610
2.0,2.1.1 / 2.1.2,346,36.0,"Panico A, Messina G, Lupoli GA, et al. Quality of life in overweight (obese) and normal-weight women with polycystic ovary syndrome. Patient Prefer Adherence. 2017;11:423–429",primary_citation,,Panico A,2017,"Panico A et al., 2017",10.2147/ppa.s119180,,,,,Quality of life in overweight (obese) and normal-weight women with polycystic ovary syndrome,pmid:28280314,10.2147/ppa.s119180
2.0,2.1.1 / 2.1.2,347,36.0,"Rzonca, E.; Bien, A.; Wdowiak, A.; Szymanski, R.; Iwanowicz-Palus, G. Determinants of Quality of Life and Satisfaction with Life in Women with Polycystic Ovary Syndrome. International Journal of Environmental Research & Public Health [Electronic Resource] 02 22 2018;15(2):22",primary_citation,,Rzonca,2018,"Rzonca et al., 2018",10.3390/ijerph15020376,,,,,Determinants of Quality of Life and Satisfaction with Life in Women with Polycystic Ovary Syndrome,pmid:29470449,10.3390/ijerph15020376
2.0,2.1.1 / 2.1.2,348,36.0,"Sanchez-Ferrer, M. L.; Adoamnei, E.; Prieto-Sanchez, M. T.; Mendiola, J.; Corbalan-Biyang, S.; Monino-Garcia, M.; Palomar-Rodriguez, J. A.; Torres-Cantero, A. M. Health-related quality of life in women with polycystic ovary syndrome attending to a tertiary hospital in Southeastern Spain: a case-control study. Health & Quality of Life Outcomes Jul 16 2020;18(1):232.",primary_citation,,Sanchez-Ferrer,2020,"Sanchez-Ferrer et al., 2020",10.1186/s12955-020-01484-z,,,,,Health-related quality of life in women with polycystic ovary syndrome attending to a tertiary hospital in Southeastern Spain: a case-control study,pmid:32677953,10.1186/s12955-020-01484-z
2.0,2.1.1 / 2.1.2,349,36.0,"Stevanovic, D.; Bozic-Antic, I.; Stanojlovic, O.; Vojnovic Milutinovic, D.; Bjekic-Macut, J.; Jancic, J.; Macut, D. Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): a psychometric study with the Serbian version. Women & Health 10 2019;59(9):1015-1025",primary_citation,,Stevanovic,2019,"Stevanovic et al., 2019",10.1080/03630242.2019.1587664,,,,,Health-related quality of life questionnaire for polycystic ovary syndrome (PCOSQ-50): a psychometric study with the Serbian version,pmid:30870132,10.1080/03630242.2019.1587664
2.0,2.1.1 / 2.1.2,350,36.0,"Tan, J.; Wang, Q. Y.; Feng, G. M.; Li, X. Y.; Huang, W. Increased Risk of Psychiatric Disorders in Women with Polycystic Ovary Syndrome in Southwest China. Chinese Medical Journal 02 05 2017;130(3):262-266.",primary_citation,,Tan,2017,"Tan et al., 2017",10.4103/0366-6999.198916,,,,,Increased Risk of Psychiatric Disorders in Women with Polycystic Ovary Syndrome in Southwest China,pmid:28139507,10.4103/0366-6999.198916
2.0,2.1.1 / 2.1.2,351,36.0,"Wang, Z.; Groen, H.; Cantineau, A. E. P.; van Elten, T. M.; Karsten, M. D. A.; van Oers, A. M.; Mol, B. W. J.; Roseboom, T. J.; Hoek, A. Dietary Intake, Eating Behavior, Physical Activity, and Quality of Life in Infertile Women with PCOS and Obesity Compared with Non-PCOS Obese Controls. Nutrients Oct 08 2021;13(10):08",primary_citation,,Wang,2021,"Wang et al., 2021",10.3390/nu13103526,,,,,"Dietary Intake, Eating Behavior, Physical Activity, and Quality of Life in Infertile Women with PCOS and Obesity Compared with Non-PCOS Obese Controls",pmid:34684528,10.3390/nu13103526
2.0,2.1.1 / 2.1.2,352,36.0,"Behboodi Moghadam, Z.; Fereidooni, B.; Saffari, M.; Montazeri, A. Measures of health-related quality of life in pcos women: A systematic review. International Journal of Women's Health 2018;10():397-408",primary_citation,SR,Behboodi Moghadam,2018,"Behboodi Moghadam et al., 2018",10.2147/ijwh.s165794,,,,,Measures of health-related quality of life in PCOS women: a systematic review,pmid:30123008,10.2147/ijwh.s165794
2.0,2.1.1 / 2.1.2,353,36.0,"Castelo-Branco, C.; Naumova, I. Quality of life and sexual function in women with polycystic ovary syndrome: a comprehensive review. Gynecological Endocrinology Feb 2020;36(2):96-103",primary_citation,SR,Castelo-Branco,2020,"Castelo-Branco et al., 2020",10.1080/09513590.2019.1670788,,,,,Quality of life and sexual function in women with polycystic ovary syndrome: a comprehensive review,pmid:31559883,10.1080/09513590.2019.1670788
2.0,2.1.1 / 2.1.2,354,36.0,"Dokras, A.; Stener-Victorin, E.; Yildiz, B. O.; Li, R.; Ottey, S.; Shah, D.; Epperson, N.; Teede, H. Androgen Excess- Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. Fertility & Sterility 05 2018;109(5):888-899 2018 05",primary_citation,SR,Dokras,2018,"Dokras et al., 2018",10.1016/j.fertnstert.2018.01.038,,,,,"Androgen Excess- Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome",pmid:29778388,10.1016/j.fertnstert.2018.01.038
2.0,2.1.1 / 2.1.2,355,36.0,"Wilson, N. A.; Pena, A. S. Quality of life in adolescent girls with polycystic ovary syndrome Journal of Paediatrics & Child Health Sep 2020;56(9):1351-1357. 2020 Sep",primary_citation,SR,Wilson,2020,"Wilson et al., 2020",10.1111/jpc.15097,,,,,Quality of life in adolescent girls with polycystic ovary syndrome,pmid:32810373,10.1111/jpc.15097
2.0,2.1.1 / 2.1.2,356,36.0,"Yin, X.; Ji, Y.; Chan, C. L. W.; Chan, C. H. Y. The mental health of women with polycystic ovary syndrome: a systematic review and meta-analysis Archives of Women's Mental Health 02 2021;24(1):11-27 2021 02",primary_citation,SR,Yin,2021,"Yin et al., 2021",10.1007/s00737-020-01043-x,,,,,The mental health of women with polycystic ovary syndrome: a systematic review and meta-analysis,pmid:32514730,10.1007/s00737-020-01043-x
2.0,2.1.1 / 2.1.2,357,36.0,"Acmaz G, Albayrak E, Acmaz B, Bager M, Soyak M, ZararsJz G, and Ipekmüderris I (2013). ""Level of anxiety, depression, self-esteem, social anxiety, and quality of life among the women with polycystic ovary syndrome."" The Scientific World Journal 2013: 851815.",primary_citation,prior search,Acmaz G,2013,"Acmaz G et al., 2013",10.1155/2013/851815,,,,,"Level of Anxiety, Depression, Self-Esteem, Social Anxiety, and Quality of Life among the Women with Polycystic Ovary Syndrome",pmid:23935436,10.1155/2013/851815
2.0,2.1.1 / 2.1.2,358,36.0,"Benetti-Pinto, C. L., Ferreira S. R. Antunes Jr. A. Yela D. A. (2015). ""The influence of body weight on sexual function and quality of life in women with polycystic ovary syndrome."" Archives of Gynecology & Obstetrics 291(2): 451-455.",primary_citation,prior search,Benetti-Pinto,2015,"Benetti-Pinto et al., 2015",10.1007/s00404-014-3423-1,,,,,The influence of body weight on sexual function and quality of life in women with polycystic ovary syndrome,pmid:25138126,10.1007/s00404-014-3423-1
2.0,2.1.1 / 2.1.2,359,36.0,"Benson, S., Janssen O.E., Hahn S. Tan S. Dietz T. Mann K. Pleger K. Schedlowski M. Arck PC. Elsenbruch S (2008). ""Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome."" Brain, Behavior, & Immunity 22(2): 177-184.",primary_citation,prior search,Benson,2008,"Benson et al., 2008",10.1016/j.bbi.2007.07.003,,,,,"Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome",pmid:17716857,10.1016/j.bbi.2007.07.003
2.0,2.1.1 / 2.1.2,360,36.0,"Drosdzol, A., Skrzypulec V, Mazur B, Pawliñska-Chmara R (2007). ""Quality of life and marital sexual satisfaction in women with polycystic ovary syndrome."" Folia Histochemica et Cytobiologica 45 Suppl 1: S93-97.",primary_citation,prior search,Drosdzol,2007,"Drosdzol et al., 2007",,18292843.0,W2115750705,38876279.0,,Quality of life and marital sexual satisfaction in women with polycystic ovary syndrome.,pmid:18292843,
2.0,2.1.1 / 2.1.2,361,36.0,"Elsenbruch, S., Hahn, S., Kowalsky, D., Offner, A. H., Schedlowski, M., Mann, K. and Janssen, O. E. 2003 Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 88 [12]: 5801-7.",primary_citation,prior search,Elsenbruch,2003,"Elsenbruch et al., 2003",10.1210/jc.2003-030562,,,,,"Quality of Life, Psychosocial Well-Being, and Sexual Satisfaction in Women with Polycystic Ovary Syndrome",pmid:14671172,10.1210/jc.2003-030562
2.0,2.1.1 / 2.1.2,362,36.0,"Hahn, S., Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M, Kimmig R, Benson S, Balamitsa E and Elsenbruch S(2005). ""Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome."" European Journal of Endocrinology 153(6): 853-860.",primary_citation,prior search,Hahn,2005,"Hahn et al., 2005",10.1530/eje.1.02024,,,,,Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome,pmid:16322391,10.1530/eje.1.02024
2.0,2.1.1 / 2.1.2,363,36.0,"Kumarapeli, V., Seneviratne R de A, Wijeyaratnec CN. (2011). ""Health-related quality of life and psychological distress in polycystic ovary syndrome: a hidden facet in South Asian women."" BJOG: An International Journal of Obstetrics & Gynaecology 118(3): 319-328.",primary_citation,prior search,Kumarapeli,2011,"Kumarapeli et al., 2011",10.1111/j.1471-0528.2010.02799.x,,,,,Health-related quality of life and psychological distress in polycystic ovary syndrome: a hidden facet in South Asian women,pmid:21134104,10.1111/j.1471-0528.2010.02799.x
2.0,2.1.1 / 2.1.2,364,36.0,"Ozcan Dag, Z., Alpua M, Isik Y, S. Buturak V, Ozlem B., Tulmac & Yakup Turkel (2016). ""The evaluation of temperament and quality of life in patients with polycystic ovary syndrome."" Gynecological Endocrinology: 1-4.",primary_citation,prior search,Ozcan Dag,2016,"Ozcan Dag et al., 2016",10.1080/09513590.2016.1254610,,,,,The evaluation of temperament and quality of life in patients with polycystic ovary syndrome,pmid:27908217,10.1080/09513590.2016.1254610
2.0,2.1.1 / 2.1.2,365,36.0,"Ozcan Dag, Z., Oguzturk O, Isik Y, Turkel Y & Bulcun E (2015). ""Personality profile in patients with polycystic ovary syndrome."" Gynecological Endocrinology 31(7): 540-542.",primary_citation,prior search,Ozcan Dag,2015,"Ozcan Dag et al., 2015",10.3109/09513590.2015.1018162,,,,,Personality profile in patients with polycystic ovary syndrome,pmid:25884894,10.3109/09513590.2015.1018162
2.0,2.1.1 / 2.1.2,366,36.0,"Ramos, F. K., Lara LS, Kogure GS, Silva RC, Ferriani RA, de Sá MFS, dos Reis RM (2016). ""Quality of Life in Women with Polycystic Ovary Syndrome after a Program of Resistance Exercise Training."" Revista Brasileira de Ginecologia e Obstetricia 38(7): 340-347.",primary_citation,prior search,Ramos,2016,"Ramos et al., 2016",10.1055/s-0036-1585457,,,,,Quality of Life in Women with Polycystic Ovary Syndrome after a Program of Resistance Exercise Training,pmid:27472811,10.1055/s-0036-1585457
2.0,2.1.1 / 2.1.2,367,36.0,"Shafti, V. and S. Shahbazi (2016). ""Comparing Sexual Function and Quality of Life in Polycystic Ovary Syndrome and Healthy Women."" Journal of Family & Reproductive Health 10(2): 92-98.",primary_citation,prior search,Shafti,2016,"Shafti et al., 2016",,27648099.0,W2517888967,8524156.0,,Comparing Sexual Function and Quality of Life in Polycystic Ovary Syndrome and Healthy Women.,pmid:27648099,
2.0,2.1.1 / 2.1.2,368,36.0,"Shishehgar F, Tehrani FR, Mirmiran P, Hajian S, Baghestani AR (2016). ""Comparison of the Association of Excess Weight on Health Related Quality of Life of Women with Polycystic Ovary Syndrome: An Age- and BMI- Matched Case Control Study."" PLoS ONE [Electronic Resource] 11(10): e0162911.",primary_citation,prior search,Shishehgar F,2016,"Shishehgar F et al., 2016",10.1371/journal.pone.0162911,,,,,Comparison of the Association of Excess Weight on Health Related Quality of Life of Women with Polycystic Ovary Syndrome: An Age- and BMI-Matched Case Control Study,pmid:27736861,10.1371/journal.pone.0162911
2.0,2.1.1 / 2.1.2,369,36.0,"Trent, M. E Rich M, Austin B, Gordon C (2002). ""Quality of life in adolescent girls with polycystic ovary syndrome."" Archives of Pediatrics & Adolescent Medicine 156(6): 556-560.",primary_citation,prior search,Trent,2002,"Trent et al., 2002",10.1001/archpedi.156.6.556,,,,,Quality of Life in Adolescent Girls With Polycystic Ovary Syndrome,pmid:12038887,10.1001/archpedi.156.6.556
2.0,2.2,370,80.0,"Açmaz G, Albayrak E, Acmaz B, Başer M, Soyak M, Zararsız G, IpekMüderris I. Level of anxiety, depression, self-esteem, social anxiety, and quality of life among the women with polycystic ovary syndrome. ScientificWorldJournal. 2013 Jul 9;2013:851815. doi: 10.1155/2013/851815. PMID: 23935436; PMCID: PMC3725786.",primary_citation,,Açmaz G,2013,"Açmaz G et al., 2013",10.1155/2013/851815,23935436.0,,,,"Level of Anxiety, Depression, Self-Esteem, Social Anxiety, and Quality of Life among the Women with Polycystic Ovary Syndrome",pmid:23935436,
2.0,2.2,371,80.0,"Adali E, Yildizhan R, Kurdoglu M, Kolusari A, Edirne T, Sahin HG, Yildizhan B, Kamaci M. The relationship between clinico-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome. J Int Med Res. 2008 Nov-Dec;36(6):1188-96. doi: 10.1177/147323000803600604. PMID: 19094426.",primary_citation,,Adali E,2008,"Adali E et al., 2008",10.1177/147323000803600604,19094426.0,,,,The Relationship between Clinico-Biochemical Characteristics and Psychiatric Distress in Young Women with Polycystic Ovary Syndrome,pmid:19094426,
2.0,2.2,372,80.0,"Ahmadi M, Faramarzi M, Basirat Z, Kheirkhah F, Chehrazi M, Ashabi F. Mental and personality disorders in infertile women with polycystic ovary: a case-control study. Afr Health Sci. 2020 Sep;20(3):1241-1249. doi: 10.4314/ahs.v20i3.28. PMID: 33402971; PMCID: PMC7751531.",primary_citation,,Ahmadi M,2020,"Ahmadi M et al., 2020",10.4314/ahs.v20i3.28,33402971.0,,,,Mental and personality disorders in infertile women with polycystic ovary: a case-control study,pmid:33402971,
2.0,2.2,373,80.0,"Akdağ Cirik D, Dilbaz B, Aksakal S, Kotan Z, Özelçi R, Akpınar F, Mollamahmutoğlu L. Do anxiety and depression statuses differ in differentpolycystic ovary syndrome phenotypes? Turk J Med Sci. 2016 Dec 20;46(6):1846-1853. doi: 10.3906/sag-1511-112. PMID: 28081337.",primary_citation,,Akdağ Cirik D,2016,"Akdağ Cirik D et al., 2016",10.3906/sag-1511-112,28081337.0,,,,Do anxiety and depression statuses differ in differentpolycystic ovary syndrome phenotypes?,pmid:28081337,
2.0,2.2,374,80.0,"Erson Aksu, Elmas Beyazyüz, Yakup Albayrak, Nihan Potas, Ferit Durankuş, Gamze Uvaçin & Murat Beyazyüz (2019) Altered cooperativeness in patients with polycystic ovary syndrome, Psychiatry and Clinical Psychopharmacology, 29:4, 880-886, DOI: 10.1080/24750573.2019.1691357",primary_citation,,Erson Aksu,2019,"Erson Aksu et al., 2019",10.1080/24750573.2019.1691357,,,,,Altered cooperativeness in patients with polycystic ovary syndrome,,10.1080/24750573.2019.1691357
2.0,2.2,375,80.0,"Almis H, Orhon FŞ, Bolu S, Almis BH. Self-Concept, Depression, and Anxiety Levels of Adolescents with Polycystic Ovary Syndrome. J Pediatr Adolesc Gynecol. 2021 Jun;34(3):311-316. doi: 10.1016/j.jpag.2020.12.011. Epub 2020 Dec 23. PMID: 33347988.",primary_citation,,Almis H,2021,"Almis H et al., 2021",10.1016/j.jpag.2020.12.011,33347988.0,,,,"Self-Concept, Depression, and Anxiety Levels of Adolescents with Polycystic Ovary Syndrome",pmid:33347988,
2.0,2.2,376,80.0,"Altinkaya, O., Nergiz, S., Kucuk, M., & Yuksel, H. (2014). Depression and anxiety in relation with hormonal and metabolic profile in women with polycystic ovarian syndrome. Turkiye Klinikleri J Gynecol Obst, 24(3), 159-65.",primary_citation,,Altinkaya,2014,"Altinkaya et al., 2014",,,W1524022481,59115787.0,Beta-cell dysfunction and hyperandrogenemia in PCOS early pubertal female relatives,Depression and Anxiety in Relation with Hormonal and Metabolic Profile in Women with Polycystic Ovarian Syndrome,,
2.0,2.2,377,80.0,"Alur-Gupta S, Chemerinski A, Liu C, Lipson J, Allison K, Sammel MD, Dokras A. Body-image distress is increased in women with polycystic ovary syndrome and mediates depression and anxiety. Fertil Steril. 2019 Nov;112(5):930-938.e1. doi: 10.1016/j.fertnstert.2019.06.018. Epub 2019 Aug 5. PMID: 31395311; PMCID: PMC6858949.",primary_citation,,Alur-Gupta S,2019,"Alur-Gupta S et al., 2019",10.1016/j.fertnstert.2019.06.018,31395311.0,,,,Body-image distress is increased in women with polycystic ovary syndrome and mediates depression and anxiety,pmid:31395311,
2.0,2.2,378,80.0,"Annagür BB, Tazegül A, Akbaba N. Body Image, Self-Esteem and Depressive Symptomatology in Women with Polycystic Ovary Syndrome. Noro Psikiyatr Ars. 2014 Jun;51(2):129-132. doi: 10.4274/npa.y6778. Epub 2014 Jun 1. PMID: 28360612; PMCID: PMC5353087.",primary_citation,,Annagür BB,2014,"Annagür BB et al., 2014",10.4274/npa.y6778,28360612.0,,,,"Polikistik Over Sendromu Olan Kadınlarda Beden Algısı, Benlik Saygısı ve Depresif Belirtiler",pmid:28360612,
2.0,2.2,379,80.0,"Asdaq SMB, Yasmin F. Risk of psychological burden in polycystic ovary syndrome: A case control study in Riyadh, Saudi Arabia. J Affect Disord. 2020 Sep 1;274:205-209. doi: 10.1016/j.jad.2020.05.086. Epub 2020 May 22. PMID: 32469805.",primary_citation,,Asdaq SMB,2020,"Asdaq SMB et al., 2020",10.1016/j.jad.2020.05.086,32469805.0,,,,"Risk of psychological burden in polycystic ovary syndrome: A case control study in Riyadh, Saudi Arabia",pmid:32469805,
2.0,2.2,380,80.0,"Asik M, Altinbas K, Eroglu M, Karaahmet E, Erbag G, Ertekin H, Sen H. Evaluation of affective temperament and anxiety-depression levels of patients with polycystic ovary syndrome. J Affect Disord. 2015 Oct 1;185:214-8. doi: 10.1016/j.jad.2015.06.043. Epub 2015 Jul 26. PMID: 26241866.",primary_citation,,Asik M,2015,"Asik M et al., 2015",10.1016/j.jad.2015.06.043,26241866.0,,,,Evaluation of affective temperament and anxiety–depression levels of patients with polycystic ovary syndrome,pmid:26241866,
2.0,2.2,381,80.0,"Balikci A, Erdem M, Keskin U, Bozkurt Zincir S, Gülsün M, Özçelik F, Akgül EÖ, Akarsu S, Öztosun M, Ergün A. Depression, Anxiety, and Anger in Patients with Polycystic Ovary Syndrome. Noro Psikiyatr Ars. 2014 Dec;51(4):328-333. doi: 10.5152/npa.2014.6898. Epub 2014 Dec 1. PMID: 28360650; PMCID: PMC5353166.",primary_citation,,Balikci A,2014,"Balikci A et al., 2014",10.5152/npa.2014.6898,28360650.0,,,,"Depression, Anxiety, and Anger in Patients with Polycystic Ovary Syndrome",pmid:28360650,
2.0,2.2,382,80.0,"Barry, John A., Hardiman, Paul J., Saxby, Brian K., & Kuczmierczyk, Andrew. (2011). Testosterone and mood dysfunction in women with polycystic ovarian syndrome compared to subfertile controls. Journal of Psychosomatic Obstetrics and Gynaecology, 32(2), 104–111. https://doi.org/10.3109/0167482X.2011.568129. ",primary_citation,,Barry,2011,"Barry et al., 2011",10.3109/0167482x.2011.568129,,,,,Testosterone and mood dysfunction in women with polycystic ovarian syndrome compared to subfertile controls,pmid:21473679,10.3109/0167482x.2011.568129
2.0,2.2,383,80.0,"Basirat Z, Faramarzi M, Chehrazi M, Amiri M, Ghofrani F, Tajalli Z. Differences between infertile women with and without PCOS in terms of anxiety, coping styles, personality traits, and social adjustment: a case-control study. Arch Gynecol Obstet. 2020 Feb;301(2):619-626. doi: 10.1007/s00404-019-05391-7. Epub 2019 Nov 27. PMID: 31776708.",primary_citation,,Basirat Z,2020,"Basirat Z et al., 2020",10.1007/s00404-019-05391-7,31776708.0,,,,"Differences between infertile women with and without PCOS in terms of anxiety, coping styles, personality traits, and social adjustment: a case–control study",pmid:31776708,
2.0,2.2,384,80.0,"Basirat Z, Faramarzi M, Esmaelzadeh S, Abedi Firoozjai SH, Mahouti T, Geraili Z. Stress, Depression, Sexual Function, and Alexithymia in Infertile Females with and without Polycystic Ovary Syndrome: A Case-Control Study. Int J Fertil Steril. 2019 Oct;13(3):203-208. doi: 10.22074/ijfs.2019.5703. Epub 2019 Jul 14. PMID: 31310074; PMCID: PMC6642420.",primary_citation,,Basirat Z,2019,"Basirat Z et al., 2019",10.22074/ijfs.2019.5703,31310074.0,,,,"Stress, Depression, Sexual Function, and Alexithymia in Infertile Females with and without Polycystic Ovary Syndrome: A Case-Control Study.",pmid:31310074,
2.0,2.2,385,80.0,"Battaglia C, Nappi RE, Mancini F, Cianciosi A, Persico N, Busacchi P, Facchinetti F, Sisti G. PCOS, sexuality, and clitoral vascularisation: a pilot study. J Sex Med. 2008 Dec;5(12):2886-94. doi: 10.1111/j.1743-6109.2008.01010.x. PMID: 19090942.",primary_citation,,Battaglia C,2008,"Battaglia C et al., 2008",10.1111/j.1743-6109.2008.01010.x,19090942.0,,,,"PCOS, Sexuality, and Clitoral Vascularisation: A Pilot Study",pmid:19090942,
2.0,2.2,386,80.0,"Benson S, Arck PC, Tan S, Hahn S, Mann K, Rifaie N, Janssen OE, Schedlowski M, Elsenbruch S. Disturbed stress responses in women with polycystic ovary syndrome. Psychoneuroendocrinology. 2009 Jun;34(5):727-35. doi: 10.1016/j.psyneuen.2008.12.001. Epub 2009 Jan 15. PMID: 19150179.",primary_citation,,Benson S,2009,"Benson S et al., 2009",10.1016/j.psyneuen.2008.12.001,19150179.0,,,,Disturbed stress responses in women with polycystic ovary syndrome,pmid:19150179,
2.0,2.2,387,80.0,"Benson J, Severn C, Hudnut-Beumler J, Simon SL, Abramson N, Shomaker LB, Gulley LD, Taylor A, Kelsey MM, Nadeau KJ, Zeitler PS, Pyle L, Cree-Green M. Depression in Girls With Obesity and Polycystic Ovary Syndrome and/or Type 2 Diabetes. Can J Diabetes. 2020 Aug;44(6):507-513. doi: 10.1016/j.jcjd.2020.05.015. Epub 2020 Jun 6. PMID: 32792104; PMCID: PMC7428465.",primary_citation,,Benson J,2020,"Benson J et al., 2020",10.1016/j.jcjd.2020.05.015,32792104.0,,,,Depression in Girls With Obesity and Polycystic Ovary Syndrome and/or Type 2 Diabetes,pmid:32792104,
2.0,2.2,388,80.0,"Benson S, Janssen OE, Hahn S, Tan S, Dietz T, Mann K, Pleger K, Schedlowski M, Arck PC, Elsenbruch S. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain Behav Immun. 2008 Feb;22(2):177-84. doi: 10.1016/j.bbi.2007.07.003. Epub 2007 Aug 22. PMID: 17716857.",primary_citation,,Benson S,2008,"Benson S et al., 2008",10.1016/j.bbi.2007.07.003,17716857.0,,,,"Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome",pmid:17716857,
2.0,2.2,389,80.0,"Besenek M, Gurlek B. Hyperandrogenism in polycystic ovary syndrome affects psychological well-being of adolescents. J Obstet Gynaecol Res. 2021 Jan;47(1):137-146. doi: 10.1111/jog.14444. Epub 2020 Aug 23. PMID: 32830412.",primary_citation,,Besenek M,2021,"Besenek M et al., 2021",10.1111/jog.14444,32830412.0,,,,Hyperandrogenism in polycystic ovary syndrome affects psychological well‐being of adolescents,pmid:32830412,
2.0,2.2,390,80.0,"Bhattacharya SM, Jha A. Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS). Fertil Steril. 2010 Jun;94(1):357-9. doi: 10.1016/j.fertnstert.2009.09.025. Epub 2009 Nov 6. PMID: 19896652.",primary_citation,,Bhattacharya SM,2010,"Bhattacharya SM et al., 2010",10.1016/j.fertnstert.2009.09.025,19896652.0,,,,Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS),pmid:19896652,
2.0,2.2,391,80.0,"Borghi L, Leone D, Vegni E, Galiano V, Lepadatu C, Sulpizio P, Garzia E. Psychological distress, anger and quality of life in polycystic ovary syndrome: associations with biochemical, phenotypical andsocio-demographic factors. J Psychosom Obstet Gynaecol. 2018 Jun;39(2):128-137. doi: 10.1080/0167482X.2017.1311319. Epub 2017 Apr 6. PMID: 28385114.",primary_citation,,Borghi L,2018,"Borghi L et al., 2018",10.1080/0167482x.2017.1311319,28385114.0,,,,"Psychological distress, anger and quality of life in polycystic ovary syndrome: associations with biochemical, phenotypical andsocio-demographic factors",pmid:28385114,
2.0,2.2,392,80.0,"Caltekin, M., Hamamci, M., Onat, T., Kirmizi, D., Baser, E., & Yalvac, E. (2021). Evaluation of Sleep Quality, Restless Legs Syndrome, Anxiety and Depression in Polycystic Ovary Syndrome. Journal Of Turkish Sleep Medicine, 3, 243-249.",primary_citation,,Caltekin,2021,"Caltekin et al., 2021",10.4274/jtsm.galenos.2021.85057,,,,,"Evaluation of Sleep Quality, Restless Legs Syndrome, Anxiety and Depression in Polycystic Ovary Syndrome",,10.4274/jtsm.galenos.2021.85057
2.0,2.2,393,80.0,"Cinar N, Kizilarslanoglu MC, Harmanci A, Aksoy DY, Bozdag G, Demir B, Yildiz BO. Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome. Hum Reprod. 2011 Dec;26(12):3339-45. doi: 10.1093/humrep/der338. Epub 2011 Oct 7. PMID: 21984577.",primary_citation,,Cinar N,2011,"Cinar N et al., 2011",10.1093/humrep/der338,21984577.0,,,,"Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome",pmid:21984577,
2.0,2.2,394,80.0,"Ozcan Dag Z, Alpua M, Isik Y, Buturak SV, Tulmac OB, Turkel Y. The evaluation of temperament and quality of life in patients with polycystic ovary syndrome. Gynecol Endocrinol. 2017 Mar;33(3):250-253. doi: 10.1080/09513590.2016.1254610. Epub 2016 Dec 2. PMID: 27908217.",primary_citation,,Ozcan Dag Z,2017,"Ozcan Dag Z et al., 2017",10.1080/09513590.2016.1254610,27908217.0,,,,The evaluation of temperament and quality of life in patients with polycystic ovary syndrome,pmid:27908217,
2.0,2.2,395,80.0,"Davari-Tanha F, Hosseini Rashidi B, Ghajarzadeh M, Noorbala AA. Bipolar disorder in women with polycystic ovarian syndrome (PCO). Acta Med Iran. 2014;52(1):46-8. PMID: 24658986.",primary_citation,,Davari-Tanha F,2014,"Davari-Tanha F et al., 2014",,24658986.0,,,,Bipolar disorder in women with polycystic ovarian syndrome (PCO).,pmid:24658986,
2.0,2.2,396,80.0,"Deeks AA, Gibson-Helm ME, Paul E, Teede HJ. Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression? Hum Reprod. 2011 Jun;26(6):1399-407. doi: 10.1093/humrep/der071. Epub 2011 Mar 23. PMID: 21436137.",primary_citation,,Deeks AA,2011,"Deeks AA et al., 2011",10.1093/humrep/der071,21436137.0,,,,Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression?,pmid:21436137,
2.0,2.2,397,80.0,"Donbaloğlu Z, Tuhan H, Çoban ÖG, Kızılay DÖ, İsmailoğlu E, Önder A, Acar S, Bedel A, Çetiner EB, Singin B, Erdem H, Parlak M. Hyperandrogenism correlates with psychological symptoms in adolescents with polycystic ovary syndrome. Clin Pediatr Endocrinol. 2022;31(2):68-76. doi: 10.1297/cpe.2022-0010. Epub 2022 Mar 19. PMID: 35431449; PMCID: PMC8981047.",primary_citation,,Donbaloğlu Z,2022,"Donbaloğlu Z et al., 2022",10.1297/cpe.2022-0010,35431449.0,,,,Hyperandrogenism correlates with psychological symptoms in adolescents with polycystic ovary syndrome,pmid:35431449,
2.0,2.2,398,80.0,"Dybciak P, Humeniuk E, Raczkiewicz D, Krakowiak J, Wdowiak A, Bojar I. Anxiety and Depression in Women with Polycystic Ovary Syndrome. Medicina (Kaunas). 2022 Jul 16;58(7):942. doi: 10.3390/medicina58070942. PMID: 35888661; PMCID: PMC9319705.",primary_citation,,Dybciak P,2022,"Dybciak P et al., 2022",10.3390/medicina58070942,35888661.0,,,,Anxiety and Depression in Women with Polycystic Ovary Syndrome,pmid:35888661,
2.0,2.2,399,80.0,"Elsenbruch S, Hahn S, Kowalsky D, Offner AH, Schedlowski M, Mann K, Janssen OE. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 Dec;88(12):5801-7. doi: 10.1210/jc.2003-030562. PMID: 14671172.",primary_citation,,Elsenbruch S,2003,"Elsenbruch S et al., 2003",10.1210/jc.2003-030562,14671172.0,,,,"Quality of Life, Psychosocial Well-Being, and Sexual Satisfaction in Women with Polycystic Ovary Syndrome",pmid:14671172,
2.0,2.2,400,80.0,"Emeksiz HC, Bideci A, Nalbantoğlu B, Nalbantoğlu A, Çelik C, Yulaf Y, Çamurdan MO, Cinaz P. Anxiety and depression states of adolescents with polycystic ovary syndrome. Turk J Med Sci. 2018 Jun 14;48(3):531-536. doi: 10.3906/sag-1708-131. PMID: 29914248.",primary_citation,,Emeksiz HC,2018,"Emeksiz HC et al., 2018",10.3906/sag-1708-131,29914248.0,,,,Anxiety and depression states of adolescents with polycystic ovary syndrome,pmid:29914248,
2.0,2.2,401,80.0,"Enjezab B, Eftekhar M, Ghadiri-Anari A. Association between severity of depression and clinico-biochemical markers of polycystic ovary syndrome. Electron Physician. 2017 Nov 25;9(11):5820-5825. doi: 10.19082/5820. PMID: 29403625; PMCID: PMC5783134.",primary_citation,,Enjezab B,2017,"Enjezab B et al., 2017",10.19082/5820,29403625.0,,,,Association between severity of depression and clinico-biochemical markers of polycystic ovary syndrome,pmid:29403625,
2.0,2.2,402,80.0,"Ercan CM, Coksuer H, Aydogan U, Alanbay I, Keskin U, Karasahin KE, Baser I. Sexual dysfunction assessment and hormonal correlations in patients with polycystic ovary syndrome. Int J Impot Res. 2013 Jul-Aug;25(4):127-32. doi: 10.1038/ijir.2013.2. Epub 2013 Feb 14. PMID: 23407282.",primary_citation,,Ercan CM,2013,"Ercan CM et al., 2013",10.1038/ijir.2013.2,23407282.0,,,,Sexual dysfunction assessment and hormonal correlations in patients with polycystic ovary syndrome,pmid:23407282,
2.0,2.2,403,80.0,"Ghazeeri G, Ibrahim N, Khalifeh F, Beyrouthy C, El-Taha L, Bizri M. Character strengths of women with polycystic ovary syndrome in a single center. PLoS One. 2022 Apr 1;17(4):e0266398. doi: 10.1371/journal.pone.0266398. PMID: 35363827; PMCID: PMC8975165.",primary_citation,,Ghazeeri G,2022,"Ghazeeri G et al., 2022",10.1371/journal.pone.0266398,35363827.0,,,,Character strengths of women with polycystic ovary syndrome in a single center,pmid:35363827,
2.0,2.2,404,80.0,"Ghazeeri G, Fakih A, Abbas HA, Harajly S, Awwad J. Anxiety, cognitive, and depressive assessment in adolescents with polycystic ovarian syndrome: a pilot study. J Pediatr Adolesc Gynecol. 2013 Oct;26(5):269-73. doi: 10.1016/j.jpag.2013.04.005. Epub 2013 Jul 10. PMID: 23849090.",primary_citation,,Ghazeeri G,2013,"Ghazeeri G et al., 2013",10.1016/j.jpag.2013.04.005,23849090.0,,,,"Anxiety, Cognitive, and Depressive Assessment in Adolescents with Polycystic Ovarian Syndrome: A Pilot Study",pmid:23849090,
2.0,2.2,405,80.0,"Glowinska A, Duleba AJ, Zielona-Jenek M, Siakowska M, Pawelczyk L, Banaszewska B. Disparate Relationship of Sexual Satisfaction, Self-Esteem, Anxiety, and Depression with Endocrine Profiles of Women With or Without PCOS. Reprod Sci. 2020 Jan;27(1):432-442. doi: 10.1007/s43032-019-00061-0. Epub 2020 Jan 1. PMID: 32046411.",primary_citation,,Glowinska A,2020,"Glowinska A et al., 2020",10.1007/s43032-019-00061-0,32046411.0,,,,"Disparate Relationship of Sexual Satisfaction, Self-Esteem, Anxiety, and Depression with Endocrine Profiles of Women With or Without PCOS",pmid:32046411,
2.0,2.2,406,80.0,"Greenwood EA, Yaffe K, Wellons MF, Cedars MI, Huddleston HG. Depression Over the Lifespan in a Population-Based Cohort of Women With Polycystic Ovary Syndrome: Longitudinal Analysis. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2809-2819. doi: 10.1210/jc.2019-00234. PMID: 30985868; PMCID: PMC6534493.",primary_citation,,Greenwood EA,2019,"Greenwood EA et al., 2019",10.1210/jc.2019-00234,30985868.0,,,,Depression Over the Lifespan in a Population-Based Cohort of Women With Polycystic Ovary Syndrome: Longitudinal Analysis,pmid:30985868,
2.0,2.2,407,80.0,"Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M, Kimmig R, Benson S, Balamitsa E, Elsenbruch S. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol. 2005 Dec;153(6):853-60. doi: 10.1530/eje.1.02024. PMID: 16322391.",primary_citation,,Hahn S,2005,"Hahn S et al., 2005",10.1530/eje.1.02024,16322391.0,,,,Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome,pmid:16322391,
2.0,2.2,408,80.0,"HARMANCI, H., HERGÜNER, S., & TOY, H. (2013). Polikistik Over Sendromu olan Kadınlarda Psikiyatrik Belirtiler / Psychiatric Symptoms in Women with Polycystic Ovary Syndrome. Dusunen Adam: The Journal Of Psychiatry And Neurological Sciences, 26, 157-163. doi: 10.5350/dajpn2013260205",primary_citation,,HARMANCI,2013,"HARMANCI et al., 2013",10.5350/dajpn2013260205,,,,,Polikistik Over Sendromu olan Kadınlarda Psikiyatrik Belirtiler / Psychiatric Symptoms in Women with Polycystic Ovary Syndrome,,10.5350/dajpn2013260205
2.0,2.2,409,80.0,"Harnod, T., Tsai, I., Wang, J., Lin, S., & Ding, D. (2020). Women with polycystic ovary syndrome associated with increased anxiety risk: A population-based cohort study in Taiwan. Journal Of Affective Disorders, 273, 532-537. doi: 10.1016/j.jad.2020.04.032",primary_citation,,Harnod,2020,"Harnod et al., 2020",10.1016/j.jad.2020.04.032,,,,,Women with polycystic ovary syndrome associated with increased anxiety risk: A population-based cohort study in Taiwan,pmid:32560950,10.1016/j.jad.2020.04.032
2.0,2.2,410,80.0,"Himelein MJ, Thatcher SS. Depression and body image among women with polycystic ovary syndrome. J Health Psychol. 2006 Jul;11(4):613-25. doi: 10.1177/1359105306065021. PMID: 16769740.",primary_citation,,Himelein MJ,2006,"Himelein MJ et al., 2006",10.1177/1359105306065021,16769740.0,,,,Depression and Body Image among Women with Polycystic Ovary Syndrome,pmid:16769740,
2.0,2.2,411,80.0,"Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril. 2007 Jun;87(6):1369-76. doi: 10.1016/j.fertnstert.2006.11.039. Epub 2007 Mar 29. PMID: 17397839.",primary_citation,,Hollinrake E,2007,"Hollinrake E et al., 2007",10.1016/j.fertnstert.2006.11.039,17397839.0,,,,Increased risk of depressive disorders in women with polycystic ovary syndrome,pmid:17397839,
2.0,2.2,412,80.0,"Hussain A, Chandel RK, Ganie MA, Dar MA, Rather YH, Wani ZA, Shiekh JA, Shah MS. Prevalence of psychiatric disorders in patients with a diagnosis of polycystic ovary syndrome in kashmir. Indian J Psychol Med. 2015 Jan-Mar;37(1):66-70. doi: 10.4103/0253-7176.150822. PMID: 25722515; PMCID: PMC4341314.",primary_citation,,Hussain A,2015,"Hussain A et al., 2015",10.4103/0253-7176.150822,25722515.0,,,,Prevalence of Psychiatric Disorders in Patients with a Diagnosis of Polycystic Ovary Syndrome in Kashmir,pmid:25722515,
2.0,2.2,413,80.0,"Jedel E, Waern M, Gustafson D, Landén M, Eriksson E, Holm G, Nilsson L, Lind AK, Janson PO, Stener-Victorin E. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod. 2010 Feb;25(2):450-6. doi: 10.1093/humrep/dep384. Epub 2009 Nov 19. PMID: 19933236.",primary_citation,,Jedel E,2010,"Jedel E et al., 2010",10.1093/humrep/dep384,19933236.0,,,,Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index,pmid:19933236,
2.0,2.2,414,80.0,"Komarowska H, Stangierski A, Warmuz-Stangierska I, Lodyga M, Ochmanska K, Wasko R, Wanic-Kossowska M, Ruchala M. Differences in the psychological and hormonal presentation of lean and obese patients with polycystic ovary syndrome. Neuro Endocrinol Lett. 2013;34(7):669-74. PMID: 24464003.",primary_citation,,Komarowska H,2013,"Komarowska H et al., 2013",,24464003.0,,,,Differences in the psychological and hormonal presentation of lean and obese patients with polycystic ovary syndrome.,pmid:24464003,
2.0,2.2,415,80.0,"Karjula S, Morin-Papunen L, Auvinen J, Ruokonen A, Puukka K, Franks S, Järvelin MR, Tapanainen JS, Jokelainen J, Miettunen J, Piltonen TT. Psychological Distress Is More Prevalent in Fertile Age and Premenopausal Women With PCOS Symptoms: 15-Year Follow-Up. J Clin Endocrinol Metab. 2017 Jun 1;102(6):1861-1869. doi: 10.1210/jc.2016-3863. PMID: 28323926; PMCID: PMC5470769.",primary_citation,,Karjula S,2017,"Karjula S et al., 2017",10.1210/jc.2016-3863,28323926.0,,,,Psychological Distress Is More Prevalent in Fertile Age and Premenopausal Women With PCOS Symptoms: 15-Year Follow-Up,pmid:28323926,
2.0,2.2,416,80.0,"Aydogan Kirmizi D, Baser E, Onat T, Demir Caltekin M, Yalvac ES, Kara M, Gocmen AY. Sexual function and depression in polycystic ovary syndrome: Is it associated with inflammation and neuromodulators? Neuropeptides. 2020 Dec;84:102099. doi: 10.1016/j.npep.2020.102099. Epub 2020 Oct 23. PMID: 33120204.",primary_citation,,Aydogan Kirmizi D,2020,"Aydogan Kirmizi D et al., 2020",10.1016/j.npep.2020.102099,33120204.0,,,,Sexual function and depression in polycystic ovary syndrome: Is it associated with inflammation and neuromodulators?,pmid:33120204,
2.0,2.2,417,80.0,"Koseoglu SB, Koseoglu S, Deveer R, Derin S, Kececioglu M, Sahan M. Impaired olfactory function in patients with polycystic ovary syndrome. Kaohsiung J Med Sci. 2016 Jun;32(6):313-6. doi: 10.1016/j.kjms.2016.04.015. Epub 2016 Jun 1. PMID: 27377844.",primary_citation,,Koseoglu SB,2016,"Koseoglu SB et al., 2016",10.1016/j.kjms.2016.04.015,27377844.0,,,,Impaired olfactory function in patients with polycystic ovary syndrome,pmid:27377844,
2.0,2.2,418,80.0,"Laggari V, Diareme S, Christogiorgos S, Deligeoroglou E, Christopoulos P, Tsiantis J, Creatsas G. Anxiety and depression in adolescents with polycystic ovary syndrome and Mayer-Rokitansky-Küster-Hauser syndrome. J Psychosom Obstet Gynaecol. 2009 Jun;30(2):83-8. doi: 10.1080/01674820802546204. PMID: 19533486.",primary_citation,,Laggari V,2009,"Laggari V et al., 2009",10.1080/01674820802546204,19533486.0,,,,Anxiety and depression in adolescents with polycystic ovary syndrome and Mayer-Rokitansky-Küster-Hauser syndrome,pmid:19533486,
2.0,2.2,419,80.0,"Lee I, Cooney LG, Saini S, Smith ME, Sammel MD, Allison KC, Dokras A. Increased risk of disordered eating in polycystic ovary syndrome. Fertil Steril. 2017 Mar;107(3):796-802. doi: 10.1016/j.fertnstert.2016.12.014. Epub 2017 Jan 16. PMID: 28104244.",primary_citation,,Lee I,2017,"Lee I et al., 2017",10.1016/j.fertnstert.2016.12.014,28104244.0,,,,Increased risk of disordered eating in polycystic ovary syndrome,pmid:28104244,
2.0,2.2,420,80.0,"Li SJ, Zhou DN, Li W, Yang J. Mental health status assessment in polycystic ovarian syndrome infertility patients: A pilot study. J Huazhong Univ Sci Technolog Med Sci. 2017 Oct;37(5):750-754. doi: 10.1007/s11596-017-1799-4. Epub 2017 Oct 20. PMID: 29058290.",primary_citation,,Li SJ,2017,"Li SJ et al., 2017",10.1007/s11596-017-1799-4,29058290.0,,,,Mental health status assessment in polycystic ovarian syndrome infertility patients: A pilot study,pmid:29058290,
2.0,2.2,421,80.0,"Månsson M, Norström K, Holte J, Landin-Wilhelmsen K, Dahlgren E, Landén M. Sexuality and psychological wellbeing in women with polycystic ovary syndrome compared with healthy controls. Eur J Obstet Gynecol Reprod Biol. 2011 Apr;155(2):161-5. doi: 10.1016/j.ejogrb.2010.12.012. Epub 2011 Jan 12. PMID: 21232840.",primary_citation,,Månsson M,2011,"Månsson M et al., 2011",10.1016/j.ejogrb.2010.12.012,21232840.0,,,,Sexuality and psychological wellbeing in women with polycystic ovary syndrome compared with healthy controls,pmid:21232840,
2.0,2.2,422,80.0,"Månsson M, Holte J, Landin-Wilhelmsen K, Dahlgren E, Johansson A, Landén M. Women with polycystic ovary syndrome are often depressed or anxious--a case control study. Psychoneuroendocrinology. 2008 Sep;33(8):1132-8. doi: 10.1016/j.psyneuen.2008.06.003. Epub 2008 Jul 30. PMID: 18672334.",primary_citation,,Månsson M,2008,"Månsson M et al., 2008",10.1016/j.psyneuen.2008.06.003,18672334.0,,,,Women with polycystic ovary syndrome are often depressed or anxious—A case control study,pmid:18672334,
2.0,2.2,423,80.0,"March WA, Whitrow MJ, Davies MJ, Fernandez RC, Moore VM. Postnatal depression in a community-based study of women with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2018 Jul;97(7):838-844. doi: 10.1111/aogs.13332. Epub 2018 Mar 13. PMID: 29460299.",primary_citation,,March WA,2018,"March WA et al., 2018",10.1111/aogs.13332,29460299.0,,,,Postnatal depression in a community‐based study of women with polycystic ovary syndrome,pmid:29460299,
2.0,2.2,424,80.0,"Maya J, Siegel J, Cheng TQ, Rousseau-Pierre T. Prevalence and risk factors of polycystic ovarian syndrome among an ethnically diverse overweight/obese adolescent population. Int J Adolesc Med Health. 2020 Jan 11;34(1). doi: 10.1515/ijamh-2019-0109. PMID: 31926080.",primary_citation,,Maya J,2020,"Maya J et al., 2020",10.1515/ijamh-2019-0109,31926080.0,,,,Prevalence and risk factors of polycystic ovarian syndrome among an ethnically diverse overweight/obese adolescent population,pmid:31926080,
2.0,2.2,425,80.0,"Mehrabadi S, Sadatmahalleh SJ, Kazemnejad A, Moini A. Association of acne, hirsutism, androgen, anxiety, and depression on cognitive performance in polycystic ovary syndrome: A cross-sectional study. Int J Reprod Biomed. 2020 Dec 21;18(12):1049-1058. doi: 10.18502/ijrm.v18i12.8026. PMID: 33426415; PMCID: PMC7778752.",primary_citation,,Mehrabadi S,2020,"Mehrabadi S et al., 2020",10.18502/ijrm.v18i12.8026,33426415.0,,,,"Association of acne, hirsutism, androgen, anxiety, and depression on cognitive performance in polycystic ovary syndrome: A cross-sectional study",pmid:33426415,
2.0,2.2,426,80.0,"Moran L, Gibson-Helm M, Teede H, Deeks A. Polycystic ovary syndrome: a biopsychosocial understanding in young women to improve knowledge and treatment options. J Psychosom Obstet Gynaecol. 2010 Mar;31(1):24-31. doi: 10.3109/01674820903477593. PMID: 20050767.",primary_citation,,Moran L,2010,"Moran L et al., 2010",10.3109/01674820903477593,20050767.0,,,,Polycystic ovary syndrome: a biopsychosocial understanding in young women to improve knowledge and treatment options,pmid:20050767,
2.0,2.2,427,80.0,"Moran LJ, Deeks AA, Gibson-Helm ME, Teede HJ. Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod. 2012 Jul;27(7):2082-8. doi: 10.1093/humrep/des114. Epub 2012 Apr 4. PMID: 22493025.",primary_citation,,Moran LJ,2012,"Moran LJ et al., 2012",10.1093/humrep/des114,22493025.0,,,,Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome,pmid:22493025,
2.0,2.2,428,80.0,"Moran LJ, March WA, Whitrow MJ, Giles LC, Davies MJ, Moore VM. Sleep disturbances in a community-based sample of women with polycystic ovary syndrome. Hum Reprod. 2015 Feb;30(2):466-72. doi: 10.1093/humrep/deu318. Epub 2014 Nov 28. PMID: 25432918.",primary_citation,,Moran LJ,2015,"Moran LJ et al., 2015",10.1093/humrep/deu318,25432918.0,,,,Sleep disturbances in a community-based sample of women with polycystic ovary syndrome,pmid:25432918,
2.0,2.2,429,80.0,"Mukundan, A., & Jayakumari, S. (2019). RISK OF DEVELOPING DEPRESSION AND ITS IMPACT ON QUALITY OF LIFE IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME - A SOUTH INDIAN SCENARIO. International Journal Of Pharmaceutical Sciences And Research, 10(6), 2956-2961.",primary_citation,,Mukundan,2019,"Mukundan et al., 2019",10.13040/ijpsr.0975-8232.10(6).2956-61,,,212468337.0,,,,10.13040/ijpsr.0975-8232.10(6).2956-61
2.0,2.2,430,80.0,"Naumova I, Castelo-Branco C, Casals G. Psychological Issues and Sexual Function in Women with Different Infertility Causes: Focus on Polycystic Ovary Syndrome. Reprod Sci. 2021 Oct;28(10):2830-2838. doi: 10.1007/s43032-021-00546-x. Epub 2021 Mar 24. PMID: 33763818.",primary_citation,,Naumova I,2021,"Naumova I et al., 2021",10.1007/s43032-021-00546-x,33763818.0,,,,Psychological Issues and Sexual Function in Women with Different Infertility Causes: Focus on Polycystic Ovary Syndrome,pmid:33763818,
2.0,2.2,431,80.0,"Özdemir O, Kurdoglu Z, Yıldız S, Özdemir PG, Yilmaz E. The relationship between atypical depression and insülin resistance in patients with polycystic ovary syndrome and major depression. Psychiatry Res. 2017 Dec;258:171-176. doi: 10.1016/j.psychres.2016.11.043. Epub 2016 Dec 3. PMID: 28168992.",primary_citation,,Özdemir O,2017,"Özdemir O et al., 2017",10.1016/j.psychres.2016.11.043,28168992.0,,,,The relationship between atypical depression and insülin resistance in patients with polycystic ovary syndrome and major depression,pmid:28168992,
2.0,2.2,432,80.0,"Ozenli, Y., Haydardedeoglu, B., Micozkadioglu, I., Simsek, E., Bulgan Kilicdag, E., & Bagis, T. (2008). Anxiety, Depression and Ways of Coping Skills by Women with Polycystic Ovary Syndrome: A Controlled Study. J Turkish-German Gynecol Assoc, 9(4), 190-194.",primary_citation,,Ozenli,2008,"Ozenli et al., 2008",,,,146131120.0,"Anxiety, Depression and Ways of Coping Skills by Women with Polycystic Ovary Syndrome: A Controlled Study",,,
2.0,2.2,433,80.0,"Öztürk A, Kucur SK, Seven A, Deveci E, Şencan H, Yilmaz O, Kiliç A. Temperament and character differences of patients with polycystic ovary syndrome. J Gynecol Obstet Hum Reprod. 2019 Apr;48(4):255-259. doi: 10.1016/j.jogoh.2019.01.006. Epub 2019 Jan 31. PMID: 30711689.",primary_citation,,Öztürk A,2019,"Öztürk A et al., 2019",10.1016/j.jogoh.2019.01.006,30711689.0,,,,Temperament and character differences of patients with polycystic ovary syndrome,pmid:30711689,
2.0,2.2,434,80.0,"Pastore LM, Patrie JT, Morris WL, Dalal P, Bray MJ. Depression symptoms and body dissatisfaction association among polycystic ovary syndrome women. J Psychosom Res. 2011 Oct;71(4):270-6. doi: 10.1016/j.jpsychores.2011.02.005. Epub 2011 Mar 23. PMID: 21911106; PMCID: PMC3172572.",primary_citation,,Pastore LM,2011,"Pastore LM et al., 2011",10.1016/j.jpsychores.2011.02.005,21911106.0,,,,Depression symptoms and body dissatisfaction association among polycystic ovary syndrome women,pmid:21911106,
2.0,2.2,435,80.0,"Sahingöz M, Uguz F, Gezginc K, Korucu DG. Axis I and Axis II diagnoses in women with PCOS. Gen Hosp Psychiatry. 2013 Sep-Oct;35(5):508-11. doi: 10.1016/j.genhosppsych.2013.04.003. Epub 2013 May 30. PMID: 23726743.",primary_citation,,Sahingöz M,2013,"Sahingöz M et al., 2013",10.1016/j.genhosppsych.2013.04.003,23726743.0,,,,Axis I and Axis II diagnoses in women with PCOS,pmid:23726743,
2.0,2.2,436,80.0,"Sari SA, Celik N, Uzun Cicek A. Body Perception, Self-Esteem, and Comorbid Psychiatric Disorders in Adolescents Diagnosed with Polycystic Ovary Syndrome. J Pediatr Adolesc Gynecol. 2020 Dec;33(6):691-696. doi: 10.1016/j.jpag.2020.08.018. Epub 2020 Sep 9. PMID: 32916303.",primary_citation,,Sari SA,2020,"Sari SA et al., 2020",10.1016/j.jpag.2020.08.018,32916303.0,,,,"Body Perception, Self-Esteem, and Comorbid Psychiatric Disorders in Adolescents Diagnosed with Polycystic Ovary Syndrome",pmid:32916303,
2.0,2.2,437,80.0,"Sayyah-Melli M, Alizadeh M, Pourafkary N, Ouladsahebmadarek E, Jafari-Shobeiri M, Abbassi J, Kazemi-Shishvan MA, Sedaghat K. Psychosocial Factors Associated with Polycystic Ovary Syndrome: a Case Control Study. J Caring Sci. 2015 Sep 1;4(3):225-31. doi: 10.15171/jcs.2015.023. PMID: 26464839; PMCID: PMC4591610.",primary_citation,,Sayyah-Melli M,2015,"Sayyah-Melli M et al., 2015",10.15171/jcs.2015.023,26464839.0,,,,Psychosocial Factors Associated with Polycystic Ovary Syndrome: a Case Control Study,pmid:26464839,
2.0,2.2,438,80.0,"Shi X, Zhang L, Fu S, Li N. Co-involvement of psychological and neurological abnormalities in infertility with polycystic ovarian syndrome. Arch Gynecol Obstet. 2011 Sep;284(3):773-8. doi: 10.1007/s00404-011-1947-1. Epub 2011 Jun 19. PMID: 21688169.",primary_citation,,Shi X,2011,"Shi X et al., 2011",10.1007/s00404-011-1947-1,21688169.0,,,,Co-involvement of psychological and neurological abnormalities in infertility with polycystic ovarian syndrome,pmid:21688169,
2.0,2.2,439,80.0,"Sirmans SM, Parish RC, Blake S, Wang X. Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population. J Investig Med. 2014 Aug;62(6):868-74. doi: 10.1097/01.JIM.0000446834.90599.5d. PMID: 24844662.",primary_citation,,Sirmans SM,2014,"Sirmans SM et al., 2014",10.1097/01.jim.0000446834.90599.5d,24844662.0,,,,Epidemiology and Comorbidities of Polycystic Ovary Syndrome in an Indigent Population,pmid:24844662,
2.0,2.2,440,80.0,"Soyupek F, Guney M, Eris S, Cerci S, Yildiz S, Mungan T. Evaluation of hand functions in women with polycystic ovary syndrome. Gynecol Endocrinol. 2008 Oct;24(10):571-5. doi: 10.1080/09513590802288218. PMID: 19012100.",primary_citation,,Soyupek F,2008,"Soyupek F et al., 2008",10.1080/09513590802288218,19012100.0,,,,Evaluation of hand functions in women with polycystic ovary syndrome,pmid:19012100,
2.0,2.2,441,80.0,"Soyupek, F., Yildiz, S., Akkus, S., Guney, M., Mungan, M., & Eris, S. (2010). The Frequency of Fibromyalgia Syndrome in Patients with Polycystic Ovary Syndrome. Journal Of Musculoskeletal Pain, 18(2), 120-126. doi: 10.3109/10582452.2010.483968",primary_citation,,Soyupek,2010,"Soyupek et al., 2010",10.3109/10582452.2010.483968,,,,,The Frequency of Fibromyalgia Syndrome in Patients with Polycystic Ovary Syndrome,,10.3109/10582452.2010.483968
2.0,2.2,442,80.0,"Sulaiman MA, Al-Farsi YM, Al-Khaduri MM, Waly MI, Saleh J, Al-Adawi S. Psychological burden among women with polycystic ovarian syndrome in Oman: a case-control study. Int J Womens Health. 2017 Dec 12;9:897-904. doi: 10.2147/IJWH.S145383. PMID: 29276413; PMCID: PMC5731436.",primary_citation,,Sulaiman MA,2017,"Sulaiman MA et al., 2017",10.2147/ijwh.s145383,29276413.0,,,,Psychological burden among women with polycystic ovarian syndrome in Oman: a case&amp;ndash;control study,pmid:29276413,
2.0,2.2,443,80.0,"Tan J, Wang QY, Feng GM, Li XY, Huang W. Increased Risk of Psychiatric Disorders in Women with Polycystic Ovary Syndrome in Southwest China. Chin Med J (Engl). 2017 Feb 5;130(3):262-266. doi: 10.4103/0366-6999.198916. PMID: 28139507; PMCID: PMC5308006.",primary_citation,,Tan J,2017,"Tan J et al., 2017",10.4103/0366-6999.198916,28139507.0,,,,Increased Risk of Psychiatric Disorders in Women with Polycystic Ovary Syndrome in Southwest China,pmid:28139507,
2.0,2.2,444,80.0,"Tseng PH, Chiu HM, Tu CH, Wu MS, Ho HN, Chen MJ. Obesity Exacerbates Irritable Bowel Syndrome-Related Sleep and Psychiatric Disorders in Women With Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). 2021 Nov 16;12:779456. doi: 10.3389/fendo.2021.779456. PMID: 34867827; PMCID: PMC8635163.",primary_citation,,Tseng PH,2021,"Tseng PH et al., 2021",10.3389/fendo.2021.779456,34867827.0,,,,Obesity Exacerbates Irritable Bowel Syndrome-Related Sleep and Psychiatric Disorders in Women With Polycystic Ovary Syndrome,pmid:34867827,
2.0,2.2,445,80.0,"Varanasi LC, Subasinghe A, Jayasinghe YL, Callegari ET, Garland SM, Gorelik A, Wark JD. Polycystic ovarian syndrome: Prevalence and impact on the wellbeing of Australian women aged 16-29 years. Aust N Z J Obstet Gynaecol. 2018 Apr;58(2):222-233. doi: 10.1111/ajo.12730. Epub 2017 Oct 19. PMID: 29052216.",primary_citation,,Varanasi LC,2018,"Varanasi LC et al., 2018",10.1111/ajo.12730,29052216.0,,,,Polycystic ovarian syndrome: Prevalence and impact on the wellbeing of Australian women aged 16–29 years,pmid:29052216,
2.0,2.2,446,80.0,"Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med. 2004 May-Jun;66(3):356-62. doi: 10.1097/01.psy.0000127871.46309.fe. PMID: 15184695.",primary_citation,,Weiner CL,2004,"Weiner CL et al., 2004",10.1097/01.psy.0000127871.46309.fe,15184695.0,,,,Androgens and Mood Dysfunction in Women: Comparison of Women With Polycystic Ovarian Syndrome to Healthy Controls,pmid:15184695,
2.0,2.2,447,80.0,"Zachurzok A, Pasztak-Opilka A, Gawlik AM. Depression, anxiety and self-esteem in adolescent girls with polycystic ovary syndrome. Ginekol Pol. 2021 Mar 10. doi: 10.5603/GP.a2021.0042. Epub ahead of print. PMID: 33751507.",primary_citation,,Zachurzok A,2021,"Zachurzok A et al., 2021",10.5603/gp.a2021.0042,33751507.0,,,,"Depression, anxiety and self-esteem in adolescent girls with polycystic ovary syndrome",pmid:33751507,
2.0,2.2,448,80.0,"Deniz A, Kehribar DY. Evaluation of sexual functions in infertile Women with Polycystic Ovary Syndrome. Niger J Clin Pract. 2020 Nov;23(11):1548-1554. doi: 10.4103/njcp.njcp_15_20. PMID: 33221780.",primary_citation,,Deniz A,2020,"Deniz A et al., 2020",10.4103/njcp.njcp_15_20,33221780.0,,,,Evaluation of sexual functions in infertile Women with Polycystic Ovary Syndrome,pmid:33221780,
2.0,2.2,449,80.0,"Zueff LN, Lara LA, Vieira CS, Martins Wde P, Ferriani RA. Body composition characteristics predict sexual functioning in obese women with or without PCOS. J Sex Marital Ther. 2015;41(3):227-37. doi: 10.1080/0092623X.2013.864369. Epub 2014 Jan 23. PMID: 24274091.",primary_citation,,Zueff LN,2015,"Zueff LN et al., 2015",10.1080/0092623x.2013.864369,24274091.0,,,,Body Composition Characteristics Predict Sexual Functioning in Obese Women With or Without PCOS,pmid:24274091,
2.0,2.3,450,29.0,"Benetti-Pinto, C.L., Ferreira, S.R., Antunes Jr, A. and Yela, D.A., (2014). The influence of body weight on sexual function and quality of life in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2014; doi: 10.1007/s00404-014-3423-1. ",primary_citation,prior search,Benetti-Pinto,2014,"Benetti-Pinto et al., 2014",10.1007/s00404-014-3423-1,,,,,The influence of body weight on sexual function and quality of life in women with polycystic ovary syndrome,pmid:25138126,10.1007/s00404-014-3423-1
2.0,2.3,451,29.0,"Caruso, S., Rugolo, S., Agnello, C., Romano, M. and Cianci, A., (2009). Quality of sexual life in hyperandrogenic women treated with an oral contraceptive containing chlormadinone acetate. J Sex Med. 2009; 6, 3376-84.  doi: 10.1111/j.1743-6109.2009.01529.x.",primary_citation,prior search,Caruso,2009,"Caruso et al., 2009",10.1111/j.1743-6109.2009.01529.x,,,,,Quality of Sexual Life in Hyperandrogenic Women Treated with an Oral Contraceptive Containing Chlormadinone Acetate,pmid:19832931,10.1111/j.1743-6109.2009.01529.x
2.0,2.3,452,29.0,"Diamond, M.P., Legro, R.S., Coutifaris, C., Alvero, R., Robinson, R.D., Casson, P.A., Christman, G.M., Huang, H., Hansen, K.R., Baker, V., Usadi, R., Seungdamrong, A., Bates, G.W., Rosen, R.M., Schlaff, W., Haisenleder, D., Krawetz, S.A., Barnhart, K., Trussell, J.C., Santoro, N., Eisenberg, E. and Zhang, H., (2017). Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility. Am J Obstet Gynecol.2017. doi: 10.1016/j.ajog.2017.04.034.",primary_citation,prior search,Diamond,2017,"Diamond et al., 2017",10.1016/j.ajog.2017.04.034,,,,,Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility,pmid:28455078,10.1016/j.ajog.2017.04.034
2.0,2.3,453,29.0,"Drosdzol, A., Skrzypulec, V., Mazur, B. and Pawlinska-Chmara, R., (2007). Quality of life and marital sexual satisfaction in women with polycystic ovary syndrome. Folia Histochem Cytobiol. 2007; 45, 93-97. doi.org/10.2478/4495.",primary_citation,prior search,Drosdzol,2007,"Drosdzol et al., 2007",,18292843.0,W2115750705,38876279.0,,Quality of life and marital sexual satisfaction in women with polycystic ovary syndrome.,pmid:18292843,
2.0,2.3,454,29.0,"Elkhiat, Y., Zedan, A., Mostafa, M. and Elhalwagi, A., (2015). Sexual desire in a sample of married Egyptian women with polycystic ovarian syndrome. Human Andrology. 2015; 5(3):49-57. DOI:10.1097/01.XHA.0000470182.71509.1b",primary_citation,prior search,Elkhiat,2015,"Elkhiat et al., 2015",10.1097/01.xha.0000470182.71509.1b,,,,,Sexual desire in a sample of married Egyptian women with polycystic ovarian syndrome,,10.1097/01.xha.0000470182.71509.1b
2.0,2.3,455,29.0,"Elsenbruch, S., Hahn, S., Kowalsky, D., Offner, A.H., Schedlowski, M., Mann, K. and Janssen, O.E., (2003). Quality of Life, Psychosocial Well-Being, and Sexual Satisfaction in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 88, 5801-5807. 2013. doi: 10.1210/jc.2003-030562.",primary_citation,prior search,Elsenbruch,2003,"Elsenbruch et al., 2003",10.1210/jc.2003-030562,,,,,"Quality of Life, Psychosocial Well-Being, and Sexual Satisfaction in Women with Polycystic Ovary Syndrome",pmid:14671172,10.1210/jc.2003-030562
2.0,2.3,456,29.0,"Ercan, C.M., Coksuer, H., Aydogan, U., Alanbay, I., Keskin, U., Karasahin, K.E. and Baser, I., (2013). Sexual dysfunction assessment and hormonal correlations in patients with polycystic ovary syndrome. Int J Impotence Res. 2013; 25, 127-132. doi: 10.1038/ijir.2013.2. ",primary_citation,prior search,Ercan,2013,"Ercan et al., 2013",10.1038/ijir.2013.2,,,,,Sexual dysfunction assessment and hormonal correlations in patients with polycystic ovary syndrome,pmid:23407282,10.1038/ijir.2013.2
2.0,2.3,457,29.0,"Ferraresi, S.R., Lara, L.A.S., Reis, R.M. and de Sa Rosa e Silva, A.C.J.,( 2013). Changes in Sexual Function among Women with Polycystic Ovary Syndrome: A Pilot Study. J Sex Med. 2013; 10, 467-473. DOI: 10.1111/jsm.12011",primary_citation,prior search,Ferraresi,2013,"Ferraresi et al., 2013",10.1111/jsm.12011,,,,,Changes in Sexual Function Among Women with Polycystic Ovary Syndrome: A Pilot Study,pmid:23210985,10.1111/jsm.12011
2.0,2.3,458,29.0,"Gateva, A. and Kamenov, Z., (2012). Sexual Function in Patients with PCOS and/or Obesity before and after Metformin Treatment. Advances in Sexual Medicine. 2012.  DOI: 10.4236/asm.2012.22005.",primary_citation,prior search,Gateva,2012,"Gateva et al., 2012",10.4236/asm.2012.22005,,,,,Sexual Function in Patients with PCOS and/or Obesity before and after Metformin Treatment,,10.4236/asm.2012.22005
2.0,2.3,459,29.0,"Hahn, S., Janssen, O.E., Tan, S., Pleger, K., Mann, K., Schedlowski, M., Kimmig, R., Benson, S., Balamitsa, E. and Elsenbruch, S., (2005). Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol. 2005, 153, 853-60. doi: 10.1530/eje.1.02024.",primary_citation,prior search,Hahn,2005,"Hahn et al., 2005",10.1530/eje.1.02024,,,,,Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome,pmid:16322391,10.1530/eje.1.02024
2.0,2.3,460,29.0,"Kowalczyk, R., Skrzypulec-Plinta, V., Nowosielski, K. and Lew-Starowicz, Z., (2015). Sexuality in women with polycystic ovary syndrome. Ginekol Pol. 2015; 86, 100-106. doi: 10.17772/gp/1995.",primary_citation,prior search,Kowalczyk,2015,"Kowalczyk et al., 2015",10.17772/gp/1995,,,,,Sexuality in women with polycystic ovary syndrome,pmid:25807833,10.17772/gp/1995
2.0,2.3,461,29.0,"Lara, L.A.S., Ramos, F.K.P., Kogure, G.S., Costa, R.S., Silva de Sá, M.F., Ferriani, R.A. and dos Reis, R.M.,( 2015). Impact of Physical Resistance Training on the Sexual Function of Women with Polycystic Ovary Syndrome. J Sex Med. 2015; 12, 1584-1590. doi: 10.1111/jsm.12909",primary_citation,prior search,Lara,2015,"Lara et al., 2015",10.1111/jsm.12909,,,,,Impact of Physical Resistance Training on the Sexual Function of Women with Polycystic Ovary Syndrome,pmid:25982537,10.1111/jsm.12909
2.0,2.3,462,29.0,"Mansson, M., Norstrom, K., Holte, J., Landin-Wilhelmsen, K., Dahlgren, E. and Landen, M., (2011). Sexuality and psychological wellbeing in women with polycystic ovary syndrome compared with healthy controls. Eur J Obstet Gynecol Reprod Biol. 2011; 155, 161-5. doi: 10.1016/j.ejogrb.2010.12.012.",primary_citation,prior search,Mansson,2011,"Mansson et al., 2011",10.1016/j.ejogrb.2010.12.012,,,,,Sexuality and psychological wellbeing in women with polycystic ovary syndrome compared with healthy controls,pmid:21232840,10.1016/j.ejogrb.2010.12.012
2.0,2.3,463,29.0,"Noroozzadeh, M., Tehrani, F.R., Mobarakabadi, S.S., Farahmand, M. and Dovom, M.R., (2016). Sexual function and hormonal profiles in women with and without polycystic ovary syndrome: a population-based study. Int J Impotence Res. 2016.  doi: 10.1038/ijir.2016.35. ",primary_citation,prior search,Noroozzadeh,2016,"Noroozzadeh et al., 2016",10.1038/ijir.2016.35,,,,,Sexual function and hormonal profiles in women with and without polycystic ovary syndrome: a population-based study,pmid:27654035,10.1038/ijir.2016.35
2.0,2.3,464,29.0,"Shafti, V. and Shahbazi, S., (2016). Comparing sexual function and quality of life in polycystic ovary syndrome and healthy women. J Fam Reprod Health. 2016; 10, 92-98.",primary_citation,prior search,Shafti,2016,"Shafti et al., 2016",,27648099.0,W2517888967,8524156.0,,Comparing Sexual Function and Quality of Life in Polycystic Ovary Syndrome and Healthy Women.,pmid:27648099,
2.0,2.3,465,29.0,"Stovall, D.W., Scriver, J.L., Clayton, A.H., Williams, C.D. and Pastore, L.M., (2012). Sexual function in women with polycystic ovary syndrome. J Sex Med 2012; 9, 224-230. doi: 10.1111/j.1743-6109.2011.02539.x.",primary_citation,prior search,Stovall,2012,"Stovall et al., 2012",10.1111/j.1743-6109.2011.02539.x,,,,,Sexual Function in Women with Polycystic Ovary Syndrome,pmid:22082203,10.1111/j.1743-6109.2011.02539.x
2.0,2.3,466,29.0,"Tan, S., Hahn, S., Benson, S., Janssen, O.E., Dietz, T., Kimmig, R., Hesse-Hussain, J., Mann, K., Schedlowski, M., Arck, P.C. and Elsenbruch, S., (2008). Psychological implications of infertility in women with polycystic ovary syndrome. Hum Reprod. 2008; 23, 2064-71. doi: 10.1093/humrep/den227.",primary_citation,prior search,Tan,2008,"Tan et al., 2008",10.1093/humrep/den227,,,,,Psychological implications of infertility in women with polycystic ovary syndrome,pmid:18583330,10.1093/humrep/den227
2.0,2.3,467,29.0,"Zueff, L.N., Lara, L.A., Vieira, C.S., Martins Wde, P. and Ferriani, R.A., (2015). Body composition characteristics predict sexual functioning in obese women with or without PCOS. J Sex Marital Ther. 2015; 41, 227-37. doi: 10.1080/0092623X.2013.864369.",primary_citation,prior search,Zueff,2015,"Zueff et al., 2015",10.1080/0092623x.2013.864369,,,,,Body Composition Characteristics Predict Sexual Functioning in Obese Women With or Without PCOS,pmid:24274091,10.1080/0092623x.2013.864369
2.0,2.3,468,29.0,"Akbari Sene A, Tahmasbi B, Keypour F, Zamanian H, Golbabaei F, Amini-Tehrani M. (2021) Differences in and correlates of sexual function in infertile women with and without polycystic ovary syndrome. Int J Fertil Steril. 2021; 15(1): 65-72. doi: 10.22074/IJFS.2021.6206.",primary_citation,,Akbari Sene A,2021,"Akbari Sene A et al., 2021",10.22074/ijfs.2021.6206,,,,,Differences in and Correlates of Sexual Function in Infertile Women with and without Polycystic Ovary Syndrome.,pmid:33497050,10.22074/ijfs.2021.6206
2.0,2.3,469,29.0,"Ashrafi, M., Jahangiri, N., Sadatmahalleh, S.J., Mirzaei, N., Hesari, N.G., Rostami, F., Mousavi, S.S., & Zeinaloo, M. (2022). Does prevalence of sexual dysfunction differ among the most common casuse of infertility? A cross-sectional study. BMC Women’s Health, 2022: 22:140. doi.org/10.1186/s12905-022-01708-y",primary_citation,,Ashrafi,2022,"Ashrafi et al., 2022",10.1186/s12905-022-01708-y,,,,,Does prevalence of sexual dysfunction differ among the most common causes of infertility? A cross-sectional study,pmid:35477457,10.1186/s12905-022-01708-y
2.0,2.3,470,29.0,"Aydogan Kirmizi, D, Base, E, Onat, T, Caltekin, MD, Yalvac, ES, Kara, M & Gocmen, AY. (2020). Sexual function and depression in polycystic ovary syndrome: is it associated with inflammation and neuromdulators?  Neuropeptides. 2020; 84. 10.1016/j.npep.2020.102099",primary_citation,,Aydogan Kirmizi,2020,"Aydogan Kirmizi et al., 2020",10.1016/j.npep.2020.102099,,,,,Sexual function and depression in polycystic ovary syndrome: Is it associated with inflammation and neuromodulators?,pmid:33120204,10.1016/j.npep.2020.102099
2.0,2.3,471,29.0,"Basirat, Z, Faramarzi, M, Esmaelzadeh, S, Firoozjai, SA, Mahouti, T, & Geraili, Z. (2019) Stress, depression, sexual function, and alexithymia in infertile females with and without polycystic ovary syndrome: a case-control study. Int J Fert STerl. 2019;13(3):203-208. doi: 10.22074/ijfs.2019.5703.",primary_citation,,Basirat,2019,"Basirat et al., 2019",10.22074/ijfs.2019.5703,,,,,"Stress, Depression, Sexual Function, and Alexithymia in Infertile Females with and without Polycystic Ovary Syndrome: A Case-Control Study.",pmid:31310074,10.22074/ijfs.2019.5703
2.0,2.3,472,29.0,"Deniz, A & Kehribar, DY. (2020). Evalulation of sexual functions in infertile women with polycystic ovary syndrome. Niger J Clin Pract, 2020; 23:1548-54. DOI: 10.4103/njcp.njcp_15_20",primary_citation,,Deniz,2020,"Deniz et al., 2020",10.4103/njcp.njcp_15_20,,,,,Evaluation of sexual functions in infertile Women with Polycystic Ovary Syndrome,pmid:33221780,10.4103/njcp.njcp_15_20
2.0,2.3,473,29.0,"Glowinska, A, Duleba, AJ, Zielona-Jenek, M, Siakoswka, M, Pawelczyk, L, & Banaszweska, B. (2020). Disparate Relationship of sexual satisfaction, self-esteem, anxiety, and depression with endocrine profiles of women with or without PCOS. Reproductive Sciences, 2020; 27:432-44. doi.org/10.1007/s43032-019-00061-0",primary_citation,,Glowinska,2020,"Glowinska et al., 2020",10.1007/s43032-019-00061-0,,,,,"Disparate Relationship of Sexual Satisfaction, Self-Esteem, Anxiety, and Depression with Endocrine Profiles of Women With or Without PCOS",pmid:32046411,10.1007/s43032-019-00061-0
2.0,2.3,474,29.0,"Karsten, MDA, Wekker, V, Groen, H, Painter, RC, Mol, BWJ, Laan, ETM, Roseboom, TJ, & Hoek, A. (2021). The role of PCOS in mental health and sexual function in women with obesity and a history of infertility. Human Reproduction Open. 2021;1:1-11. doi.org/10.1093/hropen/hoab038",primary_citation,,Karsten,2021,"Karsten et al., 2021",10.1093/hropen/hoab038,,,,,The role of PCOS in mental health and sexual function in women with obesity and a history of infertility,pmid:34877412,10.1093/hropen/hoab038
2.0,2.3,475,29.0,"Kaluzna, M, Nomejko, A, Slowinska, A, Wachowiak-Ochmanska, K, Pikosz, K, Ziemnicka, K, & Ruchala, M. (2021). Lower sexual satisfaction in women with polycystic ovary syndrome and metabolic syndrome. Endocrine connnections. 2021;10(9):1035-1044. doi.org/10.1530/EC-21-0257",primary_citation,,Kaluzna,2021,"Kaluzna et al., 2021",10.1530/ec-21-0257,,,,,Lower sexual satisfaction in women with polycystic ovary syndrome and metabolic syndrome,pmid:34319905,10.1530/ec-21-0257
2.0,2.3,476,29.0,"Mantzou, D, Stamou, MI, Armeni, AK, Roupas, ND, Assimakopoulos, K, Adonakis, G, Georgopoulos, NA & Markantes, GK. (2021). Impaired sexual function in young women with PCOS: the detrimental effect of anovulation. J Sexual Medicine, 2021;18:1872-1879. doi.org/10.1016/j.jsxm.2021.09.004",primary_citation,,Mantzou,2021,"Mantzou et al., 2021",10.1016/j.jsxm.2021.09.004,,,,,Impaired Sexual Function in Young Women with PCOS: The Detrimental Effect of Anovulation,pmid:37057487,10.1016/j.jsxm.2021.09.004
2.0,2.3,477,29.0,"Naumova, I, Castelo-Branco, C, & Casals, G. (2021). Psychological issues and sexual function in women with different infertility causes: focus on polycystic ovary syndrome. Reproductive Sciences. 2021;28:2830-2838. doi.org/10.1007/s43032-021-00546-x",primary_citation,,Naumova,2021,"Naumova et al., 2021",10.1007/s43032-021-00546-x,,,,,Psychological Issues and Sexual Function in Women with Different Infertility Causes: Focus on Polycystic Ovary Syndrome,pmid:33763818,10.1007/s43032-021-00546-x
2.0,2.3,478,29.0,"Thagavi, SA, Aramesh, S, Azizi-Kutenaee, M, Allan, H, Safarzadeh, T, Taheri, M, Salari, S, Khashavi & Bazarganipour, F. (2021) The influence of infertility on sexual and marital satisfaction in Iranian women with polycystic ovary syndrome: a case-control study. Middel East Fertilty Society Journal. 2021;26(2). doi.org/10.1186/s43043-020-00047-y",primary_citation,,Thagavi,2021,"Thagavi et al., 2021",10.1186/s43043-020-00047-y,,,,,The influence of infertility on sexual and marital satisfaction in Iranian women with polycystic ovary syndrome: a case-control study,,10.1186/s43043-020-00047-y
2.0,2.4,479,9.0,"Alur-Gupta, S., Chemerinski, A., Dokras, A., Liu, C., Lipson, J., Allison, K., & Sammel Mary D. AO - Dokras, A. O. http://orcid. org/0000-0002-1085-3969. (2019). Body-image distress is increased in women with polycystic ovary syndrome and mediates depression and anxiety. Fertility and Sterility, 112(5), 930. ",primary_citation,,Alur-Gupta,2019,"Alur-Gupta et al., 2019",10.1016/j.fertnstert.2019.06.018,,,,,Body-image distress is increased in women with polycystic ovary syndrome and mediates depression and anxiety,pmid:31395311,10.1016/j.fertnstert.2019.06.018
2.0,2.4,480,9.0,"Annagür BB, Tazegül A, Akbaba N. Body Image, Self-Esteem and Depressive Symptomatology in Women with Polycystic Ovary Syndrome. Noro Psikiyatr Ars. 2014 Jun;51(2):129-132",primary_citation,,Annagür BB,2014,"Annagür BB et al., 2014",10.4274/npa.y6778,,,,,"Polikistik Over Sendromu Olan Kadınlarda Beden Algısı, Benlik Saygısı ve Depresif Belirtiler",pmid:28360612,10.4274/npa.y6778
2.0,2.4,481,9.0,"Azizi Kutenaee, M., Amirjani, S., Taghavi, S.-A., Asemi, Z., Allan, H., Kamalnadian, S.-N., Khashavi, Z., & Bazarganipour, F. (2020). The impact of depression, self-esteem, and body image on sleep quality in patients with PCOS: a cross-sectional study. Sleep and Breathing, 24(3), 1027–1034. ",primary_citation,,Azizi Kutenaee,2020,"Azizi Kutenaee et al., 2020",10.1007/s11325-019-01946-9,,,,,"The impact of depression, self-esteem, and body image on sleep quality in patients with PCOS: a cross-sectional study",pmid:31630370,10.1007/s11325-019-01946-9
2.0,2.4,482,9.0,"Deeks, A. A., Gibson-Helm, M. E., Paul, E., & Teede, H. J. (2011). Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression? Human Reproduction, 26(6), 1399–1407. ",primary_citation,,Deeks,2011,"Deeks et al., 2011",10.1093/humrep/der071,,,,,Is having polycystic ovary syndrome a predictor of poor psychological function including anxiety and depression?,pmid:21436137,10.1093/humrep/der071
2.0,2.4,483,9.0,"Himelein, M. J., & Thatcher, S. S. (2006). Depression and body image among women with polycystic ovary syndrome. Journal of Health Psychology, 11(4), 613–625.",primary_citation,,Himelein,2006,"Himelein et al., 2006",10.1177/1359105306065021,,,,,Depression and Body Image among Women with Polycystic Ovary Syndrome,pmid:16769740,10.1177/1359105306065021
2.0,2.4,484,9.0,"Karacan, E., Caglar, G. S., Gursoy, A. Y., & Yilmaz, M. B. (2014). Body satisfaction and eating attitudes among girls and young women with and without polycystic ovary syndrome. Journal of Pediatric and Adolescent Gynecology, 27(2), 72–77.",primary_citation,,Karacan,2014,"Karacan et al., 2014",10.1016/j.jpag.2013.08.003,,,,,Body Satisfaction and Eating Attitudes among Girls and Young Women with and without Polycystic Ovary Syndrome,pmid:24602301,10.1016/j.jpag.2013.08.003
2.0,2.4,485,9.0,"Morotti, E., Battaglia, B., Fabbri, R., Meriggiola, M. C., Venturoli, S., Battaglia, C., & Persico, N. (2013). Body imaging and sexual behavior in lean women with polycystic ovary syndrome. Journal of Sexual Medicine, 10(11), 2752–2760. ",primary_citation,,Morotti,2013,"Morotti et al., 2013",10.1111/jsm.12284,,,,,Body Imaging and Sexual Behavior in Lean Women with Polycystic Ovary Syndrome,pmid:23981769,10.1111/jsm.12284
2.0,2.4,486,9.0,"Pastore, L. M., Dalal, P., Bray, M. J., Patrie, J. T., & Morris, W. L. (2011). Depression symptoms and body dissatisfaction association among polycystic ovary syndrome women. Journal of Psychosomatic Research, 71(4), 270–276.",primary_citation,,Pastore,2011,"Pastore et al., 2011",10.1016/j.jpsychores.2011.02.005,,,,,Depression symptoms and body dissatisfaction association among polycystic ovary syndrome women,pmid:21911106,10.1016/j.jpsychores.2011.02.005
2.0,2.4,487,9.0,"Scaruffi, E., Franzoi, I. G., Civilotti, C., Guglielmucci, F., la Marca, L., Tomelini, M., Veglia, F., & Granieri, A. (2019). Body image, personality profiles and alexithymia in patients with polycystic ovary syndrome (PCOS). Journal of Psychosomatic Obstetrics and Gynaecology, 40(4), 294–303. ",primary_citation,,Scaruffi,2019,"Scaruffi et al., 2019",10.1080/0167482x.2018.1530210,,,,,"Body image, personality profiles and alexithymia in patients with polycystic ovary syndrome (PCOS)",pmid:30398405,10.1080/0167482x.2018.1530210
2.0,2.5,488,14.0,"Hollinrake, E., Abrea, A., Maifield, M., Van Voorhis, B., Dokras, A. (2007). Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertility and Sterility, 2007.",primary_citation,Prior search,Hollinrake,2007,"Hollinrake et al., 2007",10.1016/j.fertnstert.2006.11.039,,,,,Increased risk of depressive disorders in women with polycystic ovary syndrome,pmid:17397839,10.1016/j.fertnstert.2006.11.039
2.0,2.5,489,14.0,"Mansson, M., Holte, J., Landin-Wilhelmsen, K., Dahlgren, E., Johansson, A., Landen, M. (2008). Women with polycystic ovary syndrome are often depressed or anxious—a case control study. Psychoneuroendocrinology, 2008.",primary_citation,Prior search,Mansson,2008,"Mansson et al., 2008",10.1016/j.psyneuen.2008.06.003,,,,,Women with polycystic ovary syndrome are often depressed or anxious—A case control study,pmid:18672334,10.1016/j.psyneuen.2008.06.003
2.0,2.5,490,14.0,"Batcheller, A., Ressler, I., Sroga, J., Martinez, A., Thomas, M., Di Paola, K. (2013). Binge eating disorder in the infertile polycystic ovary syndrome patient. Fertility and Sterility, 2013.",primary_citation,Prior search,Batcheller,2013,"Batcheller et al., 2013",10.1016/j.fertnstert.2013.07.631,,,,,Binge eating disorder in the infertile polycystic ovary syndrome patient,,10.1016/j.fertnstert.2013.07.631
2.0,2.5,491,14.0,"Karacan, E., Caglar, G., Gursoy, A., Yilmaz, M. (2014). Body satisfaction and eating attitudes among girls and young women with and without polycystic ovary syndrome. Journal of Pediatric & Adolescent Gynecology, 2014.",primary_citation,Prior search,Karacan,2014,"Karacan et al., 2014",10.1016/j.jpag.2013.08.003,,,,,Body Satisfaction and Eating Attitudes among Girls and Young Women with and without Polycystic Ovary Syndrome,pmid:24602301,10.1016/j.jpag.2013.08.003
2.0,2.5,492,14.0,"Larsson, I., Hulthen, L., Landen, M., Palsson, E., Janson, P., Stener-Victorin, E. (2016). Dietary intake, resting energy expenditure, and eating behavior in women with and without polycystic ovary syndrome. Clinical Nutrition, 2016.",primary_citation,Prior search,Larsson,2016,"Larsson et al., 2016",10.1016/j.clnu.2015.02.006,,,,,"Dietary intake, resting energy expenditure, and eating behavior in women with and without polycystic ovary syndrome",pmid:25743212,10.1016/j.clnu.2015.02.006
2.0,2.5,493,14.0,"Lee, I., Cooney, L., Saini, S., Smith, M., Allison, K. Dokras, A. (2016). Increased risk of eating disorders in women with polycystic ovary syndrome. Fertility and Sterility, 2016.",primary_citation,Prior search,Lee,2016,"Lee et al., 2016",10.1016/j.fertnstert.2016.07.750,,,,,Increased risk of eating disorders in women with polycystic ovary syndrome,,10.1016/j.fertnstert.2016.07.750
2.0,2.5,494,14.0,"Jeanes, Y., Reeves, S., Gibson, E., Piggot, C., May, V., Hart, K. (2017). Binge eating behaviors and food cravings in women with polycystic ovary syndrome. Appetite, 2017.",primary_citation,Prior search,Jeanes,2017,"Jeanes et al., 2017",10.1016/j.appet.2016.11.010,,,,,Binge eating behaviours and food cravings in women with Polycystic Ovary Syndrome,pmid:27825940,10.1016/j.appet.2016.11.010
2.0,2.5,495,14.0,"Sirmans, S., Parish, R., Blake, S., Wang, X. (2014). Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population. Journal of Investigative medicine, 2014.",primary_citation,,Sirmans,2014,"Sirmans et al., 2014",10.1097/01.jim.0000446834.90599.5d,,,,,Epidemiology and Comorbidities of Polycystic Ovary Syndrome in an Indigent Population,pmid:24844662,10.1097/01.jim.0000446834.90599.5d
2.0,2.5,496,14.0,"Cesta, C., Mansson, M., Palm, C., Lichtenstein, P., Iliadou, A., Landen, M. (2016). Polycystic ovary syndrome and psychiatric disorders: co-morbidity and heritability in a nationwide Swedish cohort. Psychoneuroendocrinology, 2016.",primary_citation,,Cesta,2016,"Cesta et al., 2016",10.1016/j.psyneuen.2016.08.005,,,,,Polycystic ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a nationwide Swedish cohort,pmid:27513883,10.1016/j.psyneuen.2016.08.005
2.0,2.5,497,14.0,"Maher, M., Sanders, A.(2018). Eating indicators in women with polycystic ovary syndrome and weight-matched controls. FASEB Journal, 2018.",primary_citation,,Maher,2018,"Maher et al., 2018",10.1096/fasebj.31.1_supplement.lb374,,,,,Eating Indicators In Women With Polycystic Ovary Syndrome And Weight‐Matched Controls,,10.1096/fasebj.31.1_supplement.lb374
2.0,2.5,498,14.0,"Lidaka, L., Lazdane, G., Kivite-Urtane, A., Gailite, L., Dzivite-Krisane, I., Stokenberga, I. (2019). Health-related quality of life and binge eating among adolescent girls with PCOS. Clinical and Experimental Obstetrics and Gynecology, 2019.",primary_citation,,Lidaka,2019,"Lidaka et al., 2019",10.31083/j.ceog4903057,,,,,Health-related quality of life and binge eating among adolescent girls with PCOS,,10.31083/j.ceog4903057
2.0,2.5,499,14.0,"Pirotta, S., Barillaro, M., Brennan, L., Grassi, A., Jeanes, Y., Joham, A., Kulkarni, J., Monahan Couch, L., Lim, S., Moran, L. (2019). Disordered eating behaviors and eating disorders in women in Australia with and without polycystic ovary syndrome: a cross-sectional study. Journal of Clinical Medicine, 2019.",primary_citation,,Pirotta,2019,"Pirotta et al., 2019",10.3390/jcm8101682,,,,,Disordered Eating Behaviours and Eating Disorders in Women in Australia with and Without Polycystic Ovary Syndrome: A Cross-Sectional Study,pmid:31615157,10.3390/jcm8101682
2.0,2.5,500,14.0,"Tay, C., Teede, H., Hill, B., Loxton, D., Joham, A. (2019). Increased prevalence of eating disorders, low self-esteem, and psychological distress in women with polycystic ovary syndrome: a community-based cohort study. Fertility and Sterility, 2019.",primary_citation,,Tay,2019,"Tay et al., 2019",10.1016/j.fertnstert.2019.03.027,,,,,"Increased prevalence of eating disorders, low self-esteem, and psychological distress in women with polycystic ovary syndrome: a community-based cohort study",pmid:31056307,10.1016/j.fertnstert.2019.03.027
2.0,2.5,501,14.0,"Asdaq, S., Jomah, S., Hasa, R., Al-Baroundi, D., Alharbi, M., Alsubaie, S., Buhamad, M., Alyahya, B., Al-Yamani, MM. (2020). Impact of polycystic ovary syndrome on eating behavior, depression, and health related quality of life: A cross-sectional study in Riyadh. Saudi J Biol Sci, 2020.",primary_citation,,Asdaq,2020,"Asdaq et al., 2020",10.1016/j.sjbs.2020.08.039,,,,,"Impact of polycystic ovary syndrome on eating behavior, depression and health related quality of life: A cross-sectional study in Riyadh",pmid:33304140,10.1016/j.sjbs.2020.08.039
2.0,2.6.1,502,41.0,"Alzamil H, Aloraini K, AlAgeel R, Ghanim A, Alsaaran R, Alsomali N, Albahlal R, Alnuaim L. Disparity among Endocrinologists and Gynaecologists in the Diagnosis of Polycystic Ovarian Syndrome. Sultan Qaboos Univ Med J. 2020 Aug;20(3):e323-e329. doi: 10.18295/squmj.2020.20.03.012. Epub 2020 Oct 5. PMID: 33110648; PMCID: PMC7574802.",primary_citation,,Alzamil H,2020,"Alzamil H et al., 2020",10.18295/squmj.2020.20.03.012,33110648.0,,,,Disparity among Endocrinologists and Gynaecologists in the Diagnosis of Polycystic Ovarian Syndrome,pmid:33110648,
2.0,2.6.1,503,41.0,"Arif N, Khawaja S, Iqbal Q. Awareness of Polycystic Ovarian Disease: Knowledge and Presence of Presenting Symptoms. Pakistan Journal of Medical and Health Sciences. 2020;14(2):627-30.",primary_citation,,Arif N,2020,"Arif N et al., 2020",,,,,Awareness of Polycystic Ovarian Disease: Knowledge and Presence of Presenting Symptoms,,,
2.0,2.6.1,504,41.0,"Asante A, Omurtag K, Stewart EA, Coddington CC. Screening for Insulin Resistance in Polycystic Ovary Syndrome: Views of Physician Members of the American Society for Reproductive Medicine. The Journal of reproductive medicine. 2015 Sep 1;60(9-10):371-7.",primary_citation,,Asante A,2015,"Asante A et al., 2015",,26592060.0,W2285565969,32001745.0,,Screening for Insulin Resistance in Polycystic Ovary Syndrome: Views of Physician Members of the American Society for Reproductive Medicine.,pmid:26592060,
2.0,2.6.1,505,41.0,"Carron R, Simon N, Gilman-Kehrer E, Boyle DK. Improving rural nurse practitioner knowledge about polycystic ovary syndrome through continuing education. The Journal of Continuing Education in Nursing. 2018 Apr 1;49(4):164-70.",primary_citation,,Carron R,2018,"Carron R et al., 2018",10.3928/00220124-20180320-06,,,,,Improving Rural Nurse Practitioner Knowledge About Polycystic Ovary Syndrome Through Continuing Education,pmid:29596703,10.3928/00220124-20180320-06
2.0,2.6.1,506,41.0,"Chemerinski A, Cooney L, Shah D, Butts S, Gibson-Helm M, Dokras A. Knowledge of PCOS in physiciansin- training: identifying gaps and educational opportunities. Gynecological Endocrinology. 2020 Oct 2;36(10):854-9.",primary_citation,,Chemerinski A,2020,"Chemerinski A et al., 2020",10.1080/09513590.2020.1746761,,,,,Knowledge of PCOS in physicians-in-training: identifying gaps and educational opportunities,pmid:32252571,10.1080/09513590.2020.1746761
2.0,2.6.1,507,41.0,"Copp T, Muscat DM, Hersch J, McCaffery KJ, Doust J, Mol BW, Dokras A, Jansen J. Cliniciansâ€™ perspectives on diagnosing polycystic ovary syndrome in Australia: a qualitative study. Human Reproduction. 2020 Mar 27;35(3):660-8.",primary_citation,,Copp T,2020,"Copp T et al., 2020",10.1093/humrep/deaa005,,,,,Clinicians’ perspectives on diagnosing polycystic ovary syndrome in Australia: a qualitative study,pmid:32101283,10.1093/humrep/deaa005
2.0,2.6.1,508,41.0,"Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney L, Teede H. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertility and sterility. 2017 Jun 1;107(6):1380-6.",primary_citation,,Dokras A,2017,"Dokras A et al., 2017",10.1016/j.fertnstert.2017.04.011,,,,,Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome,pmid:28483503,10.1016/j.fertnstert.2017.04.011
2.0,2.6.1,509,41.0,"Doll I, Doll R, Buhling KJ. Diagnosis and therapy of polycystic ovarian syndrome: results of a survey among German gynecologists with a review on literature. Archives of gynecology and obstetrics. 2012 Mar;285(3):689-97.",primary_citation,,Doll I,2012,"Doll I et al., 2012",10.1007/s00404-011-2014-7,,,,,Diagnosis and therapy of polycystic ovarian syndrome: results of a survey among German gynecologists with a review on literature,pmid:21830009,10.1007/s00404-011-2014-7
2.0,2.6.1,510,41.0,"Dutta, D., Bhattacharya, S., Khandelwal, D., Aggarwal, S., Singla, R., Surana, V., & Dhingra, A. (2020). Clinical Practice Patterns of Polycystic Ovary Syndrome Among Doctors of Different Specialtiesâ€”An Indian Perspective. US Endocrinology, 16(2), 74-79.",primary_citation,,Dutta,2020,"Dutta et al., 2020",10.17925/use.2020.16.2.74,,,,,Clinical Practice Patterns of Polycystic Ovary Syndrome Among Doctors of Different Specialties—An Indian Perspective,,10.17925/use.2020.16.2.74
2.0,2.6.1,511,41.0,"Gibson-Helm M, Dokras A, Karro H, Piltonen T, Teede HJ. Knowledge and practices regarding polycystic ovary syndrome among physicians in Europe, North America, and internationally: an online questionnaire-based study. InSeminars in Reproductive Medicine 2018 Jan (Vol. 36, No. 01, pp. 019- 027). Thieme Medical Publishers.",primary_citation,,Gibson-Helm M,2018,"Gibson-Helm M et al., 2018",10.1055/s-0038-1667155,,,,,"Knowledge and Practices Regarding Polycystic Ovary Syndrome among Physicians in Europe, North America, and Internationally: An Online Questionnaire-Based Study",pmid:30189447,10.1055/s-0038-1667155
2.0,2.6.1,512,41.0,"Ma R, Zou Y, Wang W, Zheng Q, Feng Y, Dong H, Tan Z, Zeng X, Zhao Y, Deng Y, Wang Y. Obesity management in polycystic ovary syndrome: disparity in knowledge between obstetrician-gynecologists and reproductive endocrinologists in China. BMC endocrine disorders. 2021 Dec;21(1):1-0.",primary_citation,,Ma R,2021,"Ma R et al., 2021",10.1186/s12902-021-00848-w,,,,,Obesity management in polycystic ovary syndrome: disparity in knowledge between obstetrician-gynecologists and reproductive endocrinologists in China,pmid:34488736,10.1186/s12902-021-00848-w
2.0,2.6.1,513,41.0,"Moran LJ, Tan ZQ, Bayer S, Boyle JA, Robinson T, Lim SS. Perspectives of allied health professionals on implementation of the lifestyle polycystic ovary syndrome guidelines: a qualitative study. Journal of the Academy of Nutrition and Dietetics. 2022 Jul 1;122(7):1305-16.",primary_citation,,Moran LJ,2022,"Moran LJ et al., 2022",10.1016/j.jand.2021.11.013,34800697.0,,,,Perspectives of Allied Health Professionals on Implementation of the Lifestyle Polycystic Ovary Syndrome Guidelines: A Qualitative Study,pmid:34800697,
2.0,2.6.1,514,41.0,"Ning N, Balen A, Brezina PR, Leong M, Shoham Z, Wallach EE, Zhao Y. How to recognize PCOS: results of a web-based survey at IVF-worldwide. com. Reproductive biomedicine online. 2013 May 1;26(5):500-5.",primary_citation,,Ning N,2013,"Ning N et al., 2013",10.1016/j.rbmo.2013.01.009,,,,,How to recognize PCOS: results of a web-based survey at IVF-worldwide.com,pmid:23419796,10.1016/j.rbmo.2013.01.009
2.0,2.6.1,515,41.0,"Piltonen TT, RuokojÃ¤rvi M, Karro H, KujanpÃ¤Ã¤ L, Morin-Papunen L, Tapanainen JS, Stener-Victorin E, SundrstrÃ¶m-Poromaa I, Hirschberg AL, Ravn P, Glintborg D. Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe. PLoS One. 2019 Dec 26;14(12):e0226074.",primary_citation,,Piltonen TT,2019,"Piltonen TT et al., 2019",10.1371/journal.pone.0226074,,,,,Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe,pmid:31877155,10.1371/journal.pone.0226074
2.0,2.6.1,516,41.0,"Salman AD,. Nurses--Midwifes Knowledge Concerning Polycystic Ovary Syndrome in Baghdad Hospitals. Indian Journal of Forensic Medicine & Toxicology. 2020 Oct 1;14(4).",primary_citation,,Salman AD,2020,"Salman AD et al., 2020",10.37506/ijfmt.v14i4.12337,,,,,Nurses – Midwifes Knowledge Concerning Polycystic Ovary Syndrome in Baghdad Hospitals,,10.37506/ijfmt.v14i4.12337
2.0,2.6.1,517,41.0,"Yan D, Yan-Fang W, Shi-Yang Z, Rui-Lin M, Xue-Song D, Xiao M, Wei X, Aijun S. Is polycystic ovary syndrome appropriately diagnosed by obstetricians and gynaecologists across China: a nationwide survey. Journal of Ovarian Research. 2021 Dec;14(1):1-9.",primary_citation,,Yan D,2021,"Yan D et al., 2021",10.1186/s13048-021-00780-6,,,,,Is polycystic ovary syndrome appropriately diagnosed by obstetricians and gynaecologists across China: a nationwide survey,pmid:33536040,10.1186/s13048-021-00780-6
2.0,2.6.1,518,41.0,"Authier M, Normand C, Jego M, Gaborit B, Boubli L, Courbiere B. Qualitative study of self-reported experiences of infertile women with polycystic ovary syndrome through on-line discussion forums. InAnnales d'Endocrinologie 2020 Oct 1 (Vol. 81, No. 5, pp. 487-492). Elsevier Masson.",primary_citation,,Authier M,2020,"Authier M et al., 2020",10.1016/j.ando.2020.07.1110,,,,,Qualitative study of self-reported experiences of infertile women with polycystic ovary syndrome through on-line discussion forums,pmid:32827451,10.1016/j.ando.2020.07.1110
2.0,2.6.1,519,41.0,"Avery JC, Braunack-Mayer AJ. The information needs of women diagnosed with Polycystic Ovarian Syndromeâ€“implications for treatment and health outcomes. BMC women's health. 2007 Dec;7(1):1-0.",primary_citation,,Avery JC,2007,"Avery JC et al., 2007",10.1186/1472-6874-7-9,,,,,The information needs of women diagnosed with Polycystic Ovarian Syndrome – implications for treatment and health outcomes,pmid:17578583,10.1186/1472-6874-7-9
2.0,2.6.1,520,41.0,"Carron R, Kooienga S, Gilman-Kehrer E, Alvero R. Cultural experiences, patterns, and practices of American Indian women with polycystic ovary syndrome: An ethnonursing study. Journal of Transcultural Nursing. 2020 Mar;31(2):162-70.",primary_citation,,Carron R,2020,"Carron R et al., 2020",10.1177/1043659619856670,,,,,"Cultural Experiences, Patterns, and Practices of American Indian Women With Polycystic Ovary Syndrome: An Ethnonursing Study",pmid:31204601,10.1177/1043659619856670
2.0,2.6.1,521,41.0,"Ching HL, Burke V, Stuckey BG. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clinical endocrinology. 2007 Mar;66(3):373-9.",primary_citation,,Ching HL,2007,"Ching HL et al., 2007",10.1111/j.1365-2265.2007.02742.x,,,,,"Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers",pmid:17302871,10.1111/j.1365-2265.2007.02742.x
2.0,2.6.1,522,41.0,"Crete J, Adamshick P. Managing polycystic ovary syndrome: what our patients are telling us. Journal of Holistic Nursing. 2011 Dec;29(4):256-66.",primary_citation,,Crete J,2011,"Crete J et al., 2011",10.1177/0898010111398660,21357181.0,,,,Managing Polycystic Ovary Syndrome,pmid:21357181,
2.0,2.6.1,523,41.0,"Ee C, Smith C, Moran L, MacMillan F, Costello M, Baylock B, Teede H. â€œThe whole package dealâ€: experiences of overweight/obese women living with polycystic ovary syndrome. BMC women's health. 2020 Dec;20(1):1-9.",primary_citation,,Ee C,2020,"Ee C et al., 2020",10.1186/s12905-020-01090-7,,,,,“The whole package deal”: experiences of overweight/obese women living with polycystic ovary syndrome,pmid:33008386,10.1186/s12905-020-01090-7
2.0,2.6.1,524,41.0,"Gibson-Helm ME, Lucas IM, Boyle JA, Teede HJ. Womenâ€™s experiences of polycystic ovary syndrome diagnosis. Family practice. 2014 Oct 1;31(5):545-9.",primary_citation,,Gibson-Helm ME,2014,"Gibson-Helm ME et al., 2014",10.1093/fampra/cmu028,,,,,Women's experiences of polycystic ovary syndrome diagnosis,pmid:24925927,10.1093/fampra/cmu028
2.0,2.6.1,525,41.0,"Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2017 Feb 1;102(2):604-12.",primary_citation,,Gibson-Helm M,2017,"Gibson-Helm M et al., 2017",10.1210/jc.2016-2963,,,,,Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome,pmid:27906550,10.1210/jc.2016-2963
2.0,2.6.1,526,41.0,"Hadjiconstantinou M, Mani H, Patel N, Levy M, Davies M, Khunti K, Stone M. Understanding and supporting women with polycystic ovary syndrome: a qualitative study in an ethnically diverse UK sample. Endocrine Connections. 2017 Jul 1;6(5):323-30.",primary_citation,,Hadjiconstantinou M,2017,"Hadjiconstantinou M et al., 2017",10.1530/ec-17-0053,,,,,Understanding and supporting women with polycystic ovary syndrome: a qualitative study in an ethnically diverse UK sample,pmid:28515051,10.1530/ec-17-0053
2.0,2.6.1,527,41.0,"Hillman SC, Bryce C, Caleyachetty R, Dale J. Womenâ€™s experiences of diagnosis and management of polycystic ovary syndrome: a mixed-methods study in general practice. British Journal of General Practice. 2020 May 1;70(694):e322-9.",primary_citation,,Hillman SC,2020,"Hillman SC et al., 2020",10.3399/bjgp20x708881,,,,,Women’s experiences of diagnosis and management of polycystic ovary syndrome: a mixed-methods study in general practice,pmid:32152043,10.3399/bjgp20x708881
2.0,2.6.1,528,41.0,"Holbrey S, Coulson NS. A qualitative investigation of the impact of peer to peer online support for women living with polycystic ovary syndrome. BMC Women's Health. 2013 Dec;13(1):1-9.",primary_citation,,Holbrey S,2013,"Holbrey S et al., 2013",10.1186/1472-6874-13-51,,,,,A qualitative investigation of the impact of peer to peer online support for women living with Polycystic Ovary Syndrome,pmid:24341398,10.1186/1472-6874-13-51
2.0,2.6.1,529,41.0,"Hoyos LR, Putra M, Armstrong AA, Cheng CY, Riestenberg CK, Schooler TA, Dumesic DA. Measures of patient dissatisfaction with health care in polycystic ovary syndrome: retrospective analysis. Journal of medical Internet research. 2020 Apr 21;22(4):e16541.",primary_citation,,Hoyos LR,2020,"Hoyos LR et al., 2020",10.2196/16541,,,,,Measures of Patient Dissatisfaction With Health Care in Polycystic Ovary Syndrome: Retrospective Analysis,pmid:32314967,10.2196/16541
2.0,2.6.1,530,41.0,"Humphreys L, Costarelli V. Implementation of dietary and general lifestyle advice among women with polycystic ovarian syndrome. The journal of the Royal Society for the Promotion of Health. 2008 Jul;128(4):190-5.",primary_citation,,Humphreys L,2008,"Humphreys L et al., 2008",10.1177/1466424008092230,,,,,Implementation of dietary and general lifestyle advice among women with polycystic ovarian syndrome,pmid:18678115,10.1177/1466424008092230
2.0,2.6.1,531,41.0,"Ismayilova M, Yaya S. What can be done to improve polycystic ovary syndrome (PCOS) healthcare? Insights from semi-structured interviews with women in Canada. BMC women's health. 2022 Dec;22(1):1-5.",primary_citation,,Ismayilova M,2022,"Ismayilova M et al., 2022",10.1186/s12905-022-01734-w,,,,,What can be done to improve polycystic ovary syndrome (PCOS) healthcare? Insights from semi-structured interviews with women in Canada,pmid:35538531,10.1186/s12905-022-01734-w
2.0,2.6.1,532,41.0,"Ismayilova M, Yaya S. â€˜I'm usually being my own doctorâ€™: women's experiences of managing polycystic ovary syndrome in Canada. International Health. 2022 May 14.",primary_citation,,Ismayilova M,2022,"Ismayilova M et al., 2022",10.1093/inthealth/ihac028,,,,,‘I'm usually being my own doctor’: women's experiences of managing polycystic ovary syndrome in Canada,pmid:35567790,10.1093/inthealth/ihac028
2.0,2.6.1,533,41.0,"Kaur I, Suri V, Rana SV, Singh A. Treatment pathways traversed by polycystic ovary syndrome (PCOS) patients: A mixed-method study. PloS one. 2021 Aug 9;16(8):e0255830.",primary_citation,,Kaur I,2021,"Kaur I et al., 2021",10.1371/journal.pone.0255830,,,,,Treatment pathways traversed by polycystic ovary syndrome (PCOS) patients: A mixed-method study,pmid:34370764,10.1371/journal.pone.0255830
2.0,2.6.1,534,41.0,"Khan NN, Vincent A, Boyle JA, Burggraf M, Pillay M, Teede H, Gibson-Helm M. Development of a question prompt list for women with polycystic ovary syndrome. Fertility and sterility. 2018 Aug 1;110(3):514-22.",primary_citation,,Khan NN,2018,"Khan NN et al., 2018",10.1016/j.fertnstert.2018.04.028,,,,,Development of a question prompt list for women with polycystic ovary syndrome,pmid:29960706,10.1016/j.fertnstert.2018.04.028
2.0,2.6.1,535,41.0,"PeÃ±a AS, Teede H, Hewawasam E, Hull ML, Gibson-Helm M. Diagnosis experiences of adolescents with polycystic ovary syndrome: Cross-sectional study. Clinical endocrinology. 2022 Jan;96(1):62-9.",primary_citation,,PeÃ±a AS,2022,"PeÃ±a AS et al., 2022",10.1111/cen.14604,,,,,Diagnosis experiences of adolescents with polycystic ovary syndrome: Cross‐sectional study,pmid:34585425,10.1111/cen.14604
2.0,2.6.1,536,41.0,"Pirotta S, Joham AJ, Moran LJ, Skouteris H, Lim SS. Implementation of evidence-based PCOS lifestyle management guidelines: Perceived barriers and facilitators by consumers using the Theoretical Domains Framework and COM-B Model. Patient education and counseling. 2021 Aug 1;104(8):2080-8.",primary_citation,,Pirotta S,2021,"Pirotta S et al., 2021",10.1016/j.pec.2021.01.036,,,,,Implementation of evidence-based PCOS lifestyle management guidelines: Perceived barriers and facilitators by consumers using the Theoretical Domains Framework and COM-B Model,pmid:33581970,10.1016/j.pec.2021.01.036
2.0,2.6.1,537,41.0,"Pirotta S, Joham AE, Moran LJ, Skouteris H, Lim SS. Implementation of the polycystic ovary syndrome guidelines: A mixed method study to inform the design and delivery of a lifestyle management program for women with polycystic ovary syndrome. Nutrition & Dietetics. 2021 Nov;78(5):476-86.",primary_citation,,Pirotta S,2021,"Pirotta S et al., 2021",10.1111/1747-0080.12670,,,,,Implementation of the polycystic ovary syndrome guidelines: A mixed method study to inform the design and delivery of a lifestyle management program for women with polycystic ovary syndrome,pmid:33876532,10.1111/1747-0080.12670
2.0,2.6.1,538,41.0,"Sills ES, Perloe M, Tucker MJ, Kaplan CR, Genton MG, Schattman GL. Diagnostic and treatment characteristics of polycystic ovary syndrome: descriptive measurements of patient perception and awareness from 657 confidential self-reports. BMC women's health. 2001 Dec;1(1):1-5.",primary_citation,,Sills ES,2001,"Sills ES et al., 2001",10.1186/1472-6874-1-3,,,,,Diagnostic and treatment characteristics of polycystic ovary syndrome: descriptive measurements of patient perception and awareness from 657 confidential self-reports,pmid:11545683,10.1186/1472-6874-1-3
2.0,2.6.1,539,41.0,"Tomlinson J, Pinkney J, Adams L, Stenhouse E, Bendall A, Corrigan O, Letherby G. The diagnosis and lived experience of polycystic ovary syndrome: A qualitative study. Journal of advanced nursing. 2017 Oct;73(10):2318-26.",primary_citation,,Tomlinson J,2017,"Tomlinson J et al., 2017",10.1111/jan.13300,,,,,The diagnosis and lived experience of polycystic ovary syndrome: A qualitative study,pmid:28329428,10.1111/jan.13300
2.0,2.6.1,540,41.0,"Trent ME, Rich M, Austin SB, Gordon CM. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. Journal of pediatric and adolescent gynecology. 2003 Feb 1;16(1):33-7.",primary_citation,,Trent ME,2003,"Trent ME et al., 2003",10.1016/s1083-3188(02)00205-x,,,,,Fertility Concerns and Sexual Behavior in Adolescent Girls with Polycystic Ovary Syndrome,pmid:12604144,10.1016/s1083-3188(02)00205-x
2.0,2.6.1,541,41.0,"Weiss TR, Bulmer SM. Young women's experiences living with polycystic ovary syndrome. Journal of obstetric, gynecologic & neonatal nursing. 2011 Nov 1;40(6):709-18.",primary_citation,,Weiss TR,2011,"Weiss TR et al., 2011",10.1111/j.1552-6909.2011.01299.x,,,,,Young Women's Experiences Living with Polycystic Ovary Syndrome,pmid:22092488,10.1111/j.1552-6909.2011.01299.x
2.0,2.6.1,542,41.0,"Williams S, Sheffield D, Knibb RC. â€˜Everythingâ€™s from the inside out with PCOSâ€™: Exploring womenâ€™s experiences of living with polycystic ovary syndrome and co-morbidities through Skypeâ„¢ interviews. Health psychology open. 2015 Aug 28;2(2):2055102915603051.",primary_citation,,Williams S,2015,"Williams S et al., 2015",10.1177/2055102915603051,,,,,‘Everything’s from the inside out with PCOS’: Exploring women’s experiences of living with polycystic ovary syndrome and co-morbidities through Skype™ interviews,pmid:28070371,10.1177/2055102915603051
2.0,2.6.2,543,5.0,"Bekx MT, Connor EC, Allen DB. Characteristics of adolescents presenting to a multidisciplinary clinic for polycystic ovarian syndrome. J Pediatr Adolesc Gynecol. 2010 Feb;23(1):7-10. doi: 10.1016/j.jpag.2009.04.004. Epub 2009 Aug 3. PMID: 19648034.",primary_citation,,Bekx MT,2010,"Bekx MT et al., 2010",10.1016/j.jpag.2009.04.004,19648034.0,,,,Characteristics of Adolescents Presenting to a Multidisciplinary Clinic for Polycystic Ovarian Syndrome,pmid:19648034,
2.0,2.6.2,544,5.0,"Geier LM, Bekx MT, Connor EL. Factors contributing to initial weight loss among adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2012 Dec;25(6):367-70. doi: 10.1016/j.jpag.2012.06.008. Epub 2012 Oct 22. PMID: 23089571.",primary_citation,,Geier LM,2012,"Geier LM et al., 2012",10.1016/j.jpag.2012.06.008,23089571.0,,,,Factors Contributing to Initial Weight Loss Among Adolescents with Polycystic Ovary Syndrome,pmid:23089571,
2.0,2.6.2,545,5.0,"Torres-Zegarra C, Sundararajan D, Benson J, Seagle H, Witten M, Walders-Abramson N, Simon SL, Huguelet P, Nokoff NJ, Cree-Green M. Care for Adolescents With Polycystic Ovary Syndrome: Development and Prescribing Patterns of a Multidisciplinary Clinic. J Pediatr Adolesc Gynecol. 2021 Oct;34(5):617-625. doi: 10.1016/j.jpag.2021.02.002. Epub 2021 Mar 29. PMID: 33794340; PMCID: PMC8808364.",primary_citation,,Torres-Zegarra C,2021,"Torres-Zegarra C et al., 2021",10.1016/j.jpag.2021.02.002,33794340.0,,,,Care for Adolescents With Polycystic Ovary Syndrome: Development and Prescribing Patterns of a Multidisciplinary Clinic,pmid:33794340,
2.0,2.6.2,546,5.0,"Boyle J, Hollands G, Beck S, Hampel G, Wapau H, Arnot M, Browne L, Teede HJ, Moran LJ. Process evaluation of a pilot evidence-based Polycystic Ovary Syndrome clinic in the Torres Strait. Aust J Rural Health. 2017 Jun;25(3):175-181. doi: 10.1111/ajr.12288. Epub 2016 Apr 18. PMID: 27086940.",primary_citation,,Boyle J,2017,"Boyle J et al., 2017",10.1111/ajr.12288,27086940.0,,,,Process evaluation of a pilot evidence-based Polycystic Ovary Syndrome clinic in the Torres Strait,pmid:27086940,
2.0,2.6.2,547,5.0,"Tay CT, Pirotta S, Teede HJ, Moran LJ, Robinson T, Skouteris H, Joham AE, Lim SS. Polycystic Ovary Syndrome Models of Care: A Review and Qualitative Evaluation of a Guideline-Recommended Integrated Care. Semin Reprod Med. 2021 Jul;39(3-04):133-142. doi: 10.1055/s-0041-1727191. Epub 2021 Jun 29. PMID: 34187051.",primary_citation,,Tay CT,2021,"Tay CT et al., 2021",10.1055/s-0041-1727191,34187051.0,,,,Polycystic Ovary Syndrome Models of Care: A Review and Qualitative Evaluation of a Guideline-Recommended Integrated Care,pmid:34187051,
2.0,2.6.4,548,28.0,"Atkinson L, Kite C, McGregor G, James T, Clark CC, Randeva HS, Kyrou I. Uncertainty, anxiety and isolation: Experiencing the COVID-19 pandemic and lockdown as a woman with polycystic ovary syndrome (PCOS). Journal of personalized medicine. 2021 Sep 25;11(10):952.",primary_citation,,Atkinson L,2021,"Atkinson L et al., 2021",10.3390/jpm11100952,,,,,"Uncertainty, Anxiety and Isolation: Experiencing the COVID-19 Pandemic and Lockdown as a Woman with Polycystic Ovary Syndrome (PCOS)",pmid:34683093,10.3390/jpm11100952
2.0,2.6.4,549,28.0,"Authier M, Normand C, Jego M, Gaborit B, Boubli L, Courbiere B. Qualitative study of self-reported experiences of infertile women with polycystic ovary syndrome through on-line discussion forums. InAnnales d'Endocrinologie 2020 Oct 1 (Vol. 81, No. 5, pp. 487-492). Elsevier Masson.",primary_citation,,Authier M,2020,"Authier M et al., 2020",10.1016/j.ando.2020.07.1110,,,,,Qualitative study of self-reported experiences of infertile women with polycystic ovary syndrome through on-line discussion forums,pmid:32827451,10.1016/j.ando.2020.07.1110
2.0,2.6.4,550,28.0,"Avery JC, Braunack-Mayer AJ. The information needs of women diagnosed with Polycystic Ovarian Syndrome–implications for treatment and health outcomes. BMC women's health. 2007 Dec;7(1):1-0.",primary_citation,,Avery JC,2007,"Avery JC et al., 2007",10.1186/1472-6874-7-9,,,,,The information needs of women diagnosed with Polycystic Ovarian Syndrome – implications for treatment and health outcomes,pmid:17578583,10.1186/1472-6874-7-9
2.0,2.6.4,551,28.0,"Bazarganipour F, Taghavi SA, Allan H, Hosseini N. Facilitating and inhibiting factors related to treatment adherence in women with polycystic ovary syndrome: A qualitative study. International journal of reproductive biomedicine. 2017 Sep;15(9):553. ",primary_citation,,Bazarganipour F,2017,"Bazarganipour F et al., 2017",10.29252/ijrm.15.9.553,,,,,Facilitating and inhibiting factors related to treatment adherence in women with polycystic ovary syndrome: A qualitative study,,10.29252/ijrm.15.9.553
2.0,2.6.4,552,28.0,"Copp T, Muscat DM, Hersch J, McCaffery KJ, Doust J, Dokras A, Mol BW, Jansen J. The challenges with managing polycystic ovary syndrome: a qualitative study of women’s and clinicians’ experiences. Patient education and counseling. 2022 Mar 1;105(3):719-25.",primary_citation,,Copp T,2022,"Copp T et al., 2022",10.1016/j.pec.2021.05.038,,,,,The challenges with managing polycystic ovary syndrome: A qualitative study of women’s and clinicians’ experiences,pmid:34099308,10.1016/j.pec.2021.05.038
2.0,2.6.4,553,28.0,"Crete J, Adamshick P. Managing polycystic ovary syndrome: what our patients are telling us. Journal of Holistic Nursing. 2011 Dec;29(4):256-66.",primary_citation,,Crete J,2011,"Crete J et al., 2011",10.1177/0898010111429092,,,,,Continuing Nursing Education for “Managing Polycystic Ovary Syndrome: What Our Patients Are Telling Us”,,10.1177/0898010111429092
2.0,2.6.4,554,28.0,"Gibson-Helm M, Tassone EC, Teede HJ, Dokras A, Garad R. The needs of women and healthcare providers regarding polycystic ovary syndrome information, resources, and education: a systematic search and narrative review. InSeminars in reproductive medicine 2018 Jan (Vol. 36, No. 01, pp. 035-041). Thieme Medical Publishers.",primary_citation,,Gibson-Helm M,2018,"Gibson-Helm M et al., 2018",10.1055/s-0038-1668086,,,,,"The Needs of Women and Healthcare Providers regarding Polycystic Ovary Syndrome Information, Resources, and Education: A Systematic Search and Narrative Review",pmid:30189449,10.1055/s-0038-1668086
2.0,2.6.4,555,28.0,"Hadjiconstantinou M, Mani H, Patel N, Levy M, Davies M, Khunti K, Stone M. Understanding and supporting women with polycystic ovary syndrome: a qualitative study in an ethnically diverse UK sample. Endocrine Connections. 2017 Jul 1;6(5):323-30.",primary_citation,,Hadjiconstantinou M,2017,"Hadjiconstantinou M et al., 2017",10.1530/ec-17-0053,,,,,Understanding and supporting women with polycystic ovary syndrome: a qualitative study in an ethnically diverse UK sample,pmid:28515051,10.1530/ec-17-0053
2.0,2.6.4,556,28.0,"Hajivandi L, Noroozi M, Mostafavi F, Ekramzadeh M. Health system-related needs for healthy nutritional behaviors in adolescent girls with polycystic ovary syndrome (PCOS): a qualitative study in Iran. BMC health services research. 2022 Dec;22(1):1-1.",primary_citation,,Hajivandi L,2022,"Hajivandi L et al., 2022",10.1186/s12913-022-08334-2,,,,,Health system-related needs for healthy nutritional behaviors in adolescent girls with polycystic ovary syndrome (PCOS): a qualitative study in Iran,pmid:35932079,10.1186/s12913-022-08334-2
2.0,2.6.4,557,28.0,"Hillman SC, Bryce C, Caleyachetty R, Dale J. Women’s experiences of diagnosis and management of polycystic ovary syndrome: a mixed-methods study in general practice. British Journal of General Practice. 2020 May 1;70(694):e322-9.",primary_citation,,Hillman SC,2020,"Hillman SC et al., 2020",10.3399/bjgp20x708881,,,,,Women’s experiences of diagnosis and management of polycystic ovary syndrome: a mixed-methods study in general practice,pmid:32152043,10.3399/bjgp20x708881
2.0,2.6.4,558,28.0,"Holbrey S, Coulson NS. A qualitative investigation of the impact of peer to peer online support for women living with polycystic ovary syndrome. BMC Women's Health. 2013 Dec;13(1):1-9.",primary_citation,,Holbrey S,2013,"Holbrey S et al., 2013",10.1186/1472-6874-13-51,,,,,A qualitative investigation of the impact of peer to peer online support for women living with Polycystic Ovary Syndrome,pmid:24341398,10.1186/1472-6874-13-51
2.0,2.6.4,559,28.0,"Ismayilova M, Yaya S. What can be done to improve polycystic ovary syndrome (PCOS) healthcare? Insights from semi-structured interviews with women in Canada. BMC women's health. 2022 Dec;22(1):1-5.",primary_citation,,Ismayilova M,2022,"Ismayilova M et al., 2022",10.1186/s12905-022-01734-w,,,,,What can be done to improve polycystic ovary syndrome (PCOS) healthcare? Insights from semi-structured interviews with women in Canada,pmid:35538531,10.1186/s12905-022-01734-w
2.0,2.6.4,560,28.0,"Ismayilova M, Yaya S. ‘I'm usually being my own doctor’: women's experiences of managing polycystic ovary syndrome in Canada. International Health. 2022 May 14.",primary_citation,,Ismayilova M,2022,"Ismayilova M et al., 2022",10.1093/inthealth/ihac028,,,,,‘I'm usually being my own doctor’: women's experiences of managing polycystic ovary syndrome in Canada,pmid:35567790,10.1093/inthealth/ihac028
2.0,2.6.4,561,28.0,"Kaur I, Suri V, Rana SV, Singh A. Treatment pathways traversed by polycystic ovary syndrome (PCOS) patients: A mixed-method study. PloS one. 2021 Aug 9;16(8):e0255830.",primary_citation,,Kaur I,2021,"Kaur I et al., 2021",10.1371/journal.pone.0255830,,,,,Treatment pathways traversed by polycystic ovary syndrome (PCOS) patients: A mixed-method study,pmid:34370764,10.1371/journal.pone.0255830
2.0,2.6.4,562,28.0,"Kitzinger C, Willmott J. ‘The thief of womanhood’: women's experience of polycystic ovarian syndrome. Social science & medicine. 2002 Feb 1;54(3):349-61.",primary_citation,,Kitzinger C,2002,"Kitzinger C et al., 2002",10.1016/s0277-9536(01)00034-x,,,,,‘The thief of womanhood’: women's experience of polycystic ovarian syndrome,,10.1016/s0277-9536(01)00034-x
2.0,2.6.4,563,28.0,"Lim S, Smith CA, Costello MF, MacMillan F, Moran L, Teede H, Ee C. Health literacy needs in weight management of women with Polycystic Ovary Syndrome. Health Promotion Journal of Australia. 2021 Feb;32:41-8.",primary_citation,,Lim S,2021,"Lim S et al., 2021",10.1002/hpja.349,,,,,Health literacy needs in weight management of women with Polycystic Ovary Syndrome,pmid:32323376,10.1002/hpja.349
2.0,2.6.4,564,28.0,"Lim S, Wright B, Savaglio M, Goodwin D, Pirotta S, Moran L. An analysis on the implementation of the evidence-based PCOS lifestyle guideline: recommendations from women with PCOS. InSeminars in Reproductive Medicine 2021 Jul (Vol. 39, No. 03/04, pp. 153-160). Thieme Medical Publishers, Inc..",primary_citation,,Lim S,2021,"Lim S et al., 2021",10.1055/s-0041-1735575,,,,,An Analysis on the Implementation of the Evidence-based PCOS Lifestyle Guideline: Recommendations from Women with PCOS,pmid:34461671,10.1055/s-0041-1735575
2.0,2.6.4,565,28.0,"Lin AW, Bergomi EJ, Dollahite JS, Sobal J, Hoeger KM, Lujan ME. Trust in physicians and medical experience beliefs differ between women with and without polycystic ovary syndrome. Journal of the Endocrine Society. 2018 Sep;2(9):1001-9.",primary_citation,,Lin AW,2018,"Lin AW et al., 2018",10.1210/js.2018-00181,,,,,Trust in Physicians and Medical Experience Beliefs Differ Between Women With and Without Polycystic Ovary Syndrome,pmid:30140785,10.1210/js.2018-00181
2.0,2.6.4,566,28.0,"Pirotta S, Joham AE, Moran LJ, Skouteris H, Lim SS. Implementation of the polycystic ovary syndrome guidelines: A mixed method study to inform the design and delivery of a lifestyle management program for women with polycystic ovary syndrome. Nutrition & Dietetics. 2021 Nov;78(5):476-86.",primary_citation,,Pirotta S,2021,"Pirotta S et al., 2021",10.1111/1747-0080.12670,,,,,Implementation of the polycystic ovary syndrome guidelines: A mixed method study to inform the design and delivery of a lifestyle management program for women with polycystic ovary syndrome,pmid:33876532,10.1111/1747-0080.12670
2.0,2.6.4,567,28.0,"Sharma S, Mishra AJ. Tabooed disease in alienated bodies: A study of women suffering from Polycystic Ovary Syndrome (PCOS). Clinical Epidemiology and Global Health. 2018 Sep 1;6(3):130-6.",primary_citation,,Sharma S,2018,"Sharma S et al., 2018",10.1016/j.cegh.2017.09.001,,,,,Tabooed disease in alienated bodies: A study of women suffering from Polycystic Ovary Syndrome (PCOS),,10.1016/j.cegh.2017.09.001
2.0,2.6.4,568,28.0,"Soucie K, Samardzic T, Schramer K, Ly C, Katzman R. The diagnostic experiences of women with polycystic ovary syndrome (PCOS) in Ontario, Canada. Qualitative Health Research. 2021 Feb;31(3):523-34.",primary_citation,,Soucie K,2021,"Soucie K et al., 2021",10.1177/1049732320971235,,,,,"The Diagnostic Experiences of Women With Polycystic Ovary Syndrome (PCOS) in Ontario, Canada",pmid:33213256,10.1177/1049732320971235
2.0,2.6.4,569,28.0,"Snyder BS,. The lived experience of women diagnosed with polycystic ovary syndrome. Journal of obstetric, gynecologic & neonatal nursing. 2006 May 1;35(3):385-92.",primary_citation,,Snyder BS,2006,"Snyder BS et al., 2006",10.1111/j.1552-6909.2006.00047.x,,,,,The Lived Experience of Women Diagnosed With Polycystic Ovary Syndrome,pmid:16700688,10.1111/j.1552-6909.2006.00047.x
2.0,2.6.4,570,28.0,"Tay CT, Pirotta S, Teede HJ, Moran LJ, Robinson T, Skouteris H, Joham AE, Lim SS. Polycystic ovary syndrome models of care: a review and qualitative evaluation of a guideline-recommended integrated care. InSeminars in Reproductive Medicine 2021 Jul (Vol. 39, No. 03/04, pp. 133-142). Thieme Medical Publishers, Inc..",primary_citation,,Tay CT,2021,"Tay CT et al., 2021",10.1055/s-0041-1727191,,,,,Polycystic Ovary Syndrome Models of Care: A Review and Qualitative Evaluation of a Guideline-Recommended Integrated Care,pmid:34187051,10.1055/s-0041-1727191
2.0,2.6.4,571,28.0,"Tomlinson J, Pinkney J, Adams L, Stenhouse E, Bendall A, Corrigan O, Letherby G. The diagnosis and lived experience of polycystic ovary syndrome: A qualitative study. Journal of advanced nursing. 2017 Oct;73(10):2318-26.",primary_citation,,Tomlinson J,2017,"Tomlinson J et al., 2017",10.1111/jan.13300,,,,,The diagnosis and lived experience of polycystic ovary syndrome: A qualitative study,pmid:28329428,10.1111/jan.13300
2.0,2.6.4,572,28.0,"Weiss TR, Bulmer SM. Young women's experiences living with polycystic ovary syndrome. Journal of obstetric, gynecologic & neonatal nursing. 2011 Nov 1;40(6):709-18.",primary_citation,,Weiss TR,2011,"Weiss TR et al., 2011",10.1111/j.1552-6909.2011.01299.x,,,,,Young Women's Experiences Living with Polycystic Ovary Syndrome,pmid:22092488,10.1111/j.1552-6909.2011.01299.x
2.0,2.6.4,573,28.0,"Williams S, Sheffield D, Knibb RC. ‘Everything’s from the inside out with PCOS’: Exploring women’s experiences of living with polycystic ovary syndrome and co-morbidities through Skype™ interviews. Health psychology open. 2015 Aug 28;2(2):2055102915603051.",primary_citation,,Williams S,2015,"Williams S et al., 2015",10.1177/2055102915603051,,,,,‘Everything’s from the inside out with PCOS’: Exploring women’s experiences of living with polycystic ovary syndrome and co-morbidities through Skype™ interviews,pmid:28070371,10.1177/2055102915603051
2.0,2.6.4,574,28.0,"Williams S, Sheffield D, Knibb RC. A snapshot of the lives of women with polycystic ovary syndrome: A photovoice investigation. Journal of Health Psychology. 2016 Jun;21(6):1170-82.",primary_citation,,Williams S,2016,"Williams S et al., 2016",10.1177/1359105314547941,,,,,A snapshot of the lives of women with polycystic ovary syndrome: A photovoice investigation,pmid:25205774,10.1177/1359105314547941
2.0,2.6.4,575,28.0,"Wright PJ, Dawson RM, Corbett CF. Social construction of biopsychosocial and medical experiences of women with polycystic ovary syndrome. Journal of Advanced Nursing. 2020 Jul;76(7):1728-36.",primary_citation,,Wright PJ,2020,"Wright PJ et al., 2020",10.1111/jan.14371,,,,,Social construction of biopsychosocial and medical experiences of women with polycystic ovary syndrome,pmid:32215949,10.1111/jan.14371
2.0,2.8,576,1.0,"Masoudi M, Ansari S, Kashani L, Tavolinejad H, Hossein Rashidi B, Esalatmanesh S, Ghazizadeh-Hashemi M, Noorbala AA, Akhondzadeh S. Effect of sertraline on depression severity and prolactin levels in women with polycystic ovary syndrome: a placebo-controlled randomized trial. Int Clin Psychopharmacol. 2021 Sep 1;36(5):238-243. doi: 10.1097/YIC.0000000000000367. PMID: 34030169.",primary_citation,,Masoudi M,2021,"Masoudi M et al., 2021",10.1097/yic.0000000000000367,34030169.0,,,,Effect of sertraline on depression severity and prolactin levels in women with polycystic ovary syndrome: a placebo-controlled randomized trial,pmid:34030169,
3.0,3.1,577,18.0,"Almenning I, Rieber‐Mohn A, Lundgren KM, Shetelig Løvvik T, Garnæs KK, Moholdt T. Effects of high intensity interval training and strength training on metabolic, cardiovascular and hormonal outcomes in women with polycystic ovary syndrome: a pilot study. PloS One 2015;10(9):e0138793.",primary_citation,prior search,Almenning I,2015,"Almenning I et al., 2015",10.1371/journal.pone.0138793,,,,,"Effects of High Intensity Interval Training and Strength Training on Metabolic, Cardiovascular and Hormonal Outcomes in Women with Polycystic Ovary Syndrome: A Pilot Study",pmid:26406234,10.1371/journal.pone.0138793
3.0,3.1,578,18.0,"Brown AJ, Setji TL, Sanders LL, Lowry KP, Otvos JD, Kraus WE, et al. Effects of exercise on lipoprotein particles in women with polycystic ovary syndrome. Medicine and Sciences in Sports and Exercise 2009;41(3):497‐504.",primary_citation,prior search,Brown AJ,2009,"Brown AJ et al., 2009",10.1249/mss.0b013e31818c6c0c,,,,,Effects of Exercise on Lipoprotein Particles in Women with Polycystic Ovary Syndrome,pmid:19204602,10.1249/mss.0b013e31818c6c0c
3.0,3.1,579,18.0,"Costa, E. C., DE Sá, J., Stepto, N. K., Costa, I., Farias-Junior, L. F., Moreira, S., Soares, E., Lemos, T., Browne, R., & Azevedo, G. D. (2018). Aerobic Training Improves Quality of Life in Women with Polycystic Ovary Syndrome. Medicine and science in sports and exercise, 50(7), 1357–1366. https://doi.org/10.1249/MSS.0000000000001579",primary_citation,,Costa,2018,"Costa et al., 2018",10.1249/mss.0000000000001579,,,,,Aerobic Training Improves Quality of Life in Women with Polycystic Ovary Syndrome,pmid:29443823,10.1249/mss.0000000000001579
3.0,3.1,580,18.0,"Dietz de Loos, A., Jiskoot, G., Beerthuizen, A., Busschbach, J., & Laven, J. (2021). Metabolic health during a randomized controlled lifestyle intervention in women with PCOS. European journal of endocrinology, 186(1), 53–64. https://doi.org/10.1530/EJE-21-0669",primary_citation,,Dietz de Loos,2021,"Dietz de Loos et al., 2021",10.1530/eje-21-0669,,,,,Metabolic health during a randomized controlled lifestyle intervention in women with PCOS,pmid:34714771,10.1530/eje-21-0669
3.0,3.1,581,18.0,"Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertility and Sterility 1994;61(4):598‐604.",primary_citation,prior search,Guzick DS,1994,"Guzick DS et al., 1994",10.1016/s0015-0282(16)56632-1,,,,,"Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women",pmid:8150098,10.1016/s0015-0282(16)56632-1
3.0,3.1,582,18.0,"Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility 2004;82(2):421‐9.",primary_citation,prior search,Hoeger KM,2004,"Hoeger KM et al., 2004",10.1016/j.fertnstert.2004.02.104,,,,,"A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: A pilot study",pmid:15302293,10.1016/j.fertnstert.2004.02.104
3.0,3.1,583,18.0,"Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo‐controlled clinical trials. Journal of Clinical Endocrinology and Metabolism 2008;93(11):4299‐306.",primary_citation,prior search,Hoeger K,2008,"Hoeger K et al., 2008",10.1210/jc.2008-0461,,,,,"The Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women in Two Randomized, Placebo-Controlled Clinical Trials",pmid:18728175,10.1210/jc.2008-0461
3.0,3.1,584,18.0,"Jedel E, Labrie F, Oden A, Holm G, Nilsson L, Janson PO, et al. Impact of electro‐acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomised controlled trial. American Journal of Physiology‐Endocrinology and Metabolism 2011;300(1):E37‐45. (primary citation)",primary_citation,prior search,Jedel E,2011,"Jedel E et al., 2011",10.1152/ajpendo.00495.2010,,,,,Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial,pmid:20943753,10.1152/ajpendo.00495.2010
3.0,3.1,585,18.0,"Leonhardt H, Hellstrom M, Gull B, Lind AK, Nilsson L, Janson OP, et al. Serum anti‐Mullerian hormone and ovarian morphology assessed by magnetic resonance imaging in response to acupuncture and exercise in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial. Acta Obstetricia et Gynecologica Scandinavica 2015;94:279‐87.",samestudy_584,prior search,Leonhardt H,2015,"Leonhardt H et al., 2015",10.1111/aogs.12571,,,,,Serum anti‐Müllerian hormone and ovarian morphology assessed by magnetic resonance imaging in response to acupuncture and exercise in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial,pmid:25545309,10.1111/aogs.12571
3.0,3.1,586,18.0,"Stener‐Victorin E, Baghaei F, Holm G, Janson PO, Olivecrona G, Lönn M, et al. Effects of acupuncture and exercise on insulin sensitivity, adipose tissue characteristics, and markers of coagulation and fibrinolysis in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial. Fertility and Sterility 2012;97(2):501‐8.",samestudy_584,prior search,Stener‐Victorin E,2012,"Stener‐Victorin E et al., 2012",10.1016/j.fertnstert.2011.11.010,,,,,"Effects of acupuncture and exercise on insulin sensitivity, adipose tissue characteristics, and markers of coagulation and fibrinolysis in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial",pmid:22154367,10.1016/j.fertnstert.2011.11.010
3.0,3.1,587,18.0,"Stener‐Victorin E, Holm G, Janson PO, Gustafson D, Waern M. Acupuncture and physical exercise for affective symptoms and health‐related quality of life in polycystic ovary syndrome: secondary analysis from a randomized controlled trial. BMC Complementary and Alternative Medicine 2013;13:131.",samestudy_584,prior search,Stener‐Victorin E,2013,"Stener‐Victorin E et al., 2013",10.1186/1472-6882-13-131,,,,,Acupuncture and physical exercise for affective symptoms and health-related quality of life in polycystic ovary syndrome: secondary analysis from a randomized controlled trial,pmid:23763822,10.1186/1472-6882-13-131
3.0,3.1,588,18.0,"Stener‐Victorin E, Jedel E, Janson PO, Sverrisdottir YB. Low‐frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. American Journal of Physiology ‐ Regulatory, Integrative and Comparative Physiology 2009;297(2):R387‐95.",samestudy_584,prior search,Stener‐Victorin E,2009,"Stener‐Victorin E et al., 2009",10.1152/ajpregu.00197.2009,,,,,Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome,pmid:19494176,10.1152/ajpregu.00197.2009
3.0,3.1,589,18.0,"Kiel, I. A., Lionett, S., Parr, E. B., Jones, H., Røset, M., Salvesen, Ø., Hawley, J. A., Vanky, E., & Moholdt, T. (2022). High-Intensity Interval Training in Polycystic Ovary Syndrome: A Two-Center, Three-Armed Randomized Controlled Trial. Medicine and science in sports and exercise, 54(5), 717–727. https://doi.org/10.1249/MSS.0000000000002849",primary_citation,,Kiel,2022,"Kiel et al., 2022",10.1249/mss.0000000000002849,,,,,"High-Intensity Interval Training in Polycystic Ovary Syndrome: A Two-Center, Three-Armed Randomized Controlled Trial",pmid:35019901,10.1249/mss.0000000000002849
3.0,3.1,590,18.0,"Kogure, G. S., Lopes, I. P., Ribeiro, V. B., Mendes, M. C., Kodato, S., Furtado, C., Silva de Sá, M. F., Ferriani, R. A., Lara, L., & Reis, R. (2020). The effects of aerobic physical exercises on body image among women with polycystic ovary syndrome. Journal of affective disorders, 262, 350–358.",primary_citation,,Kogure,2020,"Kogure et al., 2020",10.1016/j.jad.2019.11.025,,,,,The effects of aerobic physical exercises on body image among women with polycystic ovary syndrome,pmid:31735408,10.1016/j.jad.2019.11.025
3.0,3.1,591,18.0,"Moeller, L. V., Lindhardt, C. L., Andersen, M. S., Glintborg, D., & Ravn, P. (2019). Motivational interviewing in obese women with polycystic ovary syndrome - a pilot study. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology, 35(1), 76–80. https://doi.org/10.1080/09513590.2018.1498832",primary_citation,,Moeller,2019,"Moeller et al., 2019",10.1080/09513590.2018.1498832,,,,,Motivational interviewing in obese women with polycystic ovary syndrome – a pilot study,pmid:30182773,10.1080/09513590.2018.1498832
3.0,3.1,592,18.0,"Nasrekani ZA, Fathi M. Efficacy of 12 weeks aerobic training on body composition, aerobic power and some women‐hormones in polycystic ovary syndrome infertile women. Iranian Journal of Obstetrics, Gynecology and Infertility 2016;19(5):1‐10.",primary_citation,prior search,Nasrekani ZA,2016,"Nasrekani ZA et al., 2016",,,,80790917.0,"Efficacy of 12 weeks aerobic training on body composition, aerobic power and some women‐hormones in polycystic ovary syndrome infertile women",,,
3.0,3.1,593,18.0,"Oberg, E., Gidlöf, S., Jakson, I., Mitsell, M., Tollet Egnell, P., & Hirschberg, A. L. (2019). Improved menstrual function in obese women with polycystic ovary syndrome after behavioural modification intervention-A randomized controlled trial. Clinical endocrinology, 90(3), 468–478. https://doi.org/10.1111/cen.13919",primary_citation,,Oberg,2019,"Oberg et al., 2019",10.1111/cen.13919,,,,,Improved menstrual function in obese women with polycystic ovary syndrome after behavioural modification intervention—A randomized controlled trial,pmid:30565716,10.1111/cen.13919
3.0,3.1,594,18.0,"Ribeiro, V. B., Lopes, I. P., Dos Reis, R. M., Silva, R. C., Mendes, M. C., Melo, A. S., de Souza, H., Ferriani, R. A., Kogure, G. S., & Lara, L. (2021). Continuous versus intermittent aerobic exercise in the improvement of quality of life for women with polycystic ovary syndrome: A randomized controlled trial. Journal of health psychology, 26(9), 1307–1317. https://doi.org/10.1177/1359105319869806 (primary citation)",primary_citation,,Ribeiro,2021,"Ribeiro et al., 2021",10.1177/1359105319869806,,,,,Continuous versus intermittent aerobic exercise in the improvement of quality of life for women with polycystic ovary syndrome: A randomized controlled trial,pmid:31495231,10.1177/1359105319869806
3.0,3.1,595,18.0,"Ribeiro, V. B., Pedroso, D., Kogure, G. S., Lopes, I. P., Santana, B. A., Dutra de Souza, H. C., Ferriani, R. A., Calado, R. T., Furtado, C., & Reis, R. (2021). Short-Term Aerobic Exercise Did Not Change Telomere Length While It Reduced Testosterone Levels and Obesity Indexes in PCOS: A Randomized Controlled Clinical Trial Study. International journal of environmental research and public health, 18(21), 11274. https://doi.org/10.3390/ijerph182111274",samestudy_594,,Ribeiro,2021,"Ribeiro et al., 2021",10.3390/ijerph182111274,,,,,Short-Term Aerobic Exercise Did Not Change Telomere Length While It Reduced Testosterone Levels and Obesity Indexes in PCOS: A Randomized Controlled Clinical Trial Study,pmid:34769797,10.3390/ijerph182111274
3.0,3.1,596,18.0,"Saremi A, Nader, Karmali M, Kazemi M. Serum level of anti‐mullerian hormone after exercise training in women with polycystic ovary syndrome: a randomised controlled trial. Iranian Journal of Obstetrics, Gynecology and Infertility 2013;16(64):10.",primary_citation,prior search,Saremi A,2013,"Saremi A et al., 2013",,,W3121804787,, Serum level of anti‐mullerian hormone after exercise training in women with polycystic ovary syndrome: a randomised controlled trial.,Serum level of anti-mullerian hormone after exercise training in women with polycystic ovary syndrome: a randomized controlled trial.,,
3.0,3.1,597,18.0,"Stefanaki C, Bacopoulou F, Livadas S, Kandaraki A, Karacalios A, Chrousos G, et al. Impact of a mindfulness stress management program on stress, anxiety, depression and quality of life in women with polycystic ovary syndrome: a randomised controlled trial. Stress (Amsterdam, Netherlands) 2015;18(1):57‐66.",primary_citation,prior search,Stefanaki C,2015,"Stefanaki C et al., 2015",10.3109/10253890.2014.974030,,,,,"Impact of a mindfulness stress management program on stress, anxiety, depression and quality of life in women with polycystic ovary syndrome: a randomized controlled trial",pmid:25287137,10.3109/10253890.2014.974030
3.0,3.1,598,18.0,"Turan V, Mutlu EK, Solmaz U, Ekin A, Tosun O, Tosun G, et al. Benefits of short‐term structured exercise in non‐overweight women with polycystic ovary syndrome: a prospective randomised controlled study. Journal of Physical Therapy Science 2015;27(7):2293‐7.",primary_citation,prior search,Turan V,2015,"Turan V et al., 2015",10.1589/jpts.27.2293,,,,,Benefits of short-term structured exercise in non-overweight women with polycystic ovary syndrome: a prospective randomized controlled study,pmid:26311969,10.1589/jpts.27.2293
3.0,3.1,599,18.0,"Vigorito C, Giallauria F, Palomba S, Cascella T, Manguso F, Lucci R, et al. Beneficial effects of a three‐month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2007;92(4):1379‐84.",primary_citation,prior search,Vigorito C,2007,"Vigorito C et al., 2007",10.1210/jc.2006-2794,,,,,Beneficial Effects of a Three-Month Structured Exercise Training Program on Cardiopulmonary Functional Capacity in Young Women with Polycystic Ovary Syndrome,pmid:17264174,10.1210/jc.2006-2794
3.0,3.3,600,12.0,"Asemi, Z. and A. Esmaillzadeh, DASH diet, insulin resistance, and serum hs-CRP in polycystic ovary syndrome: a randomized controlled clinical trial. Hormone & Metabolic Research, 2015. 47(3): p. 232-8. (primary citation)",primary_citation,prior search,Asemi,2015,"Asemi et al., 2015",10.1055/s-0034-1376990,,,,,"DASH Diet, Insulin Resistance, and Serum hs-CRP in Polycystic Ovary Syndrome: A Randomized Controlled Clinical Trial",pmid:24956415,10.1055/s-0034-1376990
3.0,3.3,601,12.0,"Asemi, Z., et al., Effects of DASH diet on lipid profiles and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized clinical trial. Nutrition, 2014. 30(11-12): p. 1287-93.",samestudy_600,prior search,Asemi,2014,"Asemi et al., 2014",10.1016/j.nut.2014.03.008,,,,,Effects of DASH diet on lipid profiles and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: A randomized clinical trial,pmid:25194966,10.1016/j.nut.2014.03.008
3.0,3.3,602,12.0,"Azadi-Yazdi, M., Karimi-Zarchi, M., Salehi-Abargouei, A., Fallahzadeh, H., & Nadjarzadeh, A. (2017). Effects of Dietary Approach to Stop Hypertension diet on androgens, antioxidant status and body composition in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial. Journal of human nutrition and dietetics: the official journal of the British Dietetic Association, 30(3), 275–283. https://doi.org/10.1111/jhn.12433",primary_citation,,Azadi-Yazdi,2017,"Azadi-Yazdi et al., 2017",10.1111/jhn.12433,,,,,"Effects of Dietary Approach to Stop Hypertension diet on androgens, antioxidant status and body composition in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial",pmid:28466507,10.1111/jhn.12433
3.0,3.3,603,12.0,"Foroozanfard, F., Rafiei, H., Samimi, M., Gilasi, H. R., Gorjizadeh, R., Heidar, Z., & Asemi, Z. (2017). The effects of dietary approaches to stop hypertension diet on weight loss, anti-Müllerian hormone and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial. Clinical endocrinology, 87(1), 51–58. https://doi.org/10.1111/cen.13333",primary_citation,,Foroozanfard,2017,"Foroozanfard et al., 2017",10.1111/cen.13333,,,,,"The effects of dietary approaches to stop hypertension diet on weight loss, anti‐Müllerian hormone and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial",pmid:28316072,10.1111/cen.13333
3.0,3.3,604,12.0,"Gower, B. A., Chandler-Laney, P. C., Ovalle, F., Goree, L. L., Azziz, R., Desmond, R. A., Granger, W. M., Goss, A. M., & Bates, G. W. (2013). Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS. Clinical endocrinology, 79(4), 550–557. https://doi.org/10.1111/cen.12175 (primary citation)",primary_citation,prior search,Gower,2013,"Gower et al., 2013",10.1111/cen.12175,,,,,Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS,pmid:23444983,10.1111/cen.12175
3.0,3.3,605,,"Hoover, S. E., Gower, B. A., Cedillo, Y. E., Chandler-Laney, P. C., Deemer, S. E., & Goss, A. M. (2021). Changes in Ghrelin and Glucagon following a Low Glycemic Load Diet in Women with PCOS. The Journal of clinical endocrinology and metabolism, 106(5), e2151–e2161. https://doi.org/10.1210/clinem/dgab028",samestudy_604,prior search,Hoover,2021,"Hoover et al., 2021",10.1210/clinem/dgab028,,,,,Changes in Ghrelin and Glucagon following a Low Glycemic Load Diet in Women with PCOS,pmid:33491091,10.1210/clinem/dgab028
3.0,3.3,606,12.0,"Hosseini Marnani E., Ghadiri-Anari A., Ramezani-Jolfaie N., Mohammadi M., Abdollahi, A., Namayandeh S. M., et al. Effect of fennel supplementation along with high-protein, low-carbohydrate weight-loss diet on insulin resistance and percentage of fat and muscle mass in overweight/obese women with polycystic ovary syndrome. Journal of Functional Foods 2020 Vol. 67 Pages 103848. https://doi.org/10.1016/j.jff.2020.103848",primary_citation,,Hosseini Marnani E.,2020,"Hosseini Marnani E. et al., 2020",10.1016/j.jff.2020.103848,,,,,"Effect of fennel supplementation along with high-protein, low-carbohydrate weight-loss diet on insulin resistance and percentage of fat and muscle mass in overweight/obese women with polycystic ovary syndrome",,10.1016/j.jff.2020.103848
3.0,3.3,607,12.0,"Kazemi, M., McBreairty, L. E., Chizen, D. R., Pierson, R. A., Chilibeck, P. D., & Zello, G. A. (2018). A Comparison of a Pulse-Based Diet and the Therapeutic Lifestyle Changes Diet in Combination with Exercise and Health Counselling on the Cardio-Metabolic Risk Profile in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients, 10(10), 1387. https://doi.org/10.3390/nu10101387 (primary citation)",primary_citation,,Kazemi,2018,"Kazemi et al., 2018",10.3390/nu10101387,,,,,A Comparison of a Pulse-Based Diet and the Therapeutic Lifestyle Changes Diet in Combination with Exercise and Health Counselling on the Cardio-Metabolic Risk Profile in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial,pmid:30274344,10.3390/nu10101387
3.0,3.3,608,12.0,"Kazemi, M., McBreairty, L. E., Zello, G. A., Pierson, R. A., Gordon, J. J., Serrao, S. B., Chilibeck, P. D., & Chizen, D. R. (2020). A pulse-based diet and the Therapeutic Lifestyle Changes diet in combination with health counseling and exercise improve health-related quality of life in women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial. Journal of psychosomatic obstetrics and gynaecology, 41(2), 144–153. https://doi.org/10.1080/0167482X.2019.1666820",samestudy_608,,Kazemi,2020,"Kazemi et al., 2020",10.1080/0167482x.2019.1666820,,,,,A pulse-based diet and the Therapeutic Lifestyle Changes diet in combination with health counseling and exercise improve health-related quality of life in women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial,pmid:31558086,10.1080/0167482x.2019.1666820
3.0,3.3,609,12.0,"Kazemi, M., Pierson, R. A., McBreairty, L. E., Chilibeck, P. D., Zello, G. A., & Chizen, D. R. (2020). A randomized controlled trial of a lifestyle intervention with longitudinal follow-up on ovarian dysmorphology in women with polycystic ovary syndrome. Clinical endocrinology, 92(6), 525–535. https://doi.org/10.1111/cen.14179",samestudy_608,,Kazemi,2020,"Kazemi et al., 2020",10.1111/cen.14179,,,,,A randomized controlled trial of a lifestyle intervention with longitudinal follow‐up on ovarian dysmorphology in women with polycystic ovary syndrome,pmid:32092167,10.1111/cen.14179
3.0,3.3,610,12.0,"McBreairty, L. E., Kazemi, M., Chilibeck, P. D., Gordon, J. J., Chizen, D. R., & Zello, G. A. (2020). Effect of a pulse-based diet and aerobic exercise on bone measures and body composition in women with polycystic ovary syndrome: A randomized controlled trial. Bone reports, 12, 100248. https://doi.org/10.1016/j.bonr.2020.100248",samestudy_608,,McBreairty,2020,"McBreairty et al., 2020",10.1016/j.bonr.2020.100248,,,,,Effect of a pulse-based diet and aerobic exercise on bone measures and body composition in women with polycystic ovary syndrome: A randomized controlled trial,pmid:32071953,10.1016/j.bonr.2020.100248
3.0,3.3,611,12.0,"Mehrabani, H. H., Salehpour, S., Amiri, Z., Farahani, S. J., Meyer, B. J., & Tahbaz, F. (2012). Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study. Journal of the American College of Nutrition, 31(2), 117–125. https://doi.org/10.1080/07315724.2012.10720017",primary_citation,prior search,Mehrabani,2012,"Mehrabani et al., 2012",10.1080/07315724.2012.10720017,,,,,"Beneficial Effects of a High-Protein, Low-Glycemic-Load Hypocaloric Diet in Overweight and Obese Women with Polycystic Ovary Syndrome: A Randomized Controlled Intervention Study",pmid:22855917,10.1080/07315724.2012.10720017
3.0,3.3,612,12.0,"Moran, LJ.J., Noakes, M., Clifton, P.M., Tomlinson L., Norman, R. J. (2003). Dietary Composition in Restoring Reproductive and Metabolic Physiology in Overweight Women with Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism 88(2):812–819.",primary_citation,prior search,Moran,2003,"Moran et al., 2003",10.1210/jc.2002-020815,12574218.0,,,,Dietary Composition in Restoring Reproductive and Metabolic Physiology in Overweight Women with Polycystic Ovary Syndrome,pmid:12574218,
,,613,,"Galletly C, Moran LJ, Noakes M, Clifton P, Tomlinson L, Norman RJ. (2007). Psychological benefits of a high-protein, low-carbohydrate diet in obese women with polycystic ovary syndrome—A pilot study. Appetite (49) 590-593. doi:10.1016/j.appet.2007.03.222",primary_citation,prior search,Galletly C,2007,"Galletly C et al., 2007",10.1016/j.appet.2007.03.222,,,,,"Psychological benefits of a high-protein, low-carbohydrate diet in obese women with polycystic ovary syndrome—A pilot study",,
3.0,3.3,614,12.0,"Panico A, Lupoli GA, Cioffi I, Zacchia G, Caldara A, Lupoli G, Contaldo F, Pasanisi F. Effects of an isocaloric low-glycemic-load diet in polycystic ovary syndrome. Nutr Ther Metab. 2014;32:85–92.",primary_citation,prior search,Panico A,2014,"Panico A et al., 2014",10.5301/ntm.2014.12407,,,,,Effects of an isocaloric low-glycemic-load diet in polycystic ovary syndrome,,10.5301/ntm.2014.12407
3.0,3.3,615,12.0,"Stamets K, et al., A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertility & Sterility, 2004. 81(3): p. 630-637.",primary_citation,prior search,Stamets K,2004,"Stamets K et al., 2004",10.1016/j.fertnstert.2003.08.023,,,,,A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome,pmid:15037413,10.1016/j.fertnstert.2003.08.023
3.0,3.3,616,12.0,"Toscani, M. K., Mario, F. M., Radavelli-Bagatini, S., Wiltgen, D., Matos, M. C., & Spritzer, P. M. (2011). Effect of high-protein or normal-protein diet on weight loss, body composition, hormone, and metabolic profile in southern Brazilian women with polycystic ovary syndrome: a randomized study. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology, 27(11), 925–930. https://doi.org/10.3109/09513590.2011.564686",primary_citation,prior search,Toscani,2011,"Toscani et al., 2011",10.3109/09513590.2011.564686,,,,,"Effect of high-protein or normal-protein diet on weight loss, body composition, hormone, and metabolic profile in southern Brazilian women with polycystic ovary syndrome: a randomized study",pmid:21627406,10.3109/09513590.2011.564686
3.0,3.3,617,12.0,"Wong, J. M., Gallagher, M., Gooding, H., Feldman, H. A., Gordon, C. M., Ludwig, D. S., & Ebbeling, C. B. (2016). A randomized pilot study of dietary treatments for polycystic ovary syndrome in adolescents. Pediatric obesity, 11(3), 210–220. https://doi.org/10.1111/ijpo.12047",primary_citation,prior search,Wong,2016,"Wong et al., 2016",10.1111/ijpo.12047,,,,,A randomized pilot study of dietary treatments for polycystic ovary syndrome in adolescents,pmid:26132306,10.1111/ijpo.12047
3.0,3.4,618,5.0,"Almenning I, Rieber-Mohn A, Lundgren KM, Shetelig Løvvik T, Garnæs KK, Moholdt T. Effects of High Intensity Interval Training and Strength Training on Metabolic, Cardiovascular and Hormonal Outcomes in Women with Polycystic Ovary Syndrome: A Pilot Study. PLoS One. 2015 Sep 25;10(9):e0138793. doi: 10.1371/journal.pone.0138793. ",primary_citation,,Almenning I,2015,"Almenning I et al., 2015",10.1371/journal.pone.0138793,,,,,"Effects of High Intensity Interval Training and Strength Training on Metabolic, Cardiovascular and Hormonal Outcomes in Women with Polycystic Ovary Syndrome: A Pilot Study",pmid:26406234,10.1371/journal.pone.0138793
3.0,3.4,619,5.0,"Benham JL, Booth JE, Corenblum B, Doucette S, Friedenreich CM, Rabi DM, Sigal RJ. Exercise training and reproductive outcomes in women with polycystic ovary syndrome: A pilot randomized controlled trial. Clin Endocrinol (Oxf). 2021 Aug;95(2):332-343. doi: 10.1111/cen.14452.",primary_citation,,Benham JL,2021,"Benham JL et al., 2021",10.1111/cen.14452,,,,,Exercise training and reproductive outcomes in women with polycystic ovary syndrome: A pilot randomized controlled trial,pmid:33638879,10.1111/cen.14452
3.0,3.4,620,5.0,"Lopes IP, Ribeiro VB, Reis RM, Silva RC, Dutra de Souza HC, Kogure GS, Ferriani RA, Silva Lara LAD. Comparison of the Effect of Intermittent and Continuous Aerobic Physical Training on Sexual Function of Women With Polycystic Ovary Syndrome: Randomized Controlled Trial. J Sex Med. 2018 Nov;15(11):1609-1619. doi: 10.1016/j.jsxm.2018.09.002 (primary citation)",primary_citation,,Lopes IP,2018,"Lopes IP et al., 2018",10.1016/j.jsxm.2018.09.002,,,,,Comparison of the Effect of Intermittent and Continuous Aerobic Physical Training on Sexual Function of Women With Polycystic Ovary Syndrome: Randomized Controlled Trial,pmid:30316737,10.1016/j.jsxm.2018.09.002
3.0,3.4,621,5.0,"Ribeiro VB, Kogure GS, Lopes IP, Silva RC, Pedroso DCC, de Melo AS, de Souza HCD, Ferriani RA, Miranda Furtado CL, Dos Reis RM. Effects of continuous and intermittent aerobic physical training on hormonal and metabolic profile, and body composition in women with polycystic ovary syndrome: A randomized controlled trial. Clin Endocrinol (Oxf). 2020 Aug;93(2):173-186. doi: 10.1111/cen.14194.",samestudy_620,,Ribeiro VB,2020,"Ribeiro VB et al., 2020",10.1111/cen.14194,,,,,"Effects of continuous and intermittent aerobic physical training on hormonal and metabolic profile, and body composition in women with polycystic ovary syndrome: A randomized controlled trial",pmid:32286711,10.1111/cen.14194
3.0,3.4,622,5.0,"Ribeiro VB, Lopes IP, Dos Reis RM, Silva RC, Mendes MC, Melo AS, de Souza HCD, Ferriani RA, Kogure GS, Lara LADS. Continuous versus intermittent aerobic exercise in the improvement of quality of life for women with polycystic ovary syndrome: A randomized controlled trial. J Health Psychol. 2021 Aug;26(9):1307-1317. doi: 10.1177/1359105319869806.",samestudy_620,,Ribeiro VB,2021,"Ribeiro VB et al., 2021",10.1177/1359105319869806,,,,,Continuous versus intermittent aerobic exercise in the improvement of quality of life for women with polycystic ovary syndrome: A randomized controlled trial,pmid:31495231,10.1177/1359105319869806
3.0,3.4,623,5.0,"Patten RK, McIlvenna LC, Levinger I, Garnham AP, Shorakae S, Parker AG, McAinch AJ, Rodgers RJ, Hiam D, Moreno-Asso A, Stepto NK. High-intensity training elicits greater improvements in cardio-metabolic and reproductive outcomes than moderate-intensity training in women with polycystic ovary syndrome: a randomized clinical trial. Hum Reprod. 2022 May 3;37(5):1018-1029. doi: 10.1093/humrep/deac047.",primary_citation,,Patten RK,2022,"Patten RK et al., 2022",10.1093/humrep/deac047,,,,,High-intensity training elicits greater improvements in cardio-metabolic and reproductive outcomes than moderate-intensity training in women with polycystic ovary syndrome: a randomized clinical trial,pmid:35325125,10.1093/humrep/deac047
3.0,3.4,624,5.0,"Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 Sep;93(9):3373-80. doi: 10.1210/jc.2008-0751.",primary_citation,,Thomson RL,2008,"Thomson RL et al., 2008",10.1210/jc.2008-0751,,,,,"The Effect of a Hypocaloric Diet with and without Exercise Training on Body Composition, Cardiometabolic Risk Profile, and Reproductive Function in Overweight and Obese Women with Polycystic Ovary Syndrome",pmid:18583464,10.1210/jc.2008-0751
3.0,3.5,625,70.0,"Ahmadi A, Akbarzadeh M, Mohammadi F, Akbari M, Jafari B, Tolide-Ie HR. Anthropometric characteristics and dietary pattern of women with polycystic ovary syndrome. Indian J Endocrinol Metab. 2013 Jul;17(4):672-6. doi: 10.4103/2230-8210.113759. PMID: 23961484; PMCID: PMC3743368.",primary_citation,,Ahmadi A,2013,"Ahmadi A et al., 2013",10.4103/2230-8210.113759,23961484.0,,,,Anthropometric characteristics and dietary pattern of women with polycystic ovary syndrome,pmid:23961484,
3.0,3.5,626,70.0,"Alipouri, B., Roohelhami, E., Shahrdami, F., & Rashidkhani, B. (2019). Dietary glycemic index/glycemic load and their relationship with inflammatory markers in women with polycystic ovary syndrome. PROGRESS IN NUTRITION, 21, 115-121.",primary_citation,,Alipouri,2019,"Alipouri et al., 2019",,,,,,,,
3.0,3.5,627,70.0,"Altieri P, Cavazza C, Pasqui F, Morselli AM, Gambineri A, Pasquali R. Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2013 Jan;78(1):52-9. doi: 10.1111/j.1365-2265.2012.04355.x. PMID: 22288821.",primary_citation,,Altieri P,2013,"Altieri P et al., 2013",10.1111/j.1365-2265.2012.04355.x,22288821.0,,,,Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome,pmid:22288821,
3.0,3.5,628,70.0,"Alvarez-Blasco, F., Luque-Ramírez, M., & Escobar-Morreale, H. F. (2011). Diet composition and physical activity in overweight and obese premenopausal women with or without polycystic ovary syndrome. Gynecological Endocrinology, 27(12), 978-981.",primary_citation,,Alvarez-Blasco,2011,"Alvarez-Blasco et al., 2011",10.3109/09513590.2011.579658,,,,,Diet composition and physical activity in overweight and obese premenopausal women with or without polycystic ovary syndrome,pmid:21609197,10.3109/09513590.2011.579658
3.0,3.5,629,70.0,"Amirjani S, Asemi Z, Bazarganipour F, Aramesh S, Allan H, Sayadi M, Tabatabaei MS, Mohamadian Z, Zabti F, Iranpak N, Heydarzadeh A, Taghavi SA, Badehnoosh B, Khashavi Z. Dietary intake and lifestyle behaviour in different phenotypes of polycystic ovarian syndrome: a case-control study. J Hum Nutr Diet. 2019 Aug;32(4):413-421. doi: 10.1111/jhn.12646. Epub 2019 Mar 11. PMID: 30859625.",primary_citation,,Amirjani S,2019,"Amirjani S et al., 2019",10.1111/jhn.12646,30859625.0,,,,Dietary intake and lifestyle behaviour in different phenotypes of polycystic ovarian syndrome: a case–control study,pmid:30859625,
3.0,3.5,630,70.0,"Arusoglu G,. The Use of SenseWear Armband for Assessment of Daily Energy Expenditure and the Relation to Body Fat Distribution and Nutritional Intake in Lean Women with Polycystic Ovary Syndrome. J Nutr Metab. 2020 May 6;2020:9191505. doi: 10.1155/2020/9191505. PMID: 32455003; PMCID: PMC7225853.",primary_citation,,Arusoglu G,2020,"Arusoglu G et al., 2020",10.1155/2020/9191505,32455003.0,,,,The Use of SenseWear Armband for Assessment of Daily Energy Expenditure and the Relation to Body Fat Distribution and Nutritional Intake in Lean Women with Polycystic Ovary Syndrome,pmid:32455003,
3.0,3.5,631,70.0,"Badri-Fariman M, Naeini AA, Mirzaei K, Moeini A, Hosseini M, Bagheri SE, Daneshi-Maskooni M. Association between the food security status and dietary patterns with polycystic ovary syndrome (PCOS) in overweight and obese Iranian women: a case-control study. J Ovarian Res. 2021 Oct 13;14(1):134. doi: 10.1186/s13048-021-00890-1. PMID: 34645502; PMCID: PMC8515721.",primary_citation,,Badri-Fariman M,2021,"Badri-Fariman M et al., 2021",10.1186/s13048-021-00890-1,34645502.0,,,,Association between the food security status and dietary patterns with polycystic ovary syndrome (PCOS) in overweight and obese Iranian women: a case-control study,pmid:34645502,
3.0,3.5,632,70.0,"Banting LK, Gibson-Helm M, Polman R, Teede HJ, Stepto NK. Physical activity and mental health in women with polycystic ovary syndrome. BMC Womens Health. 2014 Mar 27;14(1):51. doi: 10.1186/1472-6874-14-51. PMID: 24674140; PMCID: PMC3986680.",primary_citation,,Banting LK,2014,"Banting LK et al., 2014",10.1186/1472-6874-14-51,24674140.0,,,,Physical activity and mental health in women with Polycystic Ovary Syndrome,pmid:24674140,
3.0,3.5,633,70.0,"Barrea L, Arnone A, Annunziata G, Muscogiuri G, Laudisio D, Salzano C, Pugliese G, Colao A, Savastano S. Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS). Nutrients. 2019 Sep 23;11(10):2278. doi: 10.3390/nu11102278. PMID: 31547562; PMCID: PMC6836220.",primary_citation,,Barrea L,2019,"Barrea L et al., 2019",10.3390/nu11102278,31547562.0,,,,"Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS)",pmid:31547562,
3.0,3.5,634,70.0,"Bykowska-Derda A, Czlapka-Matyasik M, Kaluzna M, Ruchala M, Ziemnicka K. Diet quality scores in relation to fatness and nutritional knowledge in women with polycystic ovary syndrome: case-control study. Public Health Nutr. 2021 Aug;24(11):3389-3398. doi: 10.1017/S1368980020001755. Epub 2020 Jul 21. PMID: 32693854.",primary_citation,,Bykowska-Derda A,2021,"Bykowska-Derda A et al., 2021",10.1017/s1368980020001755,32693854.0,,,,Diet quality scores in relation to fatness and nutritional knowledge in women with polycystic ovary syndrome: case–control study,pmid:32693854,
3.0,3.5,635,70.0,"Cutillas-Tolín A, Arense-Gonzalo JJ, Mendiola J, Adoamnei E, Navarro-Lafuente F, Sánchez-Ferrer ML, Prieto-Sánchez MT, Carmona-Barnosi A, Vioque J, Torres-Cantero AM. Are Dietary Indices Associated with Polycystic Ovary Syndrome and Its Phenotypes? A Preliminary Study. Nutrients. 2021 Jan 22;13(2):313. doi: 10.3390/nu13020313. PMID: 33499268; PMCID: PMC7911683.",primary_citation,,Cutillas-Tolín A,2021,"Cutillas-Tolín A et al., 2021",10.3390/nu13020313,33499268.0,,,,Are Dietary Indices Associated with Polycystic Ovary Syndrome and Its Phenotypes? A Preliminary Study,pmid:33499268,
3.0,3.5,636,70.0,"Cutler DA, Pride SM, Cheung AP. Low intakes of dietary fiber and magnesium are associated with insulin resistance and hyperandrogenism in polycystic ovary syndrome: A cohort study. Food Sci Nutr. 2019 Feb 27;7(4):1426-1437. doi: 10.1002/fsn3.977. PMID: 31024716; PMCID: PMC6475723.",primary_citation,,Cutler DA,2019,"Cutler DA et al., 2019",10.1002/fsn3.977,31024716.0,,,,Low intakes of dietary fiber and magnesium are associated with insulin resistance and hyperandrogenism in polycystic ovary syndrome: A cohort study,pmid:31024716,
3.0,3.5,637,70.0,"Cunha NBD, Ribeiro CT, Silva CM, Rosa-E-Silva ACJS, De-Souza DA. Dietary intake, body composition and metabolic parameters in women with polycystic ovary syndrome. Clin Nutr. 2019 Oct;38(5):2342-2348. doi: 10.1016/j.clnu.2018.10.012. Epub 2018 Nov 3. PMID: 30449604.",primary_citation,,Cunha NBD,2019,"Cunha NBD et al., 2019",10.1016/j.clnu.2018.10.012,30449604.0,,,,"Dietary intake, body composition and metabolic parameters in women with polycystic ovary syndrome",pmid:30449604,
3.0,3.5,638,70.0,"Dantas WS, Marcondes JA, Shinjo SK, Perandini LA, Zambelli VO, Neves WD, Barcellos CR, Rocha MP, Yance Vdos R, Pereira RT, Murai IH, Pinto AL, Roschel H, Gualano B. GLUT4 translocation is not impaired after acute exercise in skeletal muscle of women with obesity and polycystic ovary syndrome. Obesity (Silver Spring). 2015 Nov;23(11):2207-15. doi: 10.1002/oby.21217. Epub 2015 Sep 16. Erratum in: Obesity (Silver Spring). 2016 Sep;24(9):2012. PMID: 26373822.",primary_citation,,Dantas WS,2015,"Dantas WS et al., 2015",10.1002/oby.21217,,,,,GLUT4 translocation is not impaired after acute exercise in skeletal muscle of women with obesity and polycystic ovary syndrome,pmid:27569122,10.1002/oby.21217
3.0,3.5,639,70.0,"De Giuseppe R, Braschi V, Bosoni D, Biino G, Stanford FC, Nappi RE, Cena H. Dietary underreporting in women affected by polycystic ovary syndrome: A pilot study. Nutr Diet. 2019 Nov;76(5):560-566. doi: 10.1111/1747-0080.12460. Epub 2018 Aug 5. PMID: 30079594; PMCID: PMC6363911.",primary_citation,,De Giuseppe R,2019,"De Giuseppe R et al., 2019",10.1111/1747-0080.12460,30079594.0,,,,Dietary underreporting in women affected by polycystic ovary syndrome: A pilot study,pmid:30079594,
3.0,3.5,640,70.0,"Douglas CC, Norris LE, Oster RA, Darnell BE, Azziz R, Gower BA. Difference in dietary intake between women with polycystic ovary syndrome and healthy controls. Fertil Steril. 2006 Aug;86(2):411-7. doi: 10.1016/j.fertnstert.2005.12.054. Epub 2006 Jun 8. PMID: 16762348.",primary_citation,,Douglas CC,2006,"Douglas CC et al., 2006",10.1016/j.fertnstert.2005.12.054,16762348.0,,,,Difference in dietary intake between women with polycystic ovary syndrome and healthy controls,pmid:16762348,
3.0,3.5,641,70.0,"Eslamian G, Baghestani AR, Eghtesad S, Hekmatdoost A. Dietary carbohydrate composition is associated with polycystic ovary syndrome: a case-control study. J Hum Nutr Diet. 2017 Feb;30(1):90-97. doi: 10.1111/jhn.12388. Epub 2016 Jun 14. PMID: 27296009.",primary_citation,,Eslamian G,2017,"Eslamian G et al., 2017",10.1111/jhn.12388,27296009.0,,,,Dietary carbohydrate composition is associated with polycystic ovary syndrome: a case–control study,pmid:27296009,
3.0,3.5,642,70.0,"Forslund M, Landin-Wilhelmsen K, Trimpou P, Schmidt J, Brännström M, Dahlgren E. Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution. Hum Reprod Open. 2020 Jan 15;2020(1):hoz042. doi: 10.1093/hropen/hoz042. PMID: 31976382; PMCID: PMC6964225.",primary_citation,,Forslund M,2020,"Forslund M et al., 2020",10.1093/hropen/hoz042,31976382.0,,,,Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution,pmid:31976382,
3.0,3.5,643,70.0,"Ganie MA, Sahar T, Rashid A, Wani IA, Nisar S, Sathyapalan T, Vishnubhatla S, Ramakrishnan L, Parvez T, Geer I. Comparative Evaluation of Biomarkers of Inflammation Among Indian Women With Polycystic Ovary Syndrome (PCOS) Consuming Vegetarian vs. Non-vegetarian Diet. Front Endocrinol (Lausanne). 2019 Nov 8;10:699. doi: 10.3389/fendo.2019.00699. PMID: 31781027; PMCID: PMC6857098.",primary_citation,,Ganie MA,2019,"Ganie MA et al., 2019",10.3389/fendo.2019.00699,31781027.0,,,,Comparative Evaluation of Biomarkers of Inflammation Among Indian Women With Polycystic Ovary Syndrome (PCOS) Consuming Vegetarian vs. Non-vegetarian Diet,pmid:31781027,
3.0,3.5,644,70.0,"Pourghassem Gargari B, Houjeghani S, Farzadi L, Houjeghani S, Safaeiyan A. Relationship between Serum Leptin, Ghrelin and Dietary Macronutrients in Women with Polycystic Ovary Syndrome. Int J Fertil Steril. 2015 Oct-Dec;9(3):313-21. doi: 10.22074/ijfs.2015.4546. Epub 2015 Oct 31. PMID: 26644854; PMCID: PMC4671384.",primary_citation,,Pourghassem Gargari B,2015,"Pourghassem Gargari B et al., 2015",10.22074/ijfs.2015.4546,26644854.0,,,,"Relationship between Serum Leptin, Ghrelin and Dietary Macronutrients in Women with Polycystic Ovary Syndrome.",pmid:26644854,
3.0,3.5,645,70.0,"Gopalan U , Ghose S , Karnaboopathy R , Comparison of dietary pattern and BMI in South Indian women with PCOS and controls. Indian J Obstet Gynecol Res 2021;8(1):57-60",primary_citation,,Gopalan U ,2021,"Gopalan U  et al., 2021",10.18231/j.ijogr.2021.011,,,,,Comparison of dietary pattern and BMI in South Indian women with PCOS and controls,,10.18231/j.ijogr.2021.011
3.0,3.5,646,70.0,"Graff SK, Mário FM, Alves BC, Spritzer PM. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes. Fertil Steril. 2013 Oct;100(4):1081-8. doi: 10.1016/j.fertnstert.2013.06.005. Epub 2013 Jul 2. PMID: 23830153.",primary_citation,,Graff SK,2013,"Graff SK et al., 2013",10.1016/j.fertnstert.2013.06.005,23830153.0,,,,Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes,pmid:23830153,
3.0,3.5,647,70.0,"Graff SK, Mario FM, Magalhães JA, Moraes RS, Spritzer PM. Saturated Fat Intake Is Related to Heart Rate Variability in Women with Polycystic Ovary Syndrome. Ann Nutr Metab. 2017;71(3-4):224-233. doi: 10.1159/000484325. Epub 2017 Nov 14. PMID: 29136632.",primary_citation,,Graff SK,2017,"Graff SK et al., 2017",10.1159/000484325,29136632.0,,,,Saturated Fat Intake Is Related to Heart Rate Variability in Women with Polycystic Ovary Syndrome,pmid:29136632,
3.0,3.5,648,70.0,"Hosseini MS, Dizavi A, Rostami H, Parastouei K, Esfandiari S. Healthy eating index in women with polycystic ovary syndrome: A case-control study. Int J Reprod Biomed. 2017 Sep;15(9):575-582. PMID: 29662966; PMCID: PMC5894473.",primary_citation,,Hosseini MS,2017,"Hosseini MS et al., 2017",,29662966.0,,,,Healthy eating index in women with polycystic ovary syndrome: A case-control study.,pmid:29662966,
3.0,3.5,649,70.0,"Huijgen NA, Laven JS, Labee CT, Louwers YV, Willemsen SP, Steegers-Theunissen RP. Are Dieting and Dietary Inadequacy a Second Hit in the Association with Polycystic Ovary Syndrome Severity? PLoS One. 2015 Nov 16;10(11):e0142772. doi: 10.1371/journal.pone.0142772. PMID: 26569630; PMCID: PMC4646482.",primary_citation,,Huijgen NA,2015,"Huijgen NA et al., 2015",10.1371/journal.pone.0142772,26569630.0,,,,Are Dieting and Dietary Inadequacy a Second Hit in the Association with Polycystic Ovary Syndrome Severity?,pmid:26569630,
3.0,3.5,650,70.0,"Kazemi Jaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, Hosseinpanah F, Khalili D, Cheraghi L, Azizi F. Polycystic ovary syndrome is a risk factor for diabetes and prediabetes in middle-aged but not elderly women: a long-term population-based follow-up study. Fertil Steril. 2017 Dec;108(6):1078-1084. doi: 10.1016/j.fertnstert.2017.09.004. PMID: 29202960.",primary_citation,,Kazemi Jaliseh H,2017,"Kazemi Jaliseh H et al., 2017",10.1016/j.fertnstert.2017.09.004,29202960.0,,,,Polycystic ovary syndrome is a risk factor for diabetes and prediabetes in middle-aged but not elderly women: a long-term population-based follow-up study,pmid:29202960,
3.0,3.5,651,70.0,"Jurewicz J, Majewska J, Berg A, Owczarek K, Zajdel R, Kaleta D, Wasik A, Rachoń D. Serum bisphenol A analogues in women diagnosed with the polycystic ovary syndrome - is there an association? Environ Pollut. 2021 Mar 1;272:115962. doi: 10.1016/j.envpol.2020.115962. Epub 2020 Nov 6. PMID: 33223334.",primary_citation,,Jurewicz J,2021,"Jurewicz J et al., 2021",10.1016/j.envpol.2020.115962,33223334.0,,,,Serum bisphenol A analogues in women diagnosed with the polycystic ovary syndrome – is there an association?,pmid:33223334,
3.0,3.5,652,70.0,"Khademi A, Alleyassin A, Aghahosseini M, Tabatabaeefar L, Amini M. The Effect of Exercise in PCOS Women Who Exercise Regularly. Asian J Sports Med. 2010 Mar;1(1):35-40. doi: 10.5812/asjsm.34874. PMID: 22375190; PMCID: PMC3289164.",primary_citation,,Khademi A,2010,"Khademi A et al., 2010",10.5812/asjsm.34874,22375190.0,,,,The Effect of Exercise in PCOS Women Who Exercise Regularly,pmid:22375190,
3.0,3.5,653,70.0,"Larsson I, Hulthén L, Landén M, Pålsson E, Janson P, Stener-Victorin E. Dietary intake, resting energy expenditure, and eating behavior in women with and without polycystic ovary syndrome. Clin Nutr. 2016 Feb;35(1):213-218. doi: 10.1016/j.clnu.2015.02.006. Epub 2015 Feb 20. PMID: 25743212.",primary_citation,,Larsson I,2016,"Larsson I et al., 2016",10.1016/j.clnu.2015.02.006,25743212.0,,,,"Dietary intake, resting energy expenditure, and eating behavior in women with and without polycystic ovary syndrome",pmid:25743212,
3.0,3.5,654,70.0,"Lerchbaum E, Theiler-Schwetz V, Kollmann M, Wölfler M, Pilz S, Obermayer-Pietsch B, Trummer C. Effects of Vitamin D Supplementation on Surrogate Markers of Fertility in PCOS Women: A Randomized Controlled Trial. Nutrients. 2021 Feb 7;13(2):547. doi: 10.3390/nu13020547. PMID: 33562394; PMCID: PMC7914670.",primary_citation,,Lerchbaum E,2021,"Lerchbaum E et al., 2021",10.3390/nu13020547,33562394.0,,,,Effects of Vitamin D Supplementation on Surrogate Markers of Fertility in PCOS Women: A Randomized Controlled Trial,pmid:33562394,
3.0,3.5,655,70.0,"Liang Z, Di N, Li L, Yang D. Gut microbiota alterations reveal potential gut-brain axis changes in polycystic ovary syndrome. J Endocrinol Invest. 2021 Aug;44(8):1727-1737. doi: 10.1007/s40618-020-01481-5. Epub 2021 Jan 2. PMID: 33387350.",primary_citation,,Liang Z,2021,"Liang Z et al., 2021",10.1007/s40618-020-01481-5,33387350.0,,,,Gut microbiota alterations reveal potential gut–brain axis changes in polycystic ovary syndrome,pmid:33387350,
3.0,3.5,656,70.0,"Lin AW, Kazemi M, Jarrett BY, Vanden Brink H, Hoeger KM, Spandorfer SD, Lujan ME. Dietary and Physical Activity Behaviors in Women with Polycystic Ovary Syndrome per the New International Evidence-Based Guideline. Nutrients. 2019 Nov 8;11(11):2711. doi: 10.3390/nu11112711. PMID: 31717369; PMCID: PMC6893689.",primary_citation,,Lin AW,2019,"Lin AW et al., 2019",10.3390/nu11112711,31717369.0,,,,Dietary and Physical Activity Behaviors in Women with Polycystic Ovary Syndrome per the New International Evidence-Based Guideline,pmid:31717369,
3.0,3.5,657,70.0,"Lin AW, Siscovick D, Sternfeld B, Schreiner P, Lewis CE, Wang ET, Merkin SS, Wellons M, Steffen L, Calderon-Margalit R, Cassano PA, Lujan ME. Associations of diet, physical activity and polycystic ovary syndrome in the Coronary Artery Risk Development in Young Adults Women's Study. BMC Public Health. 2021 Jan 6;21(1):35. doi: 10.1186/s12889-020-10028-5. PMID: 33407255; PMCID: PMC7789704.",primary_citation,,Lin AW,2021,"Lin AW et al., 2021",10.1186/s12889-020-10028-5,33407255.0,,,,"Associations of diet, physical activity and polycystic ovary syndrome in the Coronary Artery Risk Development in Young Adults Women’s Study",pmid:33407255,
3.0,3.5,658,70.0,"Lu L, Li X, Lv L, Xu Y, Wu B, Huang C. Dietary and serum n-3 PUFA and polycystic ovary syndrome: a matched case-control study. Br J Nutr. 2021 Aug 10:1-10. doi: 10.1017/S0007114521003007. Epub ahead of print. PMID: 34372961.",primary_citation,,Lu L,2021,"Lu L et al., 2021",10.1017/s0007114521003007,34372961.0,,,,Dietary and serum <i>n</i>-3 PUFA and polycystic ovary syndrome: a matched case–control study,pmid:34372961,
3.0,3.5,659,70.0,"Mario FM, do Amarante F, Toscani MK, Spritzer PM. Lean muscle mass in classic or ovulatory PCOS: association with central obesity and insulin resistance. Exp Clin Endocrinol Diabetes. 2012 Oct;120(9):511-6. doi: 10.1055/s-0032-1309006. Epub 2012 May 10. PMID: 22576259.",primary_citation,,Mario FM,2012,"Mario FM et al., 2012",10.1055/s-0032-1309006,22576259.0,,,,Lean Muscle Mass in Classic or Ovulatory PCOS: Association with Central Obesity and Insulin Resistance,pmid:22576259,
3.0,3.5,660,70.0,"Mario FM, Graff SK, Spritzer PM. Habitual physical activity is associated with improved anthropometric and androgenic profile in PCOS: a cross-sectional study. J Endocrinol Invest. 2017 Apr;40(4):377-384. doi: 10.1007/s40618-016-0570-1. Epub 2016 Oct 22. PMID: 27771865.",primary_citation,,Mario FM,2017,"Mario FM et al., 2017",10.1007/s40618-016-0570-1,27771865.0,,,,Habitual physical activity is associated with improved anthropometric and androgenic profile in PCOS: a cross-sectional study,pmid:27771865,
3.0,3.5,661,70.0,"Melekoglu E, Goksuluk D, Akal Yildiz E. Association between Dietary Glycaemic Index and Glycaemic Load and Adiposity Indices in Polycystic Ovary Syndrome. J Am Coll Nutr. 2020 Aug;39(6):537-546. doi: 10.1080/07315724.2019.1705200. Epub 2019 Dec 30. PMID: 31887072.",primary_citation,,Melekoglu E,2020,"Melekoglu E et al., 2020",10.1080/07315724.2019.1705200,31887072.0,,,,Association between Dietary Glycaemic Index and Glycaemic Load and Adiposity Indices in Polycystic Ovary Syndrome,pmid:31887072,
3.0,3.5,662,70.0,"Misir A, Banjari I, Loncar I. COMPARISON OF DIET IN WOMEN OF REPRODUCTIVE AGE WITH AND WITHOUT DIAGNOSED POLYCYSTIC OVARY SYNDROME - PILOT STUDY. Med Pregl. 2016 Sep;69(9-10):274-280. English, Welsh. doi: 10.2298/mpns1610274m. PMID: 29693849.",primary_citation,,Misir A,2016,"Misir A et al., 2016",10.2298/mpns1610274m,29693849.0,,,,Comparison of diet in women of reproductive age with and without diagnosed polycystic ovary syndrome: Pilot study,pmid:29693849,
3.0,3.5,663,70.0,"Navarro-Lafuente F, Arense-Gonzalo JJ, Sánchez-Ferrer ML, Prieto-Sánchez MT, Cutillas-Tolín A, Mendiola J, Adoamnei E, Gazabat-Barbado E, Vioque J, Torres-Cantero AM. Fat intake pattern in women with polycystic ovary syndrome. Reprod Biomed Online. 2022 Jan;44(1):93-103. doi: 10.1016/j.rbmo.2021.08.015. Epub 2021 Aug 24. PMID: 34654614.",primary_citation,,Navarro-Lafuente F,2022,"Navarro-Lafuente F et al., 2022",10.1016/j.rbmo.2021.08.015,34654614.0,,,,Fat intake pattern in women with polycystic ovary syndrome,pmid:34654614,
3.0,3.5,664,70.0,"Neubronner SA, Indran IR, Chan YH, Thu AWP, Yong EL. Effect of body mass index (BMI) on phenotypic features of polycystic ovary syndrome (PCOS) in Singapore women: a prospective cross-sectional study. BMC Womens Health. 2021 Apr 1;21(1):135. doi: 10.1186/s12905-021-01277-6. PMID: 33794861; PMCID: PMC8017849.",primary_citation,,Neubronner SA,2021,"Neubronner SA et al., 2021",10.1186/s12905-021-01277-6,33794861.0,,,,Effect of body mass index (BMI) on phenotypic features of polycystic ovary syndrome (PCOS) in Singapore women: a prospective cross-sectional study,pmid:33794861,
3.0,3.5,665,70.0,"Noormohammadi M, Eslamian G, Malek S, Shoaibinobarian N, Mirmohammadali SN. The association between fertility diet score and polycystic ovary syndrome: A Case-Control study. Health Care Women Int. 2022 Jan-Mar;43(1-3):70-84. doi: 10.1080/07399332.2021.1886298. Epub 2021 Apr 2. PMID: 33797335.",primary_citation,,Noormohammadi M,2022,"Noormohammadi M et al., 2022",10.1080/07399332.2021.1886298,33797335.0,,,,The association between fertility diet score and polycystic ovary syndrome: A Case-Control study,pmid:33797335,
3.0,3.5,666,70.0,"Orio F Jr, Giallauria F, Palomba S, Cascella T, Manguso F, Vuolo L, Russo T, Tolino A, Lombardi G, Colao A, Vigorito C. Cardiopulmonary impairment in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Aug;91(8):2967-71. doi: 10.1210/jc.2006-0216. Epub 2006 Jun 6. PMID: 16757529.",primary_citation,,Orio F Jr,2006,"Orio F Jr et al., 2006",10.1210/jc.2006-0216,16757529.0,,,,Cardiopulmonary Impairment in Young Women with Polycystic Ovary Syndrome,pmid:16757529,
3.0,3.5,667,70.0,"Panjeshahin A, Salehi-Abargouei A, Anari AG, Mohammadi M, Hosseinzadeh M. Association between empirically derived dietary patterns and polycystic ovary syndrome: A case-control study. Nutrition. 2020 Nov-Dec;79-80:110987. doi: 10.1016/j.nut.2020.110987. Epub 2020 Aug 28. PMID: 32947130.",primary_citation,,Panjeshahin A,2020,"Panjeshahin A et al., 2020",10.1016/j.nut.2020.110987,32947130.0,,,,Association between empirically derived dietary patterns and polycystic ovary syndrome: A case-control study,pmid:32947130,
3.0,3.5,668,70.0,"Pokorska-Niewiada K, Brodowska A, Szczuko M. The Content of Minerals in the PCOS Group and the Correlation with the Parameters of Metabolism. Nutrients. 2021 Jun 28;13(7):2214. doi: 10.3390/nu13072214. PMID: 34203167; PMCID: PMC8308369.",primary_citation,,Pokorska-Niewiada K,2021,"Pokorska-Niewiada K et al., 2021",10.3390/nu13072214,34203167.0,,,,The Content of Minerals in the PCOS Group and the Correlation with the Parameters of Metabolism,pmid:34203167,
3.0,3.5,669,70.0,"Sedighi S, Amir Ali Akbari S, Afrakhteh M, Esteki T, Alavi Majd H, Mahmoodi Z. Comparison of lifestyle in women with polycystic ovary syndrome and healthy women. Glob J Health Sci. 2014 Aug 31;7(1):228-34. doi: 10.5539/gjhs.v7n1p228. PMID: 25560358; PMCID: PMC4796416.",primary_citation,,Sedighi S,2014,"Sedighi S et al., 2014",10.5539/gjhs.v7n1p228,25560358.0,,,,Comparison of Lifestyle in Women With Polycystic Ovary Syndrome and Healthy Women,pmid:25560358,
3.0,3.5,670,70.0,"Shahdadian F, Ghiasvand R, Abbasi B, Feizi A, Saneei P, Shahshahan Z. Association between major dietary patterns and polycystic ovary syndrome: evidence from a case-control study. Appl Physiol Nutr Metab. 2019 Jan;44(1):52-58. doi: 10.1139/apnm-2018-0145. Epub 2018 Jul 3. PMID: 29969571.",primary_citation,,Shahdadian F,2019,"Shahdadian F et al., 2019",10.1139/apnm-2018-0145,29969571.0,,,,Association between major dietary patterns and polycystic ovary syndrome: evidence from a case-control study,pmid:29969571,
3.0,3.5,671,70.0,"Shishehgar F, Ramezani Tehrani F, Mirmiran P, Hajian S, Baghestani AR, Moslehi N. Comparison of Dietary Intake between Polycystic Ovary Syndrome Women and Controls. Glob J Health Sci. 2016 Sep 1;8(9):54801. doi: 10.5539/gjhs.v8n9p302. PMID: 27157182; PMCID: PMC5064084.",primary_citation,,Shishehgar F,2016,"Shishehgar F et al., 2016",10.5539/gjhs.v8n9p302,27157182.0,,,,Comparison of Dietary Intake between Polycystic Ovary Syndrome Women and Controls,pmid:27157182,
3.0,3.5,672,70.0,"Shishehgar F, Tehrani FR, Mirmiran P, Hajian S, Baghestani AR, Moslehi N. Factors Influencing Physical Activity in Women with Polycystic Ovary Syndrome in Comparison to Eumenorrheic Non Hirsute Women. Glob J Health Sci. 2016 Oct 1;8(10):56382. doi: 10.5539/gjhs.v8n10p127. PMID: 27302456.",primary_citation,,Shishehgar F,2016,"Shishehgar F et al., 2016",10.5539/gjhs.v8n10p127,27302456.0,,,,Factors Influencing Physical Activity in Women with Polycystic Ovary Syndrome in Comparison to Eumenorrheic Non Hirsute Women,pmid:27302456,
3.0,3.5,673,70.0,"Shishehgar F, Mirmiran P, Rahmati M, Tohidi M, Ramezani Tehrani F. Does a restricted energy low glycemic index diet have a different effect on overweight women with or without polycystic ovary syndrome? BMC Endocr Disord. 2019 Sep 2;19(1):93. doi: 10.1186/s12902-019-0420-1. PMID: 31477085; PMCID: PMC6720418.",primary_citation,,Shishehgar F,2019,"Shishehgar F et al., 2019",10.1186/s12902-019-0420-1,31477085.0,,,,Does a restricted energy low glycemic index diet have a different effect on overweight women with or without polycystic ovary syndrome?,pmid:31477085,
3.0,3.5,674,70.0,"Soodi S, Keshavarz SA, Hosseini S, Abbasi B. Dietary diversity score is inversely related to the risk of polycystic ovary syndrome in Tehranian women: a case-control study. Appl Physiol Nutr Metab. 2021 Dec 8:1-6. doi: 10.1139/apnm-2021-0359. Epub ahead of print. PMID: 34878921.",primary_citation,,Soodi S,2021,"Soodi S et al., 2021",10.1139/apnm-2021-0359,34878921.0,,,,Dietary diversity score is inversely related to the risk of polycystic ovary syndrome in Tehranian women: a case-control study,pmid:34878921,
3.0,3.5,675,70.0,"Szczuko M, Szydłowska I, Nawrocka-Rutkowska J. A Properly Balanced Reduction Diet and/or Supplementation Solve the Problem with the Deficiency of These Vitamins Soluble in Water in Patients with PCOS. Nutrients. 2021 Feb 26;13(3):746. doi: 10.3390/nu13030746. PMID: 33652684; PMCID: PMC7996738.",primary_citation,,Szczuko M,2021,"Szczuko M et al., 2021",10.3390/nu13030746,33652684.0,,,,A Properly Balanced Reduction Diet and/or Supplementation Solve the Problem with the Deficiency of These Vitamins Soluble in Water in Patients with PCOS,pmid:33652684,
3.0,3.5,676,70.0,"Thara, C., & Divakar, S. U. M. A. (2017). Assessment of nutritional status of PCOS women in Kerala. International Journal of Applied Home Science, 4(9-10), 717-722.",primary_citation,,Thara,2017,"Thara et al., 2017",,,,,Serum level of anti‐mullerian hormone after exercise training in women with polycystic ovary syndrome: a randomised controlled trial,,,
3.0,3.5,677,70.0,"Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome. BJOG. 2009 Aug;116(9):1242-50. doi: 10.1111/j.1471-0528.2009.02177.x. Epub 2009 May 11. PMID: 19438498.",primary_citation,,Thomson RL,2009,"Thomson RL et al., 2009",10.1111/j.1471-0528.2009.02177.x,19438498.0,,,,Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome,pmid:19438498,
3.0,3.5,678,70.0,"Toscani MK, Mario FM, Radavelli-Bagatini S, Wiltgen D, Matos MC, Spritzer PM. Effect of high-protein or normal-protein diet on weight loss, body composition, hormone, and metabolic profile in southern Brazilian women with polycystic ovary syndrome: a randomized study. Gynecol Endocrinol. 2011 Nov;27(11):925-30. doi: 10.3109/09513590.2011.564686. Epub 2011 May 31. PMID: 21627406.",primary_citation,,Toscani MK,2011,"Toscani MK et al., 2011",10.3109/09513590.2011.564686,21627406.0,,,,"Effect of high-protein or normal-protein diet on weight loss, body composition, hormone, and metabolic profile in southern Brazilian women with polycystic ovary syndrome: a randomized study",pmid:21627406,
3.0,3.5,679,70.0,"Toscani MK, Mario FM, Radavelli-Bagatini S, Spritzer PM. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome. Nutr Res. 2011 Feb;31(2):97-103. doi: 10.1016/j.nutres.2011.01.009. PMID: 21419313.",primary_citation,,Toscani MK,2011,"Toscani MK et al., 2011",10.1016/j.nutres.2011.01.009,21419313.0,,,,Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome,pmid:21419313,
3.0,3.5,680,70.0,"Tsai YH, Wang TW, Wei HJ, Hsu CY, Ho HJ, Chen WH, Young R, Liaw CM, Chao JC. Dietary intake, glucose metabolism and sex hormones in women with polycystic ovary syndrome (PCOS) compared with women with non-PCOS-related infertility. Br J Nutr. 2013 Jun 28;109(12):2190-8. doi: 10.1017/S0007114512004369. Epub 2012 Oct 10. Erratum in: Br J Nutr. 2014 Jun 14;111(11):2045. PMID: 23046530.",primary_citation,,Tsai YH,2013,"Tsai YH et al., 2013",10.1017/s0007114512004369,,,,,"Dietary intake, glucose metabolism and sex hormones in women with polycystic ovary syndrome (PCOS) compared with women with non-PCOS-related infertility",pmid:24650676,10.1017/s0007114512004369
3.0,3.5,681,70.0,"Wang Z, Groen H, Cantineau AEP, van Elten TM, Karsten MDA, van Oers AM, Mol BWJ, Roseboom TJ, Hoek A. Dietary Intake, Eating Behavior, Physical Activity, and Quality of Life in Infertile Women with PCOS and Obesity Compared with Non-PCOS Obese Controls. Nutrients. 2021 Oct 8;13(10):3526. doi: 10.3390/nu13103526. PMID: 34684528; PMCID: PMC8538395.",primary_citation,,Wang Z,2021,"Wang Z et al., 2021",10.3390/nu13103526,34684528.0,,,,"Dietary Intake, Eating Behavior, Physical Activity, and Quality of Life in Infertile Women with PCOS and Obesity Compared with Non-PCOS Obese Controls",pmid:34684528,
3.0,3.5,682,70.0,"Wang Z, Groen H, Cantineau AEP, van Elten TM, Karsten MDA, van Oers AM, Mol BWJ, Roseboom TJ, Hoek A. Effectiveness of a 6-Month Lifestyle Intervention on Diet, Physical Activity, Quality of Life, and Markers of Cardiometabolic Health in Women with PCOS and Obesity and Non-PCOS Obese Controls: One Size Fits All? Nutrients. 2021 Sep 28;13(10):3425. doi: 10.3390/nu13103425. PMID: 34684438; PMCID: PMC8538637.",primary_citation,,Wang Z,2021,"Wang Z et al., 2021",10.3390/nu13103425,34684438.0,,,,"Effectiveness of a 6-Month Lifestyle Intervention on Diet, Physical Activity, Quality of Life, and Markers of Cardiometabolic Health in Women with PCOS and Obesity and Non-PCOS Obese Controls: One Size Fits All?",pmid:34684438,
3.0,3.5,683,70.0,"Wang Q, Sun Y, Xu Q, Liu W, Wang P, Yao J, Zhao A, Chen Y, Wang W. Higher dietary inflammation potential and certain dietary patterns are associated with polycystic ovary syndrome risk in China: A case-control study. Nutr Res. 2022 Apr;100:1-18. doi: 10.1016/j.nutres.2021.12.006. Epub 2022 Jan 5. PMID: 35108617.",primary_citation,,Wang Q,2022,"Wang Q et al., 2022",10.1016/j.nutres.2021.12.006,35108617.0,,,,Higher dietary inflammation potential and certain dietary patterns are associated with polycystic ovary syndrome risk in China: A case-control study,pmid:35108617,
3.0,3.5,684,70.0,"Wright CE, Zborowski JV, Talbott EO, McHugh-Pemu K, Youk A. Dietary intake, physical activity, and obesity in women with polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2004 Aug;28(8):1026-32. doi: 10.1038/sj.ijo.0802661. PMID: 15159768.",primary_citation,,Wright CE,2004,"Wright CE et al., 2004",10.1038/sj.ijo.0802661,15159768.0,,,,"Dietary intake, physical activity, and obesity in women with polycystic ovary syndrome",pmid:15159768,
3.0,3.5,685,70.0,"Zhang J, Liu Y, Liu X, Xu L, Zhou L, Tang L, Zhuang J, Guo W, Hu R. High Intake of Energy and Fat in Southwest Chinese Women with PCOS: A Population-Based Case-Control Study. PLoS One. 2015 May 20;10(5):e0127094. doi: 10.1371/journal.pone.0127094. PMID: 25993656; PMCID: PMC4439160.",primary_citation,,Zhang J,2015,"Zhang J et al., 2015",10.1371/journal.pone.0127094,25993656.0,,,,High Intake of Energy and Fat in Southwest Chinese Women with PCOS: A Population-Based Case-Control Study,pmid:25993656,
3.0,3.5,686,70.0,"Zhang B, Zhou W, Shi Y, Zhang J, Cui L, Chen ZJ. Lifestyle and environmental contributions to ovulatory dysfunction in women of polycystic ovary syndrome. BMC Endocr Disord. 2020 Jan 30;20(1):19. doi: 10.1186/s12902-020-0497-6. PMID: 32000752; PMCID: PMC6993477.",primary_citation,,Zhang B,2020,"Zhang B et al., 2020",10.1186/s12902-020-0497-6,32000752.0,,,,Lifestyle and environmental contributions to ovulatory dysfunction in women of polycystic ovary syndrome,pmid:32000752,
3.0,3.5,687,70.0,"Zhang J, Zhou K, Luo L, Liu Y, Liu X, Xu L. Effects of exercise and dietary habits on the occurrence of polycystic ovary syndrome over 5 years of follow-up. Int J Gynaecol Obstet. 2018 Sep;142(3):329-337. doi: 10.1002/ijgo.12563. Epub 2018 Jun 27. PMID: 29877578.",primary_citation,,Zhang J,2018,"Zhang J et al., 2018",10.1002/ijgo.12563,29877578.0,,,,Effects of exercise and dietary habits on the occurrence of polycystic ovary syndrome over 5 years of follow‐up,pmid:29877578,
3.0,3.5,688,70.0,"Zirak Sharkesh E, Keshavarz SA, Nazari L, Abbasi B. The dietary inflammatory index is directly associated with polycystic ovary syndrome: A case-control study. Clin Endocrinol (Oxf). 2022 May;96(5):698-706. doi: 10.1111/cen.14672. Epub 2022 Jan 7. PMID: 34961961.",primary_citation,,Zirak Sharkesh E,2022,"Zirak Sharkesh E et al., 2022",10.1111/cen.14672,34961961.0,,,,The dietary inflammatory index is directly associated with polycystic ovary syndrome: A case‐control study,pmid:34961961,
3.0,3.5,689,70.0,"Bialka-Kosiec, Agnieszka A., et al. ""Body mass composition and dietary habits in adolescents with polycystic ovary syndrome."" Ginekologia Polska 90.10 (2019): 589-595.",primary_citation,,Bialka-Kosiec,2019,"Bialka-Kosiec et al., 2019",10.5603/gp.2019.0103,,,,,Body mass composition and dietary habits in adolescents with polycystic ovary syndrome,pmid:31686416,10.5603/gp.2019.0103
3.0,3.5,690,70.0,"Eleftheriadou, M., et al. ""Exercise and sedentary habits among adolescents with PCOS."" Journal of Pediatric and Adolescent Gynecology 25.3 (2012): 172-174.",primary_citation,,Eleftheriadou,2012,"Eleftheriadou et al., 2012",10.1016/j.jpag.2011.11.009,,,,,Exercise and Sedentary Habits Among Adolescents with PCOS,pmid:22260889,10.1016/j.jpag.2011.11.009
3.0,3.5,691,70.0,"Eleftheriadou, Maria, et al. ""Dietary habits in adolescent girls with polycystic ovarian syndrome."" Gynecological Endocrinology 31.4 (2015): 269-271.",primary_citation,,Eleftheriadou,2015,"Eleftheriadou et al., 2015",10.3109/09513590.2014.984677,,,,,Dietary habits in adolescent girls with polycystic ovarian syndrome,pmid:25430596,10.3109/09513590.2014.984677
3.0,3.5,692,70.0,"Kulshreshtha, Bindu, et al. ""PCOS patients differ in meal timings rather than total caloric or macronutrient intake in comparison to weight matched controls."" European Journal of Obstetrics & Gynecology and Reproductive Biology 270 (2022): 11-16.",primary_citation,,Kulshreshtha,2022,"Kulshreshtha et al., 2022",10.1016/j.ejogrb.2021.12.023,,,,,PCOS patients differ in meal timings rather than total caloric or macronutrient intake in comparison to weight matched controls,pmid:35007973,10.1016/j.ejogrb.2021.12.023
3.0,3.5,693,70.0,"Mizgier, Małgorzata, et al. ""Association of Macronutrients Composition, Physical Activity and Serum Androgen Concentration in Young Women with Polycystic Ovary Syndrome."" Nutrients 14.1 (2021): 73.",primary_citation,,Mizgier,2021,"Mizgier et al., 2021",10.3390/nu14010073,,,,,"Association of Macronutrients Composition, Physical Activity and Serum Androgen Concentration in Young Women with Polycystic Ovary Syndrome",pmid:35010948,10.3390/nu14010073
3.0,3.5,694,70.0,"Mizgier, Małgorzata, et al. ""Dietary and Physical Activity Habits in Adolescent Girls with Polycystic Ovary Syndrome (PCOS)-HAstudy."" Journal of Clinical Medicine 10.16 (2021): 3469.",primary_citation,,Mizgier,2021,"Mizgier et al., 2021",10.3390/jcm10163469,,,,,Dietary and Physical Activity Habits in Adolescent Girls with Polycystic Ovary Syndrome (PCOS)-HAstudy,pmid:34441766,10.3390/jcm10163469
3.0,3.6,695,7.0,"Amiri, F. N., Tehrani, F. R., Simbar, M., Montazeri, A., & Thamtan, R. A. M. (2014). The experience of women affected by polycystic ovary syndrome: a qualitative study from Iran. International journal of endocrinology and metabolism, 12(2). https://doi.org/10.5812/ijem.13612",primary_citation,,Amiri,2014,"Amiri et al., 2014",10.5812/ijem.13612,,,,,The Experience of Women Affected by Polycystic Ovary Syndrome: A Qualitative Study From Iran,pmid:24829583,10.5812/ijem.13612
3.0,3.6,696,7.0,"Chopra, S., Zehrung, R., Shanmugam, T. A., & Choe, E. K. (2021, May). Living with uncertainty and stigma: self-experimentation and support-seeking around polycystic ovary syndrome. In Proceedings of the 2021 CHI Conference on Human Factors in Computing Systems (pp. 1-18). https://doi.org/10.1145/3411764. 3445706",primary_citation,,Chopra,2021,"Chopra et al., 2021",10.1145/3411764,,,,,Proceedings of the 2021 CHI Conference on Human Factors in Computing Systems,,10.1145/3411764
3.0,3.6,697,7.0,"Ismayilova, M., & Yaya, S. (2022). ‘I'm usually being my own doctor’: women's experiences of managing polycystic ovary syndrome in Canada. International Health. https://doi.org/10.1093/inthealth/ihac028",primary_citation,,Ismayilova,2022,"Ismayilova et al., 2022",10.1093/inthealth/ihac028,,,,,‘I'm usually being my own doctor’: women's experiences of managing polycystic ovary syndrome in Canada,pmid:35567790,10.1093/inthealth/ihac028
3.0,3.6,698,7.0,"Jones, G. L., Hall, J. M., Lashen, H. L., Balen, A. H., & Ledger, W. L. (2011). Health‐related quality of life among adolescents with polycystic ovary syndrome. Journal of Obstetric, Gynecologic & Neonatal Nursing, 40(5), 577-588. https://doi.org/10.1111/j.1552-6909.2011.01279.x",primary_citation,,Jones,2011,"Jones et al., 2011",10.1111/j.1552-6909.2011.01279.x,,,,,Health‐Related Quality of Life Among Adolescents with Polycystic Ovary Syndrome,pmid:22273414,10.1111/j.1552-6909.2011.01279.x
3.0,3.6,699,7.0,"Moran, L. J., Tan, Z. Q., Bayer, S., Boyle, J. A., Robinson, T., & Lim, S. S. (2022). Perspectives of allied health professionals on implementation of the lifestyle polycystic ovary syndrome guidelines: a qualitative study. Journal of the Academy of Nutrition and Dietetics, 122(7), 1305-1316. https://doi.org/10.1016/j.jand.2021.11.013",primary_citation,,Moran,2022,"Moran et al., 2022",10.1016/j.jand.2021.11.013,,,,,Perspectives of Allied Health Professionals on Implementation of the Lifestyle Polycystic Ovary Syndrome Guidelines: A Qualitative Study,pmid:34800697,10.1016/j.jand.2021.11.013
3.0,3.6,700,7.0,"Tomlinson, J., Pinkney, J., Adams, L., Stenhouse, E., Bendall, A., Corrigan, O., & Letherby, G. (2017). The diagnosis and lived experience of polycystic ovary syndrome: A qualitative study. Journal of advanced nursing, 73(10), 2318-2326. https://doi.org/10.1111/jan.13300",primary_citation,,Tomlinson,2017,"Tomlinson et al., 2017",10.1111/jan.13300,,,,,The diagnosis and lived experience of polycystic ovary syndrome: A qualitative study,pmid:28329428,10.1111/jan.13300
3.0,3.6,701,7.0,"Williams, S., Sheffield, D., & Knibb, R. C. (2016). A snapshot of the lives of women with polycystic ovary syndrome: A photovoice investigation. Journal of Health Psychology, 21(6), 1170-1182. https://doi.org/10.1177/1359105314547941",primary_citation,,Williams,2016,"Williams et al., 2016",10.1177/1359105314547941,,,,,A snapshot of the lives of women with polycystic ovary syndrome: A photovoice investigation,pmid:25205774,10.1177/1359105314547941
4.0,4.2 / 4.3,702,85.0,"Aghamohammadzadeh N, Aliasgarzadeh A, Baglar L, Abdollahifard S, Bahrami A, Najafipour F, et al. Comparison of metformin and cyproteroneestrodiol compound effect on hs c-reactive protein and serum androgen levels in patients with poly cystic ovary syndrome. Pakistan journal of medical sciences. 2010;26(2):347-51.",primary_citation,,Aghamohammadzadeh N,2010,"Aghamohammadzadeh N et al., 2010",,,,54806151.0,Assessment of nutritional status of PCOS women in Kerala,,,
4.0,4.2 / 4.3,703,85.0,"Allen HF, Mazzoni C, Heptulla RA, Murray MA, Miller N, Koenigs L, et al. Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2005;18(8):761-8.",primary_citation,,Allen HF,2005,"Allen HF et al., 2005",10.1515/jpem.2005.18.8.761,,,,,Randomized Controlled Trial Evaluating Response to Metformin Versus Standard Therapy in the Treatment of Adolescents with Polycystic Ovary Syndrome,pmid:16200842,10.1515/jpem.2005.18.8.761
4.0,4.2 / 4.3,704,85.0,"Alpañés M, Álvarez-Blasco F, Fernández-Durán E, Luque-Ramírez M, Escobar-Morreale HF. Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. European journal of endocrinology / European Federation of Endocrine Societies. 2017;177(5):399-408.",primary_citation,,Alpañés M,2017,"Alpañés M et al., 2017",10.1530/eje-17-0516,,,,,Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial,pmid:28912358,10.1530/eje-17-0516
4.0,4.2 / 4.3,705,85.0,"Al-Zubeidi H, Klein KO. Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. J Pediatr Endocrinol Metab. 2015;28(7-8):853-8.",primary_citation,,Al-Zubeidi H,2015,"Al-Zubeidi H et al., 2015",10.1515/jpem-2014-0283,,,,,Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome,pmid:25781525,10.1515/jpem-2014-0283
4.0,4.2 / 4.3,706,85.0,"Amiri M, Nahidi F, Bidhendi-Yarandi R, Khalili D, Tohidi M, Ramezani Tehrani F. A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. Human reproduction (Oxford, England). 2020;35(1):175-86.",primary_citation,,Amiri M,2020,"Amiri M et al., 2020",10.1093/humrep/dez255,,,,,A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial,pmid:31916574,10.1093/humrep/dez255
4.0,4.2 / 4.3,707,85.0,"Amiri M, Rahmati M, Hedayati M, Nahidi F, Ramezani Tehrani F. Effects of oral contraceptives on serum concentrations of adipokines and adiposity indices of women with polycystic ovary syndrome: a randomized controlled trial. J Endocrinol Invest. 2021;44(3):567-80.",primary_citation,,Amiri M,2021,"Amiri M et al., 2021",10.1007/s40618-020-01349-8,,,,,Effects of oral contraceptives on serum concentrations of adipokines and adiposity indices of women with polycystic ovary syndrome: a randomized controlled trial,pmid:34403133,10.1007/s40618-020-01349-8
4.0,4.2 / 4.3,708,85.0,"Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertility and sterility. 2012;98(4):1053-9.",primary_citation,,Bhattacharya SM,2012,"Bhattacharya SM et al., 2012",10.1016/j.fertnstert.2012.06.035,,,,,"Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome",pmid:22795636,10.1016/j.fertnstert.2012.06.035
4.0,4.2 / 4.3,709,85.0,"Bhattacharya SM, Jha A, DasMukhopadhyay L. Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome. Int J Gynaecol Obstet. 2016;132(2):210-3.",primary_citation,,Bhattacharya SM,2016,"Bhattacharya SM et al., 2016",10.1016/j.ijgo.2015.06.065,,,,,Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome,pmid:26613823,10.1016/j.ijgo.2015.06.065
4.0,4.2 / 4.3,710,85.0,"Bilgir O, Kebapcilar L, Taner C, Bilgir F, Kebapcilar A, Bozkaya G, et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). Intern Med. 2009;48(14):1193-9.",primary_citation,,Bilgir O,2009,"Bilgir O et al., 2009",10.2169/internalmedicine.48.2177,,,,,The Effect of Ethinylestradiol (EE)/Cyproterone Acetate (CA) and EE/CA Plus Metformin Treatment on Adhesion Molecules in Cases with Polycystic Ovary Syndrome (PCOS),pmid:19602786,10.2169/internalmedicine.48.2177
4.0,4.2 / 4.3,711,85.0,"Bodur S, Dundar O, Kanat-Pektas M, Kinci MF, Tutuncu L. The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study. Taiwan J Obstet Gynecol. 2018;57(3):411-6.",primary_citation,,Bodur S,2018,"Bodur S et al., 2018",10.1016/j.tjog.2018.04.015,,,,,The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study,pmid:29880175,10.1016/j.tjog.2018.04.015
4.0,4.2 / 4.3,712,85.0,"Cagnacci A, Tirelli A, Renzi A, Paoletti AM, Volpe A. Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome. Contraception. 2006;73(4):348-51.",primary_citation,,Cagnacci A,2006,"Cagnacci A et al., 2006",10.1016/j.contraception.2005.09.011,,,,,Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome,pmid:16531164,10.1016/j.contraception.2005.09.011
4.0,4.2 / 4.3,713,85.0,"Cetinkalp S, Karadeniz M, Erdogan M, Ozgen G, Saygl F, Ylmaz C. The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. The Endocrinologist (Baltimore, Md). 2009;19(3):94-7.",primary_citation,,Cetinkalp S,2009,"Cetinkalp S et al., 2009",10.1097/ten.0b013e3181a58772,,,,,"The Effects of Rosiglitazone, Metformin, and Estradiol-Cyproterone Acetate on Lean Patients With Polycystic Ovary Syndrome",,10.1097/ten.0b013e3181a58772
4.0,4.2 / 4.3,714,85.0,"Christakou C, Kollias A, Piperi C, Katsikis I, Panidis D, Diamanti-Kandarakis E. The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones (Athens). 2014;13(4):488-97.",primary_citation,,Christakou C,2014,"Christakou C et al., 2014",10.14310/horm.2002.1553,,,,,The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers,pmid:25555182,10.14310/horm.2002.1553
4.0,4.2 / 4.3,715,85.0,"Cibula D, Fanta M, Vrbikova J, Stanicka S, Dvorakova K, Hill M, et al. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human reproduction (Oxford, England). 2005;20(1):180-4.",primary_citation,,Cibula D,2005,"Cibula D et al., 2005",10.1093/humrep/deh588,,,,,"The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients",pmid:15576394,10.1093/humrep/deh588
4.0,4.2 / 4.3,716,85.0,"Chung JP, Yiu AK, Chung TK, Chan SS. A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome. J Pediatr Adolesc Gynecol. 2014;27(3):166-71.",primary_citation,,Chung JP,2014,"Chung JP et al., 2014",10.1016/j.jpag.2013.09.011,,,,,A Randomized Crossover Study of Medroxyprogesterone Acetate and Diane-35 in Adolescent Girls with Polycystic Ovarian Syndrome,pmid:24656700,10.1016/j.jpag.2013.09.011
4.0,4.2 / 4.3,717,85.0,"Dardzińska JA, Rachoń D, Kuligowska-Jakubowska M, Aleksandrowicz-Wrona E, Płoszyński A, Wyrzykowski B, et al. Effects of metformin or an oral contraceptive containing cyproterone acetate on serum c-reactive protein, interleukin-6 and soluble vascular cell adhesion molecule-1 concentrations in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2014;122(2):118-25.",primary_citation,,Dardzińska JA,2014,"Dardzińska JA et al., 2014",10.1055/s-0033-1363261,,,,,"Effects of Metformin or an Oral Contraceptive Containing Cyproterone Acetate on Serum C-reactive Protein, Interleukin-6 and Soluble Vascular Cell Adhesion Molecule-1 Concentrations in Women with Polycystic Ovary Syndrome",pmid:24554512,10.1055/s-0033-1363261
4.0,4.2 / 4.3,718,85.0,"De Leo V, Di Sabatino A, Musacchio MC, Morgante G, Scolaro V, Cianci A, et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception. 2010;82(3):276-80.",primary_citation,,De Leo V,2010,"De Leo V et al., 2010",10.1016/j.contraception.2010.04.002,,,,,Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome,pmid:20705157,10.1016/j.contraception.2010.04.002
4.0,4.2 / 4.3,719,85.0,"Dorgham N, Sharobim A, Haggag H, El-Kalioby M, Dorgham D. Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients. J Drugs Dermatol. 2021;20(3):302-6.",primary_citation,,Dorgham N,2021,"Dorgham N et al., 2021",,,,,,,,
4.0,4.2 / 4.3,720,85.0,"El Maghraby HA, Nafee T, Guiziry D, Elnashar A. Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 month follow up period. Middle East Fertility Society journal. 2015;20(3):131-7.",primary_citation,,El Maghraby HA,2015,"El Maghraby HA et al., 2015",10.1016/j.mefs.2014.10.003,,,,,Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24month follow up period,,10.1016/j.mefs.2014.10.003
4.0,4.2 / 4.3,721,85.0,"Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction. 2002;17(7):1729-37.",primary_citation,,Elter K,2002,"Elter K et al., 2002",10.1093/humrep/17.7.1729,,,,,"Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study",pmid:12093831,10.1093/humrep/17.7.1729
4.0,4.2 / 4.3,722,85.0,"Essah PA, Arrowood JA, Cheang KI, Adawadkar SS, Stovall DW, Nestler JE. Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertil Steril. 2011;96(2):501-4.e2.",primary_citation,,Essah PA,2011,"Essah PA et al., 2011",10.1016/j.fertnstert.2011.05.091,,,,,Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome,pmid:21733508,10.1016/j.fertnstert.2011.05.091
4.0,4.2 / 4.3,723,85.0,"Feng W, Jia YY, Zhang DY, Shi HR. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecol Endocrinol. 2016;32(2):147-50.",primary_citation,,Feng W,2016,"Feng W et al., 2016",10.3109/09513590.2015.1101441,,,,,Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin,pmid:26507097,10.3109/09513590.2015.1101441
4.0,4.2 / 4.3,724,85.0,"Fonseka S, Wijeyaratne CN, Gawarammana IB, Kalupahana NS, Rosairo S, Ratnatunga N, et al. Effectiveness of Low-dose Ethinylestradiol/Cyproterone Acetate and Ethinylestradiol/Desogestrel with and without Metformin on Hirsutism in Polycystic Ovary Syndrome: A Randomized, Double-blind, Triple-dummy Study. J Clin Aesthet Dermatol. 2020;13(7):18-23.",primary_citation,,Fonseka S,2020,"Fonseka S et al., 2020",,32983332.0,W3088805748,222155349.0,,"Effectiveness of Low-dose Ethinylestradiol/Cyproterone Acetate and Ethinylestradiol/Desogestrel with and without Metformin on Hirsutism in Polycystic Ovary Syndrome: A Randomized, Double-blind, Triple-dummy Study.",pmid:32983332,
4.0,4.2 / 4.3,725,85.0,"Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism. 2014;99(7):2584-91.",primary_citation,,Glintborg D,2014,"Glintborg D et al., 2014",10.1210/jc.2014-1135,,,,,Body Composition Is Improved During 12 Months' Treatment With Metformin Alone or Combined With Oral Contraceptives Compared With Treatment With Oral Contraceptives in Polycystic Ovary Syndrome,pmid:24742124,10.1210/jc.2014-1135
4.0,4.2 / 4.3,726,85.0,"Glintborg D, Mumm H, Altinok ML, Richelsen B, Bruun JM, Andersen M. Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome. J Endocrinol Invest. 2014;37(8):757-64.",primary_citation,,Glintborg D,2014,"Glintborg D et al., 2014",10.1007/s40618-014-0103-8,,,,,"Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome",pmid:24906976,10.1007/s40618-014-0103-8
4.0,4.2 / 4.3,727,85.0,"Altinok ML, Ravn P, Andersen M, Glintborg D. Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome. Gynecol Endocrinol. 2018;34(10):859-63.",primary_citation,,Altinok ML,2018,"Altinok ML et al., 2018",10.1080/09513590.2018.1460343,,,,,Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome,pmid:29658344,10.1080/09513590.2018.1460343
4.0,4.2 / 4.3,728,85.0,"Glintborg D, Mumm H, Holst JJ, Andersen M. Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. Endocr Connect. 2017;6(4):267-77.",primary_citation,,Glintborg D,2017,"Glintborg D et al., 2017",10.1530/ec-17-0034,,,,,Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome,pmid:28432082,10.1530/ec-17-0034
4.0,4.2 / 4.3,729,85.0,"Gu M, Ruan X, Li Y, Li T, Yin C, Mueck AO. Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat. Gynecol Endocrinol. 2022;38(7):598-602.",primary_citation,,Gu M,2022,"Gu M et al., 2022",10.1080/09513590.2022.2078805,,,,,Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat,pmid:35616272,10.1080/09513590.2022.2078805
4.0,4.2 / 4.3,730,85.0,"Hagag P, Steinschneider M, Weiss M. Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome. J Reprod Med. 2014;59(9-10):455-63.",primary_citation,,Hagag P,2014,"Hagag P et al., 2014",,25330687.0,W214894366,22317157.0,,Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome.,pmid:25330687,
4.0,4.2 / 4.3,731,85.0,"Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism. 2003;88(9):4116-23.",primary_citation,,Harborne L,2003,"Harborne L et al., 2003",10.1210/jc.2003-030424,,,,,Metformin or Antiandrogen in the Treatment of Hirsutism in Polycystic Ovary Syndrome,pmid:12970273,10.1210/jc.2003-030424
4.0,4.2 / 4.3,732,85.0,"Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. The Journal of clinical endocrinology and metabolism. 2008;93(11):4299-306.",primary_citation,,Hoeger K,2008,"Hoeger K et al., 2008",10.1210/jc.2008-0461,,,,,"The Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women in Two Randomized, Placebo-Controlled Clinical Trials",pmid:18728175,10.1210/jc.2008-0461
4.0,4.2 / 4.3,733,85.0,"Ibáñez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. The Journal of clinical endocrinology and metabolism. 2004;89(4):1592-7.",primary_citation,,Ibáñez L,2004,"Ibáñez L et al., 2004",10.1210/jc.2003-031281,,,,,"Ethinylestradiol-Drospirenone, Flutamide-Metformin, or Both for Adolescents and Women with Hyperinsulinemic Hyperandrogenism: Opposite Effects on Adipocytokines and Body Adiposity",pmid:15070917,10.1210/jc.2003-031281
4.0,4.2 / 4.3,734,85.0,"Ibáñez L, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. The Journal of clinical endocrinology and metabolism. 2005;90(1):39-43.",primary_citation,,Ibáñez L,2005,"Ibáñez L et al., 2005",10.1210/jc.2003-031281,,,,,"Ethinylestradiol-Drospirenone, Flutamide-Metformin, or Both for Adolescents and Women with Hyperinsulinemic Hyperandrogenism: Opposite Effects on Adipocytokines and Body Adiposity",pmid:15070917,10.1210/jc.2003-031281
4.0,4.2 / 4.3,735,85.0,"Ibáñez L, Díaz M, García-Beltrán C, Malpique R, Garde E, López-Bermejo A, et al. Toward a Treatment Normalizing Ovulation Rate in Adolescent Girls With Polycystic Ovary Syndrome. J Endocr Soc. 2020;4(5):bvaa032.",primary_citation,,Ibáñez L,2020,"Ibáñez L et al., 2020",10.1210/jendso/bvaa032,,,,,Toward a Treatment Normalizing Ovulation Rate in Adolescent Girls With Polycystic Ovary Syndrome,pmid:32342022,10.1210/jendso/bvaa032
4.0,4.2 / 4.3,736,85.0,"de Zegher F, Díaz M, Villarroya J, Cairó M, López-Bermejo A, Villarroya F, et al. The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat. Sci Rep. 2021;11(1):7018.",primary_citation,,de Zegher F,2021,"de Zegher F et al., 2021",10.1038/s41598-021-86317-9,,,,,The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat,pmid:33782413,10.1038/s41598-021-86317-9
4.0,4.2 / 4.3,737,85.0,"Malpique R, Sánchez-Infantes D, Garcia-Beltran C, Taxerås SD, López-Bermejo A, de Zegher F, et al. Towards a circulating marker of hepato-visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome - Evidence from randomized clinical trials. Pediatr Obes. 2019;14(5):e12500.",primary_citation,,Malpique R,2019,"Malpique R et al., 2019",10.1111/ijpo.12500,,,,,Towards a circulating marker of hepato‐visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome — Evidence from randomized clinical trials,pmid:30653851,10.1111/ijpo.12500
4.0,4.2 / 4.3,738,85.0,"Ibáñez L, del Río L, Díaz M, Sebastiani G, Pozo ÓJ, López-Bermejo A, et al. Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome. J Adolesc Health. 2017;61(4):446-53.",primary_citation,,Ibáñez L,2017,"Ibáñez L et al., 2017",10.1016/j.jadohealth.2017.04.010,,,,,Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome,pmid:28712591,10.1016/j.jadohealth.2017.04.010
4.0,4.2 / 4.3,739,85.0,"Díaz M, Gallego-Escuredo JM, López-Bermejo A, de Zegher F, Villarroya F, Ibáñez L. Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome. Int J Endocrinol. 2018;2018:4192940.",primary_citation,,Díaz M,2018,"Díaz M et al., 2018",10.1155/2018/4192940,,,,,Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome,pmid:30123261,10.1155/2018/4192940
4.0,4.2 / 4.3,740,85.0,"Kahraman K, Sükür YE, Atabekoğlu CS, Ateş C, Taşkın S, Cetinkaya SE, et al. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial. Arch Gynecol Obstet. 2014;290(2):321-8.",primary_citation,,Kahraman K,2014,"Kahraman K et al., 2014",10.1007/s00404-014-3217-5,,,,,Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial,pmid:24676694,10.1007/s00404-014-3217-5
4.0,4.2 / 4.3,741,85.0,"Kaya MG, Calapkorur B, Karaca Z, Yildirim S, Celik A, Akpek M, et al. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012;77(6):885-92.",primary_citation,,Kaya MG,2012,"Kaya MG et al., 2012",10.1111/j.1365-2265.2012.04436.x,,,,,The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome,pmid:22563947,10.1111/j.1365-2265.2012.04436.x
4.0,4.2 / 4.3,742,85.0,"Kaya MG, Yildirim S, Calapkorur B, Akpek M, Unluhizarci K, Kelestimur F. Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecol Endocrinol. 2015;31(5):401-5.",primary_citation,,Kaya MG,2015,"Kaya MG et al., 2015",10.3109/09513590.2015.1006188,,,,,Metformin improves endothelial function and carotid intima media thickness in patients with PCOS,pmid:25791462,10.3109/09513590.2015.1006188
4.0,4.2 / 4.3,743,85.0,"Kebapcilar L, Yuksel A, Bozkaya G, Taner CE, Kebapcilar AG, Bilgir O, et al. Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome. Central European journal of medicine. 2009;4(4):423-7.",primary_citation,,Kebapcilar L,2009,"Kebapcilar L et al., 2009",10.2478/s11536-009-0074-x,,,,,Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome,,10.2478/s11536-009-0074-x
4.0,4.2 / 4.3,744,85.0,"Kebapcilar L, Taner CE, Kebapcilar AG, Alacacioglu A, Sari I. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2010;281(1):35-42.",primary_citation,,Kebapcilar L,2010,"Kebapcilar L et al., 2010",10.1007/s00404-009-1051-y,,,,,"Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome",pmid:19330342,10.1007/s00404-009-1051-y
4.0,4.2 / 4.3,745,85.0,"Kilic S, Yilmaz N, Zulfikaroglu E, Erdogan G, Aydin M, Batioglu S. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecol Endocrinol. 2011;27(9):622-9.",primary_citation,,Kilic S,2011,"Kilic S et al., 2011",10.3109/09513590.2010.530706,,,,,Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment,pmid:21105835,10.3109/09513590.2010.530706
4.0,4.2 / 4.3,746,85.0,"Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception. 2010;82(2):139-46.",primary_citation,,Kriplani A,2010,"Kriplani A et al., 2010",10.1016/j.contraception.2010.02.009,,,,,Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome,pmid:20654754,10.1016/j.contraception.2010.02.009
4.0,4.2 / 4.3,747,85.0,"Kumar Y, Kotwal N, Singh Y, Upreti V, Somani S, Hari Kumar KVS. A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. J Family Med Prim Care. 2018;7(3):551-6.",primary_citation,,Kumar Y,2018,"Kumar Y et al., 2018",10.4103/jfmpc.jfmpc_83_17,,,,,"A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome",pmid:30112307,10.4103/jfmpc.jfmpc_83_17
4.0,4.2 / 4.3,748,85.0,"Leelaphiwat S, Jongwutiwes T, Lertvikool S, Tabcharoen C, Sukprasert M, Rattanasiri S, et al. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. J Obstet Gynaecol Res. 2015;41(3):402-10.",primary_citation,,Leelaphiwat S,2015,"Leelaphiwat S et al., 2015",10.1111/jog.12543,,,,,Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: A randomized controlled trial,pmid:25319761,10.1111/jog.12543
4.0,4.2 / 4.3,749,85.0,"Legro RS, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, et al. Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome. The Journal of clinical endocrinology and metabolism. 2015;100(11):4048-58.",primary_citation,,Legro RS,2015,"Legro RS et al., 2015",10.1210/jc.2015-2778,,,,,Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome,pmid:26401593,10.1210/jc.2015-2778
4.0,4.2 / 4.3,750,85.0,"Dokras A, Playford M, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, et al. Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome. Clinical endocrinology. 2017;86(5):739-46.",primary_citation,,Dokras A,2017,"Dokras A et al., 2017",10.1111/cen.13310,,,,,Impact of hormonal contraception and weight loss on high‐density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome,pmid:28199736,10.1111/cen.13310
4.0,4.2 / 4.3,751,85.0,"Shah A, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Gnatuk CL, et al. Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS. The Journal of clinical endocrinology and metabolism. 2021;106(1):108-19.",primary_citation,,Shah A,2021,"Shah A et al., 2021",10.1210/clinem/dgaa682,,,,,Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS,pmid:32968804,10.1210/clinem/dgaa682
4.0,4.2 / 4.3,752,85.0,"Steinberg Weiss M, Roe AH, Allison KC, Dodson WC, Kris-Etherton PM, Kunselman AR, et al. Lifestyle modifications alone or combined with hormonal contraceptives improve sexual dysfunction in women with polycystic ovary syndrome. Fertility and sterility. 2021;115(2):474-82.",primary_citation,,Steinberg Weiss M,2021,"Steinberg Weiss M et al., 2021",10.1016/j.fertnstert.2020.08.1396,,,,,Lifestyle modifications alone or combined with hormonal contraceptives improve sexual dysfunction in women with polycystic ovary syndrome,pmid:33059886,10.1016/j.fertnstert.2020.08.1396
4.0,4.2 / 4.3,753,85.0,"Luque-Ramírez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertility and sterility. 2009;91(6):2527-36.",primary_citation,,Luque-Ramírez M,2009,"Luque-Ramírez M et al., 2009",10.1016/j.fertnstert.2008.03.082,,,,,Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome,pmid:18565522,10.1016/j.fertnstert.2008.03.082
4.0,4.2 / 4.3,754,85.0,"Lv L, Liu Y, Sun Y, Tan K. Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. J Huazhong Univ Sci Technolog Med Sci. 2005;25(2):194-7.",primary_citation,,Lv L,2005,"Lv L et al., 2005",10.1007/bf02873575,,,,,"Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome",pmid:16116971,10.1007/bf02873575
4.0,4.2 / 4.3,755,85.0,"Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertility and sterility. 2002;77(5):919-27.",primary_citation,,Mastorakos G,2002,"Mastorakos G et al., 2002",10.1016/s0015-0282(02)02993-x,,,,,Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives,pmid:12009344,10.1016/s0015-0282(02)02993-x
4.0,4.2 / 4.3,756,85.0,"Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertility and sterility. 2006;85(2):420-7.",primary_citation,,Mastorakos G,2006,"Mastorakos G et al., 2006",10.1016/j.fertnstert.2005.07.1306,,,,,Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome,pmid:16595221,10.1016/j.fertnstert.2005.07.1306
4.0,4.2 / 4.3,757,85.0,"Mehrabian F, Ghasemi-Tehrani H, Mohamadkhani M, Moeinoddini M, Karimzadeh P. Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. J Res Med Sci. 2016;21:7.",primary_citation,,Mehrabian F,2016,"Mehrabian F et al., 2016",10.4103/1735-1995.177354,,,,,"Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome",pmid:27904553,10.4103/1735-1995.177354
4.0,4.2 / 4.3,758,85.0,"Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes care. 2007;30(3):471-8.",primary_citation,,Meyer C,2007,"Meyer C et al., 2007",10.2337/dc06-0618,,,,,Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome,pmid:17327307,10.2337/dc06-0618
4.0,4.2 / 4.3,759,85.0,"Burchall GF, Piva TJ, Ranasinha S, Teede HJ. Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS. Thromb Haemost. 2017;117(11):2053-62.",primary_citation,,Burchall GF,2017,"Burchall GF et al., 2017",10.1160/th17-04-0248,,,,,Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS,pmid:29202210,10.1160/th17-04-0248
4.0,4.2 / 4.3,760,85.0,"Hutchison SK, Harrison C, Stepto N, Meyer C, Teede HJ. Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome. Diabetes care. 2008;31(7):1427-32.",primary_citation,,Hutchison SK,2008,"Hutchison SK et al., 2008",10.2337/dc07-2265,,,,,Retinol-Binding Protein 4 and Insulin Resistance in Polycystic Ovary Syndrome,pmid:18390799,10.2337/dc07-2265
4.0,4.2 / 4.3,761,85.0,"Moran LJ, Meyer C, Hutchison SK, Zoungas S, Teede HJ. Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention. J Endocrinol Invest. 2010;33(4):258-65.",primary_citation,,Moran LJ,2010,"Moran LJ et al., 2010",10.1007/bf03345790,,,,,Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention,pmid:19834313,10.1007/bf03345790
4.0,4.2 / 4.3,762,85.0,"Mhao NS, Al-Hilli AS, Hadi NR, Jamil DA, Al-Aubaidy HA. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes Metab Syndr. 2016;10(1 Suppl 1):S95-8.",primary_citation,,Mhao NS,2016,"Mhao NS et al., 2016",10.1016/j.dsx.2015.10.001,,,,,A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome,pmid:26703220,10.1016/j.dsx.2015.10.001
4.0,4.2 / 4.3,763,85.0,"Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, et al. Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial. The Journal of clinical endocrinology and metabolism. 2018;103(3):824-38.",primary_citation,,Moretti C,2018,"Moretti C et al., 2018",10.1210/jc.2017-01186,,,,,Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial,pmid:29211888,10.1210/jc.2017-01186
4.0,4.2 / 4.3,764,85.0,"Morgante G, Cappelli V, Troìa L, De Leo V. Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2020;25(3):176-81.",primary_citation,,Morgante G,2020,"Morgante G et al., 2020",10.1080/13625187.2020.1736546,,,,,Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome,pmid:32191532,10.1080/13625187.2020.1736546
4.0,4.2 / 4.3,765,85.0,"Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of clinical endocrinology and metabolism. 2003;88(1):148-56.",primary_citation,,Morin-Papunen L,2003,"Morin-Papunen L et al., 2003",10.1210/jc.2002-020997,,,,,Metformin<i>Versus</i>Ethinyl Estradiol-Cyproterone Acetate in the Treatment of Nonobese Women with Polycystic Ovary Syndrome: A Randomized Study,pmid:12519844,10.1210/jc.2002-020997
4.0,4.2 / 4.3,766,85.0,"Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. Journal of Clinical Endocrinology & Metabolism. 2000;85(9):3161-8.",primary_citation,,Morin-Papunen LC,2000,"Morin-Papunen LC et al., 2000",10.1210/jcem.85.9.6792,,,,,Endocrine and Metabolic Effects of Metformin<i>Versus</i>Ethinyl Estradiol-Cyproterone Acetate in Obese Women with Polycystic Ovary Syndrome: A Randomized Study<sup>1</sup>,pmid:10999803,10.1210/jcem.85.9.6792
4.0,4.2 / 4.3,767,85.0,"Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism. 2003;88(10):4649-54.",primary_citation,,Morin-Papunen L,2003,"Morin-Papunen L et al., 2003",10.1210/jc.2002-021688,,,,,Metformin Reduces Serum C-Reactive Protein Levels in Women with Polycystic Ovary Syndrome,pmid:14557435,10.1210/jc.2002-021688
4.0,4.2 / 4.3,768,85.0,"Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur. 2005;152(2):269-75.",primary_citation,,Rautio K,2005,"Rautio K et al., 2005",10.1530/eje.1.01840,,,,,Effects of metformin and ethinyl estradiol–cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome,pmid:15745936,10.1530/eje.1.01840
4.0,4.2 / 4.3,769,85.0,"Moro F, Morciano A, Tropea A, Sagnella F, Palla C, Scarinci E, et al. Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reprod Sci. 2013;20(12):1508-17.",primary_citation,,Moro F,2013,"Moro F et al., 2013",10.1177/1933719113488444,,,,,Effects of Drospirenone–Ethinylestradiol and/or Metformin on CD4+CD28null T Lymphocytes Frequency in Women With Hyperinsulinemia Having Polycystic Ovary Syndrome: A Randomized Clinical Trial,pmid:23690338,10.1177/1933719113488444
4.0,4.2 / 4.3,770,85.0,"Ozdemir S, Görkemli H, Gezginç K, Ozdemir M, Kiyici A. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2008;103(1):44-9.",primary_citation,,Ozdemir S,2008,"Ozdemir S et al., 2008",10.1016/j.ijgo.2008.05.017,,,,,Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome,pmid:18635183,10.1016/j.ijgo.2008.05.017
4.0,4.2 / 4.3,771,85.0,"Ozgurtas T, Oktenli C, Dede M, Tapan S, Kenar L, Sanisoglu SY, et al. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis. 2008;200(2):336-44.",primary_citation,,Ozgurtas T,2008,"Ozgurtas T et al., 2008",10.1016/j.atherosclerosis.2007.12.054,,,,,Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS),pmid:18281049,10.1016/j.atherosclerosis.2007.12.054
4.0,4.2 / 4.3,772,85.0,"Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, et al. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol. 2011;27(8):587-92.",primary_citation,,Panidis D,2011,"Panidis D et al., 2011",10.3109/09513590.2010.507283,,,,,The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia,pmid:20836726,10.3109/09513590.2010.507283
4.0,4.2 / 4.3,773,85.0,"Podfigurna A, Meczekalski B, Petraglia F, Luisi S. Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone). J Endocrinol Invest. 2020;43(4):483-92.",primary_citation,,Podfigurna A,2020,"Podfigurna A et al., 2020",10.1007/s40618-019-01133-3,,,,,"Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone)",pmid:31654312,10.1007/s40618-019-01133-3
4.0,4.2 / 4.3,774,85.0,"Sabuncu T, Harma M, Harma M, Nazligul Y, Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertility and sterility. 2003;80(5):1199-204.",primary_citation,,Sabuncu T,2003,"Sabuncu T et al., 2003",10.1016/s0015-0282(03)02162-9,,,,,Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome,pmid:14607575,10.1016/s0015-0282(03)02162-9
4.0,4.2 / 4.3,775,85.0,"Sahu A, Tripathy P, Mohanty J, Nagy A. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial. J Gynecol Obstet Hum Reprod. 2019;48(5):335-9.",primary_citation,,Sahu A,2019,"Sahu A et al., 2019",10.1016/j.jogoh.2018.10.006,,,,,Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial,pmid:30316907,10.1016/j.jogoh.2018.10.006
4.0,4.2 / 4.3,776,85.0,"Song J, Ruan X, Gu M, Wang L, Wang H, Mueck AO. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological endocrinology. 2018;34(5):413-7.",primary_citation,,Song J,2018,"Song J et al., 2018",10.1080/09513590.2017.1407752,,,,,Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance,pmid:29172796,10.1080/09513590.2017.1407752
4.0,4.2 / 4.3,777,85.0,"Ruan X, Song J, Gu M, Wang L, Wang H, Mueck AO. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Arch Gynecol Obstet. 2018;297(6):1557-63.",primary_citation,,Ruan X,2018,"Ruan X et al., 2018",10.1007/s00404-018-4762-0,,,,,"Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients",pmid:29602978,10.1007/s00404-018-4762-0
4.0,4.2 / 4.3,778,85.0,"Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clinical endocrinology (Oxford). 2000;52(5):587-94.",primary_citation,,Spritzer PM,2000,"Spritzer PM et al., 2000",10.1046/j.1365-2265.2000.00982.x,,,,,Spironolactone as a single agent for long‐term therapy of hirsute patients,pmid:10792338,10.1046/j.1365-2265.2000.00982.x
4.0,4.2 / 4.3,779,85.0,"Taheripanah R, Sepahvandi M, Entezari A, Amiri Z, Samani EN. Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients. Middle East Fertility Society journal. 2010;15(3):159-62.",primary_citation,,Taheripanah R,2010,"Taheripanah R et al., 2010",10.1016/j.mefs.2010.06.007,,,,,Evaluation of serum PSA after cyproterone compound treatment compared with oral contraceptive pill in hirsute polycystic ovary syndrome patients,,10.1016/j.mefs.2010.06.007
4.0,4.2 / 4.3,780,85.0,"Tartagni M, Schonauer LM, De Salvia MA, Cicinelli E, De Pergola G, D'Addario V. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril. 2000;73(4):718-23.",primary_citation,,Tartagni M,2000,"Tartagni M et al., 2000",10.1016/s0015-0282(99)00633-0,,,,,Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism,pmid:10731531,10.1016/s0015-0282(99)00633-0
4.0,4.2 / 4.3,781,85.0,"Vieira CS, Martins WP, Fernandes JB, Soares GM, dos Reis RM, de Sá MF, et al. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception. 2012;86(3):268-75.",primary_citation,,Vieira CS,2012,"Vieira CS et al., 2012",10.1016/j.contraception.2011.12.011,,,,,"The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome",pmid:22464410,10.1016/j.contraception.2011.12.011
4.0,4.2 / 4.3,782,85.0,"Wang QY, Song Y, Huang W, Xiao L, Wang QS, Feng GM. Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial. Chin Med J (Engl). 2016;129(8):883-90.",primary_citation,,Wang QY,2016,"Wang QY et al., 2016",10.4103/0366-6999.179783,,,,,"Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders",pmid:27064030,10.4103/0366-6999.179783
4.0,4.2 / 4.3,783,85.0,"Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European journal of endocrinology / European Federation of Endocrine Societies. 2012;166(1):99-105.",primary_citation,,Wei W,2012,"Wei W et al., 2012",10.1530/eje-11-0616,,,,,A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome,pmid:22019891,10.1530/eje-11-0616
4.0,4.2 / 4.3,784,85.0,"Wu J, Zhu Y, Jiang Y, Cao Y. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24(7):392-8.",primary_citation,,Wu J,2008,"Wu J et al., 2008",10.1080/09513590802217027,,,,,"Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome",pmid:18608522,10.1080/09513590802217027
4.0,4.2 / 4.3,785,85.0,"Yildizhan R, Gokce AI, Yildizhan B, Cim N. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up. Gynecol Endocrinol. 2015;31(5):396-400.",primary_citation,,Yildizhan R,2015,"Yildizhan R et al., 2015",10.3109/09513590.2015.1006187,,,,,Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up,pmid:25739031,10.3109/09513590.2015.1006187
4.0,4.2 / 4.3,786,85.0," Dokras A, Sarwer DB, Allison KC, Milman L, Kris-Etherton PM, Kunselman AR, et al. Weight Loss and Lowering Androgens Predict Improvements in Health-Related Quality of Life in Women With PCOS. The Journal of clinical endocrinology and metabolism. 2016;101(8):2966-74.",primary_citation,, Dokras A,2016," Dokras A et al., 2016",10.1210/jc.2016-1896,,,,,Weight Loss and Lowering Androgens Predict Improvements in Health-Related Quality of Life in Women With PCOS,pmid:27253669,10.1210/jc.2016-1896
4.0,4.4,787,111.0,"Lingaiah, S.; Morin-Papunen, L.; Risteli, J.; Tapanainen, J. S. Metformin decreases bone turnover markers in polycystic ovary syndrome: a post hoc study, Fertility and sterility 2019",primary_citation,,Lingaiah,2019,"Lingaiah et al., 2019",10.1016/j.fertnstert.2019.04.013,,,,,Metformin decreases bone turnover markers in polycystic ovary syndrome: a post hoc study,pmid:31227287,10.1016/j.fertnstert.2019.04.013
4.0,4.4,788,111.0,"Zahra, M.; Shah, M.; Ali, A.; Rahim, R. Effects of Metformin on Endocrine and Metabolic Parameters in Patients with Polycystic Ovary Syndrome Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2017 ",primary_citation,,Zahra,2017,"Zahra et al., 2017",10.1055/s-0042-119041,,,,,Effects of Metformin on Endocrine and Metabolic Parameters in Patients with Polycystic Ovary Syndrome,pmid:27813052,10.1055/s-0042-119041
4.0,4.4,789,111.0,"Heidari B, Lerman A, Lalia AZ, Lerman LO, Chang AY. Effect of metformin on microvascular endothelial function in polycystic ovary syndrome. Mayo Clin Proc. 2019 ",primary_citation,,Heidari B,2019,"Heidari B et al., 2019",10.1016/j.mayocp.2019.06.015,,,,,Effect of Metformin on Microvascular Endothelial Function in Polycystic Ovary Syndrome,pmid:31806099,10.1016/j.mayocp.2019.06.015
4.0,4.4,790,111.0,"Bridger, T., MacDonald, S., Baltzer, F. and Rodd, C. 2006 Randomized placebo‐controlled trial of metformin for adolescents with polycystic ovary syndrome. Archives of Pediatrics & Adolescent Medicine.",primary_citation,,Bridger,2006,"Bridger et al., 2006",10.1001/archpedi.160.3.241,,,,,Randomized Placebo-Controlled Trial of Metformin for Adolescents With Polycystic Ovary Syndrome,pmid:16520442,10.1001/archpedi.160.3.241
4.0,4.4,791,111.0,"Chou, K.H., et al., Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double blind and placebo‐controlled trial. Hormone & Metabolic Research, 2003. 35(2): p. 86‐91. (ROB included in last TR under Patel 2017) ",primary_citation,,Chou,2003,"Chou et al., 2003",10.1055/s-2003-39056,,,,,"Clinical, Metabolic and Endocrine Parameters in Response to Metformin in Obese Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind and Placebo-Controlled Trial",pmid:12734787,10.1055/s-2003-39056
4.0,4.4,792,111.0,"Baillargeon, J.P, et al. Effects of metformin and rosiglitazone, alone and in combination in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility & Sterility, 2004 (ROB included in last TR under Patel 2017)",primary_citation,,Baillargeon,2004,"Baillargeon et al., 2004",10.1016/j.fertnstert.2004.02.127,,,,,"Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity",pmid:15482765,10.1016/j.fertnstert.2004.02.127
4.0,4.4,793,111.0,"Eisenhardt, S., et al., Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Endocrinology & Metabolism, 2006. 91(3): p. 946‐52. (ROB included in last TR under Patel 2017)",primary_citation,,Eisenhardt,2006,"Eisenhardt et al., 2006",10.1210/jc.2005-1994,,,,,"Early Effects of Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomized, Double-Blind, Placebo-Controlled Trial",pmid:16352680,10.1210/jc.2005-1994
4.0,4.4,794,111.0,"Fleming, R., et al., Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology & Metabolism, 2002. 87(2): p. 569‐74. (ROB included in last TR under Tang 2012)",primary_citation,,Fleming,2002,"Fleming et al., 2002",10.1210/jcem.87.2.8261,,,,,Ovarian Function and Metabolic Factors in Women with Oligomenorrhea Treated with Metformin in a Randomized Double Blind Placebo-Controlled Trial,pmid:11836287,10.1210/jcem.87.2.8261
4.0,4.4,795,111.0,"Morin‐Papunen, L., et al., Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo controlled randomized trial. Journal of Clinical Endocrinology & Metabolism, 2012. 97(5): p. 1492‐500.",primary_citation,,Morin‐Papunen,2012,"Morin‐Papunen et al., 2012",10.1210/jc.2011-3061,,,,,"Metformin Improves Pregnancy and Live-Birth Rates in Women with Polycystic Ovary Syndrome (PCOS): A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial",pmid:22419702,10.1210/jc.2011-3061
4.0,4.4,796,111.0,"Hoeger, K., et al., The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo‐controlled clinical trials. Journal of Clinical Endocrinology & Metabolism, 2008. 93(11): p. 4299‐306. (ROB included in last TR under Patel 2017 (ROB own in TR)",primary_citation,,Hoeger,2008,"Hoeger et al., 2008",10.1210/jc.2008-0461,,,,,"The Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women in Two Randomized, Placebo-Controlled Clinical Trials",pmid:18728175,10.1210/jc.2008-0461
4.0,4.4,797,111.0,"Karimzadeh MA, Eftekhar M, Taheripanah R, Tayebi N, Sakhavat L, Zare F. The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertil Soc J 2007 (ROB included in last TR under Tang 2012)",primary_citation,,Karimzadeh MA,2007,"Karimzadeh MA et al., 2007",,,,35054293.0,The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome,,,
4.0,4.4,798,111.0,"Kelly, C.J. and D. Gordon, The effect of metformin on hirsutism in polycystic ovary syndrome. European Journal of Endocrinology, 2002. 147(2): p. 217‐21. (ROB included in last TR under Patel 2017) ",primary_citation,,Kelly,2002,"Kelly et al., 2002",10.1530/eje.0.1470217,,,,,The effect of metformin on hirsutism in polycystic ovary syndrome,pmid:12153743,10.1530/eje.0.1470217
4.0,4.4,799,111.0,"Lord, J., et al., The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology, 2006. 113(7): p. 817‐24. (ROB included in last TR under Patel 2017) ",primary_citation,,Lord,2006,"Lord et al., 2006",10.1111/j.1471-0528.2006.00966.x,,,,,"The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome—a randomised, double‐blind, placebo‐controlled trial",pmid:16827766,10.1111/j.1471-0528.2006.00966.x
4.0,4.4,800,111.0,"Maciel, G.A., et al., Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility & Sterility, 2004. 81(2): p. 355‐60. (ROB included in last TR under Patel 2017) ",primary_citation,,Maciel,2004,"Maciel et al., 2004",10.1016/j.fertnstert.2003.08.012,,,,,Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin,pmid:14967373,10.1016/j.fertnstert.2003.08.012
4.0,4.4,801,111.0,"Onalan, G., et al., Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic? European Journal of Obstetrics, Gynecology, & Reproductive Biology, 2005. 123(2): p. 204‐11. (ROB included in last TR under Patel 2017) ",primary_citation,,Onalan,2005,"Onalan et al., 2005",10.1016/j.ejogrb.2005.05.010,,,,,"Predictive value of glucose–insulin ratio in PCOS and profile of women who will benefit from metformin therapy: Obese, lean, hyper or normoinsulinemic?",pmid:16316811,10.1016/j.ejogrb.2005.05.010
4.0,4.4,802,111.0,"Moghetti, P., et al. Metformin effects on clinical features, endocrine and metabolic profiles and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6 month trial, followed by open, long-term clinical evaluation. Journal of Clinical Endocrinology & Metabolism, 2000. 85(1):139-46. (ROB included in last TR under Patel 2017) ",primary_citation,,Moghetti,2000,"Moghetti et al., 2000",10.1097/00006254-200006000-00019,,,,,"Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, Followed by Open, Long-Term Clinical Evaluation",,10.1097/00006254-200006000-00019
4.0,4.4,803,111.0,"Palomba, S., et al., Insulin sensitivity after metformin suspension in normal‐weight women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 2007. 92(8): p. 3128‐35. (ROB included in last TR under Patel 2017)",primary_citation,,Palomba,2007,"Palomba et al., 2007",10.1210/jc.2007-0441,,,,,Insulin Sensitivity after Metformin Suspension in Normal-Weight Women with Polycystic Ovary Syndrome,pmid:17519312,10.1210/jc.2007-0441
4.0,4.4,804,111.0,"Ng, E.H., N.M. Wat, and P.C. Ho, Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction, 2001. 16(8): p. 1625‐31. (ROB included in last TR under Tang 2012)",primary_citation,,Ng,2001,"Ng et al., 2001",10.1093/humrep/16.8.1625,,,,,"Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial",pmid:11473953,10.1093/humrep/16.8.1625
4.0,4.4,805,111.0,"Romualdi, D., et al., Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal‐weight normoinsulinemic women with polycystic ovary syndrome: a randomized double‐blind placebo‐controlled clinical trial. Fertility & Sterility, 2010. 93(7): p. 2303‐10 (ROB included in last TR under Patel 2017)",primary_citation,,Romualdi,2010,"Romualdi et al., 2010",10.1016/j.fertnstert.2009.01.114,,,,,Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial,pmid:19268929,10.1016/j.fertnstert.2009.01.114
4.0,4.4,806,111.0,"Trolle, B., et al., Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐overtrial. Human Reproduction, 2007. 22(11): p. 2967‐73. (ROB included in last TR under Patel 2017)",primary_citation,,Trolle,2007,"Trolle et al., 2007",10.1097/01.ogx.0000300471.31456.ea,,,,,"Efficacy of Metformin in Obese and Non-obese Women With Polycystic Ovary Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Cross-Over Trial",,10.1097/01.ogx.0000300471.31456.ea
4.0,4.4,807,111.0,"Trolle, B., et al., Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. Fertility & Sterility, 2010. 94(6): p. 2234‐8. (ROB included in last TR under Patel 2017) ",primary_citation,,Trolle,2010,"Trolle et al., 2010",10.1016/j.fertnstert.2010.01.057,,,,,Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study,pmid:20189560,10.1016/j.fertnstert.2010.01.057
4.0,4.4,808,111.0,"Haydardedeoglu, B., et al., Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. International Journal of Gynaecology & Obstetrics, 2009. 105(1): p. 32‐5.",primary_citation,,Haydardedeoglu,2009,"Haydardedeoglu et al., 2009",10.1016/j.ijgo.2008.11.039,,,,,Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome,pmid:19155004,10.1016/j.ijgo.2008.11.039
4.0,4.4,809,111.0,"Moro, F., et al., Effects of drospirenone‐ethinylestradiol and/or metformin on CD4(+) CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. Reproductive Sciences, 2013. 20(12): p. 1508‐17.",primary_citation,,Moro,2013,"Moro et al., 2013",10.1177/1933719113488444,,,,,Effects of Drospirenone–Ethinylestradiol and/or Metformin on CD4+CD28null T Lymphocytes Frequency in Women With Hyperinsulinemia Having Polycystic Ovary Syndrome: A Randomized Clinical Trial,pmid:23690338,10.1177/1933719113488444
4.0,4.4,810,111.0,"Esfahanian, F., et al., Effect of metformin compared with hypocaloric diet on serum C‐reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. Journal of Obstetrics & Gynaecology Research, 2013. 39(4): p. 806‐13.",primary_citation,,Esfahanian,2013,"Esfahanian et al., 2013",10.1111/j.1447-0756.2012.02051.x,,,,,Effect of <scp>M</scp>etformin compared with hypocaloric diet on serum <scp>C</scp>‐reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome,pmid:23279603,10.1111/j.1447-0756.2012.02051.x
4.0,4.4,811,111.0,"Fux Otta, C., et al., Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double‐blind, and placebo control trial. Gynecological Endocrinology, 2010. 26(3): p. 173‐8.",primary_citation,,Fux Otta,2010,"Fux Otta et al., 2010",10.3109/09513590903215581,,,,,"Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: A randomized, double-blind, and placebo control trial",pmid:20148739,10.3109/09513590903215581
4.0,4.4,812,111.0,"Harborne, L.R., et al., Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. Journal of Clinical Endocrinology & Metabolism, 2005. 90(8): p. 4593‐8.",primary_citation,,Harborne,2005,"Harborne et al., 2005",10.1210/jc.2004-2283,,,,,Metformin and Weight Loss in Obese Women with Polycystic Ovary Syndrome: Comparison of Doses,pmid:15886247,10.1210/jc.2004-2283
4.0,4.4,813,111.0,"Altinok, Magda Lambaa; Ravn, Pernille; Andersen, Marianne; Glintborg, Dorte. Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome. Gynecological endocrinology 2018",primary_citation,,Altinok,2018,"Altinok et al., 2018",10.1080/09513590.2018.1460343,,,,,Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome,pmid:29658344,10.1080/09513590.2018.1460343
4.0,4.4,814,111.0,"Bodur, Serkan; Dundar, Ozgur; Kanat-Pektas, Mine; Kinci, Mehmet Ferdi; Tutuncu, Levent. The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystic ovary syndrome: A randomized controlled study. Taiwanese journal of obstetrics & gynecology 2018",primary_citation,,Bodur,2018,"Bodur et al., 2018",10.1016/j.tjog.2018.04.015,,,,,The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study,pmid:29880175,10.1016/j.tjog.2018.04.015
4.0,4.4,815,111.0,"Fonseka, Sanjeewani; Wijeyaratne, Chandrika N.; Gawarammana, Indika B.; Kalupahana, Nishan S.; Rosairo, Shanthini; Ratnatunga, Neelakanthi; Kumarasiri, Ranjith. Effectiveness of Low-dose Ethinylestradiol/Cyproterone Acetate and Ethinylestradiol/Desogestrel with and without Metformin on Hirsutism in Polycystic Ovary Syndrome: A Randomized, Double-blind, Triple-dummy Study, Journal of Clinical & Aesthetic Dermatology 2020",primary_citation,,Fonseka,2020,"Fonseka et al., 2020",,32983332.0,,222155349.0,,"Effectiveness of Low-dose Ethinylestradiol/Cyproterone Acetate and Ethinylestradiol/Desogestrel with and without Metformin on Hirsutism in Polycystic Ovary Syndrome: A Randomized, Double-blind, Triple-dummy Study.",pmid:32983332,
4.0,4.4,816,111.0,"Glintborg, D.; Mumm, H.; Holst, J. J.; Andersen, M. Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. Endocrine Connections 2017",primary_citation,,Glintborg,2017,"Glintborg et al., 2017",10.1530/ec-17-0034,28432082.0,,,,Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome,pmid:28432082,
4.0,4.4,817,111.0,"Sahu, Asutosh; Tripathy, Priyadarshini; Mohanty, Jayashree; Nagy, Attila. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial Journal of gynecology obstetrics and human reproduction 2019",primary_citation,,Sahu,2019,"Sahu et al., 2019",10.1016/j.jogoh.2018.10.006,,,,,Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial,pmid:30316907,10.1016/j.jogoh.2018.10.006
4.0,4.4,818,111.0,"Glintborg (1), D., Altinok, M. L., Mumm, H., Hermann, A. P., Ravn, P. and Andersen, M. 2014 Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism.",primary_citation,,Glintborg (1),2014,"Glintborg (1) et al., 2014",10.1210/jc.2014-1135,,,,,Body Composition Is Improved During 12 Months' Treatment With Metformin Alone or Combined With Oral Contraceptives Compared With Treatment With Oral Contraceptives in Polycystic Ovary Syndrome,pmid:24742124,10.1210/jc.2014-1135
4.0,4.4,819,111.0,"Glintborg (2) D, Mumm H, Altinok ML, Richelsen B, Bruun JM, Andersen M. Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome. J Endocrinol Invest. 2014;37(8):757-64 ",primary_citation,,Glintborg (2) D,2014,"Glintborg (2) D et al., 2014",10.1007/s40618-014-0103-8,24906976.0,,,,"Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome",pmid:24906976,
4.0,4.4,820,111.0,"Kaya, M. G., Yildirim, S., Calapkorur, B., Akpek, M., Unluhizarci, K. and Kelestimur, F. 2015 Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecological Endocrinology 2015 ",primary_citation,,Kaya,2015,"Kaya et al., 2015",10.3109/09513590.2015.1006188,,,,,Metformin improves endothelial function and carotid intima media thickness in patients with PCOS,pmid:25791462,10.3109/09513590.2015.1006188
4.0,4.4,821,111.0,"Kaya, M. G.; Calapkorur, B.; Karaca, Z.; Yildirim, S.; Celik, A.; Akpek, M.; Unluhizarci, K.; Kelestimur, F. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) Dec 2012;77(6):885- ",primary_citation,,Kaya,2012,"Kaya et al., 2012",10.1111/j.1365-2265.2012.04436.x,,,,,The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome,pmid:22563947,10.1111/j.1365-2265.2012.04436.x
4.0,4.4,822,111.0,"Morin‐Papunen (1), L., Rautio, K., Ruokonen, A., Hedberg, P., Puukka, M. and Tapanainen, J. S. 2003. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. Journal of Clin Endocrinol & Metabolism Oct 2003:4649-54",primary_citation,,Morin‐Papunen (1),2003,"Morin‐Papunen (1) et al., 2003",10.1210/jc.2002-021688,,,,,Metformin Reduces Serum C-Reactive Protein Levels in Women with Polycystic Ovary Syndrome,pmid:14557435,10.1210/jc.2002-021688
4.0,4.4,823,111.0,"Essah P. A., Arrowood J. A., Cheang K. I., Adawadkar S. S., Stovall D. W., and Nestler J. E., Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertil. Steril 2011 ",primary_citation,,Essah P. A.,2011,"Essah P. A. et al., 2011",10.1016/j.fertnstert.2011.05.091,,,,,Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome,pmid:21733508,10.1016/j.fertnstert.2011.05.091
4.0,4.4,824,111.0,"Feng W., Jia Y. Y., Zhang D. Y., and Shi H. R., Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin, Gynecol. Endocrinol. 2016  ",primary_citation,,Feng W.,2016,"Feng W. et al., 2016",10.3109/09513590.2015.1101441,,,,,Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin,pmid:26507097,10.3109/09513590.2015.1101441
4.0,4.4,825,111.0,"Rautio K., Tapanainen J. S., Ruokonen A., and Morin-Papunen L. C., Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome., Eur. J. Endocrinol 2005",primary_citation,,Rautio K.,2005,"Rautio K. et al., 2005",10.1530/eje.1.01840,,,,,Effects of metformin and ethinyl estradiol–cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome,pmid:15745936,10.1530/eje.1.01840
4.0,4.4,826,111.0,"Al-Zubeidi H, Klein KO. Randomized clinical trial evaluating Metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome. Journal of Pediatric Endocrinology and Metabolism 2015 (ROB included in last TR under Al Khalifa 2016) ",primary_citation,,Al-Zubeidi H,2015,"Al-Zubeidi H et al., 2015",10.1515/jpem-2014-0283,,,,,Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome,pmid:25781525,10.1515/jpem-2014-0283
4.0,4.4,827,111.0,"Christakou C, Kollias A, Piperi C, Katsikis I, Panidis D, Diamanti-Kandarakis E. The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones 2014",primary_citation,,Christakou C,2014,"Christakou C et al., 2014",10.14310/horm.2002.1553,,,,,The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers,pmid:25555182,10.14310/horm.2002.1553
4.0,4.4,828,111.0,"Aghamohammadzadeh N, Aliasgarzadeh A, Baglar L, Abdollahifard S, Bahrami A, Najafipour F, et al. Pregnancy rate in women with pcos with high lh/fsh ratio undergoing icsi. Pakistan Journal of Medical Science 2010",primary_citation,,Aghamohammadzadeh N,2010,"Aghamohammadzadeh N et al., 2010",,,,54806151.0,The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome,,,
4.0,4.4,829,111.0,"El Maghraby HA, Nafee T, Guiziry D, Elnashar A. Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period. Middle East Fertility Society Journal 2015 (ROB included in last TR under Al Khalifa 2016)",primary_citation,,El Maghraby HA,2015,"El Maghraby HA et al., 2015",10.1016/j.mefs.2014.10.003,,,,,Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24month follow up period,,10.1016/j.mefs.2014.10.003
4.0,4.4,830,111.0,"Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl-estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Human Reproduction 2002 (ROB included in last TR under Costello 2007) ",primary_citation,,Elter K,2002,"Elter K et al., 2002",10.1093/humrep/17.7.1729,,,,,"Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study",pmid:12093831,10.1093/humrep/17.7.1729
4.0,4.4,831,111.0,"Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism 2003 (ROB included in last TR under Costello 2007)",primary_citation,,Harborne L,2003,"Harborne L et al., 2003",10.1210/jc.2003-030424,,,,,Metformin or Antiandrogen in the Treatment of Hirsutism in Polycystic Ovary Syndrome,pmid:12970273,10.1210/jc.2003-030424
4.0,4.4,832,111.0,"Bilgir O, Kebapcilar L, Taner C, Bilgir F, Kebapcilar A, Bozkaya G, et al. The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS). International Medicine 2009 ",primary_citation,,Bilgir O,2009,"Bilgir O et al., 2009",10.2169/internalmedicine.48.2177,,,,,The Effect of Ethinylestradiol (EE)/Cyproterone Acetate (CA) and EE/CA Plus Metformin Treatment on Adhesion Molecules in Cases with Polycystic Ovary Syndrome (PCOS),pmid:19602786,10.2169/internalmedicine.48.2177
4.0,4.4,833,111.0,"Kilic S, Yilmaz N, Zulfikaroglu E, Erdogan G, Aydin M, Batioglu S. Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. Gynecological Endocrinology 2011 ",primary_citation,,Kilic S,2011,"Kilic S et al., 2011",10.3109/09513590.2010.530706,,,,,Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment,pmid:21105835,10.3109/09513590.2010.530706
4.0,4.4,834,111.0,"Kumar Y, Kotwal N, Singh Y, Upreti V, Somani S, Hari Kumar KV. A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome. Journal of Family Medicine and Primary Care 2018 ",primary_citation,,Kumar Y,2018,"Kumar Y et al., 2018",10.4103/jfmpc.jfmpc_83_17,,,,,"A randomized, controlled trial comparing the metformin, oral contraceptive pills and their combination in patients with polycystic ovarian syndrome",pmid:30112307,10.4103/jfmpc.jfmpc_83_17
4.0,4.4,835,111.0,"Lv L, Liu Y, Sun Y, Tan K. Effects of Metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. Journal of Huazhong University of Science and Technology 2005",primary_citation,,Lv L,2005,"Lv L et al., 2005",10.1007/bf02873575,,,,,"Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome",pmid:16116971,10.1007/bf02873575
4.0,4.4,836,111.0,"Meyer C, McGrath BP, Teede HJ. Effect of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007",primary_citation,,Meyer C,2007,"Meyer C et al., 2007",10.2337/dc06-0618,,,,,Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome,pmid:17327307,10.2337/dc06-0618
4.0,4.4,837,111.0,"Mhao NS, Al-Hilli SA, Hadi NR, Jamil DA, Al-Aubaidy HA. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 2015 ",primary_citation,,Mhao NS,2015,"Mhao NS et al., 2015",10.1016/j.dsx.2015.10.001,,,,,A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome,pmid:26703220,10.1016/j.dsx.2015.10.001
4.0,4.4,838,111.0,"Moran LJ, Meyer C, Hutchison SK, Zoungas S, Teede HJ. Novel inflammatory markers in overweight women with or without polycystic ovary syndrome and following pharmacological intervention. Journal of Endocrinological Investigation 2010",primary_citation,,Moran LJ,2010,"Moran LJ et al., 2010",10.1007/bf03345790,,,,,Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention,pmid:19834313,10.1007/bf03345790
4.0,4.4,839,111.0,"Morin-Papunen (2) L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. The Journal of Clinical Endocrinology & Metabolism 2003 (ROB included in last TR under Costello 2007) ",primary_citation,,Morin-Papunen (2) L,2003,"Morin-Papunen (2) L et al., 2003",10.1210/jc.2002-020997,,,,,Metformin<i>Versus</i>Ethinyl Estradiol-Cyproterone Acetate in the Treatment of Nonobese Women with Polycystic Ovary Syndrome: A Randomized Study,pmid:12519844,10.1210/jc.2002-020997
4.0,4.4,840,111.0,"Ozgurtas T, Oktenli C, Dede M, Tapan S, Kenar L, Sanisoglu SY, et al. Metformin and oral contraceptive treatment reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis 2008 2003 ",primary_citation,,Ozgurtas T,2008,"Ozgurtas T et al., 2008",10.1016/j.atherosclerosis.2007.12.054,,,,,Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS),pmid:18281049,10.1016/j.atherosclerosis.2007.12.054
4.0,4.4,841,111.0,"Wu J, Zhu Y, Jiang Y, Cao Y. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecological Endocrinology 2008 ",primary_citation,,Wu J,2008,"Wu J et al., 2008",10.1080/09513590802217027,,,,,"Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome",pmid:18608522,10.1080/09513590802217027
4.0,4.4,842,111.0,"Morin-Papunen L, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen J. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000 ",primary_citation,,Morin-Papunen L,2000,"Morin-Papunen L et al., 2000",10.1210/jcem.85.9.6792,,,,,Endocrine and Metabolic Effects of Metformin<i>Versus</i>Ethinyl Estradiol-Cyproterone Acetate in Obese Women with Polycystic Ovary Syndrome: A Randomized Study<sup>1</sup>,pmid:10999803,10.1210/jcem.85.9.6792
4.0,4.4,843,111.0,"Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, Diamanti-Kandarakis E. The impact of oral contraceptives and metformin on antiMullerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol 2011 ",primary_citation,,Panidis D,2011,"Panidis D et al., 2011",10.3109/09513590.2010.507283,,,,,The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia,pmid:20836726,10.3109/09513590.2010.507283
4.0,4.4,844,111.0,"Hutchison, S. K.; Harrison, C.; Stepto, N.; Meyer, C.; Teede, H. J. Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome Diabetes Care Jul 2008;31(7):1427-32 ",primary_citation,,Hutchison,2008,"Hutchison et al., 2008",10.2337/dc07-2265,,,,,Retinol-Binding Protein 4 and Insulin Resistance in Polycystic Ovary Syndrome,pmid:18390799,10.2337/dc07-2265
4.0,4.4,845,111.0,"Kebapcilar, Levent; Yuksel, Arif; Bozkaya, Giray; Taner, Cuneyt Eftal; Kebapcilar, Ayse Gul; Bilgir, Oktay; Alacacioglu, Ahmet; Sari, Ismail Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome Central European journal of medicine 2009;4(4):423-427. ",primary_citation,,Kebapcilar,2009,"Kebapcilar et al., 2009",10.2478/s11536-009-0074-x,,,,,Effects of an EE/CA compared with EE/CA-metformin on serum ADMA levels in women with polycystic ovary syndrome,,10.2478/s11536-009-0074-x
4.0,4.4,846,111.0,"Luque-Ramírez, M.; Mendieta-Azcona, C.; Alvarez-Blasco, F.; Escobar-Morreale, H. F. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome Fertil Steril Jun 2009;91(6):2527-36",primary_citation,,Luque-Ramírez,2009,"Luque-Ramírez et al., 2009",10.1016/j.fertnstert.2008.03.082,,,,,Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome,pmid:18565522,10.1016/j.fertnstert.2008.03.082
4.0,4.4,847,111.0,"Mehrabian, F., et al., Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatinj on the metabolic consequences of polycystic ovary syndrome. Journal of Research in Medical Sciences, 2016. 21(1): p. 1‐7.",primary_citation,,Mehrabian,2016,"Mehrabian et al., 2016",10.4103/1735-1995.177354,,,,,"Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome",pmid:27904553,10.4103/1735-1995.177354
4.0,4.4,848,111.0,"Cibula D, Fanta M, Vrbikova J, Stanicka S, Dvorakova K, hill M, et al. The effect of combination therapy with metformin and ovar contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenism, SHBG and lipids in PCOS patients. Human reproduction (Oxford, England). 2005;20(1):180-4. (ROB included in last TR under Costello 2007) ",primary_citation,,Cibula D,2005,"Cibula D et al., 2005",10.1093/humrep/deh588,,,,,"The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients",pmid:15576394,10.1093/humrep/deh588
4.0,4.4,849,111.0,"Wei, W.; Zhao, H.; Wang, A.; Sui, M.; Liang, K.; Deng, H.; Ma, Y.; Zhang, Y.; Zhang, H.; Guan, Y. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome Eur J Endocrinol Jan 2012;166(1):99-105.",primary_citation,,Wei,2012,"Wei et al., 2012",10.1530/eje-11-0616,,,,,A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome,pmid:22019891,10.1530/eje-11-0616
4.0,4.4,850,111.0,"Dardzinska, J.A., et al., Effects of metformin or an oral contraceptive containing cyproterone acetate on serum c‐reactive protein, interleukin‐6 and soluble vascular cell adhesion molecule‐1 concentrations in women with polycystic ovary syndrome. Experimental & Clinical Endocrinology & Diabetes, 2014. 122(2): p. 118‐25. ",primary_citation,,Dardzinska,2014,"Dardzinska et al., 2014",10.1055/s-0033-1363261,,,,,"Effects of Metformin or an Oral Contraceptive Containing Cyproterone Acetate on Serum C-reactive Protein, Interleukin-6 and Soluble Vascular Cell Adhesion Molecule-1 Concentrations in Women with Polycystic Ovary Syndrome",pmid:24554512,10.1055/s-0033-1363261
4.0,4.4,851,111.0,"Hoeger, K.M., et al., A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility & Sterility, 2004. 82(2): p. 421‐9",primary_citation,,Hoeger,2004,"Hoeger et al., 2004",10.1016/j.fertnstert.2004.02.104,,,,,"A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: A pilot study",pmid:15302293,10.1016/j.fertnstert.2004.02.104
4.0,4.4,852,111.0,"Allen, H.F., et al., Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. Journal of Pediatric Endocrinology & Metabolism, 2005. 18(8): p. 761‐8.",primary_citation,,Allen,2005,"Allen et al., 2005",10.1515/jpem.2005.18.8.761,,,,,Randomized Controlled Trial Evaluating Response to Metformin Versus Standard Therapy in the Treatment of Adolescents with Polycystic Ovary Syndrome,pmid:16200842,10.1515/jpem.2005.18.8.761
4.0,4.4,853,111.0,"Elbandrawy, A. M.; Yousef, A. M.; Morgan, E. N.; Ewais, N. F.; Eid, M. M.; Elkholi, S. M.; Abdelbasset, W.K. Effect of aerobic exercise on inflammatory markers in polycystic ovary syndrome: a randomized controlled trial European review for medical and pharmacological sciences 2022 ",primary_citation,,Elbandrawy,2022,"Elbandrawy et al., 2022",10.26355/eurrev_202205_28845,,,,,Effect of aerobic exercise on inflammatory markers in polycystic ovary syndrome: a randomized controlled trial.,pmid:35647831,10.26355/eurrev_202205_28845
4.0,4.4,854,111.0,"Tiwari, Nisha; Pasrija, Shikha; Jain, Sandhya Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome European Journal of Obstetrics & Gynecology & Reproductive Biology 2019 ",primary_citation,,Tiwari,2019,"Tiwari et al., 2019",10.1016/j.ejogrb.2018.12.021,,,,,Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome,pmid:30690191,10.1016/j.ejogrb.2018.12.021
4.0,4.4,855,111.0,"Tang T, Glanville J, Hayden CJ, et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Human Reproduc. 2006 ROB included in last TR) ",primary_citation,,Tang T,2006,"Tang T et al., 2006",10.1097/01.ogx.0000197800.07214.dc,,,,,"Combined Lifestyle Modification and Metformin in Obese Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-controlled, Double-blind Multicentre Study",,10.1097/01.ogx.0000197800.07214.dc
4.0,4.4,856,111.0,"Ladson, W.C. Dodson, S.D. Sweet, A.E. Archibong, A.R. Kunselman, L.M. Demers, N.I. Williams, P. Coney, R.S. Legro, The effects of metformin with lifestyle therapy in polycystic ovary syndrome: A randomized double-blind study. Fertil. Steril. 2011",primary_citation,,Ladson,2011,"Ladson et al., 2011",10.1016/j.fertnstert.2010.12.002,,,,,The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study,pmid:21193187,10.1016/j.fertnstert.2010.12.002
4.0,4.4,857,111.0,"Pasquali R, Gambineri A, Biscotti D et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. The journal of clin endocrinol & metabolism. 2000. ",primary_citation,,Pasquali R,2000,"Pasquali R et al., 2000",10.1210/jcem.85.8.6738,,,,,"Effect of Long-Term Treatment with Metformin Added to Hypocaloric Diet on Body Composition, Fat Distribution, and Androgen and Insulin Levels in Abdominally Obese Women with and without the Polycystic Ovary Syndrome",pmid:10946879,10.1210/jcem.85.8.6738
4.0,4.4,858,111.0,"Alpanes, Macarena; Alvarez-Blasco, Francisco; Fernandez-Duran, Elena; Luque-Ramirez, Manuel; Escobar-Morreale, Hector F. Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. European journal of endocrinology 2017 ",primary_citation,,Alpanes,2017,"Alpanes et al., 2017",10.1530/eje-17-0516,,,,,Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial,pmid:28912358,10.1530/eje-17-0516
4.0,4.4,859,111.0,"Ibáñez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. The Journal of clinical endocrinology and metabolism. 2004;89(4):1592-7.",primary_citation,,Ibáñez L,2004,"Ibáñez L et al., 2004",10.1210/jc.2003-031281,,,,,"Ethinylestradiol-Drospirenone, Flutamide-Metformin, or Both for Adolescents and Women with Hyperinsulinemic Hyperandrogenism: Opposite Effects on Adipocytokines and Body Adiposity",pmid:15070917,10.1210/jc.2003-031281
4.0,4.4,860,111.0,"Ibáñez L, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. The Journal of clinical endocrinology and metabolism. 2005;90(1):39-43.",primary_citation,,Ibáñez L,2005,"Ibáñez L et al., 2005",10.1210/jc.2004-1405,,,,,Flutamide-Metformin plus Ethinylestradiol-Drospirenone for Lipolysis and Antiatherogenesis in Young Women with Ovarian Hyperandrogenism: The Key Role of Metformin at the Start and after More than One Year of Therapy,pmid:15483105,10.1210/jc.2004-1405
4.0,4.4,861,111.0,"Burchall, Genia F.; Piva, Terrence J.; Ranasinha, Sanjeeva; Teede, Helena J. Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS Thrombosis and haemostasis 2017 ",primary_citation,,Burchall,2017,"Burchall et al., 2017",10.1160/th17-04-0248,,,,,Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS,pmid:29202210,10.1160/th17-04-0248
4.0,4.4,862,111.0,"Kebapcilar, L., Taner, C. E., Kebapcilar, A. G., Alacacioglu, A. and Sari, I. 2010 Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Archives of Gynecology & Obstetrics. (excluded from previous report – randomization not described)",primary_citation,,Kebapcilar,2010,"Kebapcilar et al., 2010",10.1007/s00404-009-1051-y,,,,,"Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome",pmid:19330342,10.1007/s00404-009-1051-y
4.0,4.4,863,111.0,"de Zegher, Francis; Diaz, Marta; Villarroya, Joan; Cairo, Montserrat; Lopez-Bermejo, Abel; Villarroya, Francesc; Ibanez, Lourdes. The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat, Scientific reports 2021",primary_citation,,de Zegher,2021,"de Zegher et al., 2021",10.1038/s41598-021-86317-9,,,,,The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat,pmid:33782413,10.1038/s41598-021-86317-9
4.0,4.4,864,111.0,"Ibáñez, Lourdes; Díaz, Marta; García-Beltrán, Cristina; Malpique, Rita; Garde, Edurne; López-Bermejo, Abel; Zegher, Francis de. Toward a Treatment Normalizing Ovulation Rate in Adolescent Girls With Polycystic Ovary Syndrome Journal of the Endocrine Society 2020",primary_citation,,Ibáñez,2020,"Ibáñez et al., 2020",10.1210/jendso/bvaa032,,,,,Toward a Treatment Normalizing Ovulation Rate in Adolescent Girls With Polycystic Ovary Syndrome,pmid:32342022,10.1210/jendso/bvaa032
4.0,4.4,865,111.0,"Díaz, Marta; Gallego-Escuredo, José Miguel; López-Bermejo, Abel; de Zegher, Francis; Villarroya, Francesc; Ibáñez, Lourdes Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome, International Journal of Endocrinology 2018 ",primary_citation,,Díaz,2018,"Díaz et al., 2018",10.1155/2018/4192940,,,,,Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome,pmid:30123261,10.1155/2018/4192940
4.0,4.4,866,111.0,"Ibáñez, Lourdes; del Río, Luis; Díaz, Marta; Sebastiani, Giorgia; Pozo, Óscar J.; López-Bermejo, Abel; de Zegher, Francis. Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome. Journal of adolescent health 2017",primary_citation,,Ibáñez,2017,"Ibáñez et al., 2017",10.1016/j.jadohealth.2017.04.010,,,,,Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome,pmid:28712591,10.1016/j.jadohealth.2017.04.010
4.0,4.4,867,111.0,"Malpique, R.; Sanchez-Infantes, D.; Garcia-Beltran, C.; Taxeras, S. D.; Lopez-Bermejo, A.; de Zegher, F.; Ibanez, L. Towards a circulating marker of hepato-visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome - Evidence from randomized clinical trial. Pediatric obesity 2019 ",primary_citation,,Malpique,2019,"Malpique et al., 2019",10.1111/ijpo.12500,,,,,Towards a circulating marker of hepato‐visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome — Evidence from randomized clinical trials,pmid:30653851,10.1111/ijpo.12500
4.0,4.4,868,111.0,"Dorgham, Nevine; Sharobim, Amin; Haggag, Hisham; El-Kalioby, Mona; Dorgham, Dina. Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients. Journal of drugs in dermatology: JDD 2021",primary_citation,,Dorgham,2021,"Dorgham et al., 2021",10.36849/jdd.5652,33683076.0,,,,Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients,pmid:33683076,
4.0,4.4,869,111.0,"Ruan, Xiangyan; Song, Jinghua; Gu, Muqing; Wang, Lijuan; Wang, Husheng; Mueck, Alfred O. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology & Obstetrics 2018 ",primary_citation,,Ruan,2018,"Ruan et al., 2018",10.1007/s00404-018-4762-0,,,,,"Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients",pmid:29602978,10.1007/s00404-018-4762-0
4.0,4.4,870,111.0,"Song, Jinghua; Ruan, Xiangyan; Gu, Muqing; Wang, Lijuan; Wang, Husheng; Mueck, Alfred Otto. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology 2018",primary_citation,,Song,2018,"Song et al., 2018",10.1080/09513590.2017.1407752,,,,,Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance,pmid:29172796,10.1080/09513590.2017.1407752
4.0,4.4,871,111.0,"Long, Tao; Zhang, Ying; Zeng, Chunping; Zheng, Siyuan; Zhou, Lin; Liu, Haiyan. Effects of Low-Dose Spironolactone Combined with Metformin or Either Drug Alone on Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Pilot Study. International Journal of Endocrinology 2022 ",primary_citation,,Long,2022,"Long et al., 2022",10.1155/2022/9927240,,,,,Effects of Low-Dose Spironolactone Combined with Metformin or Either Drug Alone on Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Pilot Study,pmid:35345424,10.1155/2022/9927240
4.0,4.4,872,111.0,"Gambineri, A., Pelusi, C., Genghini, S., Morselli‐Labate, A. M., Cacciari, M., Pagotto, U. and Pasquali, R. 2004 Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clinical Endocrinology 2004.",primary_citation,,Gambineri,2004,"Gambineri et al., 2004",10.1111/j.1365-2265.2004.01973.x,,,,,Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome,pmid:14725687,10.1111/j.1365-2265.2004.01973.x
4.0,4.4,873,111.0,"Amiri, M., et al., Effect of metformin and flutamide on anthropometric indices and laboratory tests in obese/overweight PCOS women under hypocaloric diet. Journal of Reproduction and Infertility, 2014. 15(4): p. 205‐13. ",primary_citation,,Amiri,2014,"Amiri et al., 2014",,25473629.0,W2141923412,2675980.0,,Effect of Metformin and Flutamide on Anthropometric Indices and Laboratory Tests in Obese/Overweight PCOS Women under Hypocaloric Diet.,pmid:25473629,
4.0,4.4,874,111.0,"Gambineri, A., et al., Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight‐obese women with polycystic ovary syndrome: a randomized, 12‐month, placebo‐controlled study. Journal of Clinical Endocrinology & Metabolism, 2006. 91(10): p. 3970‐80.",primary_citation,,Gambineri,2006,"Gambineri et al., 2006",10.1210/jc.2005-2250,,,,,"Treatment with Flutamide, Metformin, and Their Combination Added to a Hypocaloric Diet in Overweight-Obese Women with Polycystic Ovary Syndrome: A Randomized, 12-Month, Placebo-Controlled Study",pmid:16868063,10.1210/jc.2005-2250
4.0,4.4,875,111.0,"Ganie, M.A., et al., Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open‐labeled study. The Journal of clinical endocrinology and metabolism, 2004. 89(6): p. 2756‐62. ",primary_citation,,Ganie,2004,"Ganie et al., 2004",10.1210/jc.2003-031780,,,,,Comparison of Efficacy of Spironolactone with Metformin in the Management of Polycystic Ovary Syndrome: An Open-Labeled Study,pmid:15181054,10.1210/jc.2003-031780
4.0,4.4,876,111.0,"Ganie, M.A., et al., Improved efficacy of low‐dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six‐month, open‐label randomized study. Journal of Clinical Endocrinology & Metabolism, 2013. 98(9): p. 3599‐607. ",primary_citation,,Ganie,2013,"Ganie et al., 2013",10.1210/jc.2013-1040,,,,,"Improved Efficacy of Low-Dose Spironolactone and Metformin Combination Than Either Drug Alone in the Management of Women With Polycystic Ovary Syndrome (PCOS): A Six-Month, Open-Label Randomized Study",pmid:23846820,10.1210/jc.2013-1040
4.0,4.4,877,111.0,"Mazza, A., et al., In PCOS patients the addition of low‐dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutrition Metabolism & Cardiovascular Diseases, 2014. 24(2): p. 132‐9. ",primary_citation,,Mazza,2014,"Mazza et al., 2014",10.1016/j.numecd.2013.04.016,,,,,In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone,pmid:23845740,10.1016/j.numecd.2013.04.016
4.0,4.4,878,111.0,"Diri, H.; Bayram, F.; Simsek, Y.; Caliskan, Z.; Kocer, D. Comparison of Finasteride, Metformin, and Finasteride Plus Metformin in Pcos. Acta Endocrinol (Buchar) Jan-Mar 2017;13(1):84-89",primary_citation,,Diri,2017,"Diri et al., 2017",10.4183/aeb.2017.84,,,,,"Comparison of Finasteride, Metformin, and Finasteride Plus Metformin in PCOS",pmid:31149153,10.4183/aeb.2017.84
4.0,4.4,879,111.0,"Prabhakar, Priyanka; Mahey, Reeta; Gupta, Monica; Khadgawat, Rajesh; Kachhawa, Garima; Sharma, Jai Bhagwan; Vanamail, Perumal; Kumari, Rajesh; Bhatla, Neerja. Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology 2021",primary_citation,,Prabhakar,2021,"Prabhakar et al., 2021",10.1080/09513590.2020.1810657,,,,,Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial,pmid:32945218,10.1080/09513590.2020.1810657
4.0,4.4,880,111.0,"Jensterle M, Kravos N, Goricar K, Janez J. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS : randomized trial. BMC Endocrine Disorders 17:5, 2017. ",primary_citation,,Jensterle M,2017,"Jensterle M et al., 2017",10.1186/s12902-017-0155-9,,,,,Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial,pmid:28143456,10.1186/s12902-017-0155-9
4.0,4.4,881,111.0,"Cai, Meili; Shao, Xiaowen; Xing, Feng; Zhang, Yuqin; Gao, Xinyu; Zeng, Qiongjing; Dilimulati, Diliqingna; Qu, Shen; Zhang, Manna. Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial. Diabetes, obesity & metabolism 2022",primary_citation,,Cai,2022,"Cai et al., 2022",10.1111/dom.14583,,,,,"Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open‐label, noninferiority trial",pmid:34726324,10.1111/dom.14583
4.0,4.4,882,111.0,"Elkind-Hirsch, Karen E.; Paterson, Martha S.; Seidemann, Ericka L.; Gutowski, Hanh C. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study, Fertility & Sterility 2017",primary_citation,,Elkind-Hirsch,2017,"Elkind-Hirsch et al., 2017",10.1016/j.fertnstert.2016.09.023,,,,,"Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study",pmid:28228317,10.1016/j.fertnstert.2016.09.023
4.0,4.4,883,111.0,"Javed, Z.; Papageorgiou, M.; Deshmukh, H.; Rigby, A. S.; Qamar, U.; Abbas, J.; Khan, A. Y.; Kilpatrick, E. S.; Atkin, S. L.; Sathyapalan, T. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clinical endocrinology 2019 ",primary_citation,,Javed,2019,"Javed et al., 2019",10.1111/cen.13968,,,,,Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study,pmid:30866088,10.1111/cen.13968
4.0,4.4,884,111.0,"Li, Y.; Tan, J.; Wang, Q.; Duan, C.; Hu, Y.; Huang, W. Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertility and sterility 2020 ",primary_citation,,Li,2020,"Li et al., 2020",10.1016/j.fertnstert.2019.09.011,,,,,Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial,pmid:31718828,10.1016/j.fertnstert.2019.09.011
4.0,4.4,885,111.0,"Cetinkalp, S., Karadeniz, M., Erdogan, M., Ozgen, G., Saygl, F. and Ylmaz, C. 2009 The effects of rosiglitazone, metformin, and estradiol‐cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist. 2009 ",primary_citation,,Cetinkalp,2009,"Cetinkalp et al., 2009",10.1097/ten.0b013e3181a58772,,,,,"The Effects of Rosiglitazone, Metformin, and Estradiol-Cyproterone Acetate on Lean Patients With Polycystic Ovary Syndrome",,10.1097/ten.0b013e3181a58772
4.0,4.4,886,111.0,"Sangeeta, S. 2012 Metformin and pioglitazone in polycystic ovarian syndrome: A comparative study. Journal of Obstetrics and Gynecology of India.",primary_citation,,Sangeeta,2012,"Sangeeta et al., 2012",10.1007/s13224-012-0183-3,,,,,Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study,pmid:24082557,10.1007/s13224-012-0183-3
4.0,4.4,887,111.0,"Mohiyiddeen L, Watson AJ, Apostolopoulos NV, Berry R, Alexandraki KI, Jude EB. Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome. J Obstet Gynaecol. 2013 ",primary_citation,,Mohiyiddeen L,2013,"Mohiyiddeen L et al., 2013",10.3109/01443615.2012.745839,,,,,"Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome",pmid:23445141,10.3109/01443615.2012.745839
4.0,4.4,888,111.0,"Naka KK, Kalantaridou SN, Kravariti M, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril. 2011",primary_citation,,Naka KK,2011,"Naka KK et al., 2011",10.1016/j.fertnstert.2010.06.058,,,,,Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study,pmid:20684955,10.1016/j.fertnstert.2010.06.058
4.0,4.4,889,111.0,"Ortega-González C, Luna S, Hernández L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005",primary_citation,,Ortega-González C,2005,"Ortega-González C et al., 2005",10.1210/jc.2004-1965,,,,,"Responses of Serum Androgen and Insulin Resistance to Metformin and Pioglitazone in Obese, Insulin-Resistant Women with Polycystic Ovary Syndrome",pmid:15598674,10.1210/jc.2004-1965
4.0,4.4,890,111.0,"Shahebrahimi K, Jalilian N, Bazgir N, Rezaei M. Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome. Indian J Endocrinol Metab. 2016 ",primary_citation,,Shahebrahimi K,2016,"Shahebrahimi K et al., 2016",10.4103/2230-8210.192925,,,,,Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome,pmid:27867884,10.4103/2230-8210.192925
4.0,4.4,891,111.0,"Sohrevardi SM, Nosouhi F, Hossein Khalilzade S, et al. Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: an RCT. Int J Reprod Biomed. 2016 (added from SR)",primary_citation,,Sohrevardi SM,2016,"Sohrevardi SM et al., 2016",10.29252/ijrm.14.12.743,,,,,Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT,pmid:28331909,10.29252/ijrm.14.12.743
4.0,4.4,892,111.0,"Ahmad J, Shukla N, Khan AR, Ahmed F, Siddiqui MA. Comparisonof metabolic effects of metformin and rosiglitazone in the man-agement of polycystic ovary syndrome (PCOS): A prospective,parallel, randomized, open‐label study.Diabetes  Metab  Syndr:  ClinRes Rev. 2008 ",primary_citation,,Ahmad J,2008,"Ahmad J et al., 2008",10.1016/j.dsx.2007.12.003,,,,,"Comparison of metabolic effects of metformin and rosiglitazone in the management of polycystic ovary syndrome (PCOS): A prospective, parallel, randomized, open-label study",,10.1016/j.dsx.2007.12.003
4.0,4.4,893,111.0,"Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL. Effect of metformin, orlistat and pioglitazone treatment on mean insulinresistance and its biological variability in polycystic ovary syn-drome.Clin Endocrinol. 2009",primary_citation,,Cho LW,2009,"Cho LW et al., 2009",10.1111/j.1365-2265.2008.03309.x,,,,,"Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome",pmid:18547343,10.1111/j.1365-2265.2008.03309.x
4.0,4.4,894,111.0,"Jensterle (1) M, Janez A, Mlinar B, Marc J, Prezelj J, Pfeifer M. Impact of metformin and rosiglitazone treatment on glucose transporter 4mRNA expression in women with polycystic ovary syndrome. EurJ Endocrinol. 2008 ",primary_citation,,Jensterle (1) M,2008,"Jensterle (1) M et al., 2008",10.1530/eje-07-0857,,,,,Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome.,pmid:18322300,10.1530/eje-07-0857
4.0,4.4,895,111.0,"Jensterle (2) M, Sebestjen M, Janez A, et al. Improvement of endothelial function with metformin and rosiglitazone treatment inwomen with polycystic ovary syndrome. Eur  J  Endocrinol. 2008 ",primary_citation,,Jensterle (2) M,2008,"Jensterle (2) M et al., 2008",10.1530/eje-08-0507,,,,,Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome,pmid:18653546,10.1530/eje-08-0507
4.0,4.4,896,111.0,"Kilicdag EB, Bagis T, Zeyneloglu HB, et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod. 2005",primary_citation,,Kilicdag EB,2005,"Kilicdag EB et al., 2005",10.1093/humrep/deh700,,,,,Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study,pmid:15618250,10.1093/humrep/deh700
4.0,4.4,897,111.0,"Steiner CA, Janez A, Jensterle M, Reisinger K, Forst T, Pfützner A. Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2007",primary_citation,,Steiner CA,2007,"Steiner CA et al., 2007",10.1177/193229680700100212,,,,,Impact of Treatment with Rosiglitazone or Metformin on Biomarkers for Insulin Resistance and Metabolic Syndrome in Patients with Polycystic Ovary Syndrome,pmid:19888409,10.1177/193229680700100212
4.0,4.5,898,17.0,"Elkind-Hirsch, K. E., Chappell, N., Seidemann, E., Storment, J., & Bellanger, D. (2021). Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. The Journal of clinical endocrinology and metabolism, 106(10), 3019-3033. doi:https://dx.doi.org/10.1210/clinem/dgab408
",primary_citation,,Elkind-Hirsch,2021,"Elkind-Hirsch et al., 2021",10.1210/clinem/dgab408,,,,,"Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome",pmid:34097062,10.1210/clinem/dgab408
4.0,4.5,899,17.0,"Elkind-Hirsch, K. E., Chappell, N., Shaler, D., Storment, J., & Bellanger, D. (2022). Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertility and Sterility(evf, 0372772). doi:https://dx.doi.org/10.1016/j.fertnstert.2022.04.027",primary_citation,,Elkind-Hirsch,2022,"Elkind-Hirsch et al., 2022",10.1016/j.fertnstert.2022.04.027,,,,,"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study",pmid:35710599,10.1016/j.fertnstert.2022.04.027
4.0,4.5,900,17.0,"Gu, M., Ruan, X., Li, Y., Li, T., Yin, C., & Mueck, A. O. (2022). Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 38(7), 598-602. doi:https://dx.doi.org/10.1080/09513590.2022.2078805",primary_citation,,Gu,2022,"Gu et al., 2022",10.1080/09513590.2022.2078805,,,,,Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat,pmid:35616272,10.1080/09513590.2022.2078805
4.0,4.5,901,17.0,"Jensterle, M., Ferjan, S., Vovk, A., Battelino, T., Rizzo, M., & Janez, A. (2021). Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study. Diabetes Research and Clinical Practice, 178(ebi, 8508335), 108935. doi:https://dx.doi.org/10.1016/j.diabres.2021.108935",primary_citation,,Jensterle,2021,"Jensterle et al., 2021",10.1016/j.diabres.2021.108935,,,,,"Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study",pmid:34217774,10.1016/j.diabres.2021.108935
4.0,4.5,902,17.0,"Ma, R.-L., Deng, Y., Wang, Y.-F., Zhu, S.-Y., Ding, X.-S., & Sun, A.-J. (2021). Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. Chinese Medical Journal, 134(23), 2882-2889. doi:https://dx.doi.org/10.1097/CM9.0000000000001712",primary_citation,,Ma,2021,"Ma et al., 2021",10.1097/cm9.0000000000001712,,,,,Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome,pmid:34732660,10.1097/cm9.0000000000001712
4.0,4.5,903,17.0,"Moini, A., Kanani, M., Kashani, L., Hosseini, R., & Hosseini, L. (2015). Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome: a randomized double-blind placebo-controlled trial. Endocrine, 49(1), 286-289. doi:https://dx.doi.org/10.1007/s12020-014-0426-4",primary_citation,,Moini,2015,"Moini et al., 2015",10.1007/s12020-014-0426-4,,,,,"Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome: a randomized double-blind placebo-controlled trial",pmid:25294011,10.1007/s12020-014-0426-4
4.0,4.5,904,17.0,"Tao, T., Zhang, Y., Zhu, Y.-C., Fu, J.-R., Wang, Y.-Y., Cai, J., . . . Liu, W. (2021). Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. The Journal of clinical endocrinology and metabolism, 106(3), e1420-e1432. doi:https://dx.doi.org/10.1210/clinem/dgaa692",primary_citation,,Tao,2021,"Tao et al., 2021",10.1210/clinem/dgaa692,,,,,"Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study",pmid:32995892,10.1210/clinem/dgaa692
4.0,4.5,905,17.0,"Liu, X., Zhang, Y., Zheng, S.-Y., Lin, R., Xie, Y.-J., Chen, H., . . . Gong, Y. (2017). Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clinical Endocrinology, 87(6), 767-774. doi:https://dx.doi.org/10.1111/cen.13454 (primary citation)",primary_citation,,Liu,2017,"Liu et al., 2017",10.1111/cen.13454,,,,,"Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome",pmid:28834553,10.1111/cen.13454
4.0,4.5,906,17.0,"Li, R., Mai, T., Zheng, S., & Zhang, Y. (2022). Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. Archives of Gynecology and Obstetrics(6ys, 8710213). doi:https://dx.doi.org/10.1007/s00404-022-06700-3",samestudy_905,,Li,2022,"Li et al., 2022",10.1007/s00404-022-06700-3,,,,,Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT,pmid:35829765,10.1007/s00404-022-06700-3
4.0,4.5,907,17.0,"Nylander, M., Frossing, S., Kistorp, C., Faber, J., & Skouby, S. O. (2017). Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. Endocrine connections, 6(2), 89-99. doi:https://dx.doi.org/10.1530/EC-16-0113 (primary citation)",primary_citation,,Nylander,2017,"Nylander et al., 2017",10.1530/ec-16-0113,,,,,"Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential",pmid:28119323,10.1530/ec-16-0113
4.0,4.5,908,17.0,"Nylander, M., Frossing, S., Clausen, H. V., Kistorp, C., Faber, J., & Skouby, S. O. (2017). Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reproductive Biomedicine Online, 35(1), 121-127. doi:https://dx.doi.org/10.1016/j.rbmo.2017.03.023",samestudy_907,,Nylander,2017,"Nylander et al., 2017",10.1016/j.rbmo.2017.03.023,,,,,Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial,pmid:28479118,10.1016/j.rbmo.2017.03.023
4.0,4.5,909,17.0,"Frossing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., . . . Faber, J. (2018). Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes, Obesity & Metabolism, 20(1), 215-218. doi:https://dx.doi.org/10.1111/dom.13053",samestudy_907,,Frossing,2018,"Frossing et al., 2018",10.1111/dom.13053,,,,,Effect of liraglutide on ectopic fat in polycystic ovary syndrome: <scp>A</scp> randomized clinical trial,pmid:28681988,10.1111/dom.13053
4.0,4.5,910,17.0,"Frossing, S., Nylander, M., Kistorp, C., Skouby, S. O., & Faber, J. (2018). Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. Endocrine connections, 7(1), 115-123. doi:https://dx.doi.org/10.1530/EC-17-0327",samestudy_907,,Frossing,2018,"Frossing et al., 2018",10.1530/ec-17-0327,,,,,"Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS",pmid:29295870,10.1530/ec-17-0327
4.0,4.5,911,17.0,"Song, J., Ruan, X., Gu, M., Wang, L., Wang, H., & Mueck, A. O. (2018). Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 34(5), 413-417. doi:https://dx.doi.org/10.1080/09513590.2017.1407752 (primary citation)",primary_citation,,Song,2018,"Song et al., 2018",10.1080/09513590.2017.1407752,,,,,Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance,pmid:29172796,10.1080/09513590.2017.1407752
4.0,4.5,912,17.0,"Ruan, X., Song, J., Gu, M., Wang, L., Wang, H., & Mueck, A. O. (2018). Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of Gynecology and Obstetrics, 297(6), 1557-1563. doi:https://dx.doi.org/10.1007/s00404-018-4762-0",samestudy_911,,Ruan,2018,"Ruan et al., 2018",10.1007/s00404-018-4762-0,,,,,"Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients",pmid:29602978,10.1007/s00404-018-4762-0
4.0,4.5,913,17.0,"Zheng, S., Zhang, Y., Long, T., Lu, J., Liu, X., Yan, J., . . . Wang, F. (2017). Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women. Obesity Medicine, 7, 15-20. doi:https://doi.org/10.1016/j.obmed.2017.06.003 (primary citation)",primary_citation,,Zheng,2017,"Zheng et al., 2017",10.1016/j.obmed.2017.06.003,,,,,"Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women",,10.1016/j.obmed.2017.06.003
4.0,4.5,914,17.0,"Zheng, S., Liu, E., Zhang, Y., Long, T., Liu, X., Gong, Y., . . . Wang, F. (2019). Circulating zinc-alpha2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment. Endocrine Journal, 66(6), 555-562. doi:https://dx.doi.org/10.1507/endocrj.EJ18-0153",samestudy_913,,Zheng,2019,"Zheng et al., 2019",10.1507/endocrj.ej18-0153,,,,,"Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment",pmid:30918134,10.1507/endocrj.ej18-0153
4.0,4.6,915,26.0,"Alpañés M, Álvarez-Blasco F, Fernández-Durán E, Luque-Ramírez M, Escobar-Morreale HF. Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. European journal of endocrinology / European Federation of Endocrine Societies 2017;177(5):399-408. doi: 10.1530/EJE-17-0516.",primary_citation,,Alpañés M,2017,"Alpañés M et al., 2017",10.1530/eje-17-0516,,,,,Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial,pmid:28912358,10.1530/eje-17-0516
4.0,4.6,916,26.0,"Amiri M, Golsorkhtabaramiri M, Esmaeilzadeh S, Ghofrani F, Bijani A, Ghorbani L, Delavar MA. Effect of Metformin and Flutamide on Anthropometric Indices and Laboratory Tests in Obese/Overweight PCOS Women under Hypocaloric Diet. J Reprod Infertil 2014;15(4):205-13.",primary_citation,,Amiri M,2014,"Amiri M et al., 2014",,25473629.0,W2141923412,2675980.0,,Effect of Metformin and Flutamide on Anthropometric Indices and Laboratory Tests in Obese/Overweight PCOS Women under Hypocaloric Diet.,pmid:25473629,
4.0,4.6,917,26.0,"Burchall GF, Piva TJ, Ranasinha S, Teede HJ. Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS. Thromb Haemost 2017;117(11):2053-62. doi: 10.1160/TH17-04-0248.",primary_citation,,Burchall GF,2017,"Burchall GF et al., 2017",10.1160/th17-04-0248,,,,,Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS,pmid:29202210,10.1160/th17-04-0248
4.0,4.6,918,26.0,"de Zegher F, Diaz M, Villarroya J, Cairo M, Lopez-Bermejo A, Villarroya F, Ibanez L. The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat. Sci Rep 2021;11(1):7018. doi: 10.1038/s41598-021-86317-9.",primary_citation,,de Zegher F,2021,"de Zegher F et al., 2021",10.1038/s41598-021-86317-9,,,,,The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat,pmid:33782413,10.1038/s41598-021-86317-9
4.0,4.6,919,26.0,"Diaz M, Gallego-Escuredo JM, Lopez-Bermejo A, de Zegher F, Villarroya F, Ibanez L. Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome. Int J Endocrinol 2018;2018:4192940. doi: 10.1155/2018/4192940.",primary_citation,,Diaz M,2018,"Diaz M et al., 2018",10.1155/2018/4192940,,,,,Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome,pmid:30123261,10.1155/2018/4192940
4.0,4.6,920,26.0,"Falsetti L, De Fusco D, Eleftheriou G, Rosina B. Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. Gynecol Endocrinol 1997;11(4):251-7. doi: 10.3109/09513599709152542.",primary_citation,,Falsetti L,1997,"Falsetti L et al., 1997",10.3109/09513599709152542,,,,,Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome,pmid:9272421,10.3109/09513599709152542
4.0,4.6,921,26.0,"Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999;141(4):361-7. doi: 10.1530/eje.0.1410361.",primary_citation,,Falsetti L,1999,"Falsetti L et al., 1999",10.1530/eje.0.1410361,,,,,RETRACTED: Comparison of finasteride versus flutamide in the treatment of hirsutism,pmid:10526249,10.1530/eje.0.1410361
4.0,4.6,922,26.0,"Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U, Pasquali R. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006;91(10):3970-80. doi: 10.1210/jc.2005-2250.",primary_citation,,Gambineri A,2006,"Gambineri A et al., 2006",10.1210/jc.2005-2250,,,,,"Treatment with Flutamide, Metformin, and Their Combination Added to a Hypocaloric Diet in Overweight-Obese Women with Polycystic Ovary Syndrome: A Randomized, 12-Month, Placebo-Controlled Study",pmid:16868063,10.1210/jc.2005-2250
4.0,4.6,923,26.0,"Gambineri, A.; Pelusi, C.; Genghini, S.; Morselli-Labate, A.M.; Cacciari, M.; Pagotto, U.; Pasquali, R. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004, 60, 241-249, doi:10.1111/j.1365-2265.2004.01973.x.",primary_citation,,Gambineri,2004,"Gambineri et al., 2004",10.1111/j.1365-2265.2004.01973.x,,,,,Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome,pmid:14725687,10.1111/j.1365-2265.2004.01973.x
4.0,4.6,924,26.0,"Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60(2):241-9. doi: 10.1111/j.1365-2265.2004.01973.x",primary_citation,,Gambineri A,2004,"Gambineri A et al., 2004",10.1111/j.1365-2265.2004.01973.x,,,,,Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome,pmid:14725687,10.1111/j.1365-2265.2004.01973.x
4.0,4.6,925,26.0,"Ganie MA, Khurana ML, Eunice M, Gupta N, Gulati M, Dwivedi SN, Ammini AC. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab 2004;89(6):2756-62. doi: 10.1210/jc.2003-031780.",primary_citation,,Ganie MA,2004,"Ganie MA et al., 2004",10.1210/jc.2003-031780,,,,,Comparison of Efficacy of Spironolactone with Metformin in the Management of Polycystic Ovary Syndrome: An Open-Labeled Study,pmid:15181054,10.1210/jc.2003-031780
4.0,4.6,926,26.0,"Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, Gupta N, Zargar MA, Wani TA, Mudasir S, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab 2013;98(9):3599-607. doi: 10.1210/jc.2013-1040.",primary_citation,,Ganie MA,2013,"Ganie MA et al., 2013",10.1210/jc.2013-1040,,,,,"Improved Efficacy of Low-Dose Spironolactone and Metformin Combination Than Either Drug Alone in the Management of Women With Polycystic Ovary Syndrome (PCOS): A Six-Month, Open-Label Randomized Study",pmid:23846820,10.1210/jc.2013-1040
4.0,4.6,927,26.0,"Hagag P, Steinschneider M, Weiss M. Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome. J Reprod Med 2014;59(9-10):455-63.",primary_citation,,Hagag P,2014,"Hagag P et al., 2014",,25330687.0,W214894366,22317157.0,,Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome.,pmid:25330687,
4.0,4.6,928,26.0,"Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004;89(4):1592-7. doi: 10.1210/jc.2003-031281.",primary_citation,,Ibanez L,2004,"Ibanez L et al., 2004",10.1210/jc.2003-031281,,,,,"Ethinylestradiol-Drospirenone, Flutamide-Metformin, or Both for Adolescents and Women with Hyperinsulinemic Hyperandrogenism: Opposite Effects on Adipocytokines and Body Adiposity",pmid:15070917,10.1210/jc.2003-031281
4.0,4.6,929,26.0,"Ibáñez L, del Río L, Díaz M, Sebastiani G, Pozo ÓJ, López-Bermejo A, de Zegher F. Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome. J Adolesc Health 2017;61(4):446-53. doi: 10.1016/j.jadohealth.2017.04.010.",primary_citation,,Ibáñez L,2017,"Ibáñez L et al., 2017",10.1016/j.jadohealth.2017.04.010,,,,,Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome,pmid:28712591,10.1016/j.jadohealth.2017.04.010
4.0,4.6,930,26.0,"Ibanez L, Diaz M, Garcia-Beltran C, Malpique R, Garde E, Lopez-Bermejo A, de Zegher F. Toward a Treatment Normalizing Ovulation Rate in Adolescent Girls With Polycystic Ovary Syndrome. J Endocr Soc 2020;4(5):bvaa032. doi: 10.1210/jendso/bvaa032.",primary_citation,,Ibanez L,2020,"Ibanez L et al., 2020",10.1210/jendso/bvaa032,,,,,Toward a Treatment Normalizing Ovulation Rate in Adolescent Girls With Polycystic Ovary Syndrome,pmid:32342022,10.1210/jendso/bvaa032
4.0,4.6,931,26.0,"Malpique R, Sanchez-Infantes D, Garcia-Beltran C, Taxeras SD, Lopez-Bermejo A, de Zegher F, Ibanez L. Towards a circulating marker of hepato-visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome - Evidence from randomized clinical trials. Pediatr Obes 2019;14(5):e12500. doi: 10.1111/ijpo.12500.",primary_citation,,Malpique R,2019,"Malpique R et al., 2019",10.1111/ijpo.12500,,,,,Towards a circulating marker of hepato‐visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome — Evidence from randomized clinical trials,pmid:30653851,10.1111/ijpo.12500
4.0,4.6,932,26.0,"Mazza A, Fruci B, Guzzi P, D'Orrico B, Malaguarnera R, Veltri P, Fava A, Belfiore A. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutr Metab Cardiovasc Dis 2014;24(2):132-9. doi: 10.1016/j.numecd.2013.04.016.",primary_citation,,Mazza A,2014,"Mazza A et al., 2014",10.1016/j.numecd.2013.04.016,,,,,In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone,pmid:23845740,10.1016/j.numecd.2013.04.016
4.0,4.6,933,26.0,"Mehrabian F, Ghasemi-Tehrani H, Mohamadkhani M, Moeinoddini M, Karimzadeh P. Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome. J Res Med Sci 2016;21:7. doi: 10.4103/1735-1995.177354.",primary_citation,,Mehrabian F,2016,"Mehrabian F et al., 2016",10.4103/1735-1995.177354,,,,,"Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin on the metabolic consequences of polycystic ovary syndrome",pmid:27904553,10.4103/1735-1995.177354
4.0,4.6,934,26.0,"Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007;30(3):471-8. doi: 10.2337/dc06-0618.",primary_citation,,Meyer C,2007,"Meyer C et al., 2007",10.2337/dc06-0618,,,,,Effects of Medical Therapy on Insulin Resistance and the Cardiovascular System in Polycystic Ovary Syndrome,pmid:17327307,10.2337/dc06-0618
4.0,4.6,935,26.0,"Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, Motta C, De Leo V, Petraglia F, Lenzi A. Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial. J Clin Endocrinol Metab 2018;103(3):824-38. doi: 10.1210/jc.2017-01186.",primary_citation,,Moretti C,2018,"Moretti C et al., 2018",10.1210/jc.2017-01186,,,,,Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial,pmid:29211888,10.1210/jc.2017-01186
4.0,4.6,936,26.0,"Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf) 2000;52(5):587-94. doi: 10.1046/j.1365-2265.2000.00982.x.",primary_citation,,Spritzer PM,2000,"Spritzer PM et al., 2000",10.1046/j.1365-2265.2000.00982.x,,,,,Spironolactone as a single agent for long‐term therapy of hirsute patients,pmid:10792338,10.1046/j.1365-2265.2000.00982.x
4.0,4.6,937,26.0,"Tartagni M, Schonauer LM, De Salvia MA, Cicinelli E, De Pergola G, D'Addario V. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 2000;73(4):718-23. doi: 10.1016/s0015-0282(99)00633-0.",primary_citation,,Tartagni M,2000,"Tartagni M et al., 2000",10.1016/s0015-0282(99)00633-0,,,,,Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism,pmid:10731531,10.1016/s0015-0282(99)00633-0
4.0,4.6,938,26.0,"Tartagni MV, Alrasheed H, Damiani GR, Montagnani M, De Salvia MA, De Pergola G, Tartagni M, Loverro G. Intermittent low-dose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study. J Pediatr Adolesc Gynecol 2014;27(3):161-5. doi: 10.1016/j.jpag.2013.09.010.",primary_citation,,Tartagni MV,2014,"Tartagni MV et al., 2014",10.1016/j.jpag.2013.09.010,,,,,Intermittent Low-Dose Finasteride Administration Is Effective for Treatment of Hirsutism in Adolescent Girls: A Pilot Study,pmid:24559619,10.1016/j.jpag.2013.09.010
4.0,4.6,939,26.0,"Tartagni M, Schonauer MM, Cicinelli E, Petruzzelli F, De Pergola G, De Salvia MA, Loverro G. Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. Fertil Steril 2004;82(3):752-5. doi: 10.1016/j.fertnstert.2004.02.118.",primary_citation,,Tartagni M,2004,"Tartagni M et al., 2004",10.1016/j.fertnstert.2004.02.118,,,,,Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women,pmid:15374729,10.1016/j.fertnstert.2004.02.118
4.0,4.6,940,26.0,"Vieira CS, Martins WP, Fernandes JB, Soares GM, dos Reis RM, de Sa MF, Ferriani RA. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception 2012;86(3):268-75. doi: 10.1016/j.contraception.2011.12.011.",primary_citation,,Vieira CS,2012,"Vieira CS et al., 2012",10.1016/j.contraception.2011.12.011,,,,,"The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome",pmid:22464410,10.1016/j.contraception.2011.12.011
4.0,4.7,941,29.0,"Akbari Sene, Azadeh, Azam Tabatabaie, Hossein Nikniaz, Ahad Alizadeh, Kourosh Sheibani, Mona Mortezapour Alisaraie, Maryam Tabatabaie, Mahnaz Ashrafi, and Fatemehsadat Amjadi. 2019. “The Myo-Inositol Effect on the Oocyte Quality and Fertilization Rate among Women with Polycystic Ovary Syndrome Undergoing Assisted Reproductive Technology Cycles: A Randomized Clinical Trial.” Archives of Gynecology & Obstetrics 299 (6): 1701–7. https://doi.org/10.1007/s00404-019-05111-1.
",primary_citation,,Akbari Sene,2019,"Akbari Sene et al., 2019",10.1007/s00404-019-05111-1,,,,,The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial,pmid:30919036,10.1007/s00404-019-05111-1
4.0,4.7,942,29.0,"Angik, Riju, Shubhada S. Jajoo, C. Hariharan, and Amogh Chimote. 2017. “A Comparative Study of Metabolic and Hormonal Effects of Myoinositol vs. Metformin in Women with Polycystic Ovary Syndrome: A Randomised Controlled Trial.” International Journal of Reproduction, Contraception, Obstetrics and Gynecology; Vol 4, No 1 (2015): January-February 2015. https://www.ijrcog.org/index.php/ijrcog/article/view/1838/1588.
",primary_citation,,Angik,2017,"Angik et al., 2017",10.5455/2320-1770.ijrcog20150234,,,,,A COMPARATIVE STUDY OF METABOLIC AND HORMONAL EFFECTS OF MYOINOSITOL VS METFORMIN IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A RANDOMISED CONTROLLED TRIAL,,10.5455/2320-1770.ijrcog20150234
4.0,4.7,943,29.0,"Artini, P.G., O.M. Di Berardino, F. Papini, A.D. Genazzani, G. Simi, M. Ruggiero, and V. Cela. 2013. “Endocrine and Clinical Effects of Myo-Inositol Administration in Polycystic Ovary Syndrome. A Randomized Study.” Gynecological Endocrinology 29 (4): 375–79. https://doi.org/10.3109/09513590.2012.743020.
",primary_citation,,Artini,2013,"Artini et al., 2013",10.3109/09513590.2012.743020,,,,,Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study,pmid:23336594,10.3109/09513590.2012.743020
4.0,4.7,944,29.0,"Bahadur, Anupama, Hitanshi Arora, Anoosha K Ravi, Manisha Naithani, Yogesh Bahurupi, Jaya Chaturvedi, Megha Ajmani, and Rajlaxmi Mundhra. 2021. “Comparison of Clinical, Metabolic and Hormonal Effects of Metformin Versus Combined Therapy of Metformin With Myoinositol Plus D-Chiro-Inositol in Women With Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial.” Cureus 13 (6): e15510. https://doi.org/10.7759/cureus.15510.
",primary_citation,,Bahadur,2021,"Bahadur et al., 2021",10.7759/cureus.15510,,,,,"Comparison of Clinical, Metabolic and Hormonal Effects of Metformin Versus Combined Therapy of Metformin With Myoinositol Plus D-Chiro-Inositol in Women With Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial",pmid:34268040,10.7759/cureus.15510
4.0,4.7,945,29.0,"Benelli, E., S. Del Ghianda, C. Di Cosmo, and M. Tonacchera. 2016. “A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women.” International Journal of Endocrinology 2016 ((Benelli E., elena684@interfree.it; Del Ghianda S., scilladg@hotmail.it; Di Cosmo C., katiadicosmo@yahoo.it; Tonacchera M., mtonacchera@hotmail.com) Department of Clinical and Experimental Medicine, Section of Endocrinology, University Hospital of Pisa, V). https://doi.org/10.1155/2016/3204083.
",primary_citation,,Benelli,2016,"Benelli et al., 2016",10.1155/2016/3204083,,,,,A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women,pmid:27493664,10.1155/2016/3204083
4.0,4.7,946,29.0,"Chirania, Kishan, Sujata Misra, and Sandhya Behera. 2017. “A Randomised Clinical Trial Comparing Myoinositol and Metformin in PCOS.” International Journal of Reproduction, Contraception, Obstetrics and Gynecology; Vol 6, No 5 (2017): May 2017DO  - 10.18203/2320-1770.Ijrcog20171563. https://www.ijrcog.org/index.php/ijrcog/article/view/2671.
",primary_citation,,Chirania,2017,"Chirania et al., 2017",10.18203/2320-1770.ijrcog20171563,,,,,A randomised clinical trial comparing myoinositol and metformin in PCOS,,10.18203/2320-1770.ijrcog20171563
4.0,4.7,947,29.0,"Constantino, D., G. Minozzi, F. Minozzi, and C. Guaraldi. 2009. “Metabolic and Hormonal Effects of Myo-Inositol in Women with Polycystic Ovary Syndrome: A Double-Blind Trial.” European Review for Medical and Pharmacological Sciences 13 (2): 105–10.",primary_citation,,Constantino,2009,"Constantino et al., 2009",,19499845.0,W2171177397,8423446.0,,Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.,pmid:19499845,
4.0,4.7,948,29.0,"Donà, G., C. Sabbadin, C. Fiore, M. Bragadin, F.L. Giorgino, E. Ragazzi, G. Clari, L. Bordin, and D. Armanini. 2012. “Inositol Administration Reduces Oxidative Stress in Erythrocytes of Patients with Polycystic Ovary Syndrome.” European Journal of Endocrinology 166 (4): 703–10. https://doi.org/10.1530/EJE-11-0840.
",primary_citation,,Donà,2012,"Donà et al., 2012",10.1530/eje-11-0840,,,,,Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome,pmid:22223702,10.1530/eje-11-0840
4.0,4.7,949,29.0,"Donne, M.L.E., D. Metro, A. Alibrandi, M. Papa, and S. Benvenga. 2019. “Effects of Three Treatment Modalities (Diet, Myoinositol or Myoinositol Associated with D-Chiro-Inositol) on Clinical and Body Composition Outcomes in Women with Polycystic Ovary Syndrome.” European Review for Medical and Pharmacological Sciences 23 (5): 2293–2301. https://doi.org/10.26355/eurrev_201903_17278.
",primary_citation,,Donne,2019,"Donne et al., 2019",10.26355/eurrev_201903_17278,,,,,"Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome.",pmid:30915778,10.26355/eurrev_201903_17278
4.0,4.7,950,29.0,"Emekçi Özay, Ö., A.C. Özay, E. Çağlıyan, R.E. Okyay, and B. Gülekli. 2017. “Myo-Inositol Administration Positively Effects Ovulation Induction and Intrauterine Insemination in Patients with Polycystic Ovary Syndrome: A Prospective, Controlled, Randomized Trial.” Gynecological Endocrinology 33 (7): 524–28. https://doi.org/10.1080/09513590.2017.1296127.
",primary_citation,,Emekçi Özay,2017,"Emekçi Özay et al., 2017",10.1080/09513590.2017.1296127,,,,,"Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial",pmid:28277112,10.1080/09513590.2017.1296127
4.0,4.7,951,29.0,"Genazzani, A.D., C. Lanzoni, F. Ricchieri, and V.M. Jasonni. 2008. “Myo-Inositol Administration Positively Affects Hyperinsulinemia and Hormonal Parameters in Overweight Patients with Polycystic Ovary Syndrome.” Gynecological Endocrinology 24 (3): 139–44. https://doi.org/10.1080/09513590801893232.
",primary_citation,,Genazzani,2008,"Genazzani et al., 2008",10.1080/09513590801893232,,,,,Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome,pmid:18335328,10.1080/09513590801893232
4.0,4.7,952,29.0,"Iuorno, M.J., D.J. Jakubowicz, J.-P. Baillargeon, P. Dillon, R.D. Gunn, G. Allan, and J.E. Nestler. 2002. “Effects of D-Chiro-Inositol in Lean Women with the Polycystic Ovary Syndrome.” Endocrine Practice 8 (6): 417–23. https://doi.org/10.4158/ep.8.6.417.
",primary_citation,,Iuorno,2002,"Iuorno et al., 2002",10.4158/ep.8.6.417,,,,,Effects of D-Chiro-Inositol in Lean Women with the Polycystic Ovary Syndrome,pmid:15251831,10.4158/ep.8.6.417
4.0,4.7,953,29.0,"Khan, R.B., M. Sarosh, and S. Anwer. 2022. “Role of Myo-Inositol and D-Chiro-Inositol in Improvement of Endocrine and Clinical Parameters in Teenage Girls Affected by PCOS: A Prospective Cohort Study.” Pakistan Journal of Medical and Health Sciences 16 (1): 21–24. https://doi.org/10.53350/pjmhs2216121.
",primary_citation,,Khan,2022,"Khan et al., 2022",10.53350/pjmhs2216121,,,,,Role of Myo-inositol and D-Chiro-Inositol in Improvement of Endocrine and Clinical Parameters in Girls affected by PCOS,,10.53350/pjmhs2216121
4.0,4.7,954,29.0,"Maria Concetta Musacchio, Vincenzo De Leo. 2013. “A Combined Treatment with Myo-Inositol and Monacolin K Improve the Androgen and Lipid Profiles of Insulin-Resistant PCOS Patients.” J Metabolic Synd 02 (02). https://doi.org/10.4172/2167-0943.1000127.",primary_citation,,Maria Concetta Musacchio,2013,"Maria Concetta Musacchio et al., 2013",10.4172/2167-0943.1000127,,,,,A Combined Treatment with Myo-Inositol and Monacolin K Improve the Androgen and Lipid Profiles of Insulin-Resistant PCOS Patients,,10.4172/2167-0943.1000127
4.0,4.7,955,29.0,"Mendoza, N., M.P. Diaz-Ropero, M. Aragon, V. Maldonado, P. Llaneza, J. Lorente, R. Mendoza-Tesarik, J. Maldonado-Lobon, M. Olivares, and J. Fonolla. 2019. “Comparison of the Effect of Two Combinations of Myo-Inositol and D-Chiro-Inositol in Women with Polycystic Ovary Syndrome Undergoing ICSI: A Randomized Controlled Trial.” Gynecological Endocrinology 35 (8): 695–700. https://doi.org/10.1080/09513590.2019.1576620.",primary_citation,,Mendoza,2019,"Mendoza et al., 2019",10.1080/09513590.2019.1576620,,,,,Comparison of the effect of two combinations of myo-inositol and <scp>D</scp>-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial,pmid:30880505,10.1080/09513590.2019.1576620
4.0,4.7,956,29.0,"Nehra, J., J. Kaushal, S.R. Singhal, and V.S. Ghalaut. 2017a. “A Comparative Study of Myo Inositol versus Metformin on Biochemical Profile in Polycystic Ovarian Syndrome in Women.” International Journal of Pharmaceutical Sciences and Research 8 (4): 1664–70. https://doi.org/10.13040/IJPSR.0975-8232.8(4).1664-70. (primary citation)",primary_citation,,Nehra,2017a,"Nehra et al., 2017a",10.13040/ijpsr.0975-8232.8(4).1664-70,,,,,,,10.13040/ijpsr.0975-8232.8(4).1664-70
4.0,4.7,957,29.0,"Nehra, J., J. Kaushal, S.R. Singhal, and V.S. Ghalaut., 2017b. “Comparision of Myo-Inositol versus Metformin on Anthropometric Parameters in Polycystic Ovarian Syndrome in Women.” International Journal of Pharmacy and Pharmaceutical Sciences 9 (4): 144–48. https://doi.org/10.22159/ijpps.2017v9i4.16359.",samestudy_956,,Nehra,2017b,"Nehra et al., 2017b",10.22159/ijpps.2017v9i4.16359,,,,,COMPARISION OF MYO-INOSITOL VERSUS METFORMIN ON ANTHROPOMETRIC PARAMETERS IN POLYCYSTIC OVARIAN SYNDROME IN WOMEN,,10.22159/ijpps.2017v9i4.16359
4.0,4.7,958,29.0,"Nestler, J.E., D.J. Jakubowicz, P. Reamer, R.D. Gunn, and G. Allan. 1999. “Ovulatory and Metabolic Effects of D-Chiro-Inositol in the Polycystic Ovary Syndrome.” New England Journal of Medicine 340 (17): 1314–20. https://doi.org/10.1056/NEJM199904293401703.
",primary_citation,,Nestler,1999,"Nestler et al., 1999",10.1056/nejm199904293401703,,,,,Ovulatory and Metabolic Effects of d-<i>Chiro</i>-Inositol in the Polycystic Ovary Syndrome,pmid:10219066,10.1056/nejm199904293401703
4.0,4.7,959,29.0,"Nordio, M., S. Basciani, and E. Camajani. 2019. “The 40:1 Myo-Inositol/D-Chiro-Inositol Plasma Ratio Is Able to Restore Ovulation in PCOS Patients: Comparison with Other Ratios.” European Review for Medical and Pharmacological Sciences 23 (12): 5512–21. https://doi.org/10.26355/eurrev_201906_18223.",primary_citation,,Nordio,2019,"Nordio et al., 2019",10.26355/eurrev_201906_18223,,,,,The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.,pmid:31298405,10.26355/eurrev_201906_18223
4.0,4.7,960,29.0,"Nordio, M., and E. Proietti. 2012. “The Combined Therapy with Myo-Inositol and D-Chiro-Inositol Reduces the Risk of Metabolic Disease in PCOS Overweight Patients Compared to Myo-Inositol Supplementation Alone.” European Review for Medical and Pharmacological Sciences 16 (5): 575–81.",primary_citation,,Nordio,2012,"Nordio et al., 2012",,22774396.0,W2148920675,6082173.0,,The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.,pmid:22774396,
4.0,4.7,961,29.0,"Pacchiarotti, A., G. Carlomagno, and G. Antonini. 2016. “Effect of Myo-Inositol and Melatonin versus Myo-Inositol, in a Randomized Controlled Trial, for Improving in Vitro Fertilization of Patients with Polycystic Ovarian Syndrome.” Gynecological Endocrinology 32 (1): 69–73. https://doi.org/10.3109/09513590.2015.1101444.",primary_citation,,Pacchiarotti,2016,"Pacchiarotti et al., 2016",10.3109/09513590.2015.1101444,,,,,"Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving<i>in vitro</i>fertilization of patients with polycystic ovarian syndrome",pmid:26507336,10.3109/09513590.2015.1101444
4.0,4.7,962,29.0,"Papaleo, E., V. Unfer, J.-P. Baillargeon, F. Fusi, F. Occhi, and L. De Santis. 2009. “Myo-Inositol May Improve Oocyte Quality in Intracytoplasmic Sperm Injection Cycles. A Prospective, Controlled, Randomized Trial.” Fertility and Sterility 91 (5): 1750–54. https://doi.org/10.1016/j.fertnstert.2008.01.088.",primary_citation,,Papaleo,2009,"Papaleo et al., 2009",10.1016/j.fertnstert.2008.01.088,,,,,"Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial",pmid:18462730,10.1016/j.fertnstert.2008.01.088
4.0,4.7,963,29.0,"Pourghasem, Sajadeh, Fatemeh Bazarganipour, Seyed Abdolvahab Taghavi, and Maryam Azizi Kutenaee. 2019. “The Effectiveness of Inositol and Metformin on Infertile Polycystic Ovary Syndrome Women with Resistant to Letrozole.” Archives of Gynecology & Obstetrics 299 (4): 1193–99. https://doi.org/10.1007/s00404-019-05064-5.",primary_citation,,Pourghasem,2019,"Pourghasem et al., 2019",10.1007/s00404-019-05064-5,,,,,The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole,pmid:30847561,10.1007/s00404-019-05064-5
4.0,4.7,964,29.0,"Rajasekaran, K., N. Malhotra, R. Mahey, R. Khadgawat, and M. Kalaivani. 2022. “Myoinositol versus Metformin Pretreatment in GnRH-Antagonist Cycle for Women with PCOS Undergoing IVF: A Double-Blinded Randomized Controlled Study.” Gynecological Endocrinology 38 (2): 140–47. https://doi.org/10.1080/09513590.2021.1981282.",primary_citation,,Rajasekaran,2022,"Rajasekaran et al., 2022",10.1080/09513590.2021.1981282,,,,,Myoinositol <i>versus</i> metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study,pmid:34590929,10.1080/09513590.2021.1981282
4.0,4.7,965,29.0,"Tagliaferri, V., D. Romualdi, V. Immediata, S. De Cicco, C. Di Florio, A. Lanzone, and M. Guido. 2017. “Metformin vs Myoinositol: Which Is Better in Obese Polycystic Ovary Syndrome Patients? A Randomized Controlled Crossover Study.” Clinical Endocrinology 86 (5): 725–30. https://doi.org/10.1111/cen.13304.",primary_citation,,Tagliaferri,2017,"Tagliaferri et al., 2017",10.1111/cen.13304,,,,,Metformin <i>vs</i> myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study,pmid:28092404,10.1111/cen.13304
4.0,4.7,966,29.0,"Unfer, V., G. Carlomagno, P. Rizzo, E. Raffone, and S. Roseff. 2011. “Myo-Inositol Rather than D-Chiro-Inositol Is Able to Improve Oocyte Quality in Intracytoplasmic Sperm Injection Cycles. A Prospective, Controlled, Randomized Trial.” European Review for Medical and Pharmacological Sciences 15 (4): 452–57.",primary_citation,,Unfer,2011,"Unfer et al., 2011",,21608442.0,W2323967404,37981732.0,,"Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.",pmid:21608442,
4.0,4.7,967,29.0,"F. Fruzzetti, D. Perini, M. Russo, F. Bucci, and A. Gadducci, “Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).,” Gynecol Endocrinol, vol. 33, no. 1, pp. 39–42, 2017, doi: 10.1080/09513590.2016.1236078.",primary_citation,,F. Fruzzetti,2017,"F. Fruzzetti et al., 2017",10.1080/09513590.2016.1236078,,,,,"Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS)",pmid:27808588,10.1080/09513590.2016.1236078
4.0,4.7,968,29.0,"E. Raffone, P. Rizzo, and V. Benedetto, “Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women.,” Gynecol Endocrinol, vol. 26, no. 4, pp. 275–80, 2010, doi: 10.3109/09513590903366996.",primary_citation,,E. Raffone,2010,"E. Raffone et al., 2010",10.3109/09513590903366996,,,,,Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women,pmid:20222840,10.3109/09513590903366996
4.0,4.7,969,29.0,"V. Soldat-Stankovic et al., “The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.,” J Endocrinol Invest, vol. 45, no. 3, pp. 583–595, 2022, doi: 10.1007/s40618-021-01691-5.",primary_citation,,V. Soldat-Stankovic et al.,2022,"V. Soldat-Stankovic et al. et al., 2022",10.1007/s40618-021-01691-5,,,,,The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial,pmid:34665453,10.1007/s40618-021-01691-5
4.0,4.7,970,29.0,"Ravn P, Gram F, Andersen MS, Glintborg D. Myoinositol vs. Metformin in Women with Polycystic Ovary Syndrome: A Randomized Controlled Clinical Trial. Metabolites. 2022; 12(12):1183. DOI:10.3390/metabo12121183",primary_citation,,Ravn P,2022,"Ravn P et al., 2022",10.3390/metabo12121183,,,,,Myoinositol vs. Metformin in Women with Polycystic Ovary Syndrome: A Randomized Controlled Clinical Trial,pmid:36557221,10.3390/metabo12121183
4.0,4.8,971,8.0,"Clayton, W. J.; Lipton, M.; Elford, J.; Rustin, M.; Sherr, L. (2005). A randomised controlled trial of laser treatment among hirsute women with polycystic ovary syndrome.  British ournal of Dermatology, 2005;152(5):986-992. Doi: 10.1111/j.1365-2133.2005.06426.x",primary_citation,,Clayton,2005,"Clayton et al., 2005",10.1111/j.1365-2133.2005.06426.x,,,,,A randomized controlled trial of laser treatment among hirsute women with polycystic ovary syndrome,pmid:15888157,10.1111/j.1365-2133.2005.06426.x
4.0,4.8,972,8.0,"Dorgham, N.; Sharobim, A.; Haggag, H.; El-Kalioby, M.; Dorgham, D. (2021). Adding combined oral contraceptives or metformin to l aser treatment in polycystic ovarian syndrome hirsute patients.  Journal of drugs in dermatology: JDD 2021;20(3)302-306. Doi: 10.36849/JDD.2021.5652",primary_citation,,Dorgham,2021,"Dorgham et al., 2021",,,,,,,,
4.0,4.8,973,8.0,"Karn, D.; K C, S.; Timalsina, M.; Gyawali, P. (2014). Hormonal profile and efficacy of long pulse Nd-YAG laser in treatment of hirsutism. Journal of Nepal Health Research Council, 2014; 12(26):59-62. Doi: 10.33314/jnhrc.v0i0.440 ",primary_citation,,Karn,2014,"Karn et al., 2014",,25574987.0,,,,Hormonal profile and efficacy of long pulse Nd-YAG laser in treatment of hirsutism.,pmid:25574987,
4.0,4.8,974,8.0,"McGill, D. J.; Hutchison, C.; McKenzie, E.; McSherry, E.; Mackay, I. R.(2007). A randomised, split-face comparison of facial hair removal with the alexandrite laser and intense pulsed light system. Lasers in surgery and medicine 2007;39(10):767-772. Doi: 10.1002/lsm.20584 ",primary_citation,,McGill,2007,"McGill et al., 2007",10.1002/lsm.20584,,,,,"A randomised, split‐face comparison of facial hair removal with the alexandrite laser and intense pulsed light system",pmid:18081147,10.1002/lsm.20584
4.0,4.8,975,8.0,"McGill, D. J.; Hutchison, C.; McKenzie, E.; McSherry, E.; Mackay, I. R. (2007). Laser hair removal in women with poilycystic ovary syndrome. Journal of plastic, reconstructive & aesthetic surgery: JPRAS 2007;60(4):426-31. doi :10.1016/j.bjps.2006.11.006 ",primary_citation,,McGill,2007,"McGill et al., 2007",10.1016/j.bjps.2006.11.006,,,,,Laser hair removal in women with polycystic ovary syndrome,pmid:17349600,10.1016/j.bjps.2006.11.006
4.0,4.8,976,8.0,"Nabi, N.; Bhat, Y. J.; Dar, U. K.; Hakeem, A.; Mir, S. A.; Shah, I. H.; Tilwani, M. R. (2022). Comparative study of the clinic-trichoscopic response to treatment of hirsutism with long pulsed (1064nm) Nd:YAG laser in idiopathic hirsutism and polycystic ovarian syndrome patients. Lasers in medical science 2022;37(1):545-553. Doi: 10.1007/s10103-021-03295-0 ",primary_citation,,Nabi,2022,"Nabi et al., 2022",10.1007/s10103-021-03295-0,,,,,Comparative study of the clinico-trichoscopic response to treatment of hirsutism with long pulsed (1064 nm) Nd:YAG laser in idiopathic hirsutism and polycystic ovarian syndrome patients,pmid:33768489,10.1007/s10103-021-03295-0
4.0,4.8,977,8.0,"Pai, G. S.; Bhat, P. S.; Mallya, H.; Gold, M. (2011) Safety and efficacy of low-fluence, high-repetition rate versus high-fluence, low-repetition rate 810-nm diode laser for permanent hair removal A split-face comparison study.  Journal of Cosmetic and Laser Therapy 2011;13(4):134-137. Doi: 10.3109/14764172.2011.594057 ",primary_citation,,Pai,2011,"Pai et al., 2011",10.3109/14764172.2011.594057,,,,,"Safety and efficacy of low-fluence, high-repetition rate versus high-fluence, low-repetition rate 810-nm diode laser for permanent hair removal – A split-face comparison study",pmid:21692640,10.3109/14764172.2011.594057
4.0,4.8,978,8.0,"Rezvanian, H.; Adibi, N.; Siavash, M.; Kachuei, A.; Shojaee-Moradie, F.; Asilian, A.)2—0_. Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. Dermatology 2009;218(3):231-236. Doi: 10.1159/000187718",primary_citation,,Rezvanian,2009,"Rezvanian et al., 2009",10.1159/000187718,,,,,Increased Insulin Sensitivity by Metformin Enhances Intense-Pulsed-Light-Assisted Hair Removal in Patients with Polycystic Ovary Syndrome,pmid:19092235,10.1159/000187718
4.0,4.9,979,10.0,"Abiad, F., Khalife, D., Safadi, B., Alami, R., Awwad, J., Khalifeh, F., & Ghazeeri, G. (2018). The effect of bariatric surgery on inflammatory markers in women with polycystic ovarian syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 12(6), 999-1005. 
https://dx.doi.org/10.1016/j.dsx.2018.06.013",primary_citation,,Abiad,2018,"Abiad et al., 2018",10.1016/j.dsx.2018.06.013,,,,,The effect of bariatric surgery on inflammatory markers in women with polycystic ovarian syndrome,pmid:30168430,10.1016/j.dsx.2018.06.013
4.0,4.9,980,10.0,"Ahmed, B., Ammori, B.J., Akhtar, K., Senapati, S., New, J.P., & Syed, A.A. (2022). Weight loss and metabolic outcomes in women with or without polycystic ovarian syndrome after Roux-en-Y gastric bypass: A case-matched study. The Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, 20(3), 137-141. 
https://dx.doi.org/10.1016/j.surge.2021.02.012	",primary_citation,,Ahmed,2022,"Ahmed et al., 2022",10.1016/j.surge.2021.02.012,,,,,Weight loss and metabolic outcomes in women with or without polycystic ovarian syndrome after Roux-en-Y gastric bypass: A case-matched study,pmid:33863670,10.1016/j.surge.2021.02.012
4.0,4.9,981,10.0,"Benito, E., Gomez-Martin, J.M., Vega-Pinero, B., Priego, P., Galindo, J., Escobar-Morreale, H.F., & Botella-Carretero, J.I. (2020). Fertility and pregnancy outcomes in women with polycystic ovary syndrome following bariatric surgery. Journal of Clinical Endocrinology and Metabolism, 105(9), E3384-E3391.
https://dx.doi.org/10.1210/clinem/dgaa439",primary_citation,,Benito,2020,"Benito et al., 2020",10.1210/clinem/dgaa439,,,,,Fertility and Pregnancy Outcomes in Women with Polycystic Ovary Syndrome Following Bariatric Surgery,pmid:32754732,10.1210/clinem/dgaa439
4.0,4.9,982,10.0,"Bhandari, S., Ganguly, I., Bhandari, M., Agarwal, P., Singh, A., Gupta, N., & Mishra, A. (2016). Effect of sleeve gastrectomy bariatric surgery-induced weight loss on serum AMH levels in reproductive aged women. Gynecological Endocrinology, 32(10), 799-802. 
https://dx.doi.org/10.3109/09513590.2016.1169267",primary_citation,,Bhandari,2016,"Bhandari et al., 2016",10.3109/09513590.2016.1169267,,,,,Effect of sleeve gastrectomy bariatric surgery-induced weight loss on serum AMH levels in reproductive aged women,pmid:27087540,10.3109/09513590.2016.1169267
4.0,4.9,983,10.0,"Buyukkaba, M., Turgut, S., Ilhan, M. M., Ekinci, I., Yayllm, I., Zeybek, S. U., Turan, S., Tasan, E., & Karaman, O. (2021). Anti-Mullerian Hormone Levels Increase after Bariatric Surgery in Obese Female Patients with and Without Polycystic Ovary Syndrome. Hormone and Metabolic Research, 54(3), 194-198.
https://dx.doi.org/10.1055/a-1756-4798 ",primary_citation,,Buyukkaba,2021,"Buyukkaba et al., 2021",10.1055/a-1756-4798,,,,,Anti-Mullerian Hormone Levels Increase After Bariatric Surgery in Obese Female Patients With and Without Polycystic Ovary Syndrome,pmid:35276745,10.1055/a-1756-4798
4.0,4.9,984,10.0,"Cai, M., Gao, J., Du, L., Cheng, X., Zhou, D., Zhu, J., Qu, S., & Zhang, M. (2021). The Changes in Body Composition in Obese Patients with Polycystic Ovary Syndrome After Laparoscopic Sleeve Gastrectomy: A 12-Month Follow-Up. Obesity Surgery, 31(9), 4055-4063. 
https://dx.doi.org/10.1007/s11695-021-05496-6",primary_citation,,Cai,2021,"Cai et al., 2021",10.1007/s11695-021-05496-6,,,,,The Changes in Body Composition in Obese Patients with Polycystic Ovary Syndrome after Laparoscopic Sleeve Gastrectomy:a 12-Month Follow-up,pmid:34152560,10.1007/s11695-021-05496-6
4.0,4.9,985,10.0,"Casals, G., Andreu, A., Barral, Y., Ventosa, S., Redondo, M., Torres, F., Ibarzabal, A., Manau, D., Carmona, F., Vidal, J., & Flores, L. (2021). Bariatric Surgery on Reproductive Outcomes: the Impact According to the Diagnosis of Polycystic Ovarian Syndrome and Surgical Procedures. Obesity Surgery, 31(6), 2590-2598.
https://dx.doi.org/10.1007/s11695-021-05297-x",primary_citation,,Casals,2021,"Casals et al., 2021",10.1007/s11695-021-05297-x,,,,,Bariatric Surgery on Reproductive Outcomes: the Impact According to the Diagnosis of Polycystic Ovarian Syndrome and Surgical Procedures,pmid:33629226,10.1007/s11695-021-05297-x
4.0,4.9,986,10.0,"Chiofalo, F., Ciuoli, C., Formichi, C., Selmi, F., Forleo, R., Neri, O., Vuolo, G., Paffetti, P., & Pacini, F. (2017). Bariatric Surgery Reduces Serum Anti-mullerian Hormone Levels in Obese Women with and Without Polycystic Ovarian Syndrome. Obesity Surgery, 27(7), 1750-1754. 
https://dx.doi.org/10.1007/s11695-016-2528-y",primary_citation,,Chiofalo,2017,"Chiofalo et al., 2017",10.1007/s11695-016-2528-y,,,,,Bariatric Surgery Reduces Serum Anti-mullerian Hormone Levels in Obese Women With and Without Polycystic Ovarian Syndrome.,pmid:28378209,10.1007/s11695-016-2528-y
4.0,4.9,987,10.0,"Hu, L., Ma, L., Xia, X., Ying, T., Zhou, M., Zou, S., Yu, H., & Yin, J. (2022). Efficacy of Bariatric Surgery in the Treatment of Women with Obesity and Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology and Metabolism, 107(8), e3217-e3229.
https://dx.doi.org/10.1210/clinem/dgac294",primary_citation,,Hu,2022,"Hu et al., 2022",10.1210/clinem/dgac294,,,,,Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome,pmid:35554540,10.1210/clinem/dgac294
4.0,4.9,988,10.0,"Tatarchuk T., Todurov I., Anagnostis P., Tutchenko T., Pedachenko N., Glamazda M., Koseii N., & Regeda S. (2022). The Effect of Gastric Sleeve Resection on Menstrual Pattern and Ovulation in Premenopausal Women with Classes III-IV Obesity. Obesity Surgery, 32(3), 599-606.
https://dx.doi.org/10.1007/s11695-021-05820-0",primary_citation,,Tatarchuk T.,2022,"Tatarchuk T. et al., 2022",10.1007/s11695-021-05820-0,,,,,The Effect of Gastric Sleeve Resection on Menstrual Pattern and Ovulation in Premenopausal Women with Classes III–IV Obesity,pmid:34817794,10.1007/s11695-021-05820-0
4.0,4.10.,989,109.0,"Diamant, Y. Z.; Rimon, E.; Evron, S. (1982): High incidence of preeclamptic toxemia in patients with polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 14, 3, 199-204, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med2&AN=7160531",primary_citation,prior search,Diamant,1982,"Diamant et al., 1982",10.1016/0028-2243(82)90097-1,,,,,High incidence of preeclamptic toxemia in patients with polycystic ovarian disease,pmid:7160531,10.1016/0028-2243(82)90097-1
4.0,4.10.,990,109.0,"Levran, D.; Shoham, Z.; Habib, D.; et al. (1990): Glucose tolerance in pregnant women following treatment for sterility. Int J Fertil 35, 3, 157-159, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1973920",primary_citation,prior search,Levran,1990,"Levran et al., 1990",,1973920.0,,36394716.0,,Glucose tolerance in pregnant women following treatment for sterility.,pmid:1973920,
4.0,4.10.,991,109.0,"Wortsman, J.; de Angeles, S.; Futterweit, W.; et al. (1991): Gestational diabetes and neonatal macrosomia in the polycystic ovary syndrome. J Reprod Med 36, 9, 659-661, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1774730",primary_citation,prior search,Wortsman,1991,"Wortsman et al., 1991",,1774730.0,,29898778.0,,Gestational diabetes and neonatal macrosomia in the polycystic ovary syndrome.,pmid:1774730,
4.0,4.10.,992,109.0,"Urman, B.; Fluker, M. R.; Yuen, B. H.; et al. (1992): The outcome of in vitro fertilization and embryo transfer in women with polycystic ovary syndrome failing to conceive after ovulation induction with exogenous gonadotropins. Fertil Steril 57, 6, 1269-1273, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=1601149",primary_citation,prior search,Urman,1992,"Urman et al., 1992",10.1016/s0015-0282(16)55086-9,,,,,The outcome of in vitro fertilization and embryo transfer in women with polycystic ovary syndrome failing to conceive after ovulation induction with exogenous gonadotropins,pmid:1601149,10.1016/s0015-0282(16)55086-9
4.0,4.10.,993,109.0,"Homburg, R.; Berkowitz, D.; Levy, T.; et al. (1993): In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertil Steril 60, 5, 858-863, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med3&AN=8224271",primary_citation,prior search,Homburg,1993,"Homburg et al., 1993",10.1016/s0015-0282(16)56287-6,,,,,In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome,pmid:8224271,10.1016/s0015-0282(16)56287-6
4.0,4.10.,994,109.0,"Lesser, K. B.; Garcia, F. A. (1997): Association between polycystic ovary syndrome and glucose intolerance during pregnancy. J Matern Fetal Med 6, 5, 303-307. https://dx.doi.org/10.1002/(SICI)1520-6661(199709/10)6:5<303::AID-MFM14>3.0.CO;2-L.",primary_citation,prior search,Lesser,1997,"Lesser et al., 1997",10.1002/(sici)1520-6661(199709/10)6:5<303::aid-mfm14>3.0.co;2-l,,,,,Association between polycystic ovary syndrome and glucose intolerance during pregnancy,pmid:9360193,10.1002/(sici)1520-6661(199709/10)6:5<303::aid-mfm14>3.0.co;2-l
4.0,4.10.,995,109.0,"Urman, B.; Sarac, E.; Dogan, L.; et al. (1997): Pregnancy in infertile PCOD patients. Complications and outcome. J Reprod Med 42, 8, 501-505, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=9284012",primary_citation,prior search,Urman,1997,"Urman et al., 1997",,9284012.0,,29040757.0,,Pregnancy in infertile PCOD patients. Complications and outcome.,pmid:9284012,
4.0,4.10.,996,109.0,"Fridstrom, M.; Nisell, H.; Sjoblom, P.; et al. (1999): Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia? Hypertens 18, 1, 73-80, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10464001",primary_citation,prior search,Fridstrom,1999,"Fridstrom et al., 1999",10.3109/10641959909009612,,,,,Are Women with Polycystic Ovary Syndrome at an Increased Risk of Pregnancy-Induced Hypertension and/or Preeclampsia?,pmid:10464001,10.3109/10641959909009612
4.0,4.10.,997,109.0,"Kashyap, S.; Claman, P. (2000): Polycystic ovary disease and the risk of pregnancy-induced hypertension. J Reprod Med 45, 12, 991-994, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11153260",primary_citation,prior search,Kashyap,2000,"Kashyap et al., 2000",,11153260.0,,2142285.0,,Polycystic ovary disease and the risk of pregnancy-induced hypertension.,pmid:11153260,
4.0,4.10.,998,109.0,"Vollenhoven, B.; Clark, S.; Kovacs, G.; et al. (2000): Prevalence of gestational diabetes mellitus in polycystic ovarian syndrome (PCOS) patients pregnant after ovulation induction with gonadotrophins. Australian & New Zealand Journal of Obstetrics & Gynaecology 40, 1, 54-58, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10870780",primary_citation,prior search,Vollenhoven,2000,"Vollenhoven et al., 2000",10.1111/j.1479-828x.2000.tb03167.x,,,,,Prevalence of gestational diabetes mellitus in polycystic ovarian syndrome (PCOS) patients pregnant after ovulation induction with gonadotrophins,pmid:10870780,10.1111/j.1479-828x.2000.tb03167.x
4.0,4.10.,999,109.0,"Mikola, M.; Hiilesmaa, V.; Halttunen, M.; et al. (2001): Obstetric outcome in women with polycystic ovarian syndrome. Human Reproduction 16, 2, 226-229, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11157811",primary_citation,prior search,Mikola,2001,"Mikola et al., 2001",10.1093/humrep/16.2.226,,,,,Obstetric outcome in women with polycystic ovarian syndrome,pmid:11157811,10.1093/humrep/16.2.226
4.0,4.10.,1000,109.0,"Wang, J. X.; Davies, M. J.; Norman, R. J. (2001): Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Human Reproduction 16, 12, 2606-2609, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=11726582",primary_citation,prior search,Wang,2001,"Wang et al., 2001",10.1093/humrep/16.12.2606,,,,,Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment,pmid:11726582,10.1093/humrep/16.12.2606
4.0,4.10.,1001,109.0,"Bjercke, S.; Dale, P. O.; Tanbo, T.; et al. (2002): Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 54, 2, 94-98. https://dx.doi.org/67719.",primary_citation,prior search,Bjercke,2002,"Bjercke et al., 2002",10.1159/000067719,,,,,Impact of Insulin Resistance on Pregnancy Complications and Outcome in Women with Polycystic Ovary Syndrome,pmid:12566751,10.1159/000067719
4.0,4.10.,1002,109.0,"Sir-Petermann, T.; Maliqueo, M.; Angel, B.; et al. (2002): Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Human Reproduction 17, 10, 2573-2579, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12351531",primary_citation,prior search,Sir-Petermann,2002,"Sir-Petermann et al., 2002",10.1093/humrep/17.10.2573,,,,,Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization,pmid:12351531,10.1093/humrep/17.10.2573
4.0,4.10.,1003,109.0,"Haakova, L.; Cibula, D.; Rezabek, K.; et al. (2003): Pregnancy outcome in women with PCOS and in controls matched by age and weight. Human Reproduction 18, 7, 1438-1441, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=12832369",primary_citation,prior search,Haakova,2003,"Haakova et al., 2003",10.1093/humrep/deg289,,,,,Pregnancy outcome in women with PCOS and in controls matched by age and weight,pmid:12832369,10.1093/humrep/deg289
4.0,4.10.,1004,109.0,"Turhan, N. O.; Seckin, N. C.; Aybar, F.; et al. (2003): Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients. Int J Gynaecol Obstet 81, 2, 163-168, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=12706273",primary_citation,prior search,Turhan,2003,"Turhan et al., 2003",10.1016/s0020-7292(03)00003-1,,,,,Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients,pmid:12706273,10.1016/s0020-7292(03)00003-1
4.0,4.10.,1005,109.0,"Glueck, C. J.; Goldenberg, N.; Pranikoff, J.; et al. (2004): Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Human Reproduction 19, 6, 1323-1330. https://dx.doi.org/10.1093/humrep/deh263.",primary_citation,prior search,Glueck,2004,"Glueck et al., 2004",10.1093/humrep/deh263,,,,,"Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy",pmid:15117896,10.1093/humrep/deh263
4.0,4.10.,1006,109.0,"Glueck, C. J.; Bornovali, S.; Pranikoff, J.; et al. (2004): Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med 21, 8, 829-836. https://dx.doi.org/10.1111/j.1464-5491.2004.01251.x.",primary_citation,prior search,Glueck,2004,"Glueck et al., 2004",10.1111/j.1464-5491.2004.01251.x,,,,,"Metformin, pre‐eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome",pmid:15270785,10.1111/j.1464-5491.2004.01251.x
4.0,4.10.,1007,109.0,"Weerakiet, S.; Srisombut, C.; Rojanasakul, A.; et al. (2004): Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome. Gynecological Endocrinology 19, 3, 134-140, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=15697074",primary_citation,prior search,Weerakiet,2004,"Weerakiet et al., 2004",10.1080/09513590400007242,,,,,Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome,pmid:15697074,10.1080/09513590400007242
4.0,4.10.,1008,109.0,"Sir-Petermann, T.; Hitchsfeld, C.; Maliqueo, M.; et al. (2005): Birth weight in offspring of mothers with polycystic ovarian syndrome. Human Reproduction 20, 8, 2122-2126. https://dx.doi.org/10.1093/humrep/dei009.",primary_citation,prior search,Sir-Petermann,2005,"Sir-Petermann et al., 2005",10.1093/humrep/dei009,,,,,Birth weight in offspring of mothers with polycystic ovarian syndrome,pmid:15802312,10.1093/humrep/dei009
4.0,4.10.,1009,109.0,"Al-Ojaimi, E. H. (2006): Pregnancy outcomes after laparoscopic ovarian drilling in women with polycystic ovarian syndrome. Saudi Medical Journal 27, 4, 519-525, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16598331",primary_citation,prior search,Al-Ojaimi,2006,"Al-Ojaimi et al., 2006",,16598331.0,,743872.0,,Pregnancy outcomes after laparoscopic ovarian drilling in women with polycystic ovarian syndrome.,pmid:16598331,
4.0,4.10.,1010,109.0,"Dokras, A.; Baredziak, L.; Blaine, J.; et al. (2006): Obstetric outcomes after in vitro fertilization in obese and morbidly obese women. Obstet Gynecol 108, 1, 61-69. https://dx.doi.org/10.1097/01.AOG.0000219768.08249.b6.",primary_citation,prior search,Dokras,2006,"Dokras et al., 2006",10.1097/01.aog.0000219768.08249.b6,,,,,Obstetric Outcomes After In Vitro Fertilization in Obese and Morbidly Obese Women,pmid:16816057,10.1097/01.aog.0000219768.08249.b6
4.0,4.10.,1011,109.0,"Kovo, M.; Weissman, A.; Gur, D.; et al. (2006): Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. J Matern Fetal Neonatal Med 19, 7, 415-419. https://dx.doi.org/10.1080/14767050600682370.",primary_citation,prior search,Kovo,2006,"Kovo et al., 2006",10.1080/14767050600682370,,,,,Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy,pmid:16923696,10.1080/14767050600682370
4.0,4.10.,1012,109.0,"Hu, S.; Leonard, A.; Seifalian, A.; et al. (2007): Vascular dysfunction during pregnancy in women with polycystic ovary syndrome. Human Reproduction 22, 6, 1532-1539. https://dx.doi.org/10.1093/humrep/dem028.",primary_citation,prior search,Hu,2007,"Hu et al., 2007",10.1093/humrep/dem028,,,,,Vascular dysfunction during pregnancy in women with polycystic ovary syndrome,pmid:17369295,10.1093/humrep/dem028
4.0,4.10.,1013,109.0,"Palep-Singh, M.; Picton, H. M.; Vrotsou, K.; et al. (2007): South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts. Eur J Obstet Gynecol Reprod Biol 134, 2, 202-207. https://dx.doi.org/10.1016/j.ejogrb.2007.02.005.",primary_citation,prior search,Palep-Singh,2007,"Palep-Singh et al., 2007",10.1016/j.ejogrb.2007.02.005,,,,,South Asian women with polycystic ovary syndrome exhibit greater sensitivity to gonadotropin stimulation with reduced fertilization and ongoing pregnancy rates than their Caucasian counterparts,pmid:17367914,10.1016/j.ejogrb.2007.02.005
4.0,4.10.,1014,109.0,"Sir-Petermann, T.; Echiburu, B.; Maliqueo, M. M.; et al. (2007): Serum adiponectin and lipid concentrations in pregnant women with polycystic ovary syndrome. Human Reproduction 22, 7, 1830-1836. https://dx.doi.org/10.1093/humrep/dem090.",primary_citation,prior search,Sir-Petermann,2007,"Sir-Petermann et al., 2007",10.1093/humrep/dem090,,,,,Serum adiponectin and lipid concentrations in pregnant women with polycystic ovary syndrome,pmid:17468256,10.1093/humrep/dem090
4.0,4.10.,1015,109.0,"Beydoun, H. A.; Stadtmauer, L.; Zhao, Y.; et al. (2009): Impact of polycystic ovary syndrome on selected indicators of in vitro fertilization and intracytoplasmic sperm injection treatment success. J Womens Health (Larchmt) 18, 5, 717-723. https://dx.doi.org/10.1089/jwh.2008.1149.",primary_citation,prior search,Beydoun,2009,"Beydoun et al., 2009",10.1089/jwh.2008.1149,,,,,Impact of Polycystic Ovary Syndrome on Selected Indicators of <i>In Vitro</i> Fertilization and Intracytoplasmic Sperm Injection Treatment Success,pmid:19368509,10.1089/jwh.2008.1149
4.0,4.10.,1016,109.0,"Gupta, A.; Raina, K.; Kalkkar, T.; et al. (2009): Pregnancy outcome in women with the polycystic ovarian syndrome. JK Science 11, 2, 82-84, http://www.jkscience.org/archive/vol112/8%20Original%20Article-Pregnancy%20Outcome%20-.pdf",primary_citation,prior search,Gupta,2009,"Gupta et al., 2009",,,W2408925727,59140811.0,Pregnancy outcome in women with the polycystic ovarian syndrome,Pregnancy Outcome In Women with the Polycystic Ovarian Syndrome,,
4.0,4.10.,1017,109.0,"Maliqueo, M.; Echiburu, B.; Crisosto, N.; et al. (2009): Metabolic parameters in cord blood of newborns of women with polycystic ovary syndrome. Fertil Steril 92, 1, 277-282. https://dx.doi.org/10.1016/j.fertnstert.2008.04.022.",primary_citation,prior search,Maliqueo,2009,"Maliqueo et al., 2009",10.1016/j.fertnstert.2008.04.022,,,,,Metabolic parameters in cord blood of newborns of women with polycystic ovary syndrome,pmid:18555232,10.1016/j.fertnstert.2008.04.022
4.0,4.10.,1018,109.0,"Falbo, A.; Rocca, M.; Russo, T.; et al. (2010): Changes in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): Relationships with adverse outcomes. Journal of Ovarian Research 3 (1) (no pagination), 23. http://dx.doi.org/10.1186/1757-2215-3-23.",primary_citation,prior search,Falbo,2010,"Falbo et al., 2010",10.1186/1757-2215-3-23,,,,,Changes in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes,pmid:20942923,10.1186/1757-2215-3-23
4.0,4.10.,1019,109.0,"Li, G.; Fan, L.; Zhang, L.; et al. (2010): Metabolic parameters and perinatal outcomes of gestational diabetes mellitus in women with polycystic ovary syndrome.[Erratum appears in J Perinat Med. 2010 May;38(3):343]. Journal of Perinatal Medicine 38, 2, 141-146. https://dx.doi.org/10.1515/JPM.2010.034.",primary_citation,prior search,Li,2010,"Li et al., 2010",10.1515/jpm.2010.034,,,,,Metabolic parameters and perinatal outcomes of gestational diabetes mellitus in women with polycystic ovary syndrome,pmid:20146658,10.1515/jpm.2010.034
4.0,4.10.,1020,109.0,"Palomba, S.; Falbo, A.; Russo, T.; et al. (2010): Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes. Fertil Steril 94, 5, 1805-1811. https://dx.doi.org/10.1016/j.fertnstert.2009.10.043.",primary_citation,prior search,Palomba,2010,"Palomba et al., 2010",10.1016/j.fertnstert.2009.10.043,,,,,Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes,pmid:20004377,10.1016/j.fertnstert.2009.10.043
4.0,4.10.,1021,109.0,"Palomba, S.; Falbo, A.; Russo, T.; et al. (2010): Uterine blood flow in pregnant patients with polycystic ovary syndrome: relationships with clinical outcomes. Bjog 117, 6, 711-721. https://dx.doi.org/10.1111/j.1471-0528.2010.02525.x.",primary_citation,prior search,Palomba,2010,"Palomba et al., 2010",10.1111/j.1471-0528.2010.02525.x,,,,,Uterine blood flow in pregnant patients with polycystic ovary syndrome: relationships with clinical outcomes,pmid:20236107,10.1111/j.1471-0528.2010.02525.x
4.0,4.10.,1022,109.0,"De Leo, V.; Musacchio, M. C.; Piomboni, P.; et al. (2011): The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol 157, 1, 63-66. https://dx.doi.org/10.1016/j.ejogrb.2011.03.024.",primary_citation,prior search,De Leo,2011,"De Leo et al., 2011",10.1016/j.ejogrb.2011.03.024,,,,,The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications,pmid:21530058,10.1016/j.ejogrb.2011.03.024
4.0,4.10.,1023,109.0,"Dmitrovic, R.; Katcher, H. I.; Kunselman, A. R.; et al. (2011): Continuous glucose monitoring during pregnancy in women with polycystic ovary syndrome. Obstet Gynecol 118, 4, 878-885. https://dx.doi.org/10.1097/AOG.0b013e31822c887f.",primary_citation,prior search,Dmitrovic,2011,"Dmitrovic et al., 2011",10.1097/aog.0b013e31822c887f,,,,,Continuous Glucose Monitoring During Pregnancy in Women With Polycystic Ovary Syndrome,pmid:21934452,10.1097/aog.0b013e31822c887f
4.0,4.10.,1024,109.0,"Nejad, E. S.; Saedi, T.; Saedi, S.; et al. (2011): Comparison of in vitro fertilisation success in patients with polycystic ovary syndrome and tubal factor. Gynecological Endocrinology 27, 2, 117-120. https://dx.doi.org/10.3109/09513590.2010.501872.",primary_citation,prior search,Nejad,2011,"Nejad et al., 2011",10.3109/09513590.2010.501872,,,,,Comparison of<i>in vitro</i>fertilisation success in patients with polycystic ovary syndrome and tubal factor,pmid:20636232,10.3109/09513590.2010.501872
4.0,4.10.,1025,109.0,"Nouh, A. A.; Shalaby, S. M. (2011): The predictive value of uterine blood flow in detecting the risk of adverse pregnancy outcome in patients with polycystic ovary syndrome. Middle East Fertility Society Journal 16, 4, 284-290. http://dx.doi.org/10.1016/j.mefs.2011.09.001.",primary_citation,prior search,Nouh,2011,"Nouh et al., 2011",10.1016/j.mefs.2011.09.001,,,,,The predictive value of uterine blood flow in detecting the risk of adverse pregnancy outcome in patients with polycystic ovary syndrome,,10.1016/j.mefs.2011.09.001
4.0,4.10.,1026,109.0,"Mehrabian, F.; Kelishadi, R. (2012): Comparison of the metabolic parameters and androgen level of umbilical cord blood in newborns of mothers with polycystic ovary syndrome and controls. Journal of Research in Medical Sciences 17, 3, 207-211, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=23267369",primary_citation,prior search,Mehrabian,2012,"Mehrabian et al., 2012",,,W1953483834,24648982.0,Comparison of the metabolic parameters and androgen level of umbilical cord blood in newborns of mothers with polycystic ovary syndrome and controls,Comparison of the metabolic parameters and androgen level of umbilical cord blood in newborns of mothers with polycystic ovary syndrome and controls.,pmid:23267369,
4.0,4.10.,1027,109.0,"Palomba, S.; Falbo, A.; Russo, T.; et al. (2012): The risk of a persistent glucose metabolism impairment after gestational diabetes mellitus is increased in patients with polycystic ovary syndrome. Diabetes Care 35, 4, 861-867. https://dx.doi.org/10.2337/dc11-1971.",primary_citation,prior search,Palomba,2012,"Palomba et al., 2012",10.2337/dc11-1971,,,,,The Risk of a Persistent Glucose Metabolism Impairment After Gestational Diabetes Mellitus Is Increased in Patients With Polycystic Ovary Syndrome,pmid:22338097,10.2337/dc11-1971
4.0,4.10.,1028,109.0,"Reyes-Munoz, E.; Castellanos-Barroso, G.; Ramirez-Eugenio, B. Y.; et al. (2012): The risk of gestational diabetes mellitus among Mexican women with a history of infertility and polycystic ovary syndrome. Fertil Steril 97, 6, 1467-1471. https://dx.doi.org/10.1016/j.fertnstert.2012.03.023.",primary_citation,prior search,Reyes-Munoz,2012,"Reyes-Munoz et al., 2012",10.1016/j.fertnstert.2012.03.023,,,,,The risk of gestational diabetes mellitus among Mexican women with a history of infertility and polycystic ovary syndrome,pmid:22503417,10.1016/j.fertnstert.2012.03.023
4.0,4.10.,1029,109.0,"Yamamoto, M.; Feigenbaum, S. L.; Crites, Y.; et al. (2012): Risk of preterm delivery in non-diabetic women with polycystic ovarian syndrome. Journal of Perinatology 32, 10, 770-776. https://dx.doi.org/10.1038/jp.2011.194.",primary_citation,prior search,Yamamoto,2012,"Yamamoto et al., 2012",10.1038/jp.2011.194,,,,,Risk of preterm delivery in non-diabetic women with polycystic ovarian syndrome,pmid:22261835,10.1038/jp.2011.194
4.0,4.10.,1030,109.0,"Boutzios, G.; Livadas, S.; Piperi, C.; et al. (2013): Polycystic ovary syndrome offspring display increased oxidative stress markers comparable to gestational diabetes offspring. Fertil Steril 99, 3, 943-950. https://dx.doi.org/10.1016/j.fertnstert.2012.10.050.",primary_citation,prior search,Boutzios,2013,"Boutzios et al., 2013",10.1016/j.fertnstert.2012.10.050,,,,,Polycystic ovary syndrome offspring display increased oxidative stress markers comparable to gestational diabetes offspring,pmid:23200689,10.1016/j.fertnstert.2012.10.050
4.0,4.10.,1031,109.0,"Wang, Y.; Zhao, X.; Zhao, H.; et al. (2013): Risks for gestational diabetes mellitus and pregnancy-induced hypertension are increased in polycystic ovary syndrome. Biomed Res Int 2013, 182582. https://dx.doi.org/10.1155/2013/182582.",primary_citation,prior search,Wang,2013,"Wang et al., 2013",10.1155/2013/182582,,,,,Risks for Gestational Diabetes Mellitus and Pregnancy-Induced Hypertension Are Increased in Polycystic Ovary Syndrome,pmid:24371816,10.1155/2013/182582
4.0,4.10.,1032,109.0,"Ashrafi, M.; Sheikhan, F.; Arabipoor, A.; et al. (2014): Gestational diabetes mellitus risk factors in women with polycystic ovary syndrome (PCOS). Eur J Obstet Gynecol Reprod Biol 181, 195-199. https://dx.doi.org/10.1016/j.ejogrb.2014.07.043.",primary_citation,prior search,Ashrafi,2014,"Ashrafi et al., 2014",10.1016/j.ejogrb.2014.07.043,,,,,Gestational diabetes mellitus risk factors in women with polycystic ovary syndrome (PCOS),pmid:25150960,10.1016/j.ejogrb.2014.07.043
4.0,4.10.,1033,109.0,"Elkholi, D. G. E. Y.; Nagy, H. M. (2014): The effects of adipocytokines on the endocrino-metabolic features and obstetric outcome in pregnant obese women with polycystic ovary syndrome. Middle East Fertility Society Journal 19, 4, 293-302. http://dx.doi.org/10.1016/j.mefs.2014.02.001.",primary_citation,prior search,Elkholi,2014,"Elkholi et al., 2014",10.1016/j.mefs.2014.02.001,,,,,The effects of adipocytokines on the endocrino-metabolic features and obstetric outcome in pregnant obese women with polycystic ovary syndrome,,10.1016/j.mefs.2014.02.001
4.0,4.10.,1034,109.0,"Foroozanfard, F.; Moosavi, S. G.; Mansouri, F.; et al. (2014): Obstetric and Neonatal Outcome in PCOS with Gestational Diabetes Mellitus. J Family Reprod Health 8, 1, 7-12, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=24971127",primary_citation,prior search,Foroozanfard,2014,"Foroozanfard et al., 2014",,24971127.0,,,,Obstetric and Neonatal Outcome in PCOS with Gestational Diabetes Mellitus.,pmid:24971127,
4.0,4.10.,1035,109.0,"Huang, K.; Dong, X.; Zhang, H.; et al. (2014): Effect of overweight/obesity on IVF-ET outcomes in chinese patients with polycystic ovary syndrome. International Journal of Clinical and Experimental Medicine 7, 12, 5872-5876, http://www.ijcem.com/files/ijcem0003637.pdf",primary_citation,prior search,Huang,2014,"Huang et al., 2014",,25664123.0,,8327204.0,,Effect of overweight/obesity on IVF-ET outcomes in chinese patients with polycystic ovary syndrome.,pmid:25664123,
4.0,4.10.,1036,109.0,"Lathi, R. B.; Dahan, M. H.; Reynolds-May, M. F.; et al. (2014): The role of serum testosterone in early pregnancy outcome: a comparison in women with and without polycystic ovary syndrome. J Obstet Gynaecol Can 36, 9, 811-816, http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medl&AN=25222360",primary_citation,prior search,Lathi,2014,"Lathi et al., 2014",10.1016/s1701-2163(15)30483-7,,,,,The Role of Serum Testosterone in Early Pregnancy Outcome: A Comparison in Women With and Without Polycystic Ovary Syndrome,pmid:25222360,10.1016/s1701-2163(15)30483-7
4.0,4.10.,1037,109.0,"Li, H. W.; Lee, V. C.; Lau, E. Y.; et al. (2014): Cumulative live-birth rate in women with polycystic ovary syndrome or isolated polycystic ovaries undergoing in-vitro fertilisation treatment. J Assist Reprod Genet 31, 2, 205-211. https://dx.doi.org/10.1007/s10815-013-0151-6.",primary_citation,prior search,Li,2014,"Li et al., 2014",10.1007/s10815-013-0151-6,,,,,Cumulative live-birth rate in women with polycystic ovary syndrome or isolated polycystic ovaries undergoing in-vitro fertilisation treatment,pmid:24337962,10.1007/s10815-013-0151-6
4.0,4.10.,1038,109.0,"Liu, L.; Tong, X.; Jiang, L.; et al. (2014): A comparison of the miscarriage rate between women with and without polycystic ovarian syndrome undergoing IVF treatment. Eur J Obstet Gynecol Reprod Biol 176, 178-182. https://dx.doi.org/10.1016/j.ejogrb.2014.02.041.",primary_citation,prior search,Liu,2014,"Liu et al., 2014",10.1016/j.ejogrb.2014.02.041,,,,,A comparison of the miscarriage rate between women with and without polycystic ovarian syndrome undergoing IVF treatment,pmid:24680396,10.1016/j.ejogrb.2014.02.041
4.0,4.10.,1039,109.0,"Naver, K. V.; Grinsted, J.; Larsen, S. O.; et al. (2014): Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia. Bjog 121, 5, 575-581. https://dx.doi.org/10.1111/1471-0528.12558.",primary_citation,prior search,Naver,2014,"Naver et al., 2014",10.1111/1471-0528.12558,,,,,Increased risk of preterm delivery and pre‐eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia,pmid:24418062,10.1111/1471-0528.12558
4.0,4.10.,1040,109.0,"Palomba, S.; Falbo, A.; Chiossi, G.; et al. (2014): Lipid profile in nonobese pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. Steroids 88, 36-43. https://dx.doi.org/10.1016/j.steroids.2014.06.005.",primary_citation,prior search,Palomba,2014,"Palomba et al., 2014",10.1016/j.steroids.2014.06.005,,,,,Lipid profile in nonobese pregnant women with polycystic ovary syndrome: A prospective controlled clinical study,pmid:24945113,10.1016/j.steroids.2014.06.005
4.0,4.10.,1041,109.0,"Palomba, S.; Falbo, A.; Chiossi, G.; et al. (2014): Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. J Clin Endocrinol Metab 99, 8, 2942-2951. https://dx.doi.org/10.1210/jc.2014-1214.",primary_citation,prior search,Palomba,2014,"Palomba et al., 2014",10.1210/jc.2014-1214,,,,,Low-Grade Chronic Inflammation in Pregnant Women With Polycystic Ovary Syndrome: A Prospective Controlled Clinical Study,pmid:24873996,10.1210/jc.2014-1214
4.0,4.10.,1042,109.0,"Zhang, C. M.; Zhao, Y.; Li, R.; et al. (2014): Metabolic heterogeneity of follicular amino acids in polycystic ovary syndrome is affected by obesity and related to pregnancy outcome. BMC Pregnancy Childbirth 14, 11. https://dx.doi.org/10.1186/1471-2393-14-11.",primary_citation,prior search,Zhang,2014,"Zhang et al., 2014",10.1186/1471-2393-14-11,,,,,Metabolic heterogeneity of follicular amino acids in polycystic ovary syndrome is affected by obesity and related to pregnancy outcome,pmid:24410809,10.1186/1471-2393-14-11
4.0,4.10.,1043,109.0,"Kollmann, M.; Klaritsch, P.; Martins, W. P.; et al. (2015): Maternal and neonatal outcomes in pregnant women with PCOS: comparison of different diagnostic definitions. Human Reproduction 30, 10, 2396-2403. https://dx.doi.org/10.1093/humrep/dev187.",primary_citation,prior search,Kollmann,2015,"Kollmann et al., 2015",10.1093/humrep/dev187,,,,,Maternal and neonatal outcomes in pregnant women with PCOS: comparison of different diagnostic definitions,pmid:26223675,10.1093/humrep/dev187
4.0,4.10.,1044,109.0,"Koster, M. P.; de Wilde, M. A.; Veltman-Verhulst, S. M.; et al. (2015): Placental characteristics in women with polycystic ovary syndrome. Human Reproduction 30, 12, 2829-2837. https://dx.doi.org/10.1093/humrep/dev265.",primary_citation,prior search,Koster,2015,"Koster et al., 2015",10.1093/humrep/dev265,,,,,Placental characteristics in women with polycystic ovary syndrome,pmid:26498178,10.1093/humrep/dev265
4.0,4.10.,1045,109.0,"Mumm, H.; Jensen, D. M.; Sorensen, J. A.; et al. (2015): Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes. Acta Obstetricia et Gynecologica Scandinavica 94, 2, 204-211. https://dx.doi.org/10.1111/aogs.12545.",primary_citation,prior search,Mumm,2015,"Mumm et al., 2015",10.1111/aogs.12545,,,,,Hyperandrogenism and phenotypes of polycystic ovary syndrome are not associated with differences in obstetric outcomes,pmid:25417943,10.1111/aogs.12545
4.0,4.10.,1046,109.0,"Sawada, M.; Masuyama, H.; Hayata, K.; et al. (2015): Pregnancy complications and glucose intolerance in women with polycystic ovary syndrome. Endocr J 62, 11, 1017-1023. https://dx.doi.org/10.1507/endocrj.EJ15-0364.",primary_citation,prior search,Sawada,2015,"Sawada et al., 2015",10.1507/endocrj.ej15-0364,,,,,Pregnancy complications and glucose intolerance in women with polycystic ovary syndrome,pmid:26370557,10.1507/endocrj.ej15-0364
4.0,4.10.,1047,109.0,"Wan, H. L.; Hui, P. W.; Li, H. W.; et al. (2015): Obstetric outcomes in women with polycystic ovary syndrome and isolated polycystic ovaries undergoing in vitro fertilization: a retrospective cohort analysis. J Matern Fetal Neonatal Med 28, 4, 475-478. https://dx.doi.org/10.3109/14767058.2014.921673.",primary_citation,prior search,Wan,2015,"Wan et al., 2015",10.3109/14767058.2014.921673,,,,,Obstetric outcomes in women with polycystic ovary syndrome and isolated polycystic ovaries undergoing<i>in vitro</i>fertilization: a retrospective cohort analysis,pmid:24803007,10.3109/14767058.2014.921673
4.0,4.10.,1048,109.0,"Aktun, H. L.; Yorgunlar, B.; Acet, M.; et al. (2016): The effects of polycystic ovary syndrome on gestational diabetes mellitus. Gynecological Endocrinology 32, 2, 139-142. https://dx.doi.org/10.3109/09513590.2015.1101438.",primary_citation,prior search,Aktun,2016,"Aktun et al., 2016",10.3109/09513590.2015.1101438,,,,,The effects of polycystic ovary syndrome on gestational diabetes mellitus,pmid:26479686,10.3109/09513590.2015.1101438
4.0,4.10.,1049,109.0,"Sterling, L.; Liu, J.; Okun, N.; et al. (2016): Pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization. Fertil Steril 105, 3, 791-797.e792. https://dx.doi.org/10.1016/j.fertnstert.2015.11.019.",primary_citation,prior search,Sterling,2016,"Sterling et al., 2016",10.1016/j.fertnstert.2015.11.019,,,,,Pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization,pmid:26654973,10.1016/j.fertnstert.2015.11.019
4.0,4.10.,1050,109.0,"Wang, F.; Dai, W.; Yang, X. H.; et al. (2016): Analyses of optimal body mass index for infertile patients with either polycystic or non-polycystic ovary syndrome during assisted reproductive treatment in China. Sci 6, 34538. https://dx.doi.org/10.1038/srep34538.",primary_citation,prior search,Wang,2016,"Wang et al., 2016",10.1038/srep34538,,,,,Analyses of optimal body mass index for infertile patients with either polycystic or non-polycystic ovary syndrome during assisted reproductive treatment in China,pmid:27686055,10.1038/srep34538
4.0,4.10.,1051,109.0,"Wang, Q.; Luo, L.; Lei, Q.; et al. (2016): Low aneuploidy rate in early pregnancy loss abortuses from patients with polycystic ovary syndrome. Reproductive Biomedicine Online 33, 1, 85-92. https://dx.doi.org/10.1016/j.rbmo.2016.04.006.",primary_citation,prior search,Wang,2016,"Wang et al., 2016",10.1016/j.rbmo.2016.04.006,,,,,Low aneuploidy rate in early pregnancy loss abortuses from patients with polycystic ovary syndrome,pmid:27157933,10.1016/j.rbmo.2016.04.006
4.0,4.10.,1052,109.0,"Xiao, Q.; Cui, Y. Y.; Lu, J.; et al. (2016): Risk for Gestational Diabetes Mellitus and Adverse Birth Outcomes in Chinese Women with Polycystic Ovary Syndrome. Int 2016, 5787104. https://dx.doi.org/10.1155/2016/5787104.",primary_citation,prior search,Xiao,2016,"Xiao et al., 2016",10.1155/2016/5787104,,,,,Risk for Gestational Diabetes Mellitus and Adverse Birth Outcomes in Chinese Women with Polycystic Ovary Syndrome,pmid:27066074,10.1155/2016/5787104
4.0,4.10.,1053,109.0,"Chen, Y.; Ye, B.; Yang, X.; et al. (2017): Predicting the outcome of different protocols of in vitro fertilization with anti-Muullerian hormone levels in patients with polycystic ovary syndrome. Journal of International Medical Research 45, 3, 1138-1147. https://dx.doi.org/10.1177/0300060517704140.",primary_citation,,Chen,2017,"Chen et al., 2017",10.1177/0300060517704140,,,,,Predicting the outcome of different protocols of <i>in vitro</i> fertilization with anti-Muüllerian hormone levels in patients with polycystic ovary syndrome,pmid:28449632,10.1177/0300060517704140
4.0,4.10.,1054,109.0,"de Wilde, M. A.; Lamain-de Ruiter, M.; Veltman-Verhulst, S. M.; et al. (2017): Increased rates of complications in singleton pregnancies of women previously diagnosed with polycystic ovary syndrome predominantly in the hyperandrogenic phenotype. Fertility & Sterility 108, 2, 333-340. https://dx.doi.org/10.1016/j.fertnstert.2017.06.015.",primary_citation,,de Wilde,2017,"de Wilde et al., 2017",10.1016/j.fertnstert.2017.06.015,,,,,Increased rates of complications in singleton pregnancies of women previously diagnosed with polycystic ovary syndrome predominantly in the hyperandrogenic phenotype,pmid:28778282,10.1016/j.fertnstert.2017.06.015
4.0,4.10.,1055,109.0,"Jonsdottir, F.; Nilas, L.; Andreasen, K. R.; et al. (2017): Obstetrical complications in dichorionic twin pregnancies in women with polycystic ovary syndrome. Acta Obstetricia et Gynecologica Scandinavica 96, 12, 1453-1459. https://dx.doi.org/10.1111/aogs.13241.",primary_citation,,Jonsdottir,2017,"Jonsdottir et al., 2017",10.1111/aogs.13241,,,,,Obstetrical complications in dichorionic twin pregnancies in women with polycystic ovary syndrome,pmid:28981984,10.1111/aogs.13241
4.0,4.10.,1056,109.0,"Luo, L.; Gu, F.; Jie, H.; et al. (2017): Early miscarriage rate in lean polycystic ovary syndrome women after euploid embryo transfer - a matched-pair study. Reproductive Biomedicine Online 35, 5, 576-582. https://dx.doi.org/10.1016/j.rbmo.2017.07.010.",primary_citation,,Luo,2017,"Luo et al., 2017",10.1016/j.rbmo.2017.07.010,,,,,Early miscarriage rate in lean polycystic ovary syndrome women after euploid embryo transfer – a matched-pair study,pmid:28802704,10.1016/j.rbmo.2017.07.010
4.0,4.10.,1057,109.0,"Huang, Q.; Niu, Y.; Xu, L.; et al. (2018): Relationship between a low ratio of serum estradiol to follicle number and fertility treatment outcomes: A retrospective cohort study of 516 cases. Medicine 97, 34, e12017. https://dx.doi.org/10.1097/MD.0000000000012017.",primary_citation,,Huang,2018,"Huang et al., 2018",10.1097/md.0000000000012017,,,,,Relationship between a low ratio of serum estradiol to follicle number and fertility treatment outcomes,pmid:30142848,10.1097/md.0000000000012017
4.0,4.10.,1058,109.0,"Kent, J.; Dodson, W. C.; Kunselman, A.; et al. (2018): Gestational Weight Gain in Women With Polycystic Ovary Syndrome: A Controlled Study. Journal of Clinical Endocrinology & Metabolism 103, 11, 4315-4323. https://dx.doi.org/10.1210/jc.2017-02764.",primary_citation,,Kent,2018,"Kent et al., 2018",10.1210/jc.2017-02764,,,,,Gestational Weight Gain in Women With Polycystic Ovary Syndrome: A Controlled Study,pmid:30085187,10.1210/jc.2017-02764
4.0,4.10.,1059,109.0,"Lai, Q.; Xiang, W.; Li, Q.; et al. (2018): Oxidative stress in granulosa cells contributes to poor oocyte quality and IVF-ET outcomes in women with polycystic ovary syndrome. Fronteras en Medicina 12, 5, 518-524. https://dx.doi.org/10.1007/s11684-017-0575-y.",primary_citation,,Lai,2018,"Lai et al., 2018",10.1007/s11684-017-0575-y,,,,,Oxidative stress in granulosa cells contributes to poor oocyte quality and IVF-ET outcomes in women with polycystic ovary syndrome,pmid:29260383,10.1007/s11684-017-0575-y
4.0,4.10.,1060,109.0,"Li, Y.; Ruan, X.; Wang, H.; et al. (2018): Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment. Fertility & Sterility 109, 4, 720-727. https://dx.doi.org/10.1016/j.fertnstert.2017.12.023.",primary_citation,,Li,2018,"Li et al., 2018",10.1016/j.fertnstert.2017.12.023,,,,,Comparing the risk of adverse pregnancy outcomes of Chinese patients with polycystic ovary syndrome with and without antiandrogenic pretreatment,pmid:29525688,10.1016/j.fertnstert.2017.12.023
4.0,4.10.,1061,109.0,"March, W. A.; Whitrow, M. J.; Davies, M. J.; et al. (2018): Postnatal depression in a community-based study of women with polycystic ovary syndrome. Acta Obstetricia et Gynecologica Scandinavica 97, 7, 838-844. https://dx.doi.org/10.1111/aogs.13332.",primary_citation,,March,2018,"March et al., 2018",10.1111/aogs.13332,,,,,Postnatal depression in a community‐based study of women with polycystic ovary syndrome,pmid:29460299,10.1111/aogs.13332
4.0,4.10.,1062,109.0,"Butts, S. F.; Seifer, D. B.; Koelper, N.; et al. (2019): Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility. J Clin Endocrinol Metab 104, 2, 369-378. https://dx.doi.org/10.1210/jc.2018-00750.",primary_citation,,Butts,2019,"Butts et al., 2019",10.1210/jc.2018-00750,,,,,Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility,pmid:30085176,10.1210/jc.2018-00750
4.0,4.10.,1063,109.0,"Kollmann, M.; Obermayer-Pietsch, B.; Lerchbaum, E.; et al. (2019): Androgen and anti-mullerian hormone concentrations at term in newborns and their mothers with and without polycystic ovary syndrome. Journal of Clinical Medicine 8(11) (no pagination). https://dx.doi.org/10.3390/jcm8111817.",primary_citation,,Kollmann,2019,"Kollmann et al., 2019",10.3390/jcm8111817,,,,,Androgen and Anti-Mullerian Hormone Concentrations at Term in Newborns and Their Mothers with and without Polycystic Ovary Syndrome,pmid:31683802,10.3390/jcm8111817
4.0,4.10.,1064,109.0,"Schneider, D.; Gonzalez, J. R.; Yamamoto, M.; et al. (2019): The Association of Polycystic Ovary Syndrome and Gestational Hypertensive Disorders in a Diverse Community-Based Cohort. Journal of pregnancy 2019, 9847057. https://dx.doi.org/10.1155/2019/9847057.",primary_citation,,Schneider,2019,"Schneider et al., 2019",10.1155/2019/9847057,,,,,The Association of Polycystic Ovary Syndrome and Gestational Hypertensive Disorders in a Diverse Community-Based Cohort,pmid:30693108,10.1155/2019/9847057
4.0,4.10.,1065,109.0,"Zheng, W.; Huang, W.; Tian, Z.; et al. (2019): Early pregnancy metabolic factors associated with gestational diabetes mellitus in normal-weight women with polycystic ovary syndrome: A two-phase cohort study. Diabetology and Metabolic Syndrome 11(1) (no pagination). https://dx.doi.org/10.1186/s13098-019-0462-6.",primary_citation,,Zheng,2019,"Zheng et al., 2019",10.1186/s13098-019-0462-6,,,,,Early pregnancy metabolic factors associated with gestational diabetes mellitus in normal-weight women with polycystic ovary syndrome: a two-phase cohort study,pmid:31462934,10.1186/s13098-019-0462-6
4.0,4.10.,1066,109.0,"Benito, E.; Gomez-Martin, J. M.; Vega-Pinero, B.; et al. (2020): Fertility and pregnancy outcomes in women with polycystic ovary syndrome following bariatric surgery. Journal of Clinical Endocrinology and Metabolism 105(9), E3384-E3391. https://dx.doi.org/10.1210/clinem/dgaa439.",primary_citation,,Benito,2020,"Benito et al., 2020",10.1210/clinem/dgaa439,,,,,Fertility and Pregnancy Outcomes in Women with Polycystic Ovary Syndrome Following Bariatric Surgery,pmid:32754732,10.1210/clinem/dgaa439
4.0,4.10.,1067,109.0,"Chen, M.; Huang, X.; Liu, Y.; et al. (2020): Systematic oxidative stress is not associated with live birth rate in young non-obese patients with polycystic ovarian syndrome undergoing assisted reproduction cycles: A prospective cohort study. Eur J Obstet Gynecol Reprod Biol 253, 154-161. https://dx.doi.org/10.1016/j.ejogrb.2020.07.049.",primary_citation,,Chen,2020,"Chen et al., 2020",10.1016/j.ejogrb.2020.07.049,,,,,Systematic oxidative stress is not associated with live birth rate in young non-obese patients with polycystic ovarian syndrome undergoing assisted reproduction cycles: A prospective cohort study,pmid:32877771,10.1016/j.ejogrb.2020.07.049
4.0,4.10.,1068,109.0,"Elshewy, N.; Ji, D.; Zhang, Z.; et al. (2020): Association between mild stimulated IVF/M cycle and early embryo arrest in sub fertile women with/without PCOS. Reprod Biol Endocrinol 18, 1, 71. https://dx.doi.org/10.1186/s12958-020-00622-y.",primary_citation,,Elshewy,2020,"Elshewy et al., 2020",10.1186/s12958-020-00622-y,,,,,Association between mild stimulated IVF/M cycle and early embryo arrest in sub fertile women with/without PCOS,pmid:32669130,10.1186/s12958-020-00622-y
4.0,4.10.,1069,109.0,"Foroozanfard, F.; Asemi, Z.; Bazarganipour, F.; et al. (2020): Comparing pregnancy, childbirth, and neonatal outcomes in women with different phenotypes of polycystic ovary syndrome and healthy women: a prospective cohort study. Gynecological Endocrinology 36(1), 61-65. https://dx.doi.org/10.1080/09513590.2019.1631278.",primary_citation,,Foroozanfard,2020,"Foroozanfard et al., 2020",10.1080/09513590.2019.1631278,,,,,"Comparing pregnancy, childbirth, and neonatal outcomes in women with different phenotypes of polycystic ovary syndrome and healthy women: a prospective cohort study",pmid:31264483,10.1080/09513590.2019.1631278
4.0,4.10.,1070,109.0,"Liu, S.; Mo, M.; Xiao, S.; et al. (2020): Pregnancy Outcomes of Women With Polycystic Ovary Syndrome for the First In Vitro Fertilization Treatment: A Retrospective Cohort Study With 7678 Patients. Frontiers in Endocrinology 11, 575337. https://dx.doi.org/10.3389/fendo.2020.575337.",primary_citation,,Liu,2020,"Liu et al., 2020",10.3389/fendo.2020.575337,,,,,Pregnancy Outcomes of Women With Polycystic Ovary Syndrome for the First In Vitro Fertilization Treatment: A Retrospective Cohort Study With 7678 Patients,pmid:33101210,10.3389/fendo.2020.575337
4.0,4.10.,1071,109.0,"Tobiasz, A. M.; Duncan, J. R.; Detti, L.; et al. (2020): Lack of Fetal Insulin Resistance in Maternal Polycystic Ovary Syndrome. Reproductive Sciences 27, 6, 1253-1258. https://dx.doi.org/10.1007/s43032-019-00125-1.",primary_citation,,Tobiasz,2020,"Tobiasz et al., 2020",10.1007/s43032-019-00125-1,,,,,Lack of Fetal Insulin Resistance in Maternal Polycystic Ovary Syndrome,pmid:31994004,10.1007/s43032-019-00125-1
4.0,4.10.,1072,109.0,"Abdulkhalikova, D.; Korosec, S.; Blickstein, I.; et al. (2021): Perinatal outcome of in vitro fertilization pregnancies in women with polycystic ovary syndrome by pregravid BMI. Journal of Perinatal Medicine 49, 4, 514-519. https://dx.doi.org/10.1515/jpm-2019-0244.",primary_citation,,Abdulkhalikova,2021,"Abdulkhalikova et al., 2021",10.1515/jpm-2019-0244,,,,,Perinatal outcome of <i>in vitro</i> fertilization pregnancies in women with polycystic ovary syndrome by pregravid BMI,pmid:33554580,10.1515/jpm-2019-0244
4.0,4.10.,1073,109.0,"Cai, H.; Mol, B. W.; Gordts, S.; et al. (2021): Early and late pregnancy loss in women with polycystic ovary syndrome undergoing IVF/ICSI treatment: a retrospective cohort analysis of 21 820 pregnancies. Bjog 128, 7, 1160-1169. https://dx.doi.org/10.1111/1471-0528.16590.",primary_citation,,Cai,2021,"Cai et al., 2021",10.1111/1471-0528.16590,,,,,Early and late pregnancy loss in women with polycystic ovary syndrome undergoing IVF/ICSI treatment: a retrospective cohort analysis of 21 820 pregnancies,pmid:33142019,10.1111/1471-0528.16590
4.0,4.10.,1074,109.0,"Diboun, I.; Ramanjaneya, M.; Ahmed, L.; et al. (2021): Metabolomic Profiling of Pregnancies With Polycystic Ovary Syndrome Identifies a Unique Metabolic Signature and Potential Predictive Biomarkers of Low Birth Weight. Frontiers in Endocrinology 12, 638727. https://dx.doi.org/10.3389/fendo.2021.638727.",primary_citation,,Diboun,2021,"Diboun et al., 2021",10.3389/fendo.2021.638727,,,,,Metabolomic Profiling of Pregnancies With Polycystic Ovary Syndrome Identifies a Unique Metabolic Signature and Potential Predictive Biomarkers of Low Birth Weight,pmid:34211435,10.3389/fendo.2021.638727
4.0,4.10.,1075,109.0,"Feichtinger, M.; Linder, T.; Rosicky, I.; et al. (2021): Maternal overweight vs. Polycystic ovary syndrome: Disentangling their impact on insulin action in pregnancy-a prospective study. Journal of Clinical Medicine 10(1), 1-7. https://dx.doi.org/10.3390/jcm10010035.",primary_citation,,Feichtinger,2021,"Feichtinger et al., 2021",10.3390/jcm10010035,,,,,Maternal Overweight vs. Polycystic Ovary Syndrome: Disentangling Their Impact on Insulin Action in Pregnancy—A Prospective Study,pmid:33374430,10.3390/jcm10010035
4.0,4.10.,1076,109.0,"Gongadashetti, K.; Gupta, P.; Dada, R.; et al. (2021): Follicular fluid oxidative stress biomarkers and art outcomes in PCOS women undergoing in vitro fertilization: A cross-sectional study. International Journal of Reproductive BioMedicine 19(5), 449-456. https://dx.doi.org/10.18502/ijrm.v19i5.9254.",primary_citation,,Gongadashetti,2021,"Gongadashetti et al., 2021",10.18502/ijrm.v19i5.9254,,,,,Follicular fluid oxidative stress biomarkers and ART outcomes in PCOS women undergoing in vitro fertilization: A cross-sectional study,pmid:34278198,10.18502/ijrm.v19i5.9254
4.0,4.10.,1077,109.0,"Hu, S.; Xu, B.; Long, R.; et al. (2021): The effect of polycystic ovary syndrome without hyperandrogenism on pregnancy-related outcomes: a retrospective cohort study. BJOG: An International Journal of Obstetrics and Gynaecology 128(6), 1003-1010. https://dx.doi.org/10.1111/1471-0528.16557.",primary_citation,,Hu,2021,"Hu et al., 2021",10.1111/1471-0528.16557,,,,,The effect of polycystic ovary syndrome without hyperandrogenism on pregnancy‐related outcomes: a retrospective cohort study,pmid:33021046,10.1111/1471-0528.16557
4.0,4.10.,1078,109.0,"Jiang, L.; Tian, L.; Yuan, J.; et al. (2021): Associations Between Sex Hormone Levels and Autistic Traits in Infertile Patients With Polycystic Ovary Syndrome and Their Offspring. Frontiers in Endocrinology 12, 789395. https://dx.doi.org/10.3389/fendo.2021.789395.",primary_citation,,Jiang,2021,"Jiang et al., 2021",10.3389/fendo.2021.789395,,,,,Associations Between Sex Hormone Levels and Autistic Traits in Infertile Patients With Polycystic Ovary Syndrome and Their Offspring,pmid:35173679,10.3389/fendo.2021.789395
4.0,4.10.,1079,109.0,"Kaing, A.; Jaswa, E. A.; Diamond, M. P.; et al. (2021): Highly elevated level of antimullerian hormone associated with preterm delivery in polycystic ovary syndrome patients who underwent ovulation induction. Fertil Steril 115, 2, 438-446. https://dx.doi.org/10.1016/j.fertnstert.2020.06.015.",primary_citation,,Kaing,2021,"Kaing et al., 2021",10.1016/j.fertnstert.2020.06.015,,,,,Highly elevated level of antimüllerian hormone associated with preterm delivery in polycystic ovary syndrome patients who underwent ovulation induction,pmid:32883514,10.1016/j.fertnstert.2020.06.015
4.0,4.10.,1080,109.0,"Kollmann, M.; Obermayer-Pietsch, B.; Lerchbaum, E.; et al. (2021): Article vitamin d concentrations at term do not differ in newborns and their mothers with and without polycystic ovary syndrome. Journal of Clinical Medicine 10(3), 1-9. https://dx.doi.org/10.3390/jcm10030537.",primary_citation,,Kollmann,2021,"Kollmann et al., 2021",10.3390/jcm10030537,,,,,Vitamin D Concentrations at Term Do Not Differ in Newborns and Their Mothers with and without Polycystic Ovary Syndrome,pmid:33540556,10.3390/jcm10030537
4.0,4.10.,1081,109.0,"Lin, J.; Guo, H.; Wang, B.; et al. (2021): Neonatal outcomes in women with polycystic ovary syndrome after frozen-thawed embryo transfer. Fertil Steril 115, 2, 447-454. https://dx.doi.org/10.1016/j.fertnstert.2020.08.1435.",primary_citation,,Lin,2021,"Lin et al., 2021",10.1016/j.fertnstert.2020.08.1435,,,,,Neonatal outcomes in women with polycystic ovary syndrome after frozen-thawed embryo transfer,pmid:33272629,10.1016/j.fertnstert.2020.08.1435
4.0,4.10.,1082,109.0,"Liu, Y.; Yu, Z.; Zhao, S.; et al. (2021): Oxidative stress markers in the follicular fluid of patients with polycystic ovary syndrome correlate with a decrease in embryo quality. Journal of Assisted Reproduction and Genetics 38(2), 471-477. https://dx.doi.org/10.1007/s10815-020-02014-y.",primary_citation,,Liu,2021,"Liu et al., 2021",10.1007/s10815-020-02014-y,,,,,Oxidative stress markers in the follicular fluid of patients with polycystic ovary syndrome correlate with a decrease in embryo quality,pmid:33216309,10.1007/s10815-020-02014-y
4.0,4.10.,1083,109.0,"Liu, X.; Wang, L.; Zuo, X.; et al. (2021): Women with PCOS with a history of early pregnancy loss show a higher risk of gestational diabetes mellitus. International Journal of General Medicine 14, 6409-6416. https://dx.doi.org/10.2147/IJGM.S334666.",primary_citation,,Liu,2021,"Liu et al., 2021",10.2147/ijgm.s334666,,,,,Women with PCOS with a History of Early Pregnancy Loss Show a Higher Risk of Gestational Diabetes Mellitus,pmid:34675609,10.2147/ijgm.s334666
4.0,4.10.,1084,109.0,"Mai, Z.; Liu, M.; Pan, P.; et al. (2021): Comparison of Cumulative Live Birth Rate Between Aged PCOS Women and Controls in IVF/ICSI Cycles. Frontiers in Endocrinology 12, 724333. https://dx.doi.org/10.3389/fendo.2021.724333.",primary_citation,,Mai,2021,"Mai et al., 2021",10.3389/fendo.2021.724333,,,,,Comparison of Cumulative Live Birth Rate Between Aged PCOS Women and Controls in IVF/ICSI Cycles,pmid:34650517,10.3389/fendo.2021.724333
4.0,4.10.,1085,109.0,"Pouya, K.; Sukur, Y. E.; Israfilova, G.; et al. (2021): hCG day progesterone level has no impact on the frozen thawed embryo transfer cycle outcome. Journal of Gynecology Obstetrics and Human Reproduction 50, 6, 102120. https://dx.doi.org/10.1016/j.jogoh.2021.102120.",primary_citation,,Pouya,2021,"Pouya et al., 2021",10.1016/j.jogoh.2021.102120,,,,,hCG day progesterone level has no impact on the frozen thawed embryo transfer cycle outcome,pmid:33737250,10.1016/j.jogoh.2021.102120
4.0,4.10.,1086,109.0,"Wang, Y.; Guo, L.; Jiang, J.; et al. (2021): Development of 1-2 years offspring born to mothers with polycystic ovary syndrome. Journal of the College of Physicians and Surgeons Pakistan 31(10), 1186-1190. https://dx.doi.org/10.29271/jcpsp.2021.10.1186.",primary_citation,,Wang,2021,"Wang et al., 2021",10.29271/jcpsp.2021.10.1186,,,,,Development of 1-2 years Offspring Born to Mothers with Polycystic Ovary Syndrome,pmid:34601839,10.29271/jcpsp.2021.10.1186
4.0,4.10.,1087,109.0,"Wu, Y.; Cai, M.; Liang, X.; et al. (2021): The prevalence of cervical insufficiency in Chinese women with polycystic ovary syndrome undergone ART treatment accompanied with negative prognosis: a retrospective study. J Obstet Gynaecol 41, 6, 888-892. https://dx.doi.org/10.1080/01443615.2020.1819212.",primary_citation,,Wu,2021,"Wu et al., 2021",10.1080/01443615.2020.1819212,,,,,The prevalence of cervical insufficiency in Chinese women with polycystic ovary syndrome undergone ART treatment accompanied with negative prognosis: a retrospective study,pmid:33228414,10.1080/01443615.2020.1819212
4.0,4.10.,1088,109.0,"Zhu, J.; Zhang, J.; Yang, J.; et al. (2021): A comprehensive evaluation of progestin-primed ovarian stimulation protocol in patients with or without PCOS undergoing in vitro fertilization. Reproductive Biology 21, 4, 100540. https://dx.doi.org/10.1016/j.repbio.2021.100540.",primary_citation,,Zhu,2021,"Zhu et al., 2021",10.1016/j.repbio.2021.100540,,,,,A comprehensive evaluation of progestin-primed ovarian stimulation protocol in patients with or without PCOS undergoing in vitro fertilization,pmid:34416405,10.1016/j.repbio.2021.100540
4.0,4.10.,1089,109.0,"Liu, Q.; Wang, J.; Xu, Q.; et al. (2022): A retrospective cohort study of obstetric complications and birth outcomes in women with polycystic ovarian syndrome. J Obstet Gynaecol 42, 4, 574-579. https://dx.doi.org/10.1080/01443615.2021.1931066.",primary_citation,,Liu,2022,"Liu et al., 2022",10.1080/01443615.2021.1931066,,,,,A retrospective cohort study of obstetric complications and birth outcomes in women with polycystic ovarian syndrome,pmid:34392796,10.1080/01443615.2021.1931066
4.0,4.10.,1090,109.0,"Ni, Z.; Mei, S.; You, S.; et al. (2022): Adverse Effects of Polycystic Ovarian Syndrome on Pregnancy Outcomes in Women With Frozen-Thawed Embryo Transfer: Propensity Score-Matched Study. Frontiers in Endocrinology 13, 878853. https://dx.doi.org/10.3389/fendo.2022.878853.",primary_citation,,Ni,2022,"Ni et al., 2022",10.3389/fendo.2022.878853,,,,,Adverse Effects of Polycystic Ovarian Syndrome on Pregnancy Outcomes in Women With Frozen-Thawed Embryo Transfer: Propensity Score-Matched Study,pmid:35733779,10.3389/fendo.2022.878853
4.0,4.10.,1091,109.0,"Song, H.; Yu, Z.; Li, P.; et al. (2022): HOMA-IR for predicting clinical pregnancy rate during IVF. Gynecological Endocrinology 38(1), 33-38. https://dx.doi.org/10.1080/09513590.2021.1952976.",primary_citation,,Song,2022,"Song et al., 2022",10.1080/09513590.2021.1952976,,,,,HOMA-IR for predicting clinical pregnancy rate during IVF,pmid:34263713,10.1080/09513590.2021.1952976
4.0,4.10.,1092,109.0,"Stokkeland, L. M. T.; Giskeodegard, G. F.; Ryssdal, M.; et al. (2022): Changes in Serum Cytokines Throughout Pregnancy in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 107, 1, 39-52. https://dx.doi.org/10.1210/clinem/dgab684.",primary_citation,,Stokkeland,2022,"Stokkeland et al., 2022",10.1210/clinem/dgab684,,,,,Changes in Serum Cytokines Throughout Pregnancy in Women With Polycystic Ovary Syndrome,pmid:34529073,10.1210/clinem/dgab684
4.0,4.10.,1093,109.0,"Tu, M.; Wu, Y.; Wang, F.; et al. (2022): Effect of lncRNA MALAT1 on the Granulosa Cell Proliferation and Pregnancy Outcome in Patients With PCOS. Frontiers in Endocrinology 13, 825431. https://dx.doi.org/10.3389/fendo.2022.825431.",primary_citation,,Tu,2022,"Tu et al., 2022",10.3389/fendo.2022.825431,,,,,Effect of lncRNA MALAT1 on the Granulosa Cell Proliferation and Pregnancy Outcome in Patients With PCOS,pmid:35573984,10.3389/fendo.2022.825431
4.0,4.10.,1094,109.0,"Wang, Q.; Wang, H.; Li, P.; et al. (2022): Association of Polycystic Ovary Syndrome Phenotypes With Adverse Pregnancy Outcomes After In-Vitro Fertilization/Intracytoplasmic Sperm Injection. Frontiers in Endocrinology 13, 889029. https://dx.doi.org/10.3389/fendo.2022.889029.",primary_citation,,Wang,2022,"Wang et al., 2022",10.3389/fendo.2022.889029,,,,,Association of Polycystic Ovary Syndrome Phenotypes With Adverse Pregnancy Outcomes After In-Vitro Fertilization/Intracytoplasmic Sperm Injection,pmid:35721747,10.3389/fendo.2022.889029
4.0,4.10.,1095,109.0,"Yang, T.; Yang, Y.; Zhang, Q.; et al. (2022): Homeostatic Model Assessment for Insulin Resistance Is Associated With Late Miscarriage in Non-Dyslipidemic Women Undergoing Fresh IVF/ICSI Embryo Transfer. Frontiers in Endocrinology 13, 880518. https://dx.doi.org/10.3389/fendo.2022.880518.",primary_citation,,Yang,2022,"Yang et al., 2022",10.3389/fendo.2022.880518,,,,,Homeostatic Model Assessment for Insulin Resistance Is Associated With Late Miscarriage in Non-Dyslipidemic Women Undergoing Fresh IVF/ICSI Embryo Transfer,pmid:35784578,10.3389/fendo.2022.880518
4.0,4.11,1096,7.0,"Løvvik TS, Carlsen SM, Salvesen Ø, et al. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(4):256-266. doi:10.1016/S2213-8587(19)30002-6",primary_citation,,Løvvik TS,2019,"Løvvik TS et al., 2019",10.1016/s2213-8587(19)30002-6,,,,,"Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial",pmid:30792154,10.1016/s2213-8587(19)30002-6
4.0,4.11,1097,7.0,"Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab. 2012;97(5):1492-1500. doi:10.1210/jc.2011-3061",primary_citation,,Morin-Papunen L,2012,"Morin-Papunen L et al., 2012",10.1210/jc.2011-3061,,,,,"Metformin Improves Pregnancy and Live-Birth Rates in Women with Polycystic Ovary Syndrome (PCOS): A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial",pmid:22419702,10.1210/jc.2011-3061
4.0,4.11,1098,7.0,"Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004;19(8):1734-1740. doi:10.1093/humrep/deh347.",primary_citation,,Vanky E,2004,"Vanky E et al., 2004",10.1093/humrep/deh347,,,,,Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study,pmid:15178665,10.1093/humrep/deh347
4.0,4.11,1099,7.0,"Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95(12):E448-E455. doi:10.1210/jc.2010-0853",primary_citation,,Vanky E,2010,"Vanky E et al., 2010",10.1210/jc.2010-0853,,,,,"Metformin Versus Placebo from First Trimester to Delivery in Polycystic Ovary Syndrome: A Randomized, Controlled Multicenter Study",pmid:20926533,10.1210/jc.2010-0853
4.0,4.11,1100,7.0,"Zolghadri J, Tavana Z, Kazerooni T, Soveid M, Taghieh M. Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study. Fertil Steril. 2008;90(3):727-730. doi:10.1016/j.fertnstert.2007.06.079",primary_citation,,Zolghadri J,2008,"Zolghadri J et al., 2008",10.1016/j.fertnstert.2007.06.079,,,,,"Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study",pmid:18001723,10.1016/j.fertnstert.2007.06.079
4.0,4.11,1101,7.0,"Begum MR, Khanam NN, Quadir E, et al. Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2009;35(2):282-286. doi:10.1111/j.1447-0756.2008.00876.x",primary_citation,,Begum MR,2009,"Begum MR et al., 2009",10.1111/j.1447-0756.2008.00876.x,,,,,Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome,pmid:19708174,10.1111/j.1447-0756.2008.00876.x
4.0,4.11,1102,7.0,"Jamal A, Milani F, Al-Yasin A. Evaluation of the effect of metformin and aspirin on utero placental circulation of pregnant women with PCOS. Iran J Reprod Med. 2012;10(3):265-270.",primary_citation,,Jamal A,2012,"Jamal A et al., 2012",,25243003.0,W2147909159,18878695.0,,Evaluation of the effect of metformin and aspirin on utero placental circulation of pregnant women with PCOS.,pmid:25243003,
5.0,5.1,1103,65.0,"Abu-Fakher B, Al-Quobaili F, Alhalabi M. Follicular fluid antimullerian hormone (AMH) does not predict IVF outcomes in polycystic ovary syndrome patients. Middle East Fertility Society Journal. 2013;18(2):110-4.",primary_citation,,Abu-Fakher B,2013,"Abu-Fakher B et al., 2013",10.1016/j.mefs.2012.12.005,,,,,Follicular fluid antimullerian hormone (AMH) does not predict IVF outcomes in polycystic ovary syndrome patients,,10.1016/j.mefs.2012.12.005
5.0,5.1,1104,65.0,"Akpınar F, Demir B, Dilbaz S, Kaplanoğlu İ, Dilbaz B. Obesity is not associated with the poor pregnancy outcome following intracytoplasmic sperm injection in women with polycystic ovary syndrome. Journal of the Turkish-German Gynecological Association. 2014;15(3):144-8.",primary_citation,,Akpınar F,2014,"Akpınar F et al., 2014",10.5152/jtgga.2014.13047,,,,,Obesity is not associated with the poor pregnancy outcome following intracytoplasmic sperm injection in women with polycystic ovary syndrome,pmid:25317041,10.5152/jtgga.2014.13047
5.0,5.1,1105,65.0,"Al Safi WG, Hassan MF. Pregnancy rate in women with pcos with high lh/fsh ratio undergoing icsi. Latin American Journal of Pharmacy. 2021;40(Special Issue):336-40.",primary_citation,,Al Safi WG,2021,"Al Safi WG et al., 2021",,,,,Pregnancy rate in women with pcos with high lh/fsh ratio undergoing icsi,,,
5.0,5.1,1106,65.0,"Al-Azemi M, Omu FE, Omu AE. The effect of obesity on the outcome of infertility management in women with polycystic ovary syndrome. Archives of Gynecology and Obstetrics. 2004;270(4):205-10.",primary_citation,,Al-Azemi M,2004,"Al-Azemi M et al., 2004",10.1007/s00404-003-0537-2,,,,,The effect of obesity on the outcome of infertility management in women with polycystic ovary syndrome,pmid:12955532,10.1007/s00404-003-0537-2
5.0,5.1,1107,65.0,"Aleyasin A, Aghahoseini M, Mokhtar S, Fallahi P. Anti-mullerian hormone as a predictive factor in assisted reproductive technique of polycystic ovary syndrome patients. Acta Medica Iranica. 2011;49(11):715-20.",primary_citation,,Aleyasin A,2011,"Aleyasin A et al., 2011",,22131240.0,,42098596.0,,Anti-mullerian hormone as a predictive factor in assisted reproductive technique of polycystic ovary syndrome patients.,pmid:22131240,
5.0,5.1,1108,65.0,"Arabzadeh S, Hossein G, Rashidi BH, Hosseini MA, Zeraati H. Comparing serum basal and follicular fluid levels of anti-Mullerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome. Annals of Saudi Medicine. 2010;30(6):442-7.",primary_citation,,Arabzadeh S,2010,"Arabzadeh S et al., 2010",10.4103/0256-4947.71063,,,,,Comparing serum basal and follicular fluid levels of anti-Müllerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome,pmid:20940513,10.4103/0256-4947.71063
5.0,5.1,1109,65.0,"Bailey AP, Hawkins LK, Missmer SA, Correia KF, Yanushpolsky EH. Effect of body mass index on in vitro fertilization outcomes in women with polycystic ovary syndrome. American Journal of Obstetrics & Gynecology. 2014;211(2):163.e1-6.",primary_citation,,Bailey AP,2014,"Bailey AP et al., 2014",10.1016/j.ajog.2014.03.035,,,,,Effect of body mass index on in vitro fertilization outcomes in women with polycystic ovary syndrome,pmid:24657792,10.1016/j.ajog.2014.03.035
5.0,5.1,1110,65.0,"Bakir VL, Karahan G. Evaluation of obesity and metabolic status in polycystic ovary syndrome in fertile and infertile groups. Zeynep Kamil Tip Bulteni. 2019;50(2):44-8.",primary_citation,,Bakir VL,2019,"Bakir VL et al., 2019",10.16948/zktipb.558143,,,,,Evaluation of Obesity and Metabolic Status in Polycystic Ovary Syndrome in Fertile and Infertile Groups,,10.16948/zktipb.558143
5.0,5.1,1111,65.0,"Berker B, Kaya C, Aytac R, Satiroglu H. Homocysteine concentrations in follicular fluid are associated with poor oocyte and embryo qualities in polycystic ovary syndrome patients undergoing assisted reproduction. Human Reproduction. 2009;24(9):2293-302.",primary_citation,,Berker B,2009,"Berker B et al., 2009",10.1093/humrep/dep069,,,,,Homocysteine concentrations in follicular fluid are associated with poor oocyte and embryo qualities in polycystic ovary syndrome patients undergoing assisted reproduction,pmid:19443458,10.1093/humrep/dep069
5.0,5.1,1112,65.0,"Bousmpoula A, Benidis E, Demeridou S, Kapeta-Kourkouli R, Chasiakou A, Chasiakou S, et al. Serum and follicular fluid irisin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with insulin resistance and lipoprotein lipid profiles. Gynecological Endocrinology. 2019;35(9):803-6.",primary_citation,,Bousmpoula A,2019,"Bousmpoula A et al., 2019",10.1080/09513590.2019.1594761,,,,,Serum and follicular fluid irisin levels in women with polycystic ovaries undergoing ovarian stimulation: correlation with insulin resistance and lipoprotein lipid profiles,pmid:30982370,10.1080/09513590.2019.1594761
5.0,5.1,1113,65.0,"Cakiroglu Y, Vural F, Vural B. The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes. Journal of Endocrinological Investigation. 2016;39(8):899-907.",primary_citation,,Cakiroglu Y,2016,"Cakiroglu Y et al., 2016",10.1007/s40618-016-0446-4,,,,,The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes,pmid:26980590,10.1007/s40618-016-0446-4
5.0,5.1,1114,65.0,"Catak Z, Yavuzkir S, Kocdemir E, Ugur K, Yardim M, Sahin I, et al. NUCB2/nesfatin-1 in the blood and follicular fluid in patients with polycystic ovary syndrome and poor ovarian response. Journal of Reproduction and Infertility. 2019;20(4):225-30.",primary_citation,,Catak Z,2019,"Catak Z et al., 2019",,31897389.0,W2981960579,204869967.0,,NUCB2/Nesfatin-1 in the Blood and Follicular Fluid in Patients with Polycystic Ovary Syndrome and Poor Ovarian Response.,pmid:31897389,
5.0,5.1,1115,65.0,"Chen M, Huang X, Liu Y, Lei S, Wu Y, Chen Z, et al. Systematic oxidative stress is not associated with live birth rate in young non-obese patients with polycystic ovarian syndrome undergoing assisted reproduction cycles: A prospective cohort study. European Journal of Obstetrics & Gynecology & Reproductive Biology. 2020;253:154-61.",primary_citation,,Chen M,2020,"Chen M et al., 2020",10.1016/j.ejogrb.2020.07.049,32877771.0,,,,Systematic oxidative stress is not associated with live birth rate in young non-obese patients with polycystic ovarian syndrome undergoing assisted reproduction cycles: A prospective cohort study,pmid:32877771,
5.0,5.1,1116,65.0,"Chen R, Chen S, Liu M, He H, Xu H, Liu H, et al. Pregnancy outcomes of PCOS overweight/obese patients after controlled ovarian stimulation with the GnRH antagonist protocol and frozen embryo transfer. Reproductive Biology & Endocrinology. 2018;16(1):36.",primary_citation,,Chen R,2018,"Chen R et al., 2018",10.1186/s12958-018-0352-z,29636081.0,,,,Pregnancy outcomes of PCOS overweight/obese patients after controlled ovarian stimulation with the GnRH antagonist protocol and frozen embryo transfer,pmid:29636081,
5.0,5.1,1117,65.0,"Fedorcsak P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Human Reproduction. 2001;16(6):1086-91.",primary_citation,,Fedorcsak P,2001,"Fedorcsak P et al., 2001",10.1093/humrep/16.6.1086,,,,,The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome,pmid:11387273,10.1093/humrep/16.6.1086
5.0,5.1,1118,65.0,"Feng Y, Qi J, Xue X, Li X, Liao Y, Sun Y, et al. Follicular free fatty acid metabolic signatures and their effects on oocyte competence in non-obese PCOS patients. Reproduction. 2022;164(1):1-8.",primary_citation,,Feng Y,2022,"Feng Y et al., 2022",10.1530/rep-22-0023,,,,,Follicular free fatty acid metabolic signatures and their effects on oocyte competence in non-obese PCOS patients,pmid:35521903,10.1530/rep-22-0023
5.0,5.1,1119,65.0,"Ganesh A, Goswami SK, Chattopadhyay R, Chaudhury K, Chakravarty B. Comparison of letrozole with continuous gonadotropins and clomiphene-gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial. Journal of assisted reproduction and genetics 2009. Journal of assisted reproduction and genetics 2009;26(1): 19–24.",primary_citation,,Ganesh A,2009,"Ganesh A et al., 2009",10.1007/s10815-008-9284-4,,,,,Comparison of letrozole with continuous gonadotropins and clomiphene-gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial,pmid:19127427,10.1007/s10815-008-9284-4
5.0,5.1,1120,65.0,"Ghanem, M. E., Elboghdady, L. A., Hassan, M., Helal, A. S., Gibreel, A., Houssen, M., . . . Mesbah, Y. (2013). Clomiphene citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial. J Assist Reprod Genet, 30(11), 1477-1485. doi:10.1007/s10815-013-0090-2",primary_citation,,Ghanem,2013,"Ghanem et al., 2013",10.1007/s10815-013-0090-2,,,,,Clomiphene Citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial,pmid:24014214,10.1007/s10815-013-0090-2
5.0,5.1,1121,65.0,"Guan HJ, Pan LQ, Song H, Tang HY, Tang LS. Predictors of pregnancy after intrauterine insemination in women with polycystic ovary syndrome. Journal of International Medical Research. 2021;49(5):3000605211018600.",primary_citation,,Guan HJ,2021,"Guan HJ et al., 2021",10.1177/03000605211018600,,,,,Predictors of pregnancy after intrauterine insemination in women with polycystic ovary syndrome,pmid:34038202,10.1177/03000605211018600
5.0,5.1,1122,65.0,"Guido M, Belosi C, Selvaggi L, Lattanzi F, Apa R, Fulghesu AM, et al. The effect of age on the ovarian response to gonadotropin and on pregnancy rate in polycystic ovary syndrome. Gynecological Endocrinology. 2003;17(3):215-21.",primary_citation,,Guido M,2003,"Guido M et al., 2003",10.1080/gye.17.3.215.221,,,,,The effect of age on the ovarian response to gonadotropin and on pregnancy rate in polycystic ovary syndrome,pmid:12857429,10.1080/gye.17.3.215.221
5.0,5.1,1123,65.0,"Hashimoto DM, Schmid J, Martins FM, Fonseca AM, Andrade LH, Kirchengast S, et al. The impact of the weight status on subjective symptomatology of the Polycystic Ovary Syndrome: a cross-cultural comparison between Brazilian and Austrian women. Anthropologischer Anzeiger. 2003;61(3):297-310.",primary_citation,,Hashimoto DM,2003,"Hashimoto DM et al., 2003",10.1127/anthranz/61/2003/297,,,,,The impact of the weight status on subjective symptomatology of the Polycystic Ovary Syndrome: A cross-cultural comparison between Brazilian and Austrian women,pmid:14524003,10.1127/anthranz/61/2003/297
5.0,5.1,1124,65.0,"Hassani F, Oryan S, Eftekhari-Yazdi P, Bazrgar M, Moini A, Nasiri N, et al. Association between the number of retrieved mature oocytes and insulin resistance or sensitivity in infertile women with polycystic ovary syndrome. International Journal of Fertility and Sterility. 2019;12(4):310-5.",primary_citation,,Hassani F,2019,"Hassani F et al., 2019",10.22074/ijfs.2019.5422,,,,,Association between The Number of Retrieved Mature Oocytes and Insulin Resistance or Sensitivity in Infertile Women with Polycystic Ovary Syndrome.,pmid:30291692,10.22074/ijfs.2019.5422
5.0,5.1,1125,65.0,"Ho VNA, Pham TD, Le AH, Ho TM, Vuong LN. Live birth rate after human chorionic gonadotropin priming in vitro maturation in women with polycystic ovary syndrome. Journal of ovarian research. 2018;11(1) (no pagination).",primary_citation,,Ho VNA,2018,"Ho VNA et al., 2018",10.1186/s13048-018-0445-5,,,,,Live birth rate after human chorionic gonadotropin priming in vitro maturation in women with polycystic ovary syndrome,pmid:30149808,10.1186/s13048-018-0445-5
5.0,5.1,1126,65.0,"Huang Q, Niu Y, Xu L, Chen B, Zhang Y, Song LJ, et al. Relationship between a low ratio of serum estradiol to follicle number and fertility treatment outcomes A retrospective cohort study of 516 cases. Medicine (United States). 2018;97(34) (no pagination).",primary_citation,,Huang Q,2018,"Huang Q et al., 2018",10.1097/md.0000000000012017,30142848.0,,,,Relationship between a low ratio of serum estradiol to follicle number and fertility treatment outcomes,pmid:30142848,
5.0,5.1,1127,65.0,"Hwang YI, Cha SW, Song IO, Yang KM, Min EG, Kim HO. Fertility of patients with polycystic ovary syndrome undergoing in vitro fertilization by age. International Journal of Gynaecology & Obstetrics. 2016;135(1):91-5.",primary_citation,,Hwang YI,2016,"Hwang YI et al., 2016",10.1016/j.ijgo.2016.03.033,,,,,Fertility of patients with polycystic ovary syndrome undergoing in vitro fertilization by age,pmid:27406030,10.1016/j.ijgo.2016.03.033
5.0,5.1,1128,65.0,"Inal HA, Yilmaz N, Gorkem U, Oruc AS, Timur H. The impact of follicular fluid adiponectin and ghrelin levels based on BMI on IVF outcomes in PCOS. Journal of Endocrinological Investigation. 2016;39(4):431-7.",primary_citation,,Inal HA,2016,"Inal HA et al., 2016",10.1007/s40618-015-0392-6,,,,,The impact of follicular fluid adiponectin and ghrelin levels based on BMI on IVF outcomes in PCOS,pmid:26410834,10.1007/s40618-015-0392-6
5.0,5.1,1129,65.0,"Inal ZO, Inal HA, Erdem S. The effect of serum and follicular fluid secreted frizzle-related protein-5 on in vitro fertilization outcomes in patients with polycystic ovary syndrome. Molecular Biology Reports. 2018;45(6):2037-44.",primary_citation,,Inal ZO,2018,"Inal ZO et al., 2018",10.1007/s11033-018-4360-z,,,,,The effect of serum and follicular fluid secreted frizzle-related protein-5 on in vitro fertilization outcomes in patients with polycystic ovary syndrome,pmid:30194556,10.1007/s11033-018-4360-z
5.0,5.1,1130,65.0,"Janati S, Behmanesh MA, Najafzadehvarzi H, Akhundzade Z, Poormoosavi SM. Follicular Fluid Zinc Level and Oocyte Maturity and Embryo Quality in Women with Polycystic Ovary Syndrome. International Journal of Fertility & Sterility. 2021;15(3):197-201.",primary_citation,,Janati S,2021,"Janati S et al., 2021",10.22074/ijfs.2021.135426.1006,,,,,Follicular Fluid Zinc Level and Oocyte Maturity and Embryo Quality in Women with Polycystic Ovary Syndrome.,pmid:34155866,10.22074/ijfs.2021.135426.1006
5.0,5.1,1131,65.0,"Jaschke N, Lunger F, Wildt L, Seeber B. Beta endorphin in serum and follicular fluid of PCOS- and non-PCOS women. Archives of Gynecology & Obstetrics. 2018;298(1):217-22.",primary_citation,,Jaschke N,2018,"Jaschke N et al., 2018",10.1007/s00404-018-4793-6,,,,,Beta endorphin in serum and follicular fluid of PCOS- and non-PCOS women,pmid:29808249,10.1007/s00404-018-4793-6
5.0,5.1,1132,65.0,"Jin Y, Zhang Q, Pan JX, Wang FF, Qu F. The effects of di(2-ethylhexyl) phthalate exposure in women with polycystic ovary syndrome undergoing in vitro fertilization. Journal of International Medical Research. 2019;47(12):6278-93.",primary_citation,,Jin Y,2019,"Jin Y et al., 2019",10.1177/0300060519876467,,,,,The effects of di(2-ethylhexyl) phthalate exposure in women with polycystic ovary syndrome undergoing <i>in vitro</i> fertilization,pmid:31709857,10.1177/0300060519876467
5.0,5.1,1133,65.0,"Johnson NP, Bontekoe S, Stewart AW. Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS-related ovulation dysfunction in a randomised controlled trial. Australian & New Zealand Journal of Obstetrics & Gynaecology 2011;51:252-6.",primary_citation,,Johnson NP,2011,"Johnson NP et al., 2011",10.1111/j.1479-828x.2011.01295.x,,,,,Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS-related ovulation dysfunction in a randomised controlled trial,pmid:21631446,10.1111/j.1479-828x.2011.01295.x
5.0,5.1,1134,65.0,"Johnson, N. P., Stewart, A. W., Falkiner, J., Farquhar, C. M., Milsom, S., Singh, V. P., . . . React-Nz, a. m.-c. f. t. g. (2010). PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Hum Reprod, 25(7), 1675-1683. doi:10.1093/humrep/deq100",primary_citation,,Johnson,2010,"Johnson et al., 2010",10.1093/humrep/deq100,,,,,PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene,pmid:20435692,10.1093/humrep/deq100
5.0,5.1,1135,65.0,"Kalra SK, Ratcliffe SJ, Dokras A. Is the fertile window extended in women with polycystic ovary syndrome? Utilizing the Society for Assisted Reproductive Technology registry to assess the impact of reproductive aging on live-birth rate. Fertility & Sterility. 2013;100(1):208-13",primary_citation,,Kalra SK,2013,"Kalra SK et al., 2013",10.1016/j.fertnstert.2013.02.055,,,,,Is the fertile window extended in women with polycystic ovary syndrome? Utilizing the Society for Assisted Reproductive Technology registry to assess the impact of reproductive aging on live-birth rate,pmid:23557762,10.1016/j.fertnstert.2013.02.055
5.0,5.1,1136,65.0,"Kamardi S, Surya IHW, Mahendra INB, Adnyana IP, Suardika A, Tondohusodo N, et al. Impact of body mass index on intracytoplasmic sperm injection in women with polycystic ovary syndrome. Zygote. 2021;29(3):229-33.",primary_citation,,Kamardi S,2021,"Kamardi S et al., 2021",10.1017/s0967199420000830,,,,,Impact of body mass index on intracytoplasmic sperm injection in women with polycystic ovary syndrome,pmid:33455589,10.1017/s0967199420000830
5.0,5.1,1137,65.0,"Kjotrod, S. B., Carlsen, S. M., Rasmussen, P. E., Holst-Larsen, T., Mellembakken, J., Thurin-Kjellberg, A., . . . von During, V. (2011). Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Hum Reprod, 26(8), 2045-2053. doi:10.1093/humrep/der154",primary_citation,,Kjotrod,2011,"Kjotrod et al., 2011",10.1093/humrep/der154,,,,,"Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study",pmid:21606131,10.1093/humrep/der154
5.0,5.1,1138,65.0,"Kolibianakis E, Zikopoulos K, Albano C, Camus M, Tournaye H, Van Steirteghem A, et al. Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI. Reproductive Biomedicine Online. 2003;7(3):313-8.",primary_citation,,Kolibianakis E,2003,"Kolibianakis E et al., 2003",10.1016/s1472-6483(10)61870-6,,,,,Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI,pmid:14653891,10.1016/s1472-6483(10)61870-6
5.0,5.1,1139,65.0,"Kudesia R, Wu H, Hunter Cohn K, Tan L, Lee JA, Copperman AB, et al. The effect of female body mass index on in vitro fertilization cycle outcomes: a multi-center analysis. Journal of Assisted Reproduction & Genetics. 2018;35(11):2013-23.",primary_citation,,Kudesia R,2018,"Kudesia R et al., 2018",10.1007/s10815-018-1290-6,,,,,The effect of female body mass index on in vitro fertilization cycle outcomes: a multi-center analysis,pmid:30132171,10.1007/s10815-018-1290-6
5.0,5.1,1140,65.0,"Lai Q, Xiang W, Li Q, Zhang H, Li Y, Zhu G, et al. Oxidative stress in granulosa cells contributes to poor oocyte quality and IVF-ET outcomes in women with polycystic ovary syndrome. Frontiers of medicine. 2018;12(5):518-24.",primary_citation,,Lai Q,2018,"Lai Q et al., 2018",10.1007/s11684-017-0575-y,,,,,Oxidative stress in granulosa cells contributes to poor oocyte quality and IVF-ET outcomes in women with polycystic ovary syndrome,pmid:29260383,10.1007/s11684-017-0575-y
5.0,5.1,1141,65.0,"Legro, R. S., Brzyski, R. G., Diamond, M. P., Coutifaris, C., Schlaff, W. D., Casson, P., . . . Network, N. R. M. (2014). Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med, 371(2), 119-129. doi:10.1056/NEJMoa1313517",primary_citation,,Legro,2014,"Legro et al., 2014",10.1056/nejmoa1313517,,,,,Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome,pmid:25295506,10.1056/nejmoa1313517
5.0,5.1,1142,65.0,"Li Y, Lin H, Pan P, Yang D, Zhang Q. Impact of Central Obesity on Women with Polycystic Ovary Syndrome Undergoing in Vitro Fertilization. BioResearch Open Access. 2018;7(1):116-22.",primary_citation,,Li Y,2018,"Li Y et al., 2018",10.1089/biores.2017.0040,,,,,Impact of Central Obesity on Women with Polycystic Ovary Syndrome Undergoing <i>In Vitro</i> Fertilization,pmid:30083428,10.1089/biores.2017.0040
5.0,5.1,1143,65.0,"Lin J, Huang J, Wang N, Kuang Y, Cai R. Effects of pre-pregnancy body mass index on pregnancy and perinatal outcomes in women with PCOS undergoing frozen embryo transfer. BMC Pregnancy and Childbirth. 2019;19(1) (no pagination).",primary_citation,,Lin J,2019,"Lin J et al., 2019",10.1186/s12884-019-2611-1,,,,,Effects of pre-pregnancy body mass index on pregnancy and perinatal outcomes in women with PCOS undergoing frozen embryo transfer,pmid:31823750,10.1186/s12884-019-2611-1
5.0,5.1,1144,65.0,"Lujan ME, Kepley AL, Chizen DR, Lehotay DC, Pierson RA, Lujan ME, et al. Development of morphologically dominant follicles is associated with fewer metabolic disturbances in amenorrheic women with polycystic ovary syndrome: a pilot study. Ultrasound in Obstetrics & Gynecology. 2010;36(6):759-66.",primary_citation,,Lujan ME,2010,"Lujan ME et al., 2010",10.1002/uog.7751,,,,,Development of morphologically dominant follicles is associated with fewer metabolic disturbances in amenorrheic women with polycystic ovary syndrome: a pilot study,pmid:20645396,10.1002/uog.7751
5.0,5.1,1145,65.0,"Luo L, Wang Q, Chen M, Yuan G, Wang Z, Zhou C. IGF-1 and IGFBP-1 in peripheral blood and decidua of early miscarriages with euploid embryos: comparison between women with and without PCOS. Gynecological Endocrinology. 2016;32(7):538-42.",primary_citation,,Luo L,2016,"Luo L et al., 2016",10.3109/09513590.2016.1138459,,,,,IGF-1 and IGFBP-1 in peripheral blood and decidua of early miscarriages with euploid embryos: comparison between women with and without PCOS,pmid:27174569,10.3109/09513590.2016.1138459
5.0,5.1,1146,65.0,"Mackens S, Pareyn S, Drakopoulos P, Deckers T, Mostinckx L, Blockeel C, et al. Outcome of in-vitro oocyte maturation in patients with PCOS: does phenotype have an impact? Human Reproduction. 2020;35(10):2272-9.",primary_citation,,Mackens S,2020,"Mackens S et al., 2020",10.1093/humrep/deaa190,,,,,Outcome of in-vitro oocyte maturation in patients with PCOS: does phenotype have an impact?,pmid:32951028,10.1093/humrep/deaa190
5.0,5.1,1147,65.0,"Madani T, Irani S, Ashrafi M, Alsadat Nabavi M. The Effect of Flutamide on Ovulation Induction in PCOS Patients. International Journal of Fertility & Sterility. 2012;6(1):65-9.",primary_citation,,Madani T,2012,"Madani T et al., 2012",,25505514.0,,16735901.0,,The Effect of Flutamide on Ovulation Induction in PCOS Patients.,pmid:25505514,
5.0,5.1,1148,65.0,"Mahajan N, Kaur J. Establishing an Anti-Mullerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using the automated Anti-Mullerian hormone assay. Journal of Human Reproductive Sciences. 2019;12(2):104-13.",primary_citation,,Mahajan N,2019,"Mahajan N et al., 2019",10.4103/jhrs.jhrs_149_18,,,,,Establishing an Anti-Müllerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using the automated Anti-Müllerian hormone assay,pmid:31293324,10.4103/jhrs.jhrs_149_18
5.0,5.1,1149,65.0,"Mahran A, Abdelmeged A, El-Adawy AR, Eissa MK, Shaw RW, Amer SA. The predictive value of circulating anti-mullerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: a prospective observational study. Journal of Clinical Endocrinology & Metabolism. 2013;98(10):4170-5.",primary_citation,,Mahran A,2013,"Mahran A et al., 2013",10.1210/jc.2013-2193,,,,,The Predictive Value of Circulating Anti-Müllerian Hormone in Women With Polycystic Ovarian Syndrome Receiving Clomiphene Citrate: A Prospective Observational Study,pmid:23979947,10.1210/jc.2013-2193
5.0,5.1,1150,65.0,"McCormick B, Thomas M, Maxwell R, Williams D, Aubuchon M. Effects of polycystic ovarian syndrome on in vitro fertilization-embryo transfer outcomes are influenced by body mass index. Fertility & Sterility. 2008;90(6):2304-9.",primary_citation,,McCormick B,2008,"McCormick B et al., 2008",10.1016/j.fertnstert.2007.10.077,,,,,Effects of polycystic ovarian syndrome on in vitro fertilization–embryo transfer outcomes are influenced by body mass index,pmid:18191852,10.1016/j.fertnstert.2007.10.077
5.0,5.1,1151,65.0,"Morin-Papunen L, Rantala AS, Unkila-Kallio L, Tiitinen A, Hippeläinen M, Perheentupa A, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo- controlled randomized trial. Journal of Clinical Endocrinology and Metabolism 2012;97:1492-1500.",primary_citation,,Morin-Papunen L,2012,"Morin-Papunen L et al., 2012",10.1210/jc.2011-3061,,,,,"Metformin Improves Pregnancy and Live-Birth Rates in Women with Polycystic Ovary Syndrome (PCOS): A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial",pmid:22419702,10.1210/jc.2011-3061
5.0,5.1,1152,65.0,"Mostinckx L, Segers I, Belva F, Buyl R, Santos-Ribeiro S, Blockeel C, et al. Obstetric and neonatal outcome of ART in patients with polycystic ovary syndrome: IVM of oocytes versus controlled ovarian stimulation. Human Reproduction. 2019;34(8):1595-607.",primary_citation,,Mostinckx L,2019,"Mostinckx L et al., 2019",10.1093/humrep/dez086,,,,,Obstetric and neonatal outcome of ART in patients with polycystic ovary syndrome: IVM of oocytes versus controlled ovarian stimulation,pmid:31347678,10.1093/humrep/dez086
5.0,5.1,1153,65.0,"Muharam R, Prasetyo YD, Prabowo KA, Putri YI, Maidarti M, Hestiantoro A. IVF outcome with a high level of AMH: a focus on PCOS versus non-PCOS. BMC Women's Health. 2022;22(1):172.",primary_citation,,Muharam R,2022,"Muharam R et al., 2022",10.1186/s12905-022-01756-4,,,,,IVF outcome with a high level of AMH: a focus on PCOS versus non-PCOS,pmid:35568864,10.1186/s12905-022-01756-4
5.0,5.1,1154,65.0,"Namlı Kalem M, Kalem Z, Sarı T, Ateş C, Gürgan T. Effect of body mass index and age on in vitro fertilization in polycystic ovary syndrome. Journal of the Turkish-German Gynecological Association. 2016;17(2):83-90.",primary_citation,,Namlı Kalem M,2016,"Namlı Kalem M et al., 2016",10.5152/jtgga.2016.15235,,,,,Effect of body mass index and age on in vitro fertilization in polycystic ovary syndrome,pmid:27403074,10.5152/jtgga.2016.15235
5.0,5.1,1155,65.0,"Niu Z, Ye Y, Xia L, Feng Y, Zhang A. Follicular fluid cytokine composition and oocyte quality of polycystic ovary syndrome patients with metabolic syndrome undergoing in vitro fertilization. Cytokine. 2017;91:180-6.",primary_citation,,Niu Z,2017,"Niu Z et al., 2017",10.1016/j.cyto.2016.12.020,,,,,Follicular fluid cytokine composition and oocyte quality of polycystic ovary syndrome patients with metabolic syndrome undergoing in vitro fertilization,pmid:28082237,10.1016/j.cyto.2016.12.020
5.0,5.1,1156,65.0,"Oberg E, Gidlof S, Jakson I, Mitsell M, Tollet Egnell P, Hirschberg AL. Improved menstrual function in obese women with polycystic ovary syndrome after behavioural modification intervention-A randomized controlled trial. Clinical Endocrinology. 2019;90(3):468-78",primary_citation,,Oberg E,2019,"Oberg E et al., 2019",10.1111/cen.13919,,,,,Improved menstrual function in obese women with polycystic ovary syndrome after behavioural modification intervention—A randomized controlled trial,pmid:30565716,10.1111/cen.13919
5.0,5.1,1157,65.0,"Palomba S, Falbo A, Russo T, Di Cello A, Morelli M, Orio F, et al. Metformin administration in patients with polycystic ovary syndrome who receive gonadotropins for in vitro fertilization cycles: 10-year experience in a large infertile population. Gynecological Endocrinology. 2012;28(2):81-6.",primary_citation,,Palomba S,2012,"Palomba S et al., 2012",10.3109/09513590.2011.588749,,,,,Metformin administration in patients with polycystic ovary syndrome who receive gonadotropins for <i>in vitro</i> fertilization cycles: 10-year experience in a large infertile population,pmid:21770836,10.3109/09513590.2011.588749
5.0,5.1,1158,65.0,"Provost MP, Acharya KS, Acharya CR, Yeh JS, Steward RG, Eaton JL, et al. Pregnancy outcomes decline with increasing body mass index: analysis of 239,127 fresh autologous in vitro fertilization cycles from the 2008-2010 Society for Assisted Reproductive Technology registry. Fertility & Sterility. 2016;105(3):663-9.",primary_citation,,Provost MP,2008,"Provost MP et al., 2008",10.1016/j.fertnstert.2015.11.008,,,,,"Pregnancy outcomes decline with increasing body mass index: analysis of 239,127 fresh autologous in vitro fertilization cycles from the 2008–2010 Society for Assisted Reproductive Technology registry",pmid:26627120,10.1016/j.fertnstert.2015.11.008
5.0,5.1,1159,65.0,"Shalom-Paz E, Marzal A, Wiser A, Almog B, Reinblatt S, Tulandi T, et al. Effects of different body mass indices on in vitro maturation in women with polycystic ovaries. Fertility & Sterility. 2011;96(2):336-9.",primary_citation,,Shalom-Paz E,2011,"Shalom-Paz E et al., 2011",10.1016/j.fertnstert.2011.05.076,,,,,Effects of different body mass indices on in vitro maturation in women with polycystic ovaries,pmid:21704986,10.1016/j.fertnstert.2011.05.076
5.0,5.1,1160,65.0,"Sheng Y, Lu G, Liu J, Liang X, Ma Y, Zhang X, et al. Effect of body mass index on the outcomes of controlled ovarian hyperstimulation in Chinese women with polycystic ovary syndrome: a multicenter, prospective, observational study. Journal of Assisted Reproduction and Genetics. 2017;34(1):61-70.",primary_citation,,Sheng Y,2017,"Sheng Y et al., 2017",10.1007/s10815-016-0830-1,,,,,"Effect of body mass index on the outcomes of controlled ovarian hyperstimulation in Chinese women with polycystic ovary syndrome: a multicenter, prospective, observational study",pmid:27817037,10.1007/s10815-016-0830-1
5.0,5.1,1161,65.0,"Siebert T, Kruger T, Lombard C. Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics 2009;26(4):165-71.",primary_citation,,Siebert T,2009,"Siebert T et al., 2009",10.1007/s10815-009-9304-z,,,,,Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients,pmid:19396538,10.1007/s10815-009-9304-z
5.0,5.1,1162,65.0,"Wang J, Wei Y, Diao F, Cui Y, Mao Y, Wang W, et al. The association between polycystic ovary syndrome and ectopic pregnancy after in vitro fertilization and embryo transfer. American Journal of Obstetrics & Gynecology. 2013;209(2):139.e1-9.",primary_citation,,Wang J,2013,"Wang J et al., 2013",10.1016/j.ajog.2013.05.007,,,,,The association between polycystic ovary syndrome and ectopic pregnancy after in vitro fertilization and embryo transfer,pmid:23659986,10.1016/j.ajog.2013.05.007
5.0,5.1,1163,65.0,"Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Human Reproduction. 2001;16(12):2606-9.",primary_citation,,Wang JX,2001,"Wang JX et al., 2001",10.1093/humrep/16.12.2606,,,,,Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment,pmid:11726582,10.1093/humrep/16.12.2606
5.0,5.1,1164,65.0,"Yang W, Yang R, Lin M, Yang Y, Song X, Zhang J, et al. Body mass index and basal androstenedione are independent risk factors for miscarriage in polycystic ovary syndrome. Reproductive Biology & Endocrinology. 2018;16(1):119.",primary_citation,,Yang W,2018,"Yang W et al., 2018",10.1186/s12958-018-0438-7,,,,,Body mass index and basal androstenedione are independent risk factors for miscarriage in polycystic ovary syndrome,pmid:30454060,10.1186/s12958-018-0438-7
5.0,5.1,1165,65.0,"Zhang CM, Zhao Y, Li R, Yu Y, Yan LY, Li L, et al. Metabolic heterogeneity of follicular amino acids in polycystic ovary syndrome is affected by obesity and related to pregnancy outcome. BMC Pregnancy & Childbirth. 2014;14:11.",primary_citation,,Zhang CM,2014,"Zhang CM et al., 2014",10.1186/1471-2393-14-11,,,,,Metabolic heterogeneity of follicular amino acids in polycystic ovary syndrome is affected by obesity and related to pregnancy outcome,pmid:24410809,10.1186/1471-2393-14-11
5.0,5.1,1166,65.0,"Zhao Y, Ruan X, Mueck AO. Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study. Gynecological Endocrinology. 2017;33(6):462-6.",primary_citation,,Zhao Y,2017,"Zhao Y et al., 2017",10.1080/09513590.2017.1292241,,,,,Letrozole combined with low dose highly purified HMG for ovulation induction in clomiphene citrate-resistant infertile Chinese women with polycystic ovary syndrome: a prospective study,pmid:28277124,10.1080/09513590.2017.1292241
5.0,5.1,1167,65.0,"Zhou H, Zhang D, Luo Z, Yang A, Cui N, Hao G, et al. Association between Body Mass Index and Reproductive Outcome in Women with Polycystic Ovary Syndrome Receiving IVF/ICSI-ET. BioMed Research International. 2020:1-7.",primary_citation,,Zhou H,2020,"Zhou H et al., 2020",10.1155/2020/6434080,,,,,Association between Body Mass Index and Reproductive Outcome in Women with Polycystic Ovary Syndrome Receiving IVF/ICSI-ET,pmid:32908902,10.1155/2020/6434080
5.0,5.3,1168,14.0,"Atay, V., Cam, C., Muhcu, M., Cam, M., & Karateke, A. (2006). Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. Journal of international medical research, 34(1), 73-76.",primary_citation,,Atay,2006,"Atay et al., 2006",10.1177/147323000603400109,,,,,Comparison of Letrozole and Clomiphene Citrate in Women with Polycystic Ovaries Undergoing Ovarian Stimulation,pmid:16604826,10.1177/147323000603400109
5.0,5.3,1169,14.0,"Amer SA, Smith J, Mahran A, Fox P, Fakis A. Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome. Hum Reprod. 2017 Aug 1;32(8):1631-1638. doi: 10.1093/humrep/dex227. PMID: 28854590; PMCID: PMC5850470.",primary_citation,,Amer SA,2017,"Amer SA et al., 2017",10.1093/humrep/dex227,28854590.0,,,,Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome,pmid:28854590,
5.0,5.3,1170,14.0,"Bansal S, Goyal M, Sharma C, Shekhar S. Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial. Int J Gynaecol Obstet. 2021 Mar;152(3):345-350. doi: 10.1002/ijgo.13375. Epub 2020 Oct 14. PMID: 32920843.",primary_citation,,Bansal S,2021,"Bansal S et al., 2021",10.1002/ijgo.13375,32920843.0,,,,Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial,pmid:32920843,
5.0,5.3,1171,14.0,"Bayar U, Basaran M, Kiran S, Coskun A, Gezer S. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertil Steril. 2006 Nov;86(5):1447-51. doi: 10.1016/j.fertnstert.2006.04.026. PMID: 17070196.",primary_citation,,Bayar U,2006,"Bayar U et al., 2006",10.1016/j.fertnstert.2006.04.026,17070196.0,,,,Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial,pmid:17070196,
5.0,5.3,1172,14.0,"Begum, M. R., J. Ferdous, et al. (2009). ""Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome."" Fertility & Sterility 92(3): 853‐7.",primary_citation,,Begum,2009,"Begum et al., 2009",10.1016/j.fertnstert.2007.08.044,,,,,Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome,pmid:18177867,10.1016/j.fertnstert.2007.08.044
5.0,5.3,1173,14.0,"Ganesh A, Goswami SK, Chattopadhyay R, Chaudhury K, Chakravarty B. Comparison of letrozole with continuous gonadotropins and clomiphene-gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial. J Assist Reprod Genet. 2009 Jan;26(1):19-24. doi: 10.1007/s10815-008-9284-4.",primary_citation,,Ganesh A,2009,"Ganesh A et al., 2009",10.1007/s10815-008-9284-4,,,,,Comparison of letrozole with continuous gonadotropins and clomiphene-gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial,pmid:19127427,10.1007/s10815-008-9284-4
5.0,5.3,1174,14.0,"Legro, R. S., R. G. Brzyski, et al. (2014). ""Letrozole versus clomiphene for infertility in the polycystic ovary syndrome."" New England Journal of Medicine 371(2): 119‐129.",primary_citation,,Legro,2014,"Legro et al., 2014",10.1056/nejmoa1313517,,,,,Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome,pmid:25295506,10.1056/nejmoa1313517
5.0,5.3,1175,14.0,"Liu, C., G. Feng, W. Huang, Q. Wang, S. Yang, J. Tan, J. Fu and D. Liu (2017). ""Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial."" Gynecol Endocrinol 33(11): 872-876.",primary_citation,,Liu,2017,"Liu et al., 2017",10.1080/09513590.2017.1332174,,,,,Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial,pmid:28557652,10.1080/09513590.2017.1332174
5.0,5.3,1176,14.0,"Nazik, H., & Kumtepe, Y. (2012). Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction for women with polycystic ovarian syndrome. HealthMED, 6(3), 879-83.",primary_citation,,Nazik,2012,"Nazik et al., 2012",10.1007/s00404-011-2091-7,,,,,Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction in Indian women with polycystic ovarian syndrome,pmid:21984038,10.1007/s00404-011-2091-7
5.0,5.3,1177,14.0,"Pourghasem S, Bazarganipour F, Taghavi SA, Kutenaee MA. The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. Arch Gynecol Obstet. 2019 Apr;299(4):1193-1199. doi: 10.1007/s00404-019-05064-5. Epub 2019 Feb 5. PMID: 30847561.",primary_citation,,Pourghasem S,2019,"Pourghasem S et al., 2019",10.1007/s00404-019-05064-5,30847561.0,,,,The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole,pmid:30847561,
5.0,5.3,1178,14.0,"Ray Banerjee P, Ray A, Chakraborti PS. Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction in Indian women with polycystic ovarian syndrome  Archives Gynecology and Obstetrics (2012) 285:873–877",primary_citation,,Ray Banerjee P,2012,"Ray Banerjee P et al., 2012",10.1007/s00404-011-2091-7,,,,,Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction in Indian women with polycystic ovarian syndrome,pmid:21984038,10.1007/s00404-011-2091-7
5.0,5.3,1179,14.0,"Roy KK, Baruah J, Singla S, Sharma JB, Singh N, Jain SK, Goyal M. A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. J Hum Reprod Sci. 2012 Jan;5(1):20-5. doi: 10.4103/0974-1208.97789. PMID: 22870010; PMCID: PMC3409915.",primary_citation,,Roy KK,2012,"Roy KK et al., 2012",10.4103/0974-1208.97789,22870010.0,,,,A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome,pmid:22870010,
5.0,5.3,1180,14.0,"Sohrabvand F, Ansari Sh, Bagheri M. Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. Hum Reprod. 2006 Jun;21(6):1432-5. doi: 10.1093/humrep/del020. ",primary_citation,,Sohrabvand F,2006,"Sohrabvand F et al., 2006",10.1093/humrep/del020,,,,,Efficacy of combined metformin–letrozole in comparison with metformin–clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease,pmid:16478764,10.1093/humrep/del020
5.0,5.3,1181,14.0,"Zeinalzadeh, M., Z. Basirat and M. Esmailpour (2010). ""Efficacy of letrozole in ovulation induction compared to that of clomiphene citrate in patients with polycystic ovarian syndrome."" J Reprod Med 55(1‐2): 36‐40.",primary_citation,,Zeinalzadeh,2010,"Zeinalzadeh et al., 2010",,20337206.0,,,,Efficacy of letrozole in ovulation induction compared to that of clomiphene citrate in patients with polycystic ovarian syndrome.,pmid:20337206,
5.0,5.4,1182,34.0,"Amer SA, Li TC, Metwally M, Emarh M, Ledger WL. Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome. Hum Reprod. 2009 Jan;24(1):219-25. doi: 10.1093/humrep/den325. Epub 2008 Sep 14.",primary_citation,,Amer SA,2009,"Amer SA et al., 2009",10.1093/humrep/den325,,,,,Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome,pmid:18794162,10.1093/humrep/den325
5.0,5.4,1183,34.0,"Amer SA, Smith J, Mahran A, Fox P, Fakis A. Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome. Hum Reprod. 2017 Aug 1;32(8):1631-1638. doi: 10.1093/humrep/dex227.",primary_citation,,Amer SA,2017,"Amer SA et al., 2017",10.1093/humrep/dex227,,,,,Double-blind randomized controlled trial of letrozole versus clomiphene citrate in subfertile women with polycystic ovarian syndrome,pmid:28854590,10.1093/humrep/dex227
5.0,5.4,1184,34.0,"Atay, V., Cam, C., Muhcu, M., Cam, M., & Karateke, A. (2006). Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. Journal of international medical research, 34(1), 73-76.",primary_citation,,Atay,2006,"Atay et al., 2006",10.1177/147323000603400109,,,,,Comparison of Letrozole and Clomiphene Citrate in Women with Polycystic Ovaries Undergoing Ovarian Stimulation,pmid:16604826,10.1177/147323000603400109
5.0,5.4,1185,34.0,"Bansal S, Goyal M, Sharma C, Shekhar S. Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial. Int J Gynaecol Obstet. 2021 Mar;152(3):345-350. doi: 10.1002/ijgo.13375. Epub 2020 Oct 14. ",primary_citation,,Bansal S,2021,"Bansal S et al., 2021",10.1002/ijgo.13375,,,,,Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial,pmid:32920843,10.1002/ijgo.13375
5.0,5.4,1186,34.0,"Bayar U, Basaran M, Kiran S, Coskun A, Gezer S. Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial. Fertil Steril. 2006 Nov;86(5):1447-51. doi: 10.1016/j.fertnstert.2006.04.026. ",primary_citation,,Bayar U,2006,"Bayar U et al., 2006",10.1016/j.fertnstert.2006.04.026,,,,,Use of an aromatase inhibitor in patients with polycystic ovary syndrome: a prospective randomized trial,pmid:17070196,10.1016/j.fertnstert.2006.04.026
5.0,5.4,1187,34.0,"Begum, M. R., J. Ferdous, et al. (2009). ""Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome."" Fertility & Sterility 92(3): 853‐7.",primary_citation,,Begum,2009,"Begum et al., 2009",10.1016/j.fertnstert.2007.08.044,,,,,Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome,pmid:18177867,10.1016/j.fertnstert.2007.08.044
5.0,5.4,1188,34.0,"Begum, M. R., S. Akhter, et al. (2013). ""Pretreatment and co‐administration of oral anti‐diabetic agent with clomiphene citrate or rFSH for ovulation induction in clomiphene‐citrate‐resistant polycystic ovary syndrome."" Journal of Obstetrics & Gynaecology Research 39(5): 966‐973.",primary_citation,,Begum,2013,"Begum et al., 2013",10.1111/j.1447-0756.2012.02072.x,,,,,Pretreatment and co‐administration of oral anti‐diabetic agent with clomiphene citrate or <scp>rFSH</scp> for ovulation induction in clomiphene‐citrate‐resistant polycystic ovary syndrome,pmid:23379651,10.1111/j.1447-0756.2012.02072.x
5.0,5.4,1189,34.0,"De Leo V, la Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 1999 Aug;72(2):282-5. doi: 10.1016/s0015-0282(99)00208-3. ",primary_citation,,De Leo V,1999,"De Leo V et al., 1999",10.1016/s0015-0282(99)00208-3,,,,,Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome,pmid:10438996,10.1016/s0015-0282(99)00208-3
5.0,5.4,1190,34.0,"Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. 2002 Feb;87(2):569-74. doi: 10.1210/jcem.87.2.8261. ",primary_citation,,Fleming R,2002,"Fleming R et al., 2002",10.1210/jcem.87.2.8261,,,,,Ovarian Function and Metabolic Factors in Women with Oligomenorrhea Treated with Metformin in a Randomized Double Blind Placebo-Controlled Trial,pmid:11836287,10.1210/jcem.87.2.8261
5.0,5.4,1191,34.0,"Ganesh A, Goswami SK, Chattopadhyay R, Chaudhury K, Chakravarty B. Comparison of letrozole with continuous gonadotropins and clomiphene-gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial. J Assist Reprod Genet. 2009 Jan;26(1):19-24. doi: 10.1007/s10815-008-9284-4. Epub 2009 Jan 7. PMID: 19127427.",primary_citation,,Ganesh A,2009,"Ganesh A et al., 2009",10.1007/s10815-008-9284-4,19127427.0,,,,Comparison of letrozole with continuous gonadotropins and clomiphene-gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial,pmid:19127427,
5.0,5.4,1192,34.0,"Ghanem, M. E.; Elboghdady, L. A.; Hassan, M.; Helal, A. S.; Gibreel, A.; Houssen, M.; Shaker, M. E.; Bahlol, I.; Mesbah, Y. Clomiphene citrate cotreatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial. J Assist Reprod Genet 2013, 30, 1477‐85",primary_citation,,Ghanem,2013,"Ghanem et al., 2013",10.1007/s10815-013-0090-2,,,,,Clomiphene Citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial,pmid:24014214,10.1007/s10815-013-0090-2
5.0,5.4,1193,34.0,"George SS, George K, Irwin C, Job V, Selvakumar R, Jeyaseelan V, Seshadri MS. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Hum Reprod. 2003 Feb;18(2):299-304. doi: 10.1093/humrep/deg105. ",primary_citation,,George SS,2003,"George SS et al., 2003",10.1093/humrep/deg105,,,,,"Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial",pmid:12571165,10.1093/humrep/deg105
5.0,5.4,1194,34.0,"Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril. 2004 Aug;82(2):421-9. doi: 10.1016/j.fertnstert.2004.02.104. ",primary_citation,,Hoeger KM,2004,"Hoeger KM et al., 2004",10.1016/j.fertnstert.2004.02.104,,,,,"A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: A pilot study",pmid:15302293,10.1016/j.fertnstert.2004.02.104
5.0,5.4,1195,34.0,"Homburg R, Hendriks ML, König TE, and Anderson RA, et al., Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum Reprod. 2012 Feb;27(2):468-73. doi: 10.1093/humrep/der401. Epub 2011 Nov 28. ",primary_citation,,Homburg R,2012,"Homburg R et al., 2012",10.1093/humrep/der401,,,,,Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study,pmid:22128296,10.1093/humrep/der401
5.0,5.4,1196,34.0,"Johnson NP, Stewart AW, Falkiner J, Farquhar CM, Milsom S, Singh VP, Okonkwo QL, Buckingham KL; REACT-NZ (REproduction And Collaborative Trials in New Zealand), a multi-centre fertility trials group. PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Hum Reprod. 2010 Jul;25(7):1675-83. doi: 10.1093/humrep/deq100. Epub 2010 Apr 30. ",primary_citation,,Johnson NP,2010,"Johnson NP et al., 2010",10.1093/humrep/deq100,,,,,PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene,pmid:20435692,10.1093/humrep/deq100
5.0,5.4,1197,34.0,"Kar S, Sanchita S. Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: A randomized controlled trial. J Hum Reprod Sci. 2015 Oct-Dec;8(4):197-201. doi: 10.4103/0974-1208.170373.",primary_citation,,Kar S,2015,"Kar S et al., 2015",10.4103/0974-1208.170373,,,,,"Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: A randomized controlled trial",pmid:26752854,10.4103/0974-1208.170373
5.0,5.4,1198,34.0,"Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril. 2002 Jan;77(1):101-6. doi: 10.1016/s0015-0282(01)02941-7. ",primary_citation,,Kocak M,2002,"Kocak M et al., 2002",10.1016/s0015-0282(01)02941-7,,,,,"Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome",pmid:11779598,10.1016/s0015-0282(01)02941-7
5.0,5.4,1199,34.0,"Kjotrod, S. B.; Carlsen, S. M.; Rasmussen, P. E.; Holst‐Larsen, T.; Mellembakken, J.; Thurin‐Kjellberg, A.; Haapaniemikouru, K.; Morin‐Papunen, L.; et al. Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study. Hum Reprod 2011, 26, 2045‐53",primary_citation,,Kjotrod,2011,"Kjotrod et al., 2011",10.1093/humrep/der154,,,,,"Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study",pmid:21606131,10.1093/humrep/der154
5.0,5.4,1200,34.0,"Liu C, Feng G, Huang W, Wang Q, Yang S, Tan J, Fu J, Liu D. Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial. Gynecol Endocrinol. 2017 Nov;33(11):872-876. doi: 10.1080/09513590.2017.1332174. Epub 2017 May 30. ",primary_citation,,Liu C,2017,"Liu C et al., 2017",10.1080/09513590.2017.1332174,,,,,Comparison of clomiphene citrate and letrozole for ovulation induction in women with polycystic ovary syndrome: a prospective randomized trial,pmid:28557652,10.1080/09513590.2017.1332174
5.0,5.4,1201,34.0,"Lopez, E., et al., Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low‐dose recombinant FSH as first line therapy. Reproductive Biomedicine Online, 2004. 9(4): p. 382‐90.",primary_citation,,Lopez,2004,"Lopez et al., 2004",10.1016/s1472-6483(10)61273-4,,,,,Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy,pmid:15511336,10.1016/s1472-6483(10)61273-4
5.0,5.4,1202,34.0,"Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007 Feb 8;356(6):551-66. ",primary_citation,,Legro RS,2007,"Legro RS et al., 2007",10.1056/nejmoa063971,,,,,"Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome",pmid:17287476,10.1056/nejmoa063971
5.0,5.4,1203,34.0,"Legro, R. S., R. G. Brzyski, et al. (2014). ""Letrozole versus clomiphene for infertility in the polycystic ovary syndrome."" New England Journal of Medicine 371(2): 119‐129.",primary_citation,,Legro,2014,"Legro et al., 2014",10.1056/nejmoa1313517,,,,,Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome,pmid:25295506,10.1056/nejmoa1313517
5.0,5.4,1204,34.0,"Morin-Papunen L, Rantala AS, Unkila-Kallio L, Tiitinen A, Hippeläinen M, Perheentupa A, Tinkanen H, Bloigu R, Puukka K, Ruokonen A, Tapanainen JS. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab. 2012 May;97(5):1492-500. doi: 10.1210/jc.2011-3061. Epub 2012 Mar 14. ",primary_citation,,Morin-Papunen L,2012,"Morin-Papunen L et al., 2012",10.1210/jc.2011-3061,,,,,"Metformin Improves Pregnancy and Live-Birth Rates in Women with Polycystic Ovary Syndrome (PCOS): A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial",pmid:22419702,10.1210/jc.2011-3061
5.0,5.4,1205,34.0,"Nazik, H., & Kumtepe, Y. (2012). Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction for women with polycystic ovarian syndrome. HealthMED, 6(3), 879-83.",primary_citation,,Nazik,2012,"Nazik et al., 2012",10.1007/s00404-011-2091-7,,,,,Comparison of efficacy of letrozole and clomiphene citrate in ovulation induction in Indian women with polycystic ovarian syndrome,pmid:21984038,10.1007/s00404-011-2091-7
5.0,5.4,1206,34.0,"Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod. 2001 Aug;16(8):1625-31. doi: 10.1093/humrep/16.8.1625.",primary_citation,,Ng EH,2001,"Ng EH et al., 2001",10.1093/humrep/16.8.1625,,,,,"Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial",pmid:11473953,10.1093/humrep/16.8.1625
5.0,5.4,1207,34.0,"Pourghasem S, Bazarganipour F, Taghavi SA, Kutenaee MA. The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. Arch Gynecol Obstet. 2019 Apr;299(4):1193-1199. doi: 10.1007/s00404-019-05064-5. Epub 2019 Feb 5. PMID: 30847561.",primary_citation,,Pourghasem S,2019,"Pourghasem S et al., 2019",10.1007/s00404-019-05064-5,30847561.0,,,,The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole,pmid:30847561,
5.0,5.4,1208,34.0,"Qublan HS, Al-Khaderei S, Abu-Salem AN, Al-Zpoon A, Al-Khateeb M, Al-Ibrahim N, Megdadi M, Al-Ahmad N. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. J Obstet Gynaecol. 2009 Oct;29(7):651-5. doi: 10.1080/01443610903147576. ",primary_citation,,Qublan HS,2009,"Qublan HS et al., 2009",10.1080/01443610903147576,,,,,Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing<i>in vitro</i>fertilisation treatment: A randomised controlled trial,pmid:19757275,10.1080/01443610903147576
5.0,5.4,1209,34.0,"Roy KK, Baruah J, Singla S, Sharma JB, Singh N, Jain SK, Goyal M. A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. J Hum Reprod Sci. 2012 Jan;5(1):20-5. doi: 10.4103/0974-1208.97789. PMID: 22870010.",primary_citation,,Roy KK,2012,"Roy KK et al., 2012",10.4103/0974-1208.97789,22870010.0,,,,A prospective randomized trial comparing the efficacy of Letrozole and Clomiphene citrate in induction of ovulation in polycystic ovarian syndrome,pmid:22870010,
5.0,5.4,1210,34.0,"Sahin Y, Yirmibeş U, Keleştimur F, Aygen E. The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2004 Apr 15;113(2):214-20. doi: 10.1016/j.ejogrb.2003.09.036.",primary_citation,,Sahin Y,2004,"Sahin Y et al., 2004",10.1016/j.ejogrb.2003.09.036,,,,,"The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome",pmid:15063963,10.1016/j.ejogrb.2003.09.036
5.0,5.4,1211,34.0,"Siebert TI, Kruger TF, Lombard C. Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. J Assist Reprod Genet. 2009 Apr;26(4):165-71. doi: 10.1007/s10815-009-9304-z. Epub 2009 Apr 25.",primary_citation,,Siebert TI,2009,"Siebert TI et al., 2009",10.1007/s10815-009-9304-z,,,,,Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients,pmid:19396538,10.1007/s10815-009-9304-z
5.0,5.4,1212,34.0,"Sohrabvand F, Ansari Sh, Bagheri M. Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. Hum Reprod. 2006 Jun;21(6):1432-5. doi: 10.1093/humrep/del020. Epub 2006 Feb 14.",primary_citation,,Sohrabvand F,2006,"Sohrabvand F et al., 2006",10.1093/humrep/del020,,,,,Efficacy of combined metformin–letrozole in comparison with metformin–clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease,pmid:16478764,10.1093/humrep/del020
5.0,5.4,1213,34.0,"Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod. 2006 Jan;21(1):80-9. doi: 10.1093/humrep/dei311. Epub 2005 Sep 30 [Tang 2006b]",primary_citation,,Tang T,2006,"Tang T et al., 2006",10.1093/humrep/dei311,,,,,"Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study",pmid:16199429,10.1093/humrep/dei311
5.0,5.4,1214,34.0,"Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril. 2001 Feb;75(2):310-5. doi: 10.1016/s0015-0282(00)01675-7. ",primary_citation,,Vandermolen DT,2001,"Vandermolen DT et al., 2001",10.1016/s0015-0282(00)01675-7,,,,,Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone,pmid:11172832,10.1016/s0015-0282(00)01675-7
5.0,5.4,1215,34.0,"Zeinalzadeh, M., Z. Basirat and M. Esmailpour (2010). ""Efficacy of letrozole in ovulation induction compared to that of clomiphene citrate in patients with polycystic ovarian syndrome."" J Reprod Med 55(1‐2): 36‐40.",primary_citation,,Zeinalzadeh,2010,"Zeinalzadeh et al., 2010",,20337206.0,,22894601.0,,Efficacy of letrozole in ovulation induction compared to that of clomiphene citrate in patients with polycystic ovarian syndrome.,pmid:20337206,
5.0,5.5,1216,12.0,"Baryam N, van Wely M, Kaaijk EM, Bossuyt PM, van der Veen F. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ. 2004 Jan 24;328(7433):192. doi: 10.1136/bmj.328.7433.192.",primary_citation,,Baryam N,2004,"Baryam N et al., 2004",10.1136/bmj.328.7433.192,,,,,Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial,pmid:14739186,10.1136/bmj.328.7433.192
5.0,5.5,1217,12.0,"Begum, M. R., S. Akhter, et al. (2013). ""Pretreatment and co‐administration of oral anti‐diabetic agent with clomiphene citrate or rFSH for ovulation induction in clomiphene‐citrate‐resistant polycystic ovary syndrome."" Journal of Obstetrics & Gynaecology Research 39(5): 966‐973.",primary_citation,,Begum,2013,"Begum et al., 2013",10.1111/j.1447-0756.2012.02072.x,,,,,Pretreatment and co‐administration of oral anti‐diabetic agent with clomiphene citrate or <scp>rFSH</scp> for ovulation induction in clomiphene‐citrate‐resistant polycystic ovary syndrome,pmid:23379651,10.1111/j.1447-0756.2012.02072.x
5.0,5.5,1218,12.0,"De Leo V, la Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 1999 Aug;72(2):282-5. doi: 10.1016/s0015-0282(99)00208-3.",primary_citation,,De Leo V,1999,"De Leo V et al., 1999",10.1016/s0015-0282(99)00208-3,,,,,Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome,pmid:10438996,10.1016/s0015-0282(99)00208-3
5.0,5.5,1219,12.0,"Farquhar CM, Williamson K, Gudex G, Johnson NP, Garland J, Sadler L. A randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril. 2002 Aug;78(2):404-11. doi: 10.1016/s0015-0282(02)03225-9.",primary_citation,,Farquhar CM,2002,"Farquhar CM et al., 2002",10.1016/s0015-0282(02)03225-9,,,,,A randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome,pmid:12137881,10.1016/s0015-0282(02)03225-9
5.0,5.5,1220,12.0,"Ganesh A, Goswami SK, Chattopadhyay R, Chaudhury K, Chakravarty B. Comparison of letrozole with continuous gonadotropins and clomiphene-gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial. J Assist Reprod Genet. 2009 Jan;26(1):19-24. doi: 10.1007/s10815-008-9284-4. Epub 2009 Jan 7..",primary_citation,,Ganesh A,2009,"Ganesh A et al., 2009",10.1007/s10815-008-9284-4,,,,,Comparison of letrozole with continuous gonadotropins and clomiphene-gonadotropin combination for ovulation induction in 1387 PCOS women after clomiphene citrate failure: a randomized prospective clinical trial,pmid:19127427,10.1007/s10815-008-9284-4
5.0,5.5,1221,12.0,"Ghanem, M. E.; Elboghdady, L. A.; Hassan, M.; Helal, A. S.; Gibreel, A.; Houssen, M.; Shaker, M. E.; Bahlol, I.; Mesbah, Y. Clomiphene citrate cotreatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial.[Erratum appears in J Assist Reprod Genet. 2014 Apr;31(4):505‐6]. J Assist Reprod Genet 2013, 30, 1477‐85",primary_citation,,Ghanem,2014,"Ghanem et al., 2014",10.1007/s10815-013-0090-2,,,,,Clomiphene Citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial,pmid:24014214,10.1007/s10815-013-0090-2
5.0,5.5,1222,12.0,"George SS, George K, Irwin C, Job V, Selvakumar R, Jeyaseelan V, Seshadri MS. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Hum Reprod. 2003 Feb;18(2):299-304. doi: 10.1093/humrep/deg105. ",primary_citation,,George SS,2003,"George SS et al., 2003",10.1093/humrep/deg105,,,,,"Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial",pmid:12571165,10.1093/humrep/deg105
5.0,5.5,1223,12.0,"Homburg R, Hendriks ML, König TE, and Anderson RA, et al., Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum Reprod. 2012 Feb;27(2):468-73. doi: 10.1093/humrep/der401. Epub 2011 Nov 28. ",primary_citation,,Homburg R,2012,"Homburg R et al., 2012",10.1093/humrep/der401,,,,,Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study,pmid:22128296,10.1093/humrep/der401
5.0,5.5,1224,12.0,"Lopez, E., et al., Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low‐dose recombinant FSH as first line therapy. Reproductive Biomedicine Online, 2004. 9(4): p. 382‐90.",primary_citation,,Lopez,2004,"Lopez et al., 2004",10.1016/s1472-6483(10)61273-4,,,,,Ovulation induction in women with polycystic ovary syndrome: randomized trial of clomiphene citrate versus low-dose recombinant FSH as first line therapy,pmid:15511336,10.1016/s1472-6483(10)61273-4
5.0,5.5,1225,12.0,"Tasdemir S, Ficicioglu C, Yalti S, Gurbuz B, Basaran T, Yildirim G. The effect of metformin treatment to ovarian response in cases with PCOS. Arch Gynecol Obstet. 2004 Jan;269(2):121-4. doi: 10.1007/s00404-002-0447-8.",primary_citation,,Tasdemir S,2004,"Tasdemir S et al., 2004",10.1007/s00404-002-0447-8,,,,,The effect of metformin treatment to ovarian response in cases with PCOS,pmid:12764624,10.1007/s00404-002-0447-8
5.0,5.5,1226,12.0,"Yadav P, Singh S, Singh R, Jain M, Awasthi S, Raj P. To study the effect on fertility outcome by gonadotropins vs laparoscopic ovarian drilling in clomiphene-resistant cases of polycystic ovarian syndrome. Journal of SAFOG 2017; 9(4): 336‐340.",primary_citation,,Yadav P,2017,"Yadav P et al., 2017",10.5005/jp-journals-10006-1525,,,,,To Study the Effect on Fertility Outcome by Gonadotropins vs Laparoscopic Ovarian Drilling in Clomiphene-resistant Cases of Polycystic Ovarian Syndrome,,10.5005/jp-journals-10006-1525
5.0,5.5,1227,12.0,"Yarali H, Yildiz BO, Demirol A, Zeyneloğlu HB, Yiğit N, Bükülmez O, Koray Z. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod. 2002 Feb;17(2):289-94. doi: 10.1093/humrep/17.2.289. PMID: 11821265.",primary_citation,,Yarali H,2002,"Yarali H et al., 2002",10.1093/humrep/17.2.289,11821265.0,,,,Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial,pmid:11821265,
5.0,5.6,1228,6.0,"Amer SA, Li TC, Metwally M, Emarh M, Ledger WL. Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome. Hum Reprod. 2009 Jan;24(1):219-25. doi: 10.1093/humrep/den325. Epub 2008 Sep 14.",primary_citation,,Amer SA,2009,"Amer SA et al., 2009",10.1093/humrep/den325,,,,,Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome,pmid:18794162,10.1093/humrep/den325
5.0,5.6,1229,6.0,"Baryam N, van Wely M, Kaaijk EM, Bossuyt PM, van der Veen F. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. BMJ. 2004 Jan 24;328(7433):192. doi: 10.1136/bmj.328.7433.192.",primary_citation,,Baryam N,2004,"Baryam N et al., 2004",10.1136/bmj.328.7433.192,,,,,Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial,pmid:14739186,10.1136/bmj.328.7433.192
5.0,5.6,1230,6.0,"Farquhar CM, Williamson K, Gudex G, Johnson NP, Garland J, Sadler L. A randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril. 2002 Aug;78(2):404-11. doi: 10.1016/s0015-0282(02)03225-9.",primary_citation,,Farquhar CM,2002,"Farquhar CM et al., 2002",10.1016/s0015-0282(02)03225-9,,,24959997.0,,A randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome,pmid:12137881,10.1016/s0015-0282(02)03225-9
5.0,5.6,1231,6.0,"Roy KK, Baruah J, Moda N, Kumar S. Evaluation of unilateral versus bilateral ovarian drilling in clomiphene citrate resistant cases of polycystic ovarian syndrome. Arch Gynecol Obstet. 2009 Oct;280(4):573-8. doi: 10.1007/s00404-009-0961-z. Epub 2009 Feb 13. PMID: 19214545.",primary_citation,,Roy KK,2009,"Roy KK et al., 2009",10.1007/s00404-009-0961-z,19214545.0,,,,Evaluation of unilateral versus bilateral ovarian drilling in clomiphene citrate resistant cases of polycystic ovarian syndrome,pmid:19214545,
5.0,5.6,1232,6.0,"Sharma, M., Kriplani, A., & Agarwal, N. (2006). Laparoscopic bipolar versus unipolar ovarian drilling in infertile women with resistant polycystic ovarian syndrome: a pilot study. Journal of gynecologic surgery, 22(3), 105-111.",primary_citation,,Sharma,2006,"Sharma et al., 2006",10.1089/gyn.2006.22.105,,,,,Laparoscopic Bipolar Versus Unipolar Ovarian Drilling in Infertile Women with Resistant Polycystic Ovarian Syndrome: A Pilot Study,,10.1089/gyn.2006.22.105
5.0,5.6,1233,6.0,"Yadav P, Singh S, Singh R, Jain M, Awasthi S, Raj P. To study the effect on fertility outcome by gonadotropins vs laparoscopic ovarian drilling in clomiphene-resistant cases of polycystic ovarian syndrome. Journal of SAFOG 2017; 9(4): 336‐340.",primary_citation,,Yadav P,2017,"Yadav P et al., 2017",10.5005/jp-journals-10006-1525,,,,,To Study the Effect on Fertility Outcome by Gonadotropins vs Laparoscopic Ovarian Drilling in Clomiphene-resistant Cases of Polycystic Ovarian Syndrome,,10.5005/jp-journals-10006-1525
5.0,5.7.1,1234,7.0,"Ashrafi, Mahnaz & Moini, Ashraf & Mohammadzadeh, Afsaneh & Ezabadi, Zahra & Zafarani, Fatemeh & Baghestani, Ahmad. (2005). A comparative study of GnRH antagonist and GnRH agonist in PCO patients undergoing IVF/ICSI cycles. Iranian Journal of Reproductive Medicine (ISSN: 1680-6433) Vol 3 Num 1. 3. ",primary_citation,,Ashrafi,2005,"Ashrafi et al., 2005",,,W2162847277,54603939.0,A comparative study of GnRH antagonist and GnRH agonist in PCO patients undergoing IVF/ICSI cycles. Iranian Journal of Reproductive Medicine,A COMPARATIVE STUDY OF GNRH ANTAGONIST AND GNRH AGONIST IN PCO PATIENTS UNDERGOING IVF/ICSI CYCLES,,
5.0,5.7.1,1235,7.0,"Bahceci, M.; Ulug, U.; Ben‐Shlomo, I.; Erden, H. F.; Akman, M. A. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. Journal of Reproductive Medicine 2005, 50, 84‐90",primary_citation,,Bahceci,2005,"Bahceci et al., 2005",,15755044.0,,42473780.0,,"Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.",pmid:15755044,
5.0,5.7.1,1236,7.0,"Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008 Jan;89(1):84-91. doi: 10.1016/j.fertnstert.2007.02.002. Epub 2007 Apr 26. PMID: 17462639.",primary_citation,,Engmann L,2008,"Engmann L et al., 2008",10.1016/j.fertnstert.2007.02.002,17462639.0,,,,The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study,pmid:17462639,
5.0,5.7.1,1237,7.0,"Haydardedeoglu, B., Kilicdag, E. B., Parlakgumus, A. H., & Zeyneloglu, H. B. (2012). IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial. Archives of Gynecology & Obstetrics, 286(3), 763‐769",primary_citation,,Haydardedeoglu,2012,"Haydardedeoglu et al., 2012",10.1007/s00404-012-2348-9,,,,,IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial,pmid:22569710,10.1007/s00404-012-2348-9
5.0,5.7.1,1238,7.0,"Kurzawa, R.; Ciepiela, P.; Baczkowski, T.; Safranow, K.; Brelik, P. Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non‐obese patients. A prospective randomized study. J Assist Reprod Genet 2008, 25, 365‐74",primary_citation,,Kurzawa,2008,"Kurzawa et al., 2008",10.1007/s10815-008-9249-7,,,,,Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study,pmid:18802744,10.1007/s10815-008-9249-7
5.0,5.7.1,1239,7.0,"Lainas, T. G.; Petsas, G. K.; Zorzovilis, I. Z.; Iliadis, G. S.; Lainas, G. T.; Cazlaris, H. E.; Kolibianakis, E. M. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development. Hum Reprod 2007, 22, 1540‐6",primary_citation,,Lainas,2007,"Lainas et al., 2007",10.1093/humrep/dem033,,,,,Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development,pmid:17347165,10.1093/humrep/dem033
5.0,5.7.1,1240,7.0,"Lainas, T. G., Sfontouris, I. A., Zorzovilis, I. Z., Petsas, G. K., Lainas, G. T., Alexopoulou, E., & Kolibianakis, E. M. (2010). Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Human Reproduction, 25(3), 683‐689.",primary_citation,,Lainas,2010,"Lainas et al., 2010",10.1093/humrep/dep436,,,,,Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT),pmid:20008886,10.1093/humrep/dep436
5.0,5.7.5,1241,8.0,"Doldi, N., Persico, P., Di Sebastiano, F., Marsiglio, E., & Ferrari, A. (2006). Gonadotropin‐releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization‐embryo transfer. Gynecological Endocrinology, 22(5), 235‐238.",primary_citation,,Doldi,2006,"Doldi et al., 2006",10.1080/14767050600761893,,,,,Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing<i>in vitro</i>fertilization–embryo transfer,pmid:16785142,10.1080/14767050600761893
5.0,5.7.5,1242,8.0,"Fedorcsak, P.; Dale, P. O.; Storeng, R.; Abyholm, T.; Tanbo, T. The effect of metformin on ovarian stimulation and in vitro fertilization in insulin‐resistant women with polycystic ovary syndrome: an open‐label randomized crossover trial. Gynecol Endocrinol 2003, 17, 207‐14 DOI: 10.1080/gye.17.3.207.214",primary_citation,,Fedorcsak,2003,"Fedorcsak et al., 2003",10.1080/gye.17.3.207.214,,,,,The effect of metformin on ovarian stimulation and<i>in vitro</i>fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial,pmid:12857428,10.1080/gye.17.3.207.214
5.0,5.7.5,1243,8.0,"Jacob SL, Brewer C, Tang T, Picton HM, Barth JH, Balen AH. A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial. Hum Reprod. 2016 Dec;31(12):2756-2764. doi: 10.1093/humrep/dew268. Epub 2016 Nov 5. PMID: 27816925.",primary_citation,,Jacob SL,2016,"Jacob SL et al., 2016",10.1093/humrep/dew268,27816925.0,,,,A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial,pmid:27816925,
5.0,5.7.5,1244,8.0,"Onalan G, Pabuçcu R, Goktolga U, Ceyhan T, Bagis T, Cincik M. Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. Fertil Steril. 2005 Sep;84(3):798-801. doi: 10.1016/j.fertnstert.2005.03.043. PMID: 16169430.",primary_citation,,Onalan G,2005,"Onalan G et al., 2005",10.1016/j.fertnstert.2005.03.043,16169430.0,,,,Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial,pmid:16169430,
5.0,5.7.5,1245,8.0,"Kjotrod, S. B.; von During, V.; Carlsen, S. M. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum Reprod 2004, 19, 1315‐22",primary_citation,,Kjotrod,2004,"Kjotrod et al., 2004",10.1093/humrep/deh248,,,,,"Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study",pmid:15117902,10.1093/humrep/deh248
5.0,5.7.5,1246,8.0,"Kjotrod, S. B., S. M. Carlsen, et al. (2011). ""Use of metformin before and during assisted reproductive technology in non‐obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double‐blind, multi‐centre study."" Human Reproduction 26(8): 2045‐2053.",primary_citation,,Kjotrod,2011,"Kjotrod et al., 2011",10.1093/humrep/der154,,,,,"Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study",pmid:21606131,10.1093/humrep/der154
5.0,5.7.5,1247,8.0,"Qublan HS, Al-Khaderei S, Abu-Salem AN, Al-Zpoon A, Al-Khateeb M, Al-Ibrahim N, Megdadi M, Al-Ahmad N. Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. J Obstet Gynaecol. 2009 Oct;29(7):651-5. doi: 10.1080/01443610903147576. PMID: 19757275. ",primary_citation,,Qublan HS,2009,"Qublan HS et al., 2009",10.1080/01443610903147576,19757275.0,,,,Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing<i>in vitro</i>fertilisation treatment: A randomised controlled trial,pmid:19757275,
5.0,5.7.5,1248,8.0,"Tang, T.; Glanville, J.; Orsi, N.; Barth, J. H.; Balen, A. H. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 2006, 21, 1416‐25",primary_citation,,Tang,2006,"Tang et al., 2006",10.1093/humrep/del025,,,,,The use of metformin for women with PCOS undergoing IVF treatment,pmid:16501038,10.1093/humrep/del025
5.0,5.7.6,1249,1.0,"Zheng X, Guo W, Zeng L, Zheng D, Yang S, Xu Y, Wang L, Wang R, Mol BW, Li R, Qiao J. In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial. Hum Reprod. 2022 Jan 28;37(2):242-253. doi: 10.1093/humrep/deab243. PMID: 34849920; PMCID: PMC9115328.",primary_citation,,Zheng X,2022,"Zheng X et al., 2022",10.1093/humrep/deab243,34849920.0,,,,<i>In vitro</i> maturation without gonadotropins versus <i>in vitro</i> fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial,pmid:34849920,
